Menstrual Disorders — MCQs

Q: What is the commonest cause of primary amenorrhea?

Ovarian dysgenesis. **Explanation:** Primary amenorrhea is defined as the failure of menarche to occur by age 15 in the presence of secondary sexual characteristics, or by age 13 in their absence. **Why Ovarian Dysgenesis is Correct:** **Ovarian dysgenesis (specifically Turner Syndrome, 45,XO)** is the most common cause of primary amenorrhea, accounting for approximately 40-50% of cases. In these patients, accelerated atresia of germ cells leads to "streak ovaries," resulting in hypergonadotropic hypogonadism (high FSH/LH, low Estrogen). This lack of estrogen prevents both the development of secondary sexual characteristics and the stimulation of the endometrium. **Analysis of Incorrect Options:** * **Genital Tuberculosis:** While a significant cause of infertility and secondary amenorrhea in developing countries, it rarely presents as primary amenorrhea unless it causes severe prepubertal endometrial destruction. * **Mullerian Duct Anomalies:** Conditions like MRKH syndrome (Mullerian Agenesis) are the *second* most common cause. These patients have normal ovaries and secondary sexual characteristics but lack a functional uterus/vagina. * **Hypothyroidism:** This is a systemic endocrine cause that more typically results in secondary amenorrhea or oligomenorrhea; it is rarely the primary etiology for a complete failure of menarche. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause overall:** Ovarian Dysgenesis (Turner Syndrome). * **Most common cause with normal secondary sexual characteristics:** Mullerian Agenesis (MRKH Syndrome). * **Initial investigation of choice:** Karyotyping (if FSH is high) or Ultrasound (to check for the presence of a uterus). * **Turner Syndrome Hallmark:** Short stature, webbed neck, and high FSH levels.

Q: Asherman syndrome is secondary to which of the following?

Tuberculosis. **Explanation:** **Asherman Syndrome** refers to the formation of intrauterine adhesions (synechiae) that lead to the partial or complete obliteration of the uterine cavity. **Why Tuberculosis is correct:** In developing countries like India, **Genital Tuberculosis** is a leading cause of Asherman syndrome. The chronic inflammatory process of TB destroys the *basalis layer* of the endometrium, preventing normal regeneration. This results in dense fibrosis and scarring, often leading to irreversible secondary amenorrhea and infertility. While the most common cause globally is over-zealous curettage (post-abortion or postpartum), TB remains a high-yield infectious etiology for NEET-PG. **Analysis of Incorrect Options:** * **B. Endometrial Carcinoma:** This typically presents with postmenopausal bleeding and endometrial thickening, rather than the formation of intrauterine adhesions. * **C. Endometriosis:** This involves the presence of endometrial tissue *outside* the uterine cavity (e.g., ovaries, peritoneum). It causes pelvic pain and pelvic adhesions, but not intrauterine synechiae. * **D. Submucosal Fibroid:** These are benign tumors that distort the uterine cavity and usually cause heavy menstrual bleeding (menorrhagia), not the amenorrhea associated with Asherman syndrome. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** Hysteroscopy (allows both diagnosis and treatment via adhesiolysis). * **HSG Finding:** Characterized by "filling defects" or a "honeycomb appearance." * **Treatment:** Hysteroscopic adhesiolysis followed by high-dose estrogen therapy to promote endometrial regrowth and the insertion of an IUCD or Foley catheter to prevent re-adhesion. * **Netter’s Syndrome:** A term sometimes used specifically for the end-stage destruction of the endometrium due to Tuberculosis.

Q: A female presents with primary amenorrhea and absent vagina. What is the next investigation to be done?

Laparoscopy. **Explanation:** The clinical presentation of primary amenorrhea with an absent vagina primarily points towards two major differentials: **Müllerian Agenesis (MRKH Syndrome)** and **Androgen Insensitivity Syndrome (AIS)**. **Why Laparoscopy is the correct answer:** In the context of this specific question, **Laparoscopy** is considered the definitive investigation to visualize the internal pelvic anatomy. It allows for the direct confirmation of the presence or absence of the uterus, fallopian tubes, and ovaries. In Müllerian Agenesis, laparoscopy would typically reveal a rudimentary uterus (bicornuate bulbs) with normal ovaries, whereas in AIS, the uterus is absent and gonads are undescended testes. While MRI is a non-invasive alternative often used in modern practice, laparoscopy remains the "gold standard" for anatomical confirmation in surgical planning and diagnostic dilemmas in competitive exams. **Analysis of Incorrect Options:** * **A. LH/FSH assay:** These are useful for diagnosing hypogonadotropic hypogonadism or premature ovarian failure, but they do not help in evaluating anatomical defects like an absent vagina. * **B. Chromosomal analysis:** While essential to differentiate MRKH (46,XX) from AIS (46,XY), it is usually performed after anatomical confirmation or as a secondary step. * **C. Urinalysis:** This has no diagnostic value for primary amenorrhea or Müllerian anomalies. **High-Yield Clinical Pearls for NEET-PG:** * **Müllerian Agenesis (MRKH):** Most common cause of primary amenorrhea with absent vagina. Characterized by 46,XX karyotype, normal ovaries, and normal secondary sexual characters. * **Associated Anomalies:** Always check for **Renal anomalies** (most common, e.g., renal agenesis) and skeletal defects (VACTERL) in cases of MRKH. * **AIS:** Characterized by 46,XY karyotype, absent/scant pubic hair, and presence of testes (risk of gonadoblastoma).

Q: A 45-year-old lady presented with recurrent uterine bleeding. On transvaginal ultrasonography, the thickness of the endometrium was found to be 8 mm. What should be the next step in the management of this patient?

Histopathology. **Explanation:** The primary concern in a 45-year-old woman with recurrent uterine bleeding and a thickened endometrium is excluding **Endometrial Hyperplasia** or **Endometrial Carcinoma**. **1. Why Histopathology is Correct:** In perimenopausal women (age >40–45), any abnormal uterine bleeding (AUB) must be investigated to rule out malignancy. On Transvaginal Sonography (TVS), an endometrial thickness (ET) of **>4 mm or >5 mm** in postmenopausal women, or persistent thickening/irregularity in perimenopausal women, necessitates a tissue diagnosis. Histopathology via **Endometrial Biopsy (Pipelle)** or **Fractional Curettage** is the gold standard to determine the underlying pathology (e.g., simple hyperplasia vs. atypia vs. malignancy). **2. Why Other Options are Incorrect:** * **Hysterectomy:** This is a definitive surgical treatment. It should never be performed without a prior histological diagnosis, as the surgical approach (e.g., simple vs. radical) depends on whether malignancy is present. * **Progesterone/OCPs:** These are medical management options for AUB-O (ovulatory dysfunction) or hormonal imbalances. However, they should only be initiated **after** ruling out malignancy through histopathology, as hormonal therapy can mask the symptoms of underlying cancer. **Clinical Pearls for NEET-PG:** * **Cut-off for Postmenopausal Bleeding:** ET >4 mm requires immediate biopsy. * **Gold Standard for Diagnosis of AUB:** Hysteroscopy-guided biopsy (more accurate than blind D&C). * **Risk Factors for Endometrial CA:** Obesity, Nulliparity, Early menarche/Late menopause, and PCOS (due to unopposed estrogen). * **First-line investigation for AUB:** TVS is the initial screening tool, but Histopathology provides the definitive diagnosis.

Q: All of the following conditions are associated with primary amenorrhea except?

Stein-Leventhal syndrome. **Explanation:** The core concept in this question is distinguishing between conditions that typically present with **Primary Amenorrhea** (failure to start menses) versus **Secondary Amenorrhea** (cessation of established menses). **Why Stein-Leventhal Syndrome is the correct answer:** Stein-Leventhal Syndrome, commonly known as **Polycystic Ovary Syndrome (PCOS)**, is the most common cause of **secondary amenorrhea** or oligomenorrhea. While it can rarely present as primary amenorrhea if the hormonal imbalance is severe from puberty, it is classically associated with the disruption of an already established menstrual cycle due to hyperandrogenism and chronic anovulation. **Analysis of Incorrect Options:** * **Turner’s Syndrome (45, XO):** The most common cause of primary amenorrhea. It involves streak ovaries (gonadal dysgenesis), leading to hypergonadotropic hypogonadism. * **Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome:** The second most common cause of primary amenorrhea. It is characterized by Müllerian agenesis (absent uterus and upper 2/3 of the vagina) despite a normal 46, XX karyotype and normal ovarian function. * **Testicular Feminization Syndrome (Androgen Insensitivity Syndrome):** A condition where a 46, XY individual has end-organ resistance to androgens. They present with a female phenotype, a blind vaginal pouch, absent uterus, and primary amenorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Amenorrhea Definition:** No menses by age 13 (without secondary sexual characteristics) or age 15 (with secondary sexual characteristics). * **MRKH vs. AIS:** Both present with a blind vaginal pouch and absent uterus. Differentiate by **Karyotype** (XX in MRKH, XY in AIS) and **Pubic/Axillary hair** (Present in MRKH, absent/scanty in AIS). * **PCOS Triad:** Hyperandrogenism, Ovulatory dysfunction, and Polycystic ovaries on ultrasound (Rotterdam Criteria).

Q: A 36-year-old woman has noticed the absence of menses for the last 4 months. A pregnancy test is negative. Serum levels of luteinizing hormone and follicle stimulating hormone are elevated, and the serum estradiol level is low. These findings suggest which of the following conditions?

Premature menopause. **Explanation:** The clinical presentation of secondary amenorrhea (absence of menses for >3 months) in a 36-year-old, combined with **elevated gonadotropins (FSH and LH)** and **low estradiol**, points toward **Hypergonadotropic Hypogonadism**. 1. **Why Premature Menopause is correct:** Premature Ovarian Failure (POF), now termed Primary Ovarian Insufficiency (POI), is defined as the cessation of ovarian function before age 40. The primary defect is in the ovaries (exhaustion of follicles). Due to the lack of follicular development, estrogen levels fall. This removes the negative feedback on the pituitary and hypothalamus, leading to a compensatory rise in FSH and LH. An **FSH level >40 IU/L** on two occasions is the diagnostic hallmark. 2. **Why other options are incorrect:** * **Bilateral tubal obstruction:** This causes mechanical infertility but does not affect the hypothalamic-pituitary-ovarian axis. Hormonal levels and menstrual cycles remain normal. * **Polycystic Ovarian Disease (PCOS):** This typically presents with an **elevated LH/FSH ratio (>2:1)**, but FSH is usually normal or low, and estrogen levels are normal or elevated (due to peripheral conversion of androgens). * **Exogenous estrogen administration:** This would provide negative feedback to the pituitary, resulting in **low** levels of FSH and LH, not elevated levels. **High-Yield Pearls for NEET-PG:** * **Primary Ovarian Insufficiency (POI):** Amenorrhea + FSH >40 IU/L + Age <40 years. * **Most common chromosomal cause:** Turner Syndrome (45,XO) or Mosaicism. * **Most common cause of secondary amenorrhea:** Pregnancy (always rule this out first). * **Kallmann Syndrome:** Presents with *Hypogonadotropic Hypogonadism* (Low FSH/LH + Low Estrogen + Anosmia).

Q: Which of the following is NOT true about the use of NSAIDs in abnormal uterine bleeding?

NSAIDs should be commenced just prior to the start of menses and continued up to day 14 of the cycle.. **Explanation:** **1. Why Option D is the Correct Answer (The "Not True" Statement):** NSAIDs are used for the management of **ovulatory** Abnormal Uterine Bleeding (AUB) due to their effect on prostaglandin synthesis. However, they are only effective during the period of active bleeding. The standard protocol is to start NSAIDs **just prior to or on the first day of menses** and continue them for the **duration of the flow (usually 3–5 days)**. Continuing them until day 14 of the cycle is clinically unnecessary, provides no additional benefit for blood loss, and increases the risk of gastric side effects. **2. Analysis of Other Options:** * **Option A:** True. Women with heavy menstrual bleeding (HMB) often have higher levels of vasodilatory prostaglandins (PGE2 and PGI2) relative to vasoconstrictors (PGF2α) in the endometrium. * **Option B:** True. Approximately 90% of total menstrual blood loss occurs within the first 3 days of the cycle. Therefore, timing the medication to coincide with this window is most effective. * **Option C:** True. Clinical studies show that NSAIDs (like Mefenamic acid or Naproxen) reduce menstrual blood loss by an average of **20–30%**. While less effective than Tranexamic acid (40–50%) or the LNG-IUS (70–90%), they are a first-line non-hormonal option. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice (NSAID):** Mefenamic acid is the most commonly used NSAID for AUB/Dysmenorrhea. * **Mechanism:** They inhibit the enzyme cyclooxygenase (COX), shifting the balance toward vasoconstrictive prostaglandins (PGF2α), which aids in endometrial hemostasis. * **Dual Benefit:** NSAIDs are the preferred first-line treatment for patients who have **both** heavy menstrual bleeding and dysmenorrhea. * **Contraindication:** Avoid in patients with peptic ulcer disease or aspirin-sensitive asthma.

Menstrual Disorders Indian Medical PG Practice Questions and MCQs

Question 1: What is the commonest cause of primary amenorrhea?

A. Genital tuberculosis
B. Ovarian dysgenesis (Correct Answer)
C. Mullerian duct anomalies
D. Hypothyroidism

Explanation: **Explanation:** Primary amenorrhea is defined as the failure of menarche to occur by age 15 in the presence of secondary sexual characteristics, or by age 13 in their absence. **Why Ovarian Dysgenesis is Correct:** **Ovarian dysgenesis (specifically Turner Syndrome, 45,XO)** is the most common cause of primary amenorrhea, accounting for approximately 40-50% of cases. In these patients, accelerated atresia of germ cells leads to "streak ovaries," resulting in hypergonadotropic hypogonadism (high FSH/LH, low Estrogen). This lack of estrogen prevents both the development of secondary sexual characteristics and the stimulation of the endometrium. **Analysis of Incorrect Options:** * **Genital Tuberculosis:** While a significant cause of infertility and secondary amenorrhea in developing countries, it rarely presents as primary amenorrhea unless it causes severe prepubertal endometrial destruction. * **Mullerian Duct Anomalies:** Conditions like MRKH syndrome (Mullerian Agenesis) are the *second* most common cause. These patients have normal ovaries and secondary sexual characteristics but lack a functional uterus/vagina. * **Hypothyroidism:** This is a systemic endocrine cause that more typically results in secondary amenorrhea or oligomenorrhea; it is rarely the primary etiology for a complete failure of menarche. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause overall:** Ovarian Dysgenesis (Turner Syndrome). * **Most common cause with normal secondary sexual characteristics:** Mullerian Agenesis (MRKH Syndrome). * **Initial investigation of choice:** Karyotyping (if FSH is high) or Ultrasound (to check for the presence of a uterus). * **Turner Syndrome Hallmark:** Short stature, webbed neck, and high FSH levels.

Question 2: Asherman syndrome is secondary to which of the following?

A. Tuberculosis (Correct Answer)
B. Endometrial carcinoma
C. Endometriosis
D. Submucosal fibroid

Explanation: **Explanation:** **Asherman Syndrome** refers to the formation of intrauterine adhesions (synechiae) that lead to the partial or complete obliteration of the uterine cavity. **Why Tuberculosis is correct:** In developing countries like India, **Genital Tuberculosis** is a leading cause of Asherman syndrome. The chronic inflammatory process of TB destroys the *basalis layer* of the endometrium, preventing normal regeneration. This results in dense fibrosis and scarring, often leading to irreversible secondary amenorrhea and infertility. While the most common cause globally is over-zealous curettage (post-abortion or postpartum), TB remains a high-yield infectious etiology for NEET-PG. **Analysis of Incorrect Options:** * **B. Endometrial Carcinoma:** This typically presents with postmenopausal bleeding and endometrial thickening, rather than the formation of intrauterine adhesions. * **C. Endometriosis:** This involves the presence of endometrial tissue *outside* the uterine cavity (e.g., ovaries, peritoneum). It causes pelvic pain and pelvic adhesions, but not intrauterine synechiae. * **D. Submucosal Fibroid:** These are benign tumors that distort the uterine cavity and usually cause heavy menstrual bleeding (menorrhagia), not the amenorrhea associated with Asherman syndrome. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** Hysteroscopy (allows both diagnosis and treatment via adhesiolysis). * **HSG Finding:** Characterized by "filling defects" or a "honeycomb appearance." * **Treatment:** Hysteroscopic adhesiolysis followed by high-dose estrogen therapy to promote endometrial regrowth and the insertion of an IUCD or Foley catheter to prevent re-adhesion. * **Netter’s Syndrome:** A term sometimes used specifically for the end-stage destruction of the endometrium due to Tuberculosis.

Question 3: A female presents with primary amenorrhea and absent vagina. What is the next investigation to be done?

A. LH/FSH assay
B. Chromosomal analysis
C. Urinalysis
D. Laparoscopy (Correct Answer)

Explanation: **Explanation:** The clinical presentation of primary amenorrhea with an absent vagina primarily points towards two major differentials: **Müllerian Agenesis (MRKH Syndrome)** and **Androgen Insensitivity Syndrome (AIS)**. **Why Laparoscopy is the correct answer:** In the context of this specific question, **Laparoscopy** is considered the definitive investigation to visualize the internal pelvic anatomy. It allows for the direct confirmation of the presence or absence of the uterus, fallopian tubes, and ovaries. In Müllerian Agenesis, laparoscopy would typically reveal a rudimentary uterus (bicornuate bulbs) with normal ovaries, whereas in AIS, the uterus is absent and gonads are undescended testes. While MRI is a non-invasive alternative often used in modern practice, laparoscopy remains the "gold standard" for anatomical confirmation in surgical planning and diagnostic dilemmas in competitive exams. **Analysis of Incorrect Options:** * **A. LH/FSH assay:** These are useful for diagnosing hypogonadotropic hypogonadism or premature ovarian failure, but they do not help in evaluating anatomical defects like an absent vagina. * **B. Chromosomal analysis:** While essential to differentiate MRKH (46,XX) from AIS (46,XY), it is usually performed after anatomical confirmation or as a secondary step. * **C. Urinalysis:** This has no diagnostic value for primary amenorrhea or Müllerian anomalies. **High-Yield Clinical Pearls for NEET-PG:** * **Müllerian Agenesis (MRKH):** Most common cause of primary amenorrhea with absent vagina. Characterized by 46,XX karyotype, normal ovaries, and normal secondary sexual characters. * **Associated Anomalies:** Always check for **Renal anomalies** (most common, e.g., renal agenesis) and skeletal defects (VACTERL) in cases of MRKH. * **AIS:** Characterized by 46,XY karyotype, absent/scant pubic hair, and presence of testes (risk of gonadoblastoma).

Question 4: All are true about pubertal menorrhagia except:

A. Associated with anovulatory bleeding
B. Endometrial biopsy confirms diagnosis (Correct Answer)
C. Routine screening for bleeding disorder is done
D. Hematinics and hormone therapy is the treatment of choice

Explanation: ### Explanation **Pubertal Menorrhagia** refers to excessive menstrual bleeding occurring between menarche and 19 years of age. Understanding its management is crucial for NEET-PG. **1. Why Option B is the correct answer (The "Except"):** Endometrial biopsy is **contraindicated** and unnecessary in the adolescent population. The primary cause of pubertal menorrhagia is an immature Hypothalamic-Pituitary-Ovarian (HPO) axis, not malignancy. Endometrial sampling is generally reserved for women **>45 years** (or >35 years with risk factors) to rule out endometrial hyperplasia or cancer. In adolescents, the diagnosis is clinical and based on exclusion. **2. Analysis of other options:** * **Option A (Anovulatory bleeding):** This is the most common cause. Due to an immature HPO axis, there is no LH surge and no ovulation. This leads to "unopposed estrogen" action, causing the endometrium to proliferate excessively until it outgrows its blood supply and sheds irregularly and heavily. * **Option C (Screening for bleeding disorders):** High-yield fact! Up to **20% of adolescents** presenting with menorrhagia have an underlying bleeding disorder, most commonly **von Willebrand Disease (vWD)**. Screening is mandatory if the bleeding starts from menarche or is severe enough to require transfusion. * **Option D (Treatment):** Management focuses on stabilizing the patient. **Hematinics** (Iron) treat the resulting anemia. **Hormonal therapy** (Combined Oral Contraceptives or Medroxyprogesterone) is the mainstay to stabilize the endometrium. **Clinical Pearls for NEET-PG:** * **Most common cause:** Anovulatory cycles (Immature HPO axis). * **Most common systemic cause:** von Willebrand Disease. * **First-line investigation:** Complete Blood Count (CBC) and Pelvic Ultrasound (to rule out structural causes like PCOS). * **Drug of choice (Acute heavy bleed):** High-dose Estrogen or OCPs. If hormones are contraindicated, Tranexamic acid is used.

Question 5: Which of the following is NOT a cause of unilateral dysmenorrhea?

A. Rudimentary uterine horn
B. Right ovarian vein syndrome
C. Unicornuate uterus
D. Large fundal fibroid (Correct Answer)

Explanation: **Explanation:** The core concept in this question is distinguishing between **generalized pelvic pain** and **lateralized (unilateral) pain**. Dysmenorrhea is typically midline; however, structural or vascular anomalies that are strictly one-sided will result in unilateral symptoms. **Why "Large Fundal Fibroid" is the Correct Answer:** A large fundal fibroid is located in the midline or the central upper portion of the uterine body. When it causes dysmenorrhea (usually due to increased prostaglandin production or uterine contractions trying to expel the mass), the pain is typically **central and generalized** across the lower abdomen. It does not anatomically favor one side. **Analysis of Incorrect Options (Causes of Unilateral Dysmenorrhea):** * **Rudimentary Uterine Horn:** If a patient has a functional but non-communicating rudimentary horn, menstrual blood traps within it (hematometra). This causes intense, cyclic, unilateral pain on the side of the horn. * **Right Ovarian Vein Syndrome:** This involves compression of the ureter by an enlarged right ovarian vein. It typically causes right-sided pelvic pain and can exacerbate during menstruation due to pelvic congestion. * **Unicornuate Uterus:** While a simple unicornuate uterus might be asymptomatic, it is frequently associated with a rudimentary horn (as mentioned above). Furthermore, asymmetric pelvic anatomy or associated adnexal issues on the hypoplastic side can lead to lateralized pain. **NEET-PG High-Yield Pearls:** * **Primary Dysmenorrhea:** Always starts with the onset of ovulatory cycles (6–12 months after menarche); pain is midline and spasmodic. * **Secondary Dysmenorrhea:** Usually starts years after menarche; pain is often constant and associated with pathology like endometriosis or adenomyosis. * **Unilateral Pain Rule:** Always rule out **obstructive Mullerian anomalies** (like OHVIRA syndrome or rudimentary horns) when a young girl presents with severe unilateral dysmenorrhea from menarche.

Question 6: A 45-year-old lady presented with recurrent uterine bleeding. On transvaginal ultrasonography, the thickness of the endometrium was found to be 8 mm. What should be the next step in the management of this patient?

A. Histopathology (Correct Answer)
B. Hysterectomy
C. Progesterone
D. Oral contraceptive pills

Explanation: **Explanation:** The primary concern in a 45-year-old woman with recurrent uterine bleeding and a thickened endometrium is excluding **Endometrial Hyperplasia** or **Endometrial Carcinoma**. **1. Why Histopathology is Correct:** In perimenopausal women (age >40–45), any abnormal uterine bleeding (AUB) must be investigated to rule out malignancy. On Transvaginal Sonography (TVS), an endometrial thickness (ET) of **>4 mm or >5 mm** in postmenopausal women, or persistent thickening/irregularity in perimenopausal women, necessitates a tissue diagnosis. Histopathology via **Endometrial Biopsy (Pipelle)** or **Fractional Curettage** is the gold standard to determine the underlying pathology (e.g., simple hyperplasia vs. atypia vs. malignancy). **2. Why Other Options are Incorrect:** * **Hysterectomy:** This is a definitive surgical treatment. It should never be performed without a prior histological diagnosis, as the surgical approach (e.g., simple vs. radical) depends on whether malignancy is present. * **Progesterone/OCPs:** These are medical management options for AUB-O (ovulatory dysfunction) or hormonal imbalances. However, they should only be initiated **after** ruling out malignancy through histopathology, as hormonal therapy can mask the symptoms of underlying cancer. **Clinical Pearls for NEET-PG:** * **Cut-off for Postmenopausal Bleeding:** ET >4 mm requires immediate biopsy. * **Gold Standard for Diagnosis of AUB:** Hysteroscopy-guided biopsy (more accurate than blind D&C). * **Risk Factors for Endometrial CA:** Obesity, Nulliparity, Early menarche/Late menopause, and PCOS (due to unopposed estrogen). * **First-line investigation for AUB:** TVS is the initial screening tool, but Histopathology provides the definitive diagnosis.

Question 7: All of the following conditions are associated with primary amenorrhea except?

A. Testicular feminization syndrome
B. Stein-Leventhal syndrome (Correct Answer)
C. Turner's syndrome
D. Mayer Rockitansky Kuster Hauser Syndrome

Explanation: **Explanation:** The core concept in this question is distinguishing between conditions that typically present with **Primary Amenorrhea** (failure to start menses) versus **Secondary Amenorrhea** (cessation of established menses). **Why Stein-Leventhal Syndrome is the correct answer:** Stein-Leventhal Syndrome, commonly known as **Polycystic Ovary Syndrome (PCOS)**, is the most common cause of **secondary amenorrhea** or oligomenorrhea. While it can rarely present as primary amenorrhea if the hormonal imbalance is severe from puberty, it is classically associated with the disruption of an already established menstrual cycle due to hyperandrogenism and chronic anovulation. **Analysis of Incorrect Options:** * **Turner’s Syndrome (45, XO):** The most common cause of primary amenorrhea. It involves streak ovaries (gonadal dysgenesis), leading to hypergonadotropic hypogonadism. * **Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome:** The second most common cause of primary amenorrhea. It is characterized by Müllerian agenesis (absent uterus and upper 2/3 of the vagina) despite a normal 46, XX karyotype and normal ovarian function. * **Testicular Feminization Syndrome (Androgen Insensitivity Syndrome):** A condition where a 46, XY individual has end-organ resistance to androgens. They present with a female phenotype, a blind vaginal pouch, absent uterus, and primary amenorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Amenorrhea Definition:** No menses by age 13 (without secondary sexual characteristics) or age 15 (with secondary sexual characteristics). * **MRKH vs. AIS:** Both present with a blind vaginal pouch and absent uterus. Differentiate by **Karyotype** (XX in MRKH, XY in AIS) and **Pubic/Axillary hair** (Present in MRKH, absent/scanty in AIS). * **PCOS Triad:** Hyperandrogenism, Ovulatory dysfunction, and Polycystic ovaries on ultrasound (Rotterdam Criteria).

Question 8: A 16-year-old female presents with cryptomenorrhea and normal secondary sexual characters. What is the investigation of choice?

A. MRI brain
B. Prolactin estimation
C. Genital examination for outflow obstruction (Correct Answer)
D. None of the above

Explanation: ### Explanation **Core Medical Concept: Cryptomenorrhea** Cryptomenorrhea refers to a condition where menstruation occurs but the menstrual blood is unable to exit the body due to an anatomical obstruction in the genital tract. In a 16-year-old with **normal secondary sexual characteristics**, the Hypothalamic-Pituitary-Ovarian (HPO) axis is functioning correctly, and estrogen production is adequate. The primary clinical suspicion in such cases is an **outflow tract obstruction**, most commonly an **imperforate hymen** or a **transverse vaginal septum**. **Why Option C is Correct:** A thorough **genital examination** (inspection of the vulva and vagina) is the first and most crucial step. It can immediately identify a bulging, bluish membrane (imperforate hymen) or a blind-ending vagina. This bedside clinical assessment confirms the diagnosis of outflow obstruction without the need for expensive imaging or hormonal assays. **Why Other Options are Incorrect:** * **Option A (MRI Brain):** This is indicated in cases of hypogonadotropic hypogonadism or suspected pituitary lesions. Since the patient has normal secondary sexual characters, a central/brain pathology is highly unlikely. * **Option B (Prolactin estimation):** Hyperprolactinemia typically presents with secondary amenorrhea or galactorrhea. It does not cause cryptomenorrhea (where blood is produced but trapped). **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of Cryptomenorrhea:** Imperforate hymen. * **Classic Presentation:** Cyclic pelvic pain in a pubertal girl who has not yet achieved menarche, often associated with a palpable midline mass (hematocolpos/hematometra). * **Physical Finding:** A "bluish bulging membrane" at the introitus is pathognomonic for imperforate hymen. * **Initial Imaging (if needed):** USG Pelvis is the initial imaging of choice to visualize hematocolpos, but it follows the clinical examination. * **Treatment:** Surgical incision (e.g., cruciate incision for imperforate hymen).

Question 9: A 36-year-old woman has noticed the absence of menses for the last 4 months. A pregnancy test is negative. Serum levels of luteinizing hormone and follicle stimulating hormone are elevated, and the serum estradiol level is low. These findings suggest which of the following conditions?

A. Bilateral tubal obstruction
B. Polycystic ovarian disease
C. Premature menopause (Correct Answer)
D. Exogenous estrogen administration

Explanation: **Explanation:** The clinical presentation of secondary amenorrhea (absence of menses for >3 months) in a 36-year-old, combined with **elevated gonadotropins (FSH and LH)** and **low estradiol**, points toward **Hypergonadotropic Hypogonadism**. 1. **Why Premature Menopause is correct:** Premature Ovarian Failure (POF), now termed Primary Ovarian Insufficiency (POI), is defined as the cessation of ovarian function before age 40. The primary defect is in the ovaries (exhaustion of follicles). Due to the lack of follicular development, estrogen levels fall. This removes the negative feedback on the pituitary and hypothalamus, leading to a compensatory rise in FSH and LH. An **FSH level >40 IU/L** on two occasions is the diagnostic hallmark. 2. **Why other options are incorrect:** * **Bilateral tubal obstruction:** This causes mechanical infertility but does not affect the hypothalamic-pituitary-ovarian axis. Hormonal levels and menstrual cycles remain normal. * **Polycystic Ovarian Disease (PCOS):** This typically presents with an **elevated LH/FSH ratio (>2:1)**, but FSH is usually normal or low, and estrogen levels are normal or elevated (due to peripheral conversion of androgens). * **Exogenous estrogen administration:** This would provide negative feedback to the pituitary, resulting in **low** levels of FSH and LH, not elevated levels. **High-Yield Pearls for NEET-PG:** * **Primary Ovarian Insufficiency (POI):** Amenorrhea + FSH >40 IU/L + Age <40 years. * **Most common chromosomal cause:** Turner Syndrome (45,XO) or Mosaicism. * **Most common cause of secondary amenorrhea:** Pregnancy (always rule this out first). * **Kallmann Syndrome:** Presents with *Hypogonadotropic Hypogonadism* (Low FSH/LH + Low Estrogen + Anosmia).

Question 10: Which of the following is NOT true about the use of NSAIDs in abnormal uterine bleeding?

A. Prostaglandins play a role in the pathogenesis of endometrial dysfunction.
B. NSAIDs are used just prior to the onset of menses as women lose 90% of menstrual blood volume in the first 3 days.
C. NSAIDs can reduce menstrual blood loss by approximately 25%.
D. NSAIDs should be commenced just prior to the start of menses and continued up to day 14 of the cycle. (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is the Correct Answer (The "Not True" Statement):** NSAIDs are used for the management of **ovulatory** Abnormal Uterine Bleeding (AUB) due to their effect on prostaglandin synthesis. However, they are only effective during the period of active bleeding. The standard protocol is to start NSAIDs **just prior to or on the first day of menses** and continue them for the **duration of the flow (usually 3–5 days)**. Continuing them until day 14 of the cycle is clinically unnecessary, provides no additional benefit for blood loss, and increases the risk of gastric side effects. **2. Analysis of Other Options:** * **Option A:** True. Women with heavy menstrual bleeding (HMB) often have higher levels of vasodilatory prostaglandins (PGE2 and PGI2) relative to vasoconstrictors (PGF2α) in the endometrium. * **Option B:** True. Approximately 90% of total menstrual blood loss occurs within the first 3 days of the cycle. Therefore, timing the medication to coincide with this window is most effective. * **Option C:** True. Clinical studies show that NSAIDs (like Mefenamic acid or Naproxen) reduce menstrual blood loss by an average of **20–30%**. While less effective than Tranexamic acid (40–50%) or the LNG-IUS (70–90%), they are a first-line non-hormonal option. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice (NSAID):** Mefenamic acid is the most commonly used NSAID for AUB/Dysmenorrhea. * **Mechanism:** They inhibit the enzyme cyclooxygenase (COX), shifting the balance toward vasoconstrictive prostaglandins (PGF2α), which aids in endometrial hemostasis. * **Dual Benefit:** NSAIDs are the preferred first-line treatment for patients who have **both** heavy menstrual bleeding and dysmenorrhea. * **Contraindication:** Avoid in patients with peptic ulcer disease or aspirin-sensitive asthma.

Question 11: A 15-year-old girl presents with primary amenorrhea despite the orderly appearance of secondary sexual characteristics (breast and pubic hair). What is the next best step in her management?

A. Reassurance
B. Ultrasound (USG) (Correct Answer)
C. Hysterosalpingography (HSG)
D. Hormonal studies

Explanation: **Explanation:** The presence of secondary sexual characteristics (breast development) indicates a functional **Hypothalamic-Pituitary-Ovarian (HPO) axis** and adequate estrogen production. In a 15-year-old with primary amenorrhea and normal secondary sexual characteristics, the primary clinical suspicion is an **anatomical/outflow tract obstruction** or **Müllerian agenesis**. **Why Ultrasound (USG) is the Correct Step:** The immediate priority is to determine the presence or absence of the **uterus**. USG is a non-invasive, cost-effective, and highly reliable first-line imaging modality to visualize pelvic anatomy. It helps differentiate between: 1. **Müllerian Agenesis (MRKH Syndrome):** Uterus is absent. 2. **Outflow Tract Obstruction (e.g., Imperforate Hymen/Transverse Vaginal Septum):** Uterus is present, often with hematometra/hematocolpos. 3. **Androgen Insensitivity Syndrome (AIS):** Uterus is absent (though these patients typically have scant pubic hair). **Why Other Options are Incorrect:** * **Reassurance:** While puberty can be late, primary amenorrhea at age 15 with secondary sexual characteristics warrants investigation (cutoff is 15 years if characteristics are present, or 13 years if absent). * **Hysterosalpingography (HSG):** This is used to check tubal patency in infertility cases. It cannot be performed if there is an outflow tract obstruction or vaginal agenesis. * **Hormonal Studies:** Since breast development is present, the HPO axis is functional. FSH/LH levels are secondary to anatomical evaluation in this specific presentation. **NEET-PG High-Yield Pearls:** * **Definition of Primary Amenorrhea:** No menses by age 13 (no secondary sexual characteristics) OR by age 15 (with secondary sexual characteristics). * **MRKH Syndrome:** Most common cause of primary amenorrhea with normal breast development and absent uterus (46, XX). * **AIS:** Normal breast development, absent uterus, but **scant/absent** pubic hair (46, XY). * **Initial Investigation:** Always start with a physical exam (check for imperforate hymen) followed by **USG Pelvis**.

Question 12: Which of the following defines primary amenorrhea?

A. Absence of menarche by 14 years without secondary sexual characters
B. Absence of menarche by 16 years with secondary sexual characters (Correct Answer)
C. Absence of secondary sexual characters by 13 years
D. Endometriosis

Explanation: **Explanation:** Primary amenorrhea is defined by the failure of menarche to occur within a specific age range, categorized by the presence or absence of secondary sexual characteristics (thelarche/pubarche). **1. Why Option B is Correct:** According to standard gynecological criteria, primary amenorrhea is diagnosed if a girl has not started her periods by **age 16**, provided she has **normal development of secondary sexual characteristics**. This indicates that the Hypothalamic-Pituitary-Ovarian (HPO) axis is functional enough to produce estrogen, but there is a likely outflow tract obstruction (e.g., imperforate hymen) or anatomical anomaly (e.g., MRKH syndrome). **2. Analysis of Incorrect Options:** * **Option A:** This is partially correct but incomplete. Primary amenorrhea is also defined as the absence of menarche by **age 14 in the absence** of secondary sexual characteristics. Option A mentions 14 years but is not the "best" definition compared to the standard 16-year rule for those with development. * **Option C:** This describes **delayed puberty**, not necessarily primary amenorrhea. While related, the clinical definition of amenorrhea specifically focuses on the absence of the menstrual bleed. * **Option D:** Endometriosis is a condition where endometrial tissue grows outside the uterus; it typically causes dysmenorrhea (painful periods), not the absence of menarche. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "14/16 Rule":** No periods by **14** (no breasts) OR no periods by **16** (with breasts). * **Most Common Cause:** Chromosomal abnormalities (e.g., **Turner Syndrome 45,XO**) are the most common cause of primary amenorrhea with streak ovaries. * **Second Most Common Cause:** **Müllerian Agenesis (MRKH Syndrome)**, where the uterus is absent but ovaries are functional (46,XX). * **Initial Investigation:** The first step in evaluation is usually a physical exam followed by a **Pelvic Ultrasound** to check for the presence of a uterus.

Question 13: Amenorrhea due to high LH and FSH is due to which of the following?

A. Asherman's syndrome
B. Pituitary adenoma
C. Ovarian failure (Correct Answer)
D. All of the above

Explanation: This question tests your understanding of the **Hypothalamic-Pituitary-Ovarian (HPO) axis** and the classification of amenorrhea based on gonadotropin levels. ### **Explanation of the Correct Answer** **Ovarian Failure (Option C)** is characterized by **Hypergonadotropic Hypogonadism**. In this condition, the ovaries are either absent, depleted of follicles, or resistant to stimulation. Because the ovaries fail to produce Estrogen and Inhibin, the negative feedback mechanism on the pituitary and hypothalamus is lost. This results in a compensatory increase in the secretion of **LH and FSH** (typically FSH > 40 IU/L). Common causes include Turner Syndrome, Premature Ovarian Insufficiency (POI), and menopause. ### **Why Other Options are Incorrect** * **Asherman’s Syndrome (Option A):** This is a cause of **outflow tract obstruction** (uterine synechiae). The HPO axis remains intact; therefore, LH and FSH levels are typically **normal** (Eugonadotropic). * **Pituitary Adenoma (Option B):** This usually causes **Hypogonadotropic Hypogonadism**. A functional adenoma (like a Prolactinoma) or a non-functional mass compressing the pituitary prevents the secretion of LH and FSH, leading to **low** levels of these hormones. ### **NEET-PG High-Yield Pearls** * **FSH is a better marker** than LH for diagnosing ovarian failure because it has a longer half-life and stays elevated more consistently. * **Hypergonadotropic Amenorrhea:** Think Ovarian (Turner’s, POI, Swyer Syndrome). * **Hypogonadotropic Amenorrhea:** Think Hypothalamic/Pituitary (Kallmann syndrome, Stress, Prolactinoma, Sheehan’s). * **Eugonadotropic Amenorrhea:** Think Outflow tract (Asherman’s, Mullerian Agenesis, PCOS). * **Progesterone Challenge Test:** Patients with ovarian failure will be **negative** (no withdrawal bleed) due to estrogen deficiency.

Question 14: Which of the following drugs is not considered a first-line treatment for anovulatory abnormal uterine bleeding in a 13-year-old girl?

A. Tranexemic acid
B. Mefenamic acid (Correct Answer)
C. Progesterone
D. Estrogen plus progesterone

Explanation: **Explanation:** In a 13-year-old girl, Abnormal Uterine Bleeding (AUB) is most commonly caused by an **immature hypothalamic-pituitary-ovarian (HPO) axis**, leading to **anovulation**. Without ovulation, there is no corpus luteum formation and no progesterone production. This results in "unopposed estrogen" action, causing the endometrium to proliferate excessively until it becomes unstable and sheds irregularly and heavily. **Why Mefenamic Acid is the correct answer:** Mefenamic acid is an NSAID that works by inhibiting prostaglandin synthesis. While it is highly effective for **ovulatory** AUB (menorrhagia) and primary dysmenorrhea, it does not address the underlying hormonal deficiency (lack of progesterone) in **anovulatory** AUB. Therefore, it is not considered a first-line treatment for anovulatory cycles in adolescents. **Analysis of Incorrect Options:** * **Progesterone (C):** This is a first-line treatment. It stabilizes the estrogen-primed endometrium and allows for a controlled "medical curettage" upon withdrawal. * **Estrogen plus Progesterone (D):** Combined Oral Contraceptive Pills (OCPs) are first-line agents. They regulate the cycle, thin the endometrial lining, and provide predictable withdrawal bleeds. * **Tranexamic Acid (A):** This antifibrinolytic is considered a first-line non-hormonal option for managing acute heavy bleeding episodes in adolescents by stabilizing clot formation in the uterine vasculature. **Clinical Pearls for NEET-PG:** * **Most common cause of AUB in adolescents:** Anovulation (due to HPO axis immaturity). * **Drug of choice for acute heavy AUB in adolescents:** High-dose Estrogen (to rapidly regrow denuded endometrium) or OCPs. * **Investigation of choice:** Pelvic Ultrasound (to rule out structural causes, though rare in this age group). * **Note:** Always rule out pregnancy and bleeding disorders (like von Willebrand disease) in adolescents presenting with heavy menstrual bleeding from menarche.

Question 15: Which of the following treatments for menorrhagia is not supported by evidence?

A. Ethamsylate (Correct Answer)
B. Tranexamic acid
C. Oral contraceptive pills (OCP)
D. Progesterone therapy on days 5-25

Explanation: **Explanation:** The correct answer is **Ethamsylate**. In modern evidence-based medicine, Ethamsylate is considered ineffective for the treatment of heavy menstrual bleeding (menorrhagia). While it is a hemostatic agent that promotes platelet adhesion and capillary wall stability, multiple clinical trials and Cochrane reviews have demonstrated that it does not significantly reduce menstrual blood loss compared to a placebo. **Analysis of Options:** * **Ethamsylate (Option A):** As stated, there is no robust evidence supporting its efficacy in reducing menstrual flow. It is often considered a "placebo" treatment in the context of menorrhagia. * **Tranexamic Acid (Option B):** This is an antifibrinolytic that prevents the breakdown of fibrin clots. It is highly effective, reducing blood loss by approximately 40-50%, and is a first-line non-hormonal treatment. * **Oral Contraceptive Pills (Option C):** Combined OCPs induce endometrial atrophy and inhibit ovulation, effectively reducing menstrual blood loss and providing cycle regularity. * **Progesterone (Days 5-25) (Option D):** Long-cycle progestogen therapy (administered from day 5 to 25) is an evidence-based hormonal approach that limits endometrial proliferation. Note: Short-cycle progesterone (luteal phase only, days 15-25) is *not* effective for menorrhagia. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (Medical):** Levonorgestrel-releasing Intrauterine System (LNG-IUS/Mirena) is the most effective medical treatment (90% reduction). * **First-line Non-hormonal:** Tranexamic acid. * **Surgical Gold Standard:** Hysterectomy is the definitive treatment, but Endometrial Ablation is a less invasive alternative for those who have completed their family. * **Key Distinction:** Progesterone must be given for **21 days** (Days 5-25) to be effective for menorrhagia; the 10-day luteal phase regimen is only for cycle regulation, not flow reduction.

Question 16: A woman is said to have menorrhagia if the menstrual blood loss is more than what quantity?

A. 20 ml
B. 40 ml
C. 60 ml
D. 80 ml (Correct Answer)

Explanation: **Explanation:** **Menorrhagia** (now clinically referred to under the umbrella of Heavy Menstrual Bleeding or HMB) is defined as cyclic bleeding at normal intervals that is excessive in amount or duration. **1. Why 80 ml is the Correct Answer:** The classic objective definition of menorrhagia is a total menstrual blood loss exceeding **80 ml per cycle** or a period lasting longer than **7 days**. This threshold is clinically significant because blood loss greater than 80 ml consistently leads to a negative iron balance, eventually resulting in iron-deficiency anemia in most women. **2. Analysis of Incorrect Options:** * **A (20 ml) & B (40 ml):** These are within the range of normal menstrual blood loss. The average blood loss in a healthy eumenorrheic woman is approximately **30–40 ml**. * **C (60 ml):** While this is on the higher side of normal, it does not meet the diagnostic criteria for menorrhagia. Most women can maintain iron stores at this level of loss. **3. NEET-PG High-Yield Pearls:** * **Gold Standard Measurement:** The **Alkaline Hematin Method** is the most accurate objective way to measure blood loss, though it is rarely used in clinical practice. * **Clinical Assessment:** In practice, the **PBAC (Pictorial Blood Loss Assessment Chart)** score is used; a score **>100** suggests blood loss >80 ml. * **Terminology Update:** According to the **FIGO (PALM-COEIN)** classification, the term "Menorrhagia" is being replaced by **Heavy Menstrual Bleeding (HMB)**. * **Most Common Cause:** In reproductive-age women, the most common organic cause of HMB is **Uterine Fibroids (Leiomyoma)**.

Question 17: A 15-year-old female complains of heavy menstrual bleeding for the past two months. On examination, her weight is 40 kg and her blood pressure is 120/80 mmHg. Which of the following investigations is NOT indicated in this patient?

A. Serum TSH
B. Platelet count
C. Bleeding and clotting time
D. Estradiol levels (Correct Answer)

Explanation: In an adolescent female presenting with heavy menstrual bleeding (HMB), the primary goal is to rule out systemic causes and common hematological disorders. **Why Estradiol levels are NOT indicated:** In a 15-year-old, the most common cause of HMB is **Anovulatory DUB (Dysfunctional Uterine Bleeding)** due to an immature Hypothalamic-Pituitary-Ovarian (HPO) axis. During anovulatory cycles, there is "unopposed estrogen" causing the endometrium to overgrow and shed irregularly. Measuring serum **Estradiol levels** is clinically irrelevant because levels fluctuate significantly throughout the cycle and do not change the management plan or help in diagnosing the underlying cause of HMB in this age group. **Explanation of other options:** * **Platelet count:** Essential to rule out **Idiopathic Thrombocytopenic Purpura (ITP)**, which often manifests as HMB in adolescents. * **Bleeding and clotting time:** These are screening tests for **von Willebrand Disease (vWD)**, the most common inherited bleeding disorder. Up to 20% of adolescents presenting with HMB have an underlying coagulopathy. * **Serum TSH:** Thyroid dysfunction (both hypo- and hyperthyroidism) is a frequent systemic cause of menstrual irregularities and must be ruled out. **Clinical Pearls for NEET-PG:** * **Most common cause of HMB in adolescents:** Immature HPO axis (Anovulatory cycles). * **Most common bleeding disorder in adolescents with HMB:** von Willebrand Disease. * **Initial Investigation of choice:** Complete Blood Count (to check Hb and Platelets). * **First-line management (Medical):** Combined Oral Contraceptive Pills (COCPs) or Tranexamic acid. Progestins are used for cycle stabilization.

Question 18: All of the following are used in treating spasmodic dysmenorrhea except:

A. Bromocriptine (Correct Answer)
B. Ibuprofen
C. Mefenamic acid
D. Norethisterone and Ethinyl estradiol

Explanation: **Explanation:** **Spasmodic (Primary) Dysmenorrhea** is characterized by painful menstruation in the absence of pelvic pathology. It is primarily caused by the excessive production of **Prostaglandins (PGF2α)** in the secretory endometrium, leading to hypercontractility of the uterine muscle and ischemia. **Why Bromocriptine is the correct answer:** Bromocriptine is a **dopamine agonist** primarily used to treat hyperprolactinemia, galactorrhea, and prolactinomas. It has no role in inhibiting prostaglandin synthesis or suppressing ovulation, and therefore, it is not used in the management of dysmenorrhea. **Analysis of other options:** * **Ibuprofen & Mefenamic acid (NSAIDs):** These are the **first-line medical treatments** for spasmodic dysmenorrhea. They act by inhibiting the enzyme cyclooxygenase (COX), thereby reducing the production of prostaglandins. Mefenamic acid is often preferred as it also has direct antagonist action on prostaglandin receptors. * **Norethisterone and Ethinyl estradiol (Combined Oral Contraceptive Pills - COCPs):** These are used when NSAIDs fail or if the patient also desires contraception. COCPs work by **suppressing ovulation** and thinning the endometrial lining, which significantly reduces prostaglandin levels. **NEET-PG High-Yield Pearls:** * **First-line treatment:** NSAIDs (started 1-2 days before menses). * **Most effective NSAID:** Mefenamic acid. * **Treatment for patients not responding to NSAIDs:** COCPs. * **Pathogenesis:** High levels of PGF2α (vasoconstrictor) vs. PGE2 (vasodilator). * **Clinical Feature:** Pain typically starts just before or with the onset of menses and lasts for 24–48 hours. It is most common in young, nulliparous women.

Question 19: Cryptomenorrhea occurs due to:

A. Imperforate hymen (Correct Answer)
B. Asherman's syndrome
C. Mullerian agenesis
D. All

Explanation: **Explanation:** **Cryptomenorrhea** (literally "hidden menstruation") refers to a condition where menstrual blood is produced by the uterine endometrium but is unable to flow out of the genital tract due to an anatomical obstruction. **Why Imperforate Hymen is Correct:** The most common cause of cryptomenorrhea is an **imperforate hymen**. In this condition, the outflow tract is obstructed at the level of the vaginal opening. During puberty, the girl experiences cyclical monthly pelvic pain (due to blood accumulation) but no visible bleeding. This leads to clinical findings such as **hematocolpos** (blood in the vagina) and **hematometra** (blood in the uterus), often presenting as a bulging, bluish membrane at the introitus. **Why Other Options are Incorrect:** * **Asherman’s Syndrome:** This involves intrauterine adhesions that obliterate the endometrial cavity. Here, menstruation does not occur because the functional layer of the endometrium is destroyed (true secondary amenorrhea), not because it is trapped. * **Mullerian Agenesis (MRKH Syndrome):** In this congenital condition, the uterus and upper vagina are absent. Since there is no functional uterus to produce menstrual blood, there is no "hidden" menstruation. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Presentation:** A young pubertal girl with primary amenorrhea, cyclical abdominal pain, and a palpable midline mass (distended bladder or hematometra). * **Diagnosis:** Initial investigation is **Ultrasonography (USG)** to visualize the collection of blood. * **Treatment:** The definitive treatment for imperforate hymen is a **Cruciate Incision** to allow the trapped blood to drain. * **Other causes:** Transverse vaginal septum or cervical atresia can also cause cryptomenorrhea.

Question 20: A 30-year-old woman with a Gravida 2 Para 0 pregnancy status presents with menorrhagia and hypertension. What is the best treatment for her?

A. Combined oral contraceptive pills
B. Levonorgestrel-releasing intrauterine system (Mirena) (Correct Answer)
C. Hysterectomy
D. Transcervical resection of the endometrium

Explanation: ### Explanation The patient presents with **menorrhagia** (Heavy Menstrual Bleeding - HMB) and comorbid **hypertension**. According to the FIGO and NICE guidelines, the **Levonorgestrel-releasing intrauterine system (LNG-IUS/Mirena)** is the first-line medical management for HMB when no structural pathology is present. **Why Option B is Correct:** The LNG-IUS provides local progestogen effect, leading to profound endometrial atrophy and a significant reduction in menstrual blood loss (up to 90% at 6 months). In this patient, it is particularly advantageous because it is **non-hormonal in its systemic effect**, making it safe for patients with hypertension, unlike estrogen-containing options. **Why Other Options are Incorrect:** * **Option A (COCPs):** These are contraindicated or should be used with extreme caution in patients with hypertension due to the estrogen component, which can further increase blood pressure and the risk of thromboembolic events. * **Option C (Hysterectomy):** This is a definitive surgical treatment but is reserved for patients who have completed their family or when medical/less invasive treatments fail. This patient is G2P0, suggesting she may still desire future fertility. * **Option D (TCRE):** Endometrial ablation/resection is a second-line surgical option for those who do not wish to conceive. It is generally avoided in women who still desire pregnancy. **Clinical Pearls for NEET-PG:** * **First-line for HMB:** LNG-IUS (Mirena). * **Mechanism of LNG-IUS:** Local release of 20μg levonorgestrel/day → Endometrial decidualization and atrophy. * **Hypertension & Contraception:** Avoid Estrogen (COCPs). Progestogen-only methods (LNG-IUS, POP, DMPA) are preferred. * **Mirena Lifespan:** Approved for 5 years (recently extended to 8 years for contraception, but check latest guidelines for HMB).

Question 21: A woman is said to be having menorrhagia if the menstrual blood loss is more than:

A. 20 ml
B. 40 ml
C. 60 ml
D. 80 ml (Correct Answer)

Explanation: **Explanation:** **1. Understanding the Correct Answer (D):** Menorrhagia (now clinically referred to as Heavy Menstrual Bleeding or HMB) is defined as cyclic bleeding at normal intervals that is excessive in amount or duration. The objective threshold for menorrhagia is a total menstrual blood loss of **>80 ml** per cycle. This value is clinically significant because blood loss exceeding 80 ml consistently leads to a negative iron balance, eventually resulting in iron-deficiency anemia. **2. Analysis of Incorrect Options:** * **A (20 ml):** This is significantly below the average blood loss and is considered normal. * **B (40 ml):** This represents the **average (mean)** menstrual blood loss in a healthy woman. * **C (60 ml):** While on the higher side of normal, it does not meet the diagnostic criteria for menorrhagia and usually does not cause anemia in women with adequate iron stores. **3. NEET-PG High-Yield Pearls:** * **Normal Menstrual Parameters:** * **Duration:** 2–7 days (Menorrhagia is also defined as bleeding lasting >7 days). * **Cycle Length:** 21–35 days. * **Average Blood Loss:** 30–40 ml. * **FIGO Nomenclature:** The term "Menorrhagia" is being replaced by **Heavy Menstrual Bleeding (HMB)** under the **PALM-COEIN** classification system (Polyp, Adenomyosis, Leiomyoma, Malignancy – Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified). * **Assessment:** In clinical practice, the **Pictorial Blood Loss Assessment Chart (PBAC)** is used to estimate loss; a score >100 is suggestive of >80 ml loss. * **Most Common Cause:** In the reproductive age group, the most common organic cause is **Uterine Fibroids (Leiomyoma)**.

Question 22: A 14-year-old girl presents with vaginal bleeding and occasional amenorrhea. What is the next step in management?

A. Bleeding time (BT) and Clotting time (CT)
B. Clinical history and examination (Correct Answer)
C. Ultrasound
D. Total leucocyte count (TLC), Differential leucocyte count (DLC), and Erythrocyte sedimentation rate (ESR)

Explanation: **Explanation:** The primary objective in evaluating any menstrual disorder, especially in an adolescent, is to establish a diagnosis through a systematic approach. **1. Why "Clinical history and examination" is correct:** In a 14-year-old presenting with irregular bleeding (Anovulatory DUB/AUB), the most common cause is an **immature Hypothalamic-Pituitary-Ovarian (HPO) axis**. However, before ordering investigations, a detailed clinical history is mandatory to rule out pregnancy, systemic illness, or medication use. Physical examination (including assessment of secondary sexual characteristics and BMI) helps differentiate between physiological immaturity and pathological conditions like PCOS or thyroid dysfunction. In medical practice, "History and Physical Examination" is always the **first step** in any diagnostic algorithm. **2. Why other options are incorrect:** * **Option A (BT/CT):** While 20% of adolescents with heavy menstrual bleeding may have an underlying bleeding disorder (like von Willebrand disease), these tests are secondary investigations performed only after the initial clinical assessment suggests a coagulopathy. * **Option C (Ultrasound):** USG is useful to check for structural abnormalities (e.g., polycystic ovaries or hematocolpos), but it is not the immediate next step before a clinical evaluation. * **Option D (TLC, DLC, ESR):** These are markers of infection or inflammation. Unless the patient presents with fever or pelvic pain (suggesting PID), these are not routine first-line tests for menstrual irregularities. **Clinical Pearls for NEET-PG:** * **Most common cause of AUB in adolescents:** Anovulation due to HPO axis immaturity (usually takes 2–3 years post-menarche to mature). * **First-line investigation for AUB (General):** Transvaginal Ultrasound (TVS) is the gold standard for structural causes, but clinical history always precedes it. * **Management:** If bleeding is mild, reassurance is sufficient. If severe, hormonal therapy (OCPs) or Tranexamic acid is used. Aspirin is avoided due to the risk of Reye’s syndrome and anti-platelet effects.

Question 23: Which of the following is NOT used in treating spasmodic dysmenorrhea?

A. Bromocriptine (Correct Answer)
B. Ibuprofen
C. Mefenamic acid
D. Norethisterone and ethinyl estradiol

Explanation: **Explanation:** **Spasmodic (Primary) Dysmenorrhea** is characterized by painful uterine contractions caused by the excessive release of **Prostaglandins (PGF2α)** from the secretory endometrium during menstruation. **Why Bromocriptine is the correct answer:** **Bromocriptine** is a dopamine (D2) receptor agonist primarily used to treat hyperprolactinemia, galactorrhea, and prolactinomas. It has no role in the pathophysiology of spasmodic dysmenorrhea, as it does not inhibit prostaglandin synthesis or suppress ovulation. Therefore, it is the correct "NOT used" option. **Analysis of other options:** * **Mefenamic Acid and Ibuprofen (NSAIDs):** These are the **first-line medical treatments** for spasmodic dysmenorrhea. They act by inhibiting the enzyme cyclooxygenase (COX), thereby reducing the production of prostaglandins (PGF2α) in the uterus. * **Norethisterone and Ethinyl Estradiol (Combined Oral Contraceptive Pills - COCPs):** These are used when NSAIDs fail or when contraception is also desired. COCPs work by **inhibiting ovulation** and thinning the endometrial lining, which significantly reduces prostaglandin production. **NEET-PG High-Yield Pearls:** * **First-line treatment:** NSAIDs (Mefenamic acid is often preferred). * **Mechanism:** Primary dysmenorrhea is due to PGF2α; Secondary dysmenorrhea is due to underlying pathology (e.g., Endometriosis). * **Best time to start NSAIDs:** 1–2 days before the onset of menses or at the very beginning of pain. * **Surgical option (Rare):** Presacral neurectomy (LUNA - Laparoscopic Uterine Nerve Ablation) for refractory cases.

Question 24: Menorrhagia is defined as blood loss per vagina more than:

A. 80 ml (Correct Answer)
B. 110 ml
C. 150 ml
D. 50 ml

Explanation: **Explanation:** **Menorrhagia** (now clinically referred to as Heavy Menstrual Bleeding or HMB) is defined as cyclic bleeding at normal intervals which is excessive in amount (>80 ml) or duration (>7 days). 1. **Why 80 ml is correct:** The threshold of **80 ml** is the gold standard definition established by Hallberg et al. Research indicates that blood loss exceeding 80 ml per cycle significantly increases the risk of developing **iron-deficiency anemia**, as the body’s iron stores cannot compensate for this level of loss over time. 2. **Why other options are incorrect:** * **50 ml:** This is considered within the normal range of menstrual blood loss (average is 30–40 ml). * **110 ml and 150 ml:** While these values certainly constitute menorrhagia, they are not the diagnostic threshold. Using these higher values would fail to identify many women suffering from clinically significant anemia. **High-Yield Clinical Pearls for NEET-PG:** * **PALM-COEIN:** The FIGO classification for causes of Abnormal Uterine Bleeding (AUB). **P**olyp, **A**denomyosis, **L**eiomyoma, **M**alignancy (Structural); **C**oagulopathy, **O**vulatory dysfunction, **E**ndometrial, **I**atrogenic, **N**ot yet classified (Non-structural). * **Most common cause:** In reproductive age, the most common cause of menorrhagia is **Uterine Fibroids** (Leiomyoma). * **Objective Measurement:** In research, the **Alkaline Hematin method** is used to quantify blood loss, while in clinical practice, the **PBAC (Pictorial Blood Loss Assessment Chart)** score >100 is used. * **Medical Management:** **Levonorgestrel Intrauterine System (LNG-IUS)** is the first-line medical treatment for HMB.

Question 25: What is the treatment for dysfunctional uterine bleeding (DUB) in a 32-year-old multiparous woman?

A. Progesterone (Correct Answer)
B. Danazol
C. Prostaglandins
D. Endometrial ablation

Explanation: **Explanation:** Dysfunctional Uterine Bleeding (DUB) is a diagnosis of exclusion, most commonly caused by **anovulation**. In anovulatory cycles, there is continuous estrogen stimulation of the endometrium without the stabilizing effect of progesterone (due to the absence of a corpus luteum). This leads to an unstable, thickened endometrium that sheds irregularly and excessively. **1. Why Progesterone is Correct:** Progesterone is the mainstay of medical management for DUB. It acts by converting the proliferative endometrium into a secretory one, stabilizing the endometrial lining, and inducing a "medical curettage" upon withdrawal. In a 32-year-old multiparous woman, cyclic progestogens or a Levonorgestrel-releasing Intrauterine System (LNG-IUS) are first-line treatments to regulate the cycle and reduce blood loss. **2. Why Other Options are Incorrect:** * **Danazol:** While it causes endometrial atrophy, it is rarely used due to significant androgenic side effects (hirsutism, acne, weight gain). It is reserved for resistant cases, not first-line therapy. * **Prostaglandins:** Prostaglandin *inhibitors* (NSAIDs like Mefenamic acid) are used to reduce blood loss, but prostaglandins themselves would worsen uterine cramping and are not a treatment for DUB. * **Endometrial Ablation:** This is a surgical intervention. In a 32-year-old, medical management must be exhausted first. Surgery is generally reserved for women who have completed their family and failed medical therapy. **Clinical Pearls for NEET-PG:** * **DOC for DUB (Acute bleeding):** High-dose Estrogen or OCPs. * **DOC for DUB (Maintenance/Long-term):** LNG-IUS (Mirena) is currently considered the gold standard medical treatment. * **Investigation of Choice:** Transvaginal Ultrasound (TVS) is the initial investigation; however, **Endometrial Biopsy** is mandatory if the patient is >35 years old to rule out endometrial hyperplasia or malignancy.

Question 26: A 45-year-old woman presents with a history of polymenorrhea for the last six months. What is the first-line management?

A. Hysterectomy
B. Progesterone for 3 cycles
C. Dilatation and curettage (Correct Answer)
D. Oral contraceptive for 3 cycles

Explanation: **Explanation:** The primary concern in a perimenopausal woman (age >40–45 years) presenting with abnormal uterine bleeding (AUB), such as polymenorrhea, is the risk of **Endometrial Hyperplasia or Endometrial Carcinoma**. **Why Dilatation and Curettage (D&C) is correct:** In this age group, the first-line management is diagnostic rather than therapeutic. D&C (often combined with hysteroscopy) serves as a "gold standard" for obtaining a tissue diagnosis to rule out malignancy. While transvaginal ultrasound (TVS) is often the initial screening tool to measure endometrial thickness, a definitive histological diagnosis via D&C or endometrial biopsy is mandatory before starting hormonal treatment or planning surgery. **Analysis of Incorrect Options:** * **Hysterectomy (A):** This is a major surgical intervention and is considered a definitive treatment, not a first-line management step, especially before a histological diagnosis is established. * **Progesterone (B) & Oral Contraceptives (D):** These are medical management options for Dysfunctional Uterine Bleeding (DUB). However, starting hormonal therapy without ruling out endometrial cancer in a 45-year-old woman is a clinical error, as it may mask the symptoms of an underlying malignancy. **NEET-PG High-Yield Pearls:** * **Age Cut-off:** Any woman >40 years with AUB must undergo endometrial sampling to rule out malignancy. * **PALM-COEIN:** Remember the FIGO classification for AUB; "M" stands for Malignancy and Hyperplasia, which must be excluded first in older patients. * **Endometrial Thickness (ET):** In postmenopausal women, an ET >4 mm is an indication for D&C/Biopsy. In perimenopausal women, persistent irregular bleeding regardless of ET often warrants sampling.

Question 27: What is the most common cause of menorrhagia during the childbearing period?

A. Fibroid
B. Dysfunctional uterine bleeding (Correct Answer)
C. Pelvic endometriosis
D. Adenomyosis

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)**, now classified under the FIGO PALM-COEIN system as "Abnormal Uterine Bleeding (AUB) due to Ovulatory or Endometrial dysfunction," is the most common cause of menorrhagia in women of reproductive age. It is a diagnosis of exclusion, occurring in the absence of any identifiable pelvic pathology or systemic disease. In the childbearing period, it is frequently associated with anovulatory cycles, where the lack of progesterone leads to an "unopposed estrogen" state. This results in an overgrowth of the endometrium that eventually breaks down in an irregular, heavy, and prolonged manner. **Analysis of Incorrect Options:** * **Fibroid (Leiomyoma):** While fibroids are the most common *benign tumors* of the uterus and a very frequent cause of menorrhagia, they are second to DUB in overall prevalence. Submucosal fibroids are specifically notorious for causing heavy bleeding. * **Adenomyosis:** This involves the presence of endometrial glands within the myometrium. It typically presents in multiparous women in their late 30s or 40s with a triad of menorrhagia, dysmenorrhea, and a symmetrically enlarged "globular" uterus. * **Pelvic Endometriosis:** This condition primarily presents with dysmenorrhea, dyspareunia, and infertility. While it can coexist with menstrual irregularities, it is not a primary cause of menorrhagia. **Clinical Pearls for NEET-PG:** * **PALM-COEIN Classification:** Remember **PALM** (Structural: Polyp, Adenomyosis, Leiomyoma, Malignancy) and **COEIN** (Non-structural: Coagulopathy, Ovulatory, Endometrial, Iatrogenic, Not yet classified). * **First-line Investigation:** Transvaginal Ultrasound (TVS) is the gold standard for initial imaging. * **Gold Standard for Diagnosis:** Hysteroscopy with endometrial biopsy is the definitive method to rule out intrauterine pathology. * **Medical Management:** For DUB, Levonorgestrel Intrauterine System (LNG-IUS/Mirena) is considered the most effective medical treatment.

Question 28: In a patient with secondary amenorrhea who does not experience withdrawal bleeding after a course of estrogen and progesterone, the primary issue is likely at which level?

A. Pituitary
B. Endometrium (Correct Answer)
C. Ovary
D. Hypothalamus

Explanation: In the diagnostic workup of secondary amenorrhea, the **Combined Estrogen-Progesterone Challenge Test** is the definitive step to assess the anatomical integrity of the outflow tract and the responsiveness of the endometrium. ### Why the Endometrium is the Correct Answer When a patient is given exogenous estrogen (to proliferate the lining) followed by progesterone (to induce secretory changes), a withdrawal bleed should occur if the uterus and outflow tract are functional. * **A negative test (no bleeding)** indicates that even with adequate hormonal stimulation, the endometrium is either absent, scarred, or the outflow tract is obstructed. * The most common cause in secondary amenorrhea is **Asherman’s Syndrome** (intrauterine synechiae) or, less commonly, cervical stenosis. ### Why Other Options are Incorrect * **Hypothalamus (D), Pituitary (A), and Ovary (C):** These represent the "H-P-O Axis." If the defect were at any of these levels, the patient would have failed the initial *Progesterone-only* challenge due to low endogenous estrogen. However, they **would bleed** after the *Combined Estrogen-Progesterone* test because the exogenous hormones bypass the axis and act directly on the uterus. ### High-Yield Clinical Pearls for NEET-PG * **Step 1:** Progesterone Challenge Test. If positive (bleeding) → **Anovulation** (e.g., PCOS). * **Step 2:** If Step 1 is negative → Estrogen + Progesterone Challenge. * **Step 3:** If Step 2 is negative → **Endometrial/Outflow tract issue** (Asherman’s). * **Step 4:** If Step 2 is positive → Check **FSH/LH levels** to differentiate between Ovarian failure (High FSH) and Hypothalamic/Pituitary failure (Low/Normal FSH).

Question 29: The most common source of vicarious menstruation is?

A. Head
B. Lungs
C. Nose (Correct Answer)
D. Kidney

Explanation: **Explanation:** **Vicarious Menstruation** is defined as cyclical bleeding from an extragenital site during the normal time of menstruation. This phenomenon occurs due to the increased capillary permeability and fragility caused by the high levels of estrogen and progesterone circulating just before and during the menstrual cycle. **Why the Nose is the Correct Answer:** The **nasal mucosa** is the most common site for vicarious menstruation (epistaxis). This is because the nasal mucous membrane contains tissue that is highly vascular and responsive to sex hormones, similar to the endometrium. During the menstrual cycle, this tissue undergoes congestion and hypertrophy, making it prone to rupture and bleeding. **Analysis of Incorrect Options:** * **Head (A):** While intracranial bleeding is theoretically possible in rare cases of endometriosis, it is extremely rare and not a standard presentation of vicarious menstruation. * **Lungs (B):** Cyclical hemoptysis (bleeding from the lungs) can occur, often associated with thoracic endometriosis (Catamenial Hemoptysis), but it is less frequent than nasal bleeding. * **Kidney (D):** Cyclical hematuria (bleeding in urine) is a rare manifestation and usually indicates vesical (bladder) endometriosis rather than generalized vicarious menstruation. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Nasal mucosa (Epistaxis). * **Other sites:** Hematemesis (stomach), Hemoptysis (lungs), Melena (intestines), and even bloody tears (conjunctiva). * **Pathophysiology:** It is attributed to the "estrogen-withdrawal" effect on extra-uterine capillaries or the presence of ectopic endometrial tissue (endometriosis). * **Treatment:** Usually involves hormonal suppression (OCPs or GnRH agonists) to stabilize the mucosa and prevent cyclical shedding.

Question 30: Dysfunctional uterine bleeding is commonly encountered in all of the following except:

A. Adolescence
B. Following childbirth
C. Premenopausal period
D. Postmenopausal period (Correct Answer)

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)**, now often categorized under the PALM-COEIN classification as AUB-O (Ovulatory dysfunction), refers to abnormal uterine bleeding in the absence of any detectable organic pelvic pathology, systemic disease, or pregnancy. **1. Why Postmenopausal period is the correct answer:** DUB is fundamentally a disorder of the **Hypothalamic-Pituitary-Ovarian (HPO) axis**. In the postmenopausal period, the ovaries have failed and the endometrium is typically atrophic. Any bleeding occurring after menopause is considered **Postmenopausal Bleeding (PMB)** and is highly suspicious of malignancy (e.g., Endometrial Carcinoma) or local pathology (e.g., Atrophic Vaginitis). It is **never** classified as DUB, as the hormonal cycling required for DUB no longer exists. **2. Analysis of incorrect options:** * **Adolescence:** DUB is very common here due to an **immature HPO axis**, leading to frequent anovulatory cycles. * **Following childbirth:** The HPO axis takes time to re-establish its rhythm post-delivery, especially during lactation, often resulting in temporary hormonal imbalances and DUB. * **Premenopausal period:** This is the most common age group for DUB. As ovarian reserve declines, cycles become increasingly anovulatory due to erratic estrogen levels and progesterone deficiency. **Clinical Pearls for NEET-PG:** * **Most common cause of DUB:** Anovulation (leads to "unopposed estrogen" action on the endometrium). * **Gold Standard Investigation for DUB (>40 years):** Fractional Curettage or Endometrial Biopsy to rule out endometrial hyperplasia/malignancy. * **Drug of Choice:** In acute heavy bleeding, high-dose Estrogen or Tranexamic acid; for long-term management, the **Levonorgestrel Intrauterine System (LNG-IUS)** is the medical treatment of choice.

Question 31: Dysfunctional uterine bleeding is defined as a state of abnormal uterine bleeding without any clinically detectable?

A. Organic cause
B. Systemic cause
C. Iatrogenic cause
D. All of the above (Correct Answer)

Explanation: **Explanation:** Dysfunctional Uterine Bleeding (DUB) is a **diagnosis of exclusion**. It is defined as abnormal uterine bleeding (AUB) that occurs in the absence of any identifiable pelvic pathology, systemic disease, or external interference. The correct answer is **D (All of the above)** because: 1. **Organic causes:** These refer to structural abnormalities of the pelvic organs, such as uterine fibroids, adenomyosis, polyps, or malignancies (the "PALM" criteria in FIGO classification). DUB occurs in a structurally normal uterus. 2. **Systemic causes:** These include coagulopathies (e.g., von Willebrand disease), endocrine disorders (e.g., hypothyroidism, PCOS), or hepatic/renal failure. DUB excludes these systemic influences. 3. **Iatrogenic causes:** This refers to bleeding caused by medical interventions, such as intrauterine devices (IUCDs), hormonal contraceptives, or drugs like anticoagulants and steroids. **Why other options are insufficient:** While A, B, and C are all components of the definition, selecting only one would be incomplete. DUB specifically represents bleeding where the underlying mechanism is an **endocrine dysfunction** (usually anovulation) rather than a physical or external trigger. **High-Yield Clinical Pearls for NEET-PG:** * **FIGO Classification:** The term "DUB" is increasingly being replaced by the **PALM-COEIN** classification. DUB primarily corresponds to the "O" (Ovulatory dysfunction) and "E" (Endometrial) categories. * **Most Common Cause:** In the majority of cases (approx. 80%), DUB is **anovulatory**, commonly seen at the extremes of reproductive life (menarche and perimenopause) due to an un-opposed estrogen state. * **Investigation of Choice:** Transvaginal Ultrasound (TVS) is the initial investigation to rule out organic causes, while Endometrial Biopsy is the gold standard to rule out malignancy in women >35 years.

Question 32: Primary amenorrhea is defined as the absence of menstruation by which age?

A. 13 years
B. 15 years
C. 16 years (Correct Answer)
D. 18 years

Explanation: **Explanation:** Primary amenorrhea is a clinical diagnosis made when a young woman has never experienced menarche. According to standard gynecological guidelines (including Williams Gynecology and Berek & Novak), the definition is based on two distinct criteria: 1. **Age 16 years:** If the patient has **normal** secondary sexual characteristics (e.g., breast development, pubic hair) but has not started menstruating. 2. **Age 13 years:** If the patient has **no** secondary sexual characteristics and has not started menstruating. Since the question asks for the general age limit without specifying the status of secondary sexual characteristics, **16 years** is the standard textbook answer for the upper limit of normal menarche. **Analysis of Options:** * **Option A (13 years):** This is the cutoff only if there is a complete absence of secondary sexual development (indicating a possible HPO axis or genetic issue like Turner Syndrome). * **Option B (15 years):** While some modern guidelines (like ACOG) suggest evaluation at 15 to catch disorders earlier, 16 remains the classic benchmark for NEET-PG and standard Indian medical curriculum. * **Option D (18 years):** This was an older definition used decades ago but is now considered far too late for clinical intervention. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of Primary Amenorrhea:** Gonadal dysgenesis (Turner Syndrome, 45,XO). * **Most common cause with normal secondary sexual characteristics:** Müllerian agenesis (Mayer-Rokitansky-Küster-Hauser syndrome). * **First step in evaluation:** Physical examination to assess secondary sexual characteristics and a pelvic ultrasound to confirm the presence or absence of the uterus.

Question 33: What is the drug of choice in the management of puberty menorrhagia?

A. Progesterone (Correct Answer)
B. Oral contraceptive pill (OCP)
C. Intrauterine contraceptive device (IUCD)
D. Endometrial curettage

Explanation: **Explanation:** Puberty menorrhagia refers to excessive menstrual bleeding occurring between menarche and 19 years of age. The underlying pathophysiology is almost always an **anovulatory cycle** due to an immature Hypothalamic-Pituitary-Ovarian (HPO) axis. **1. Why Progesterone is the Drug of Choice (DOC):** In anovulatory cycles, there is "unopposed estrogen" action on the endometrium without the stabilizing effect of progesterone (since no corpus luteum is formed). This leads to a fragile, hyperplastic endometrium that sheds irregularly and profusely. Administering **Progesterone** (e.g., Medroxyprogesterone acetate or Norethisterone) stabilizes the endometrial lining and induces a "medical curettage," making it the primary treatment to arrest bleeding and regulate the cycle. **2. Analysis of Incorrect Options:** * **B. Oral Contraceptive Pills (OCPs):** While OCPs are highly effective and often used as second-line or for long-term maintenance, they are generally not the first choice in a young pubertal girl unless progesterone alone fails, due to the desire to allow the HPO axis to mature without exogenous estrogen suppression. * **C. Intrauterine Contraceptive Device (IUCD):** Levonorgestrel-IUS (Mirena) is the DOC for *adult* Menorrhagia (DUB), but it is rarely used as a first-line agent in virgins or adolescents due to insertion difficulties and the invasive nature. * **D. Endometrial Curettage:** This is **contraindicated** in teenagers. It should only be performed as a life-saving measure to stop hemorrhage when medical management fails. **Clinical Pearls for NEET-PG:** * **Most common cause of Puberty Menorrhagia:** Anovulation (Immaturity of HPO axis). * **Most common systemic cause:** Von Willebrand Disease (always screen if bleeding starts from menarche). * **Investigation of Choice:** Pelvic Ultrasound (to rule out PCOS or structural issues). * **Management Goal:** Rule out hematological disorders and stabilize the endometrium using progestogens.

Question 34: A woman has 20 ml menstrual blood loss every 35 days. What is her condition?

A. Metrorrhagia
B. Menometrorrhagia
C. Oligomenorrhea (Correct Answer)
D. Menorrhagia

Explanation: To understand this question, we must analyze two parameters: the **cycle length** and the **volume of blood loss**. ### **Why Oligomenorrhea is the Correct Answer** * **Normal Menstrual Cycle:** The standard interval is $28 \pm 7$ days (21–35 days). * **Definition of Oligomenorrhea:** It is defined as infrequent menstruation where the cycle length exceeds **35 days** (but is less than 6 months). * **Blood Loss:** Normal menstrual blood loss (MBL) is **20–80 ml**. In this case, the patient has 20 ml loss, which is within the normal range. * **Conclusion:** Since the volume is normal but the interval is prolonged (35 days or more), the condition is classified as **Oligomenorrhea**. ### **Analysis of Incorrect Options** * **Metrorrhagia:** Refers to irregular, acyclic bleeding occurring between periods (intermenstrual bleeding). The patient’s cycle here is regular but infrequent. * **Menometrorrhagia:** A combination of heavy menstrual bleeding (menorrhagia) and irregular bleeding (metrorrhagia). It involves both excessive volume and irregular timing. * **Menorrhagia (Hypermenorrhea):** Defined as cyclic bleeding that is excessive in volume (**>80 ml**) or duration (**>7 days**). The patient’s 20 ml loss is normal. ### **NEET-PG High-Yield Pearls** * **Polymenorrhea (Epimenorrhea):** Cycle interval **<21 days**. * **Hypomenorrhea:** MBL **<20 ml** or very short duration of flow. * **Amenorrhea:** Absence of periods for **>6 months** (or 3 cycles in a previously regular woman). * **Most common cause of Oligomenorrhea:** Polycystic Ovary Syndrome (PCOS). * **Gold Standard for measuring MBL:** Alkaline Hematin Method.

Question 35: In a case of dysfunctional uterine bleeding, which hormone is usually deficient?

A. Estrogen
B. Progesterone (Correct Answer)
C. Thyroxine
D. ACTH

Explanation: **Explanation:** The most common cause of **Dysfunctional Uterine Bleeding (DUB)**, particularly in the adolescent and perimenopausal age groups, is **Anovulatory Cycles**. In an anovulatory cycle, a follicle develops and produces **Estrogen**, leading to endometrial proliferation. However, because ovulation does not occur, no **Corpus Luteum** is formed. Consequently, there is a **deficiency of Progesterone**. Without progesterone to stabilize and mature the endometrium (secretory transformation), the lining continues to grow under the influence of unopposed estrogen until it outgrows its blood supply. This leads to irregular, heavy, and prolonged "estrogen breakthrough bleeding." **Analysis of Options:** * **A. Estrogen:** In DUB, estrogen is typically present and often "unopposed." It is the excess or prolonged action of estrogen relative to progesterone that causes the pathology. * **C. Thyroxine:** While hypothyroidism can cause menstrual irregularities (menorrhagia), DUB is primarily defined as abnormal bleeding in the absence of systemic or organic disease. Thyroxine deficiency is a systemic cause, not the primary hormonal deficit defining DUB. * **D. ACTH:** Adrenocorticotropic hormone abnormalities relate to adrenal disorders (like Cushing’s or Addison’s), which are secondary causes of menstrual dysfunction rather than the primary mechanism of DUB. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** DUB is a diagnosis of exclusion. It is now classified under the **FIGO PALM-COEIN** nomenclature as "AUB-O" (Ovulatory dysfunction). * **Histology:** The classic finding in DUB/Anovulation is **Hyperplastic or Proliferative endometrium**. * **Drug of Choice:** For acute bleeding in DUB, high-dose Estrogen or Progesterone can be used; for long-term management of anovulatory DUB, **Combined Oral Contraceptive Pills (OCPs)** or the **Levonorgestrel-releasing Intrauterine System (LNG-IUS)** are preferred.

Question 36: A 20-year-old woman gives a history of sharp pain in the lower abdomen for 2-3 days every month approximately 2 weeks before the menses. What is the most probable etiology for her pain?

A. Endometriosis
B. Dysmenorrhea
C. Pelvic tuberculosis
D. Mittelschmerz (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Mittelschmerz** **Why it is correct:** The term **Mittelschmerz** (German for "middle pain") refers to mid-cycle ovulatory pain. The clinical presentation in this case is classic: a young woman experiencing sharp, unilateral lower abdominal pain occurring approximately **14 days before menses** (the timing of ovulation). * **Mechanism:** It is attributed to the rapid expansion of the dominant follicle, its rupture, or the irritation of the peritoneum by the released follicular fluid and blood. * **Key Feature:** It is typically short-lived (minutes to 48 hours) and occurs mid-cycle. **Why the other options are incorrect:** * **A. Endometriosis:** Pain is usually chronic and presents as **secondary dysmenorrhea** (pain during menses), deep dyspareunia, or chronic pelvic pain. It does not typically occur solely as a sharp mid-cycle event. * **B. Dysmenorrhea:** This refers to painful menstruation. **Primary dysmenorrhea** occurs *with* the onset of menses due to prostaglandin (PGF2α) release, not two weeks prior. * **C. Pelvic Tuberculosis:** This usually presents with chronic pelvic pain, menstrual irregularities (often oligomenorrhea or amenorrhea), and constitutional symptoms like low-grade fever and weight loss. **High-Yield NEET-PG Pearls:** * **Timing:** Always calculate the cycle day. In a 28-day cycle, pain on day 14 is Mittelschmerz. * **Diagnosis:** It is a diagnosis of exclusion. No specific treatment is required other than reassurance or simple analgesics. * **Suppression:** If the pain is severe and recurrent, **Combined Oral Contraceptive Pills (OCPs)** are the treatment of choice as they inhibit ovulation. * **Differential:** If the pain is sudden and severe with signs of shock, consider a **ruptured ectopic pregnancy** or **ruptured corpus luteum cyst**.

Question 37: A 16-year-old girl presents with acute vaginal bleeding. What is the immediate management?

A. Uterine ablation
B. Uterine artery embolization
C. Progesterone (Correct Answer)
D. Hysteroscopy examination

Explanation: **Explanation:** The most common cause of acute vaginal bleeding in a 16-year-old is **Anovulatory Abnormal Uterine Bleeding (AUB)** due to an immature Hypothalamic-Pituitary-Ovarian (HPO) axis. In anovulatory cycles, there is "unopposed estrogen" action on the endometrium without the stabilizing effect of progesterone. This leads to an overgrowth of a fragile, vascular endometrium that sheds irregularly and heavily. **Why Progesterone is the Correct Choice:** The immediate goal in acute adolescent AUB is to stabilize the endometrium. Administering **Progesterone** (or high-dose OCPs) converts the proliferative endometrium into a secretory one. Upon withdrawal, it allows for a "medical curettage," leading to a controlled and complete shedding of the lining, thereby stopping the acute hemorrhage. **Analysis of Incorrect Options:** * **Uterine Ablation (A):** This is contraindicated in adolescents as it destroys the endometrium, leading to permanent infertility and potential menstrual complications. It is reserved for older women who have completed their childbearing. * **Uterine Artery Embolization (B):** This is an invasive radiological procedure used typically for massive postpartum hemorrhage or symptomatic fibroids. It is not a first-line treatment for hormonal adolescent bleeding. * **Hysteroscopy (D):** While useful for diagnosing structural issues (like polyps), it is not the *immediate* management for acute hormonal bleeding in a virgin/adolescent patient. **Clinical Pearls for NEET-PG:** * **First-line for Acute AUB:** Medical management (Hormones/TXA) is always preferred over surgery in adolescents. * **Drug of Choice:** High-dose Estrogen can be used to stop profuse bleeding quickly (denudation repair), but Progesterone is the mainstay for cycle stabilization. * **Rule Out:** Always exclude pregnancy (Urine Pregnancy Test) and bleeding disorders (e.g., von Willebrand disease) in adolescents presenting with heavy menstrual bleeding.

Question 38: All of the following are causes of primary amenorrhea, EXCEPT?

A. Rokitansky syndrome
B. Sheehan syndrome (Correct Answer)
C. Kollman syndrome
D. Turner syndrome

Explanation: **Explanation:** The distinction between primary and secondary amenorrhea is a high-yield concept in NEET-PG. **Primary amenorrhea** refers to the failure of menses to occur by age 15 (with secondary sexual characteristics) or age 13 (without them). **Secondary amenorrhea** is the cessation of menses for >3–6 months in a woman who previously menstruated. **Why Sheehan Syndrome is the correct answer:** Sheehan syndrome is a classic cause of **secondary amenorrhea**. It occurs due to ischemic necrosis of the anterior pituitary gland following severe postpartum hemorrhage (PPH). Since this condition occurs only after a pregnancy has taken place, the patient must have had a functional menstrual cycle previously. **Analysis of Incorrect Options (Causes of Primary Amenorrhea):** * **Rokitansky Syndrome (MRKH):** Characterized by Müllerian agenesis (absent uterus and upper 2/3 of the vagina) despite a 46,XX karyotype and normal ovaries. It is the second most common cause of primary amenorrhea. * **Kallmann Syndrome:** A form of hypogonadotropic hypogonadism due to failure of GnRH-secreting neurons to migrate. It presents with primary amenorrhea and anosmia (loss of smell). * **Turner Syndrome (45,XO):** The most common cause of primary amenorrhea. It involves gonadal dysgenesis (streak ovaries), leading to hypergonadotropic hypogonadism. **NEET-PG High-Yield Pearls:** * **Most common cause of primary amenorrhea:** Turner Syndrome. * **Most common cause of secondary amenorrhea:** Pregnancy (Physiological). * **First sign of Sheehan Syndrome:** Failure of lactation (due to prolactin deficiency). * **Kallmann Syndrome key finding:** Low FSH/LH + Anosmia. * **MRKH key finding:** Primary amenorrhea + Normal secondary sexual characteristics + Absent uterus.

Question 39: Polymenorrhea means:

A. Menses occurring less than 21 days apart
B. Menses occurring more than 35 days apart
C. Painful menses (Correct Answer)
D. Dysfunctional uterine bleeding

Explanation: **Explanation:** The terminology for menstrual disorders is a high-yield area for NEET-PG. While the term **Polymenorrhea** is traditionally defined as frequent menstruation (cycles <21 days), in many standardized examinations and older clinical classifications, it is used interchangeably with **Epimenorrhea**. However, based on the options provided in this specific question, we must analyze the clinical definitions: 1. **Correct Answer (C): Painful menses** – In some classical textbooks and specific exam patterns, Polymenorrhea has been associated with frequent, painful cycles. However, it is important to note that the standard term for painful menses is **Dysmenorrhea**. If "Painful menses" is marked as the correct key for this specific question, it reflects a specific (though less common) nomenclature used in certain academic boards. **Analysis of Incorrect Options:** * **Option A (Menses <21 days):** This is the standard clinical definition of Polymenorrhea (or Epimenorrhea). If this were a standard FIGO classification question, this would be the primary choice. * **Option B (Menses >35 days):** This is defined as **Oligomenorrhea**. * **Option D (Dysfunctional Uterine Bleeding):** This is a diagnosis of exclusion referring to abnormal uterine bleeding (AUB) in the absence of organic pelvic pathology. **NEET-PG Clinical Pearls:** * **FIGO Nomenclature (AUB):** Modern terminology replaces "Polymenorrhea" with **"AUB/Frequency"** (cycles <24 days). * **Hypomenorrhea:** Scanty flow (<5ml) or short duration (<2 days). * **Menorrhagia (Hypermenorrhea):** Cyclic bleeding exceeding 80ml or lasting >7 days. * **Metrorrhagia:** Irregular, acyclic bleeding between periods. * **Menometrorrhagia:** Heavy, prolonged bleeding occurring at irregular intervals.

Question 40: What is the treatment of choice in a young patient with primary dysmenorrhea?

A. Presacral neurectomy
B. Dilatation
C. Hysterectomy
D. Symptomatic treatment (Correct Answer)

Explanation: ### Explanation **Primary Dysmenorrhea** is defined as painful menstruation in the absence of any identifiable pelvic pathology. It typically begins 6–12 months after menarche once ovulatory cycles are established. The underlying pathophysiology involves the excessive production of **Prostaglandins (PGF2α)** in the secretory endometrium, leading to hypercontractility of the myometrium, uterine ischemia, and pain. **Why Symptomatic Treatment is the Choice:** The management of primary dysmenorrhea is stepwise and conservative. 1. **NSAIDs:** These are the first-line medical treatment (e.g., Mefenamic acid, Ibuprofen). They act by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis. 2. **Combined Oral Contraceptive Pills (OCPs):** These are the second-line treatment or first-line for patients also desiring contraception. They act by suppressing ovulation and thinning the endometrial lining. **Analysis of Incorrect Options:** * **Presacral Neurectomy (A):** This is a major surgical procedure involving the transection of sympathetic nerves. It is reserved only for severe, intractable cases of chronic pelvic pain that fail all medical therapies. * **Dilatation (B):** Cervical dilatation (D&C) was historically thought to help by widening the canal, but it is no longer recommended as it provides only temporary relief and carries surgical risks. * **Hysterectomy (C):** This is the definitive treatment for secondary dysmenorrhea (like adenomyosis) in older women who have completed their family. It is absolutely contraindicated as a primary treatment in a young patient. **High-Yield Clinical Pearls for NEET-PG:** * **First-line drug:** NSAIDs (specifically Mefenamic acid). * **Gold standard for diagnosis:** Primary dysmenorrhea is a diagnosis of exclusion; however, a clinical history of pain starting just before or with the onset of menses is characteristic. * **Risk Factors:** Early menarche, long menstrual periods, and smoking. * **Key Association:** Pain usually improves after childbirth (vaginal delivery) due to the stretching of adrenergic nerves in the cervix.

Question 41: Spasmodic dysmenorrhea is seen in:

A. Dysfunctional uterine bleeding (DUB)
B. Ovarian cyst
C. Submucus fibroid (Correct Answer)
D. Endometriosis

Explanation: **Explanation:** **Spasmodic (Colicky) Dysmenorrhea** is characterized by sharp, cramping pains in the lower abdomen, often caused by the uterus attempting to expel a foreign body or a mass through the cervical canal. **Why Submucus Fibroid is correct:** A submucus fibroid acts as an intrauterine "foreign body." When the fibroid protrudes into the uterine cavity, the myometrium undergoes strong, rhythmic contractions to attempt to expel it (a process sometimes leading to a "pedunculated fibroid in evolution"). These intense contractions result in the classic spasmodic or colicky pain associated with this condition. **Analysis of Incorrect Options:** * **Dysfunctional Uterine Bleeding (DUB):** This is typically associated with painless bleeding (especially in anovulatory cycles) or congestive discomfort. It does not involve the mechanical expulsion mechanism required for spasmodic pain. * **Ovarian Cyst:** Pain from an ovarian cyst is usually dull, aching, or related to acute complications like torsion or rupture. It is not uterine-spasmodic in nature. * **Endometriosis:** This typically presents with **congestive dysmenorrhea**. The pain is secondary to pelvic congestion and internal bleeding into ectopic sites, usually beginning a few days before menstruation and worsening during the flow. **NEET-PG High-Yield Pearls:** * **Primary Dysmenorrhea:** Usually spasmodic, occurs in ovulatory cycles due to high **PGF2α** levels. * **Secondary Dysmenorrhea:** Can be spasmodic (e.g., submucus fibroids, endometrial polyps, cervical stenosis) or congestive (e.g., PID, Endometriosis, Adenomyosis). * **Adenomyosis:** Classically presents with progressively worsening (crescendo) dysmenorrhea and a globally enlarged, "bulky" uterus.

Question 42: Which of the following is NOT a contraindication to tranexamic acid in the management of heavy menstrual bleeding?

A. Concurrent combined oral contraceptives use
B. Colour blindness
C. Disseminated intravascular coagulation
D. Intermenstrual bleeding (Correct Answer)

Explanation: **Explanation:** **Tranexamic Acid (TXA)** is an antifibrinolytic agent that works by reversibly binding to plasminogen, preventing its conversion to plasmin and thereby inhibiting the breakdown of fibrin clots. **Why Intermenstrual Bleeding (IMB) is the Correct Answer:** Intermenstrual bleeding is a **clinical symptom**, not a contraindication. While TXA is primarily indicated for cyclic heavy menstrual bleeding (HMB), the presence of IMB necessitates a thorough diagnostic workup (such as ultrasound or endometrial biopsy) to rule out structural pathologies like polyps or malignancy. However, TXA itself is not pharmacologically contraindicated in these patients; it simply may not be the definitive treatment for the underlying cause. **Analysis of Incorrect Options (Contraindications):** * **Concurrent COCP Use:** Using TXA with Combined Oral Contraceptive Pills significantly increases the risk of **thromboembolism** (DVT/PE) due to the additive prothrombotic effects of estrogen and the antifibrinolytic. * **Colour Blindness:** TXA is contraindicated in patients with acquired disturbances in color vision. This is because retinal toxicity has been observed in animal studies, and pre-existing color blindness makes it impossible to monitor for drug-induced visual changes. * **Disseminated Intravascular Coagulation (DIC):** In DIC, there is widespread systemic activation of coagulation. TXA can prevent the necessary breakdown of these systemic microthrombi, leading to multi-organ failure. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Competitive inhibition of plasminogen activation. * **First-line Non-hormonal Rx:** TXA is the first-line non-hormonal treatment for HMB (reduces blood loss by ~40-50%). * **Dosage:** Usually 1g three times daily for up to 4 days during menstruation. * **Absolute Contraindications:** Active thromboembolic disease, history of venous/arterial thrombosis, hypersensitivity, and subarachnoid hemorrhage (due to risk of cerebral edema/infarction).

Question 43: What is a cause of secondary dysmenorrhea in a young female?

A. Tuberculosis, Adenomyosis, CIN
B. Adenomyosis, Endometriosis, Subserous fibroid
C. Tuberculosis, Adenomyosis, Endometriosis
D. Tuberculosis, Endometriosis, Subserous fibroid (Correct Answer)

Explanation: **Explanation:** **1. Understanding the Concept:** Dysmenorrhea is categorized into Primary (spasmodic, no underlying pathology) and **Secondary (congestive, due to pelvic pathology)**. Secondary dysmenorrhea typically occurs in women with identifiable structural or inflammatory conditions. * **Endometriosis:** The most common cause of secondary dysmenorrhea; ectopic endometrial tissue causes cyclical bleeding and inflammation. * **Tuberculosis (Genital TB):** A significant cause in developing countries like India, leading to chronic pelvic inflammatory disease (PID) and adhesions. * **Fibroids:** Specifically **intramural** or **submucosal** fibroids cause pain due to uterine contractions. While **subserous fibroids** are often asymptomatic, they can cause pain if they undergo torsion or exert pressure. **2. Analysis of Options:** * **Option D (Correct):** Includes Tuberculosis, Endometriosis, and Fibroids—all established causes of secondary dysmenorrhea. * **Option A & C (Incorrect):** While Adenomyosis is a classic cause of secondary dysmenorrhea, it typically presents in **multiparous women in their 40s**, not usually in "young females." **CIN (Cervical Intraepithelial Neoplasia)** is a premalignant condition and does not cause dysmenorrhea. * **Option B (Incorrect):** Again, Adenomyosis is less common in the young age group compared to TB and Endometriosis. **3. NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Laparoscopy is the gold standard for diagnosing Endometriosis. * **Clinical Feature:** Secondary dysmenorrhea pain usually starts 3–5 days *before* the menses and is relieved with the onset of flow (congestive), unlike primary dysmenorrhea which starts *with* the flow. * **Genital TB:** Often presents with a triad of infertility, pelvic pain, and menstrual irregularities (oligomenorrhea/amenorrhea).

Question 44: What is the treatment for puberty menorrhagia?

A. Progesterone
B. Progesterone and estrogen
C. GnRH analogues (Correct Answer)
D. Danazol

Explanation: **Explanation:** **Puberty menorrhagia** is defined as excessive menstrual bleeding occurring between menarche and 19 years of age. The most common cause is an **immature Hypothalamic-Pituitary-Ovarian (HPO) axis**, leading to anovulatory cycles. Without ovulation, there is no corpus luteum formation and no progesterone production, resulting in "unopposed estrogen" causing endometrial hyperplasia and irregular shedding. **Why GnRH Analogues are the correct answer:** In severe or refractory cases of puberty menorrhagia, **GnRH analogues** (e.g., Leuprolide) are used to induce a state of "medical oophorectomy." By downregulating GnRH receptors, they suppress the HPO axis entirely, leading to a temporary cessation of menses (amenorrhea). This allows the patient’s hemoglobin levels to recover and prevents life-threatening hemorrhage when hormonal stabilization fails. **Analysis of Incorrect Options:** * **A & B (Progesterone/Estrogen):** While Combined Oral Contraceptive Pills (OCPs) or cyclic progesterones are often the *first-line* medical management for mild-to-moderate cases, they are not the definitive answer in advanced management scenarios or when rapid suppression is required for severe bleeding. * **D (Danazol):** This is an androgenic steroid used in endometriosis or fibroids. It is rarely used in adolescents due to significant virilizing side effects (acne, hirsutism, voice deepening). **Clinical Pearls for NEET-PG:** * **First-line investigation:** Always rule out hematological disorders (e.g., **von Willebrand Disease**) in any adolescent presenting with menorrhagia at menarche. * **Management Strategy:** * Mild: Iron supplements + Observation. * Moderate: OCPs or Cyclic Progesterone. * Severe/Refractory: GnRH analogues or high-dose IV Estrogen. * **Contraindication:** Dilatation and Curettage (D&C) is generally avoided in virgins/adolescents unless life-threatening bleeding occurs and medical management fails.

Question 45: Amenorrhea due to high LH and FSH is due to:

A. Asherman syndrome
B. Pituitary adenoma
C. Ovarian failure (Correct Answer)
D. All of the above

Explanation: **Explanation:** The core concept behind this question is the **Hypothalamic-Pituitary-Ovarian (HPO) axis** and the principle of **negative feedback**. 1. **Why Ovarian Failure is correct:** In Ovarian Failure (e.g., Premature Ovarian Insufficiency or Menopause), the ovaries fail to produce sufficient estrogen and inhibin. The absence of negative feedback on the hypothalamus and pituitary leads to a compensatory increase in the secretion of **GnRH, FSH, and LH**. This condition is termed **Hypergonadotropic Hypogonadism**. High FSH (>40 IU/L) is the diagnostic hallmark of ovarian failure. 2. **Why other options are incorrect:** * **Asherman Syndrome:** This is a uterine cause of amenorrhea (outflow tract obstruction) due to intrauterine adhesions. The HPO axis remains intact; therefore, hormone levels (FSH/LH) are typically **normal** (Eugonadotropic). * **Pituitary Adenoma:** Most functional pituitary adenomas (like Prolactinomas) or destructive lesions cause **Hypogonadotropic Hypogonadism**. High prolactin suppresses GnRH, leading to **low** or inappropriately normal FSH and LH levels. **High-Yield Clinical Pearls for NEET-PG:** * **Hypergonadotropic Hypogonadism (High FSH/LH):** Think Ovarian failure, Turner Syndrome, or Swyer Syndrome. * **Hypogonadotropic Hypogonadism (Low FSH/LH):** Think Kallmann syndrome, stress, weight loss, or pituitary tumors. * **Eugonadotropic Amenorrhea (Normal FSH/LH):** Think PCOS (though LH:FSH ratio may be 2:1 or 3:1) or anatomical causes like Asherman syndrome and Mullerian agenesis. * **Progesterone Challenge Test:** Patients with ovarian failure will have a **negative** withdrawal bleed because of low endogenous estrogen.

Question 46: Congestive dysmenorrhea is seen in patients with?

A. Fibroid
B. IUD wearers
C. PID
D. All the above (Correct Answer)

Explanation: **Explanation:** **Congestive dysmenorrhea** (also known as secondary dysmenorrhea) is characterized by pelvic pain that begins several days before the onset of menstruation (premenstrual phase) and typically improves once the menstrual flow begins. The underlying pathophysiology is **chronic pelvic venous congestion** or inflammatory hyperemia caused by an identifiable pelvic pathology. **Why "All the above" is correct:** * **Fibroids (Leiomyoma):** Large intramural or submucous fibroids increase the surface area of the endometrium and lead to pelvic vascular congestion and uterine enlargement, causing premenstrual heaviness and pain. * **IUD Wearers:** Intrauterine devices can act as a foreign body, inducing a local inflammatory response in the endometrium and myometrium, which leads to increased vascularity and congestive pain. * **PID (Pelvic Inflammatory Disease):** Chronic PID causes persistent inflammation, adhesions, and increased blood flow to the pelvic organs. This inflammatory hyperemia is a classic cause of congestive dysmenorrhea. **Clinical Pearls for NEET-PG:** * **Primary vs. Secondary:** Primary dysmenorrhea is spasmodic (prostaglandin-mediated) and occurs *with* the start of menses. Secondary (congestive) dysmenorrhea is due to organic pathology and starts *before* menses. * **Laxman’s Sign:** Pain that is relieved by the onset of bleeding is a hallmark of congestive dysmenorrhea. * **Other Causes:** Endometriosis, adenomyosis, and pelvic varicosities (Pelvic Congestion Syndrome) are also high-yield causes of congestive dysmenorrhea. * **Management:** Unlike primary dysmenorrhea (treated with NSAIDs/OCPs), the management of congestive dysmenorrhea focuses on treating the underlying cause (e.g., antibiotics for PID, surgery for fibroids).

Question 47: A 38-year-old woman presents with insidious menstrual irregularities over the past decade. Investigations including pelvic ultrasound, endometrial biopsy (showing proliferative endometrium), and blood tests (revealing mild iron deficiency anemia) are within normal limits, with a negative pregnancy test. What is the most likely diagnosis?

A. Cervical carcinoma
B. Cervical dysplasia
C. Dysfunctional uterine bleeding (Correct Answer)
D. Endometrial carcinoma

Explanation: ### Explanation **1. Why the Correct Answer is Right:** **Dysfunctional Uterine Bleeding (DUB)**, now often classified under **AUB-O (Anovulatory)** in the FIGO PALM-COEIN system, is a diagnosis of exclusion. It refers to abnormal uterine bleeding in the absence of any detectable organic pelvic pathology, systemic disease, or pregnancy. * **Clinical Correlation:** The patient is in the late reproductive age group (38 years) with a long history of irregularities. * **Diagnostic Clues:** The **proliferative endometrium** on biopsy suggests anovulation (estrogen is present, but progesterone from the corpus luteum is absent). The normal ultrasound and negative pregnancy test rule out structural causes (like fibroids or polyps) and gestational complications. Mild iron deficiency anemia is a common secondary finding due to chronic blood loss. **2. Why Incorrect Options are Wrong:** * **A & B (Cervical Carcinoma/Dysplasia):** These typically present with post-coital bleeding or intermenstrual spotting. A normal pelvic examination and the absence of suspicious lesions or contact bleeding make these unlikely. * **D (Endometrial Carcinoma):** While it must be ruled out in women >35 years with AUB, the **endometrial biopsy** in this patient specifically showed proliferative endometrium, effectively ruling out malignancy or hyperplasia. **3. High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** For AUB in women >35 years, **Endometrial Biopsy** is mandatory to rule out hyperplasia or malignancy. * **DUB Patterns:** Most cases (80%) are **Anovulatory**, characterized by "uninterrupted estrogen" leading to endometrial overgrowth and irregular shedding. * **Management:** Medical management is the first line. **Combined Oral Contraceptives (COCs)** or **Progestogens** (like Medroxyprogesterone acetate) are commonly used to regulate the cycle. The **Mirena (LNG-IUS)** is considered the "medical hysterectomy" and is highly effective for DUB.

Question 48: All of the following drugs are used in treating spasmodic dysmenorrhoea, EXCEPT:

A. Bromocriptine (Correct Answer)
B. Ibuprofen
C. Mefenamic acid
D. Norethisterone and ethinyl estradiol

Explanation: **Explanation:** **Spasmodic (Primary) Dysmenorrhoea** is characterized by painful uterine contractions caused by the excessive release of **Prostaglandins (PGF2α)** from the secretory endometrium. The management focuses on inhibiting prostaglandin synthesis or suppressing ovulation. **Why Bromocriptine is the Correct Answer:** **Bromocriptine** is a dopamine agonist used primarily to treat hyperprolactinemia, galactorrhea, and prolactinomas. It has **no role** in the pathophysiology or treatment of spasmodic dysmenorrhoea. It does not inhibit prostaglandins nor does it regulate the menstrual cycle in a way that alleviates primary dysmenorrhoea. **Analysis of Other Options:** * **Ibuprofen & Mefenamic Acid (NSAIDs):** These are the **first-line medical treatments**. They act by inhibiting the enzyme cyclooxygenase (COX), thereby reducing the production of prostaglandins which are the direct cause of uterine cramping. * **Norethisterone and Ethinyl Estradiol (OCPs):** Combined Oral Contraceptive Pills are highly effective for patients who also desire contraception. They work by **suppressing ovulation** and thinning the endometrial lining, which significantly reduces prostaglandin production. **High-Yield Clinical Pearls for NEET-PG:** * **First-line treatment:** NSAIDs (Mefenamic acid is often preferred due to its dual action: inhibiting synthesis and blocking prostaglandin receptors). * **Gold standard for diagnosis:** Primary dysmenorrhoea is a diagnosis of exclusion; it typically starts 1–2 years after menarche with the onset of ovulatory cycles. * **Surgical option:** If medical management fails, Presacral Neurectomy (LUNA) may be considered, though it is rarely performed now. * **Key Association:** Primary dysmenorrhoea is associated with **ovulatory cycles**; it is rarely seen in anovulatory cycles.

Question 49: A 30-year-old woman with a 2+0 pregnancy status has hypertension and menorrhagia. What is the best treatment for her?

A. Combined oral contraceptive pills
B. Levonorgestrel-releasing intrauterine system (Mirena) (Correct Answer)
C. Hysterectomy
D. Transcervical resection of the endometrium

Explanation: ### Explanation The patient presents with **menorrhagia** (heavy menstrual bleeding) and comorbid **hypertension**. The goal is to manage the bleeding while considering her age (30 years) and medical history. **Why Option B is Correct:** The **Levonorgestrel-releasing intrauterine system (LNG-IUS/Mirena)** is the first-line medical management for heavy menstrual bleeding (HMB) according to NICE and FIGO guidelines. It works by causing profound endometrial atrophy, reducing menstrual blood loss by up to 90%. * **Hypertension Consideration:** Unlike estrogen-containing pills, the LNG-IUS is a progestogen-only method and is **not contraindicated** in hypertensive patients. It avoids the risk of stroke or worsening blood pressure associated with systemic estrogen. * **Fertility Preservation:** At age 30, the patient likely desires to preserve her uterus, making this a superior choice over surgery. **Why Other Options are Incorrect:** * **Option A (COCPs):** Combined oral contraceptive pills are contraindicated in patients with hypertension (especially if poorly controlled) due to the increased risk of thromboembolism and cardiovascular events. * **Option C (Hysterectomy):** This is a definitive surgical treatment but is considered a last resort. It is inappropriate for a 30-year-old before attempting conservative medical management. * **Option D (TCRE):** Endometrial ablation/resection is generally reserved for women who have completed their family and where medical management has failed. It is less effective than LNG-IUS in the long term for many patients. **NEET-PG High-Yield Pearls:** * **First-line for HMB:** LNG-IUS (Mirena). * **Mechanism of LNG-IUS:** Local release of 20mcg levonorgestrel/day $\rightarrow$ Endometrial decidualization and atrophy. * **WHO Eligibility Criteria (MEC):** Hypertension is Category 3/4 for COCPs (Avoid) but Category 1 for LNG-IUS (Safe to use). * **Non-hormonal first-line:** Tranexamic acid (Antifibrinolytic) is the preferred non-hormonal drug for HMB.

Question 50: What is the best line of management for a 45-year-old lady with polymenorrhoea for 6 months?

A. Progesterone for 6 months
B. Oral contraceptive pills for 6 months (Correct Answer)
C. Dilation and curettage
D. Hysterectomy

Explanation: **Explanation:** The primary goal in managing a 45-year-old with polymenorrhoea (menstrual cycles <21 days) is to regulate the cycle and stabilize the endometrium. **Why Option B is Correct:** In the perimenopausal age group (40–50 years), polymenorrhoea is frequently caused by **shortened follicular phases** or **anovulatory cycles** due to declining ovarian reserve. **Combined Oral Contraceptive Pills (OCPs)** are the first-line medical management because they provide exogenous estrogen and progesterone in a fixed ratio. This suppresses the endogenous pituitary-ovarian axis, prevents irregular endometrial shedding, and ensures predictable withdrawal bleeds, thereby regulating the cycle effectively. **Analysis of Incorrect Options:** * **Option A (Progesterone):** While progesterone is used for DUB (Dysfunctional Uterine Bleeding), it is typically used for heavy menstrual bleeding or to induce withdrawal in amenorrhea. In polymenorrhoea, OCPs are superior as they provide better cycle control by addressing the estrogen-progesterone imbalance. * **Option C (Dilation & Curettage):** D&C is primarily a diagnostic tool to rule out endometrial hyperplasia or malignancy in women >40 years. While it may be indicated if medical therapy fails or if the endometrium is thickened on USG, it is not the "best line of management" for initial cycle regulation. * **Option D (Hysterectomy):** This is a definitive surgical treatment and is reserved for cases where medical management fails or when there is associated pathology like large fibroids or malignancy. **NEET-PG High-Yield Pearls:** * **Polymenorrhoea** is defined as a cycle length of less than 21 days. * In perimenopausal women with AUB (Abnormal Uterine Bleeding), always perform a **Transvaginal Ultrasound (TVS)** first to check **Endometrial Thickness (ET)**. * If ET is **>4 mm** in postmenopausal women or **>12 mm** in perimenopausal women, an endometrial biopsy/D&C is mandatory to rule out malignancy.

Question 51: Which of the following modalities has shown the best results for premenstrual syndrome?

A. SSRI (Correct Answer)
B. Progesterone
C. Estrogen
D. Anxiolytics

Explanation: **Explanation:** **Premenstrual Syndrome (PMS)** and its more severe form, **Premenstrual Dysphoric Disorder (PMDD)**, are characterized by physical and emotional symptoms occurring during the luteal phase. **Why SSRIs are the Correct Choice:** Selective Serotonin Reuptake Inhibitors (SSRIs) are considered the **first-line pharmacological treatment** for PMS/PMDD. The underlying pathophysiology involves a maladaptive response to normal fluctuations in gonadal steroids (estrogen and progesterone), which leads to a deficit in central **serotonergic transmission**. SSRIs rapidly increase synaptic serotonin levels. Unlike in depression, SSRIs for PMS can be administered in a **luteal-phase-only** regimen (starting on day 14) with high efficacy. **Analysis of Incorrect Options:** * **B. Progesterone:** Historically used based on the "progesterone deficiency" theory; however, clinical trials have shown it is **no more effective than placebo** for treating PMS. * **C. Estrogen:** While estrogen (often via patches) can suppress ovulation, it is not first-line and must be balanced with progesterone to prevent endometrial hyperplasia, which may trigger PMS symptoms. * **D. Anxiolytics:** Drugs like Alprazolam may help with specific symptoms of anxiety or insomnia but are second/third-line due to the risk of dependence and lack of effect on physical symptoms. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis:** Prospective charting of symptoms for at least **two consecutive cycles** (e.g., using the Daily Record of Severity of Problems). * **First-line SSRIs:** Fluoxetine, Sertraline, and Paroxetine. * **Non-pharmacological first step:** Lifestyle modifications (exercise, complex carbohydrates, and stress reduction). * **Definitive Treatment:** For refractory cases, **GnRH analogues** (to induce medical menopause) or bilateral oophorectomy may be considered.

Question 52: Which of the following is not indicated in the management of menorrhagia?

A. NSAIDs
B. Clomiphene (Correct Answer)
C. Norethisterone
D. Tranexamic acid

Explanation: **Explanation:** The management of menorrhagia (Heavy Menstrual Bleeding) focuses on reducing menstrual blood loss (MBL) through medical or surgical interventions. **Why Clomiphene is the Correct Answer:** Clomiphene citrate is a **Selective Estrogen Receptor Modulator (SERM)** used primarily as an **ovulation-inducing agent** in infertility management. It works by blocking estrogen receptors in the hypothalamus, leading to increased FSH and LH secretion. It is **not** a treatment for menorrhagia; in fact, by inducing ovulation and follicular growth, it may occasionally lead to a thicker endometrium or ovarian hyperstimulation, which does not help in reducing menstrual flow. **Analysis of Other Options:** * **NSAIDs (e.g., Mefenamic acid):** These inhibit cyclooxygenase (COX) enzymes, reducing the levels of prostaglandins (PGE2 and PGF2α) in the endometrium. This leads to vasoconstriction and reduced MBL by approximately 20-30%. * **Norethisterone:** This is a synthetic progestogen. When given in the luteal phase or as a long-term regimen, it stabilizes the endometrium and prevents excessive proliferation, effectively managing dysfunctional uterine bleeding. * **Tranexamic Acid:** An antifibrinolytic agent that inhibits the breakdown of fibrin clots by blocking plasminogen activation. It is one of the most effective non-hormonal treatments, reducing MBL by up to 50%. **High-Yield Clinical Pearls for NEET-PG:** * **First-line medical management** for menorrhagia (WHO/NICE): **Levonorgestrel Intrauterine System (LNG-IUS/Mirena)**. * **Best non-hormonal treatment:** Tranexamic acid. * **Drug of choice for menorrhagia with dysmenorrhea:** NSAIDs (Mefenamic acid). * **Surgical Gold Standard:** Hysterectomy (definitive), though Endometrial Ablation is a less invasive alternative for those who have completed their family.

Question 53: What is the commonest condition associated with menorrhagia?

A. Adenomyosis
B. Fibroid (Correct Answer)
C. Granulosa cell tumour
D. Polycystic ovary

Explanation: **Explanation:** **Why Fibroid is the correct answer:** Uterine leiomyomas (fibroids) are the most common benign tumors of the uterus and the **most common cause of menorrhagia** (heavy menstrual bleeding). The increased bleeding is primarily due to: 1. **Increased Surface Area:** The presence of fibroids increases the total surface area of the endometrial cavity. 2. **Vascular Changes:** Fibroids cause congestion and dilatation of the overlying endometrial veins. 3. **Impaired Contractility:** They interfere with the normal myometrial contractions required to clamp down on spiral arteries during menstruation. *Note: Submucosal fibroids are most notorious for causing heavy bleeding, even when small.* **Analysis of Incorrect Options:** * **A. Adenomyosis:** While a significant cause of menorrhagia and dysmenorrhea, it is statistically less common than fibroids in the general population. It typically presents in multiparous women in their 40s. * **C. Granulosa Cell Tumour:** This is an estrogen-secreting ovarian tumor. While it can cause endometrial hyperplasia and subsequent bleeding, it is a rare clinical entity compared to the high prevalence of fibroids. * **D. Polycystic Ovary (PCOS):** PCOS is typically associated with **oligomenorrhea** (infrequent periods) or amenorrhea due to chronic anovulation. When bleeding does occur, it is often irregular (metrorrhagia) rather than heavy cyclical flow (menorrhagia). **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Investigation** for Fibroids: Transvaginal Ultrasound (TVS). * **Medical Management of Choice:** Levonorgestrel Intrauterine System (LNG-IUS) is often the first-line medical treatment for menorrhagia. * **Surgical Management:** Myomectomy (if fertility is desired) or Hysterectomy (definitive). * **Red Flag:** If a postmenopausal woman presents with bleeding and a "fibroid," suspect **Leiomyosarcoma**.

Question 54: What is the most common cause of secondary amenorrhea?

A. Hypogonadism
B. Hypopituitarism
C. Pregnancy (Correct Answer)
D. Ovarian tumor

Explanation: **Explanation:** **1. Why Pregnancy is the Correct Answer:** In any woman of reproductive age presenting with a cessation of menses, **pregnancy** is statistically the most common cause of secondary amenorrhea. Physiologically, during pregnancy, the persistent production of progesterone by the corpus luteum (and later the placenta) maintains the endometrial lining and inhibits the hypothalamic-pituitary-ovarian (HPO) axis through negative feedback, preventing further menstruation. In clinical practice and for NEET-PG, the first step in investigating secondary amenorrhea is always a urine pregnancy test (UPT) to rule this out. **2. Analysis of Incorrect Options:** * **A. Hypogonadism:** While conditions like Polycystic Ovary Syndrome (PCOS) or Premature Ovarian Insufficiency (POI) are significant causes of secondary amenorrhea, they are statistically less frequent than pregnancy. * **B. Hypopituitarism:** This involves a failure of the pituitary to secrete FSH/LH (e.g., Sheehan’s syndrome). While it causes amenorrhea, it is a rare clinical entity compared to physiological causes. * **D. Ovarian Tumor:** Certain tumors (like Sertoli-Leydig cell tumors) can cause amenorrhea due to hormone secretion, but these represent a very small fraction of cases. **3. NEET-PG High-Yield Pearls:** * **Definition:** Secondary amenorrhea is the absence of menses for **3 months** in a woman with previously regular cycles, or **6 months** in those with irregular cycles. * **Most common pathological cause:** Polycystic Ovary Syndrome (PCOS). * **Most common cause of primary amenorrhea:** Gonadal dysgenesis (Turner Syndrome). * **Asherman’s Syndrome:** The most common uterine cause of secondary amenorrhea, often following over-zealous curettage. * **First-line Investigation:** Urine Pregnancy Test (UPT) or serum beta-hCG.

Question 55: Which of the following statements regarding spasmodic dysmenorrhea is FALSE?

A. Pain persists for 2-3 days (Correct Answer)
B. Often cured by delivery of a child
C. Pain usually appears on the first day of menstruation
D. Rare above the age of 35 years

Explanation: **Explanation:** Spasmodic dysmenorrhea (Primary Dysmenorrhea) is characterized by painful uterine contractions without any underlying pelvic pathology. It is primarily mediated by an excess of **Prostaglandin F2α (PGF2α)**, which causes intense uterine hypercontractility and ischemia. **Why Option A is False (The Correct Answer):** The pain in spasmodic dysmenorrhea typically starts just before or at the onset of menses and lasts for **12–24 hours**. It rarely persists for 2–3 days; prolonged pain beyond 48 hours is more characteristic of secondary dysmenorrhea (e.g., endometriosis or adenomyosis). **Analysis of Other Options:** * **Option B:** It is often cured by vaginal delivery. Childbirth leads to the destruction of adrenergic nerve endings in the isthmus and cervix (Frankenhauser’s plexus) and cervical stretching, which facilitates easier menstrual flow. * **Option C:** The pain is "spasmodic" or colicky, usually appearing on the first day when the menstrual flow is heaviest and prostaglandin release is at its peak. * **Option D:** It is a condition of young age, typically appearing 1–2 years after menarche (once ovulation is established). It is rare above the age of 35, as symptoms usually improve with age or parity. **NEET-PG High-Yield Pearls:** * **Mechanism:** High PGF2α → Uterine hypercontractility → Ischemia → Pain. * **Prerequisite:** It occurs only in **ovulatory cycles** (Progesterone is required for PG synthesis). * **First-line Treatment:** NSAIDs (Mefenamic acid), which act as prostaglandin synthetase inhibitors. * **Treatment for those seeking contraception:** Combined Oral Contraceptive Pills (OCPs) – they induce anovulation.

Question 56: Primary amenorrhoea is seen in all the following conditions except:

A. Klinefelter syndrome
B. Mayer-Rokitansky-Küster-Hauser syndrome
C. Asherman syndrome (Correct Answer)
D. Turner syndrome

Explanation: **Explanation:** The core concept in this question lies in distinguishing between **Primary Amenorrhoea** (failure to initiate menstruation by age 15) and **Secondary Amenorrhoea** (cessation of established menses for >6 months). **Why Asherman Syndrome is the correct answer:** Asherman syndrome refers to the presence of intrauterine adhesions (synechiae) typically resulting from trauma to the basal layer of the endometrium (e.g., over-zealous D&C or genital tuberculosis). Since this condition requires a prior uterine insult or the destruction of an existing functional endometrium, it is a classic cause of **Secondary Amenorrhoea**. It cannot be a cause of primary amenorrhoea because the anatomy is initially normal and functional. **Analysis of Incorrect Options:** * **Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome:** Characterized by Müllerian agenesis (absent uterus and upper 2/3 of the vagina) in a 46,XX female. Since there is no uterus, menstruation never begins. * **Turner Syndrome (45,XO):** The most common cause of primary amenorrhoea. It involves gonadal dysgenesis (streak ovaries), leading to hypergonadotropic hypogonadism. * **Klinefelter Syndrome (47,XXY):** While primarily a male phenotype, it is often included in differential lists for primary amenorrhoea in the context of "disorders of sexual development" or phenotypic confusion in exams. In a phenotypic male, menses never occur; however, in the context of this question, it represents a congenital/chromosomal cause present from birth, unlike the acquired nature of Asherman’s. **High-Yield Clinical Pearls for NEET-PG:** 1. **Most common cause of Primary Amenorrhoea:** Turner Syndrome (Gonadal dysgenesis). 2. **Most common cause of Secondary Amenorrhoea:** Pregnancy (Physiological); PCOS (Pathological). 3. **Asherman Syndrome Diagnosis:** Gold standard is **Hysteroscopy**. On HSG, it shows "honeycomb" appearance or filling defects. 4. **MRKH Syndrome:** Patients have normal secondary sexual characters (ovaries are functional) but absent uterus.

Question 57: What is the most common cause of secondary amenorrhea?

A. Turner syndrome
B. Pregnancy (Correct Answer)
C. Mullerian agenesis
D. Kallmann syndrome

Explanation: **Explanation:** **1. Why Pregnancy is the Correct Answer:** In any woman of reproductive age presenting with a cessation of menstruation, **pregnancy** is the most common cause of secondary amenorrhea. Physiologically, the persistence of the corpus luteum (maintained by hCG) continues the production of progesterone, preventing the shedding of the endometrial lining. In clinical practice and for NEET-PG, the first step in investigating secondary amenorrhea is always a urine pregnancy test (UPT) to rule this out before proceeding to hormonal or anatomical evaluations. **2. Analysis of Incorrect Options:** * **Turner Syndrome (45, XO):** This is the most common cause of **primary** amenorrhea due to gonadal dysgenesis (streak ovaries). While it can rarely present as secondary amenorrhea (premature ovarian failure), it is not the most common cause. * **Mullerian Agenesis (MRKH Syndrome):** This is the second most common cause of **primary** amenorrhea. It involves the congenital absence of the uterus and upper two-thirds of the vagina; since these patients never start menstruating, it cannot be a cause of secondary amenorrhea. * **Kallmann Syndrome:** This is a form of hypogonadotropic hypogonadism (GnRH deficiency) associated with anosmia. It typically presents as **primary** amenorrhea with delayed puberty. **3. Clinical Pearls & High-Yield Facts:** * **Definition:** Secondary amenorrhea is the absence of menses for >3 months in a woman with previously regular cycles, or >6 months in a woman with irregular cycles. * **Non-Physiological Cause:** Excluding pregnancy, the most common cause of secondary amenorrhea is **Polycystic Ovary Syndrome (PCOS)**. * **Asherman Syndrome:** The most common **uterine** cause of secondary amenorrhea (often post-curettage). * **Sheehan Syndrome:** Postpartum pituitary necrosis leading to secondary amenorrhea due to gonadotropin deficiency.

Question 58: Dysfunctional uterine bleeding is defined as abnormal bleeding due to which of the following?

A. Thyroid dysfunction
B. Functioning ovarian tumor
C. Anovulatory cycle (Correct Answer)
D. Blood dyscrasias

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)** is defined as a state of abnormal uterine bleeding (AUB) in the absence of any detectable organic, systemic, or iatrogenic cause (e.g., pelvic pathology, pregnancy, or blood disorders). It is essentially a **diagnosis of exclusion**. **Why C is correct:** The underlying pathophysiology of DUB is almost always **hormonal imbalance**, most commonly resulting from an **anovulatory cycle**. In anovulation, there is no corpus luteum formation, leading to a lack of progesterone. This results in "unopposed estrogen" action on the endometrium, causing it to proliferate excessively. Eventually, the endometrium outgrows its blood supply, leading to asynchronous breakdown and heavy, irregular bleeding (Estrogen Breakthrough Bleeding). **Why other options are incorrect:** * **A & D (Thyroid dysfunction and Blood dyscrasias):** These are **systemic causes** of abnormal uterine bleeding. Once a systemic cause is identified, the diagnosis is no longer "dysfunctional" but rather AUB secondary to a specific medical condition. * **B (Functioning ovarian tumor):** This is an **organic/structural cause**. DUB specifically excludes any pelvic pathology or tumors. **NEET-PG High-Yield Pearls:** * **PALM-COEIN Classification:** The FIGO nomenclature has largely replaced the term DUB with **AUB-O** (Ovulatory dysfunction). * **Most common age groups for DUB:** Adolescence (due to immature HPO axis) and Perimenopause. * **Gold Standard Investigation:** Endometrial biopsy (to rule out hyperplasia/malignancy) in women >35 years or those with risk factors. * **Management:** Combined Oral Contraceptive Pills (COCs) or Progesterone are first-line medical treatments; the **Levonorgestrel Intrauterine System (LNG-IUS)** is the most effective medical management.

Question 59: What is the commonest cause of primary amenorrhea?

A. Genital tuberculosis
B. Ovarian dysgenesis (Correct Answer)
C. Mullerian duct anomalies
D. Hypothyroidism

Explanation: **Explanation:** Primary amenorrhea is defined as the absence of menarche by age 13 in the absence of secondary sexual characteristics, or by age 15 if secondary sexual characteristics are present. **Why Ovarian Dysgenesis is Correct:** **Ovarian dysgenesis (specifically Turner Syndrome, 45,XO)** is the most common cause of primary amenorrhea, accounting for approximately **40-50%** of cases. In these patients, the ovaries fail to develop properly and are replaced by fibrous "streak gonads." This leads to hypergonadotropic hypogonadism (elevated FSH/LH due to lack of estrogen feedback). **Analysis of Incorrect Options:** * **Genital Tuberculosis:** While a significant cause of secondary amenorrhea and infertility in developing countries (due to endometrial destruction/Asherman’s syndrome), it is a rare cause of primary amenorrhea. * **Mullerian Duct Anomalies:** Conditions like MRKH syndrome (Mullerian agenesis) are the **second** most common cause of primary amenorrhea (~15-20%). These patients have normal ovaries and secondary sexual characteristics but lack a uterus and upper vagina. * **Hypothyroidism:** Endocrine disorders can cause menstrual irregularities, but they are much less frequent causes of primary amenorrhea compared to genetic or structural defects. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause overall:** Ovarian Dysgenesis (Turner Syndrome). * **Most common cause with normal secondary sexual characteristics:** MRKH Syndrome. * **Initial investigation:** Karyotyping (if FSH is high) or Ultrasound (to check for the presence of a uterus). * **Turner Syndrome Hallmark:** Short stature, webbed neck, and high FSH levels.

Question 60: Which of the following is NOT an evidence-based treatment for menorrhagia?

A. Oral Contraceptive Pills
B. Progesterone for three months cyclically
C. Tranexamic acid
D. Ethamsylate (Correct Answer)

Explanation: **Explanation:** The goal of treating menorrhagia (Heavy Menstrual Bleeding) is to reduce menstrual blood loss (MBL) using evidence-based medical or surgical interventions. **Why Ethamsylate is the correct answer:** Ethamsylate is a hemostatic agent that acts by improving platelet adhesiveness and capillary wall stability. While it is frequently used in clinical practice, multiple Cochrane reviews and international guidelines (like NICE) have concluded that **Ethamsylate is not effective** in significantly reducing menstrual blood loss compared to other agents. Therefore, it is no longer recommended as an evidence-based treatment for menorrhagia. **Analysis of Incorrect Options:** * **Oral Contraceptive Pills (OCPs):** These are a first-line hormonal treatment. They work by inducing endometrial atrophy and inhibiting ovulation, typically reducing MBL by 40-50%. * **Cyclical Progesterone:** While 10-day luteal phase progesterone is ineffective, **long-cycle progesterone** (given for 21 days, e.g., from day 5 to 25) is an evidence-based method to regulate the cycle and reduce flow, especially in anovulatory bleeding. (Note: The Levonorgestrel-IUS is the most effective progesterone-based delivery system). * **Tranexamic Acid:** This is an antifibrinolytic that prevents the breakdown of fibrin clots in the uterine vasculature. It is a highly effective non-hormonal treatment, reducing MBL by approximately 50%. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** The **LNG-IUS (Mirena)** is the overall medical DOC for menorrhagia (70-90% reduction in blood loss). * **Non-Hormonal DOC:** Tranexamic acid is the preferred choice for women desiring pregnancy. * **NSAIDs:** (e.g., Mefenamic acid) are also evidence-based treatments, particularly useful if the patient has associated dysmenorrhea.

Question 61: A 45-year-old female presents with polymenorrhea for 6 months. On examination, nothing abnormal was found. What is the next best line of management?

A. Progesterone for 3 cycles
B. Oral contraceptive pills for 3 cycles
C. Dilation and curettage (Correct Answer)
D. Hysterectomy

Explanation: **Explanation:** The primary clinical concern in a perimenopausal woman (age >40–45 years) presenting with abnormal uterine bleeding (AUB), such as polymenorrhea, is to **exclude endometrial hyperplasia or malignancy**. **1. Why Dilation and Curettage (D&C) is the correct answer:** In women over 40 years of age, any change in menstrual frequency or flow is considered AUB until proven otherwise. D&C (often performed as a fractional curettage or alongside hysteroscopy) serves both a **diagnostic and therapeutic** purpose. It allows for a formal histopathological examination of the endometrium to rule out premalignant or malignant changes before initiating hormonal therapy. In modern practice, an Endometrial Biopsy (Pipelle) is often the first step, but among the given options, D&C is the definitive gold standard for sampling. **2. Why other options are incorrect:** * **Options A & B (Progesterone/OCPs):** Hormonal management is the treatment for Dysfunctional Uterine Bleeding (DUB). However, hormones should never be started in a woman over 40 without first ruling out malignancy via endometrial sampling. Starting hormones blindly may mask the symptoms of underlying cancer, leading to a delayed diagnosis. * **Option D (Hysterectomy):** This is a major surgical intervention and is considered a definitive treatment, not a first-line diagnostic step. It is only indicated if histopathology confirms a condition requiring organ removal (e.g., atypical hyperplasia or malignancy) or if medical management fails. **NEET-PG High-Yield Pearls:** * **Age Cut-off:** For any AUB in a female **>40 years**, the first mandatory step is **Endometrial Sampling**. * **Polymenorrhea:** Defined as a menstrual cycle interval of **<21 days**. * **Gold Standard:** While Transvaginal Sonography (TVS) helps assess endometrial thickness (cut-off >4mm in postmenopausal women), **histopathology** remains the gold standard for diagnosing endometrial pathology.

Question 62: A 45-year-old woman presents with a history of polymenorrhea for the last six months. What is the first-line management?

A. Hysterectomy
B. Progesterone for 3 cycles
C. Dilatation and curettage (Correct Answer)
D. Oral contraceptive for 3 cycles

Explanation: **Explanation:** The primary concern in a perimenopausal woman (age >40 years) presenting with abnormal uterine bleeding (AUB), such as polymenorrhea, is the risk of **Endometrial Hyperplasia or Endometrial Carcinoma**. **Why Dilatation and Curettage (D&C) is correct:** In women over 40, any change in menstrual frequency or flow necessitates a tissue diagnosis to rule out malignancy. D&C serves a dual purpose: it is **diagnostic** (obtaining a sample for histopathology) and **therapeutic** (scraping the functional layer to stop immediate bleeding). While Transvaginal Ultrasound (TVS) is often an initial screening tool to measure endometrial thickness, D&C remains a gold-standard "first-line" intervention in clinical exams to exclude hyperplasia before starting hormonal therapy. **Why other options are incorrect:** * **Hysterectomy (A):** This is a major surgical intervention and is considered definitive management only after a diagnosis is confirmed and medical management has failed. * **Progesterone (B) & Oral Contraceptives (D):** Hormonal therapy is the treatment for Dysfunctional Uterine Bleeding (DUB). However, these should **never** be started in a woman over 40 without first ruling out endometrial cancer via biopsy or D&C. **Clinical Pearls for NEET-PG:** * **Age Cut-off:** For AUB, the threshold for mandatory endometrial sampling is **>45 years**, or **>40 years** if there are additional risk factors (obesity, nulliparity, PCOD). * **Pipelle Biopsy:** In modern practice, Pipelle aspiration is the preferred office procedure, but D&C remains the classic answer for "diagnostic and therapeutic" management in exams. * **Polymenorrhea definition:** Menstrual cycle length **<21 days**.

Question 63: Cryptomenorrhea is seen in which of the following conditions?

A. Asherman's syndrome
B. Testicular feminizing syndrome
C. Imperforate hymen (Correct Answer)
D. Uterine agenesis

Explanation: **Explanation:** **Cryptomenorrhea** (hidden menstruation) refers to a condition where menstrual blood is produced by the uterine endometrium but is unable to exit the genital tract due to an anatomical obstruction in the outflow tract. **1. Why Imperforate Hymen is Correct:** In an **imperforate hymen**, the vaginal opening is completely occluded by a membrane. During puberty, the girl experiences cyclical hormonal changes and shedding of the endometrium; however, the blood accumulates in the vagina (**hematocolpos**), then the uterus (**hematometra**), and potentially the fallopian tubes (**hematosalpinx**). This presents as primary amenorrhea with cyclical pelvic pain and a bulging, bluish membrane on examination. **2. Analysis of Incorrect Options:** * **Asherman’s Syndrome:** This involves intrauterine adhesions that obliterate the uterine cavity. Here, the endometrium is scarred and non-functional, so no blood is produced (Secondary Amenorrhea), rather than being "hidden." * **Testicular Feminizing Syndrome (AIS):** This is a 46,XY condition where there is no uterus or ovaries. Since there is no endometrium to shed, menstruation does not occur. * **Uterine Agenesis (Mayer-Rokitansky-Küster-Hauser syndrome):** The uterus is absent or rudimentary. Without a functional uterus, there is no menstrual production. **Clinical Pearls for NEET-PG:** * **Most common cause of cryptomenorrhea:** Imperforate hymen. * **Second most common cause:** Transverse vaginal septum. * **Clinical Presentation:** A pubertal girl with primary amenorrhea, cyclical abdominal pain, and a palpable suprapubic mass (distended bladder or hematometra). * **Treatment:** Cruciate incision of the hymen to allow drainage.

Question 64: Which of the following is NOT a feature of anovulatory menstruation?

A. The only symptom may be failure of conception
B. It is usually associated with painless periods
C. It may be associated with premenstrual syndrome (Correct Answer)
D. It may be associated with dysfunctional uterine bleeding (DUB)

Explanation: **Explanation:** Anovulatory menstruation occurs when the ovaries fail to release an oocyte, leading to a cycle dominated by estrogen without the subsequent rise in progesterone from a corpus luteum. **Why Option C is the correct answer:** Premenstrual Syndrome (PMS) is fundamentally linked to the **luteal phase** of the menstrual cycle. It occurs due to the physiological fluctuations of progesterone following ovulation. Since anovulatory cycles lack a corpus luteum and progesterone production, **PMS does not occur**. Therefore, the presence of PMS is a clinical indicator that a cycle was likely ovulatory. **Analysis of Incorrect Options:** * **Option A:** In many women, anovulatory cycles are regular and mimic normal menses. In such cases, the inability to release an egg makes **infertility (failure of conception)** the only presenting symptom. * **Option B:** Painful periods (Dysmenorrhea) are primarily caused by prostaglandins ($PGF_{2\alpha}$) released during the breakdown of a secretory (progesterone-primed) endometrium. Anovulatory cycles result in a proliferative endometrium with low prostaglandin levels, making them **characteristically painless**. * **Option D:** Anovulatory cycles are the most common cause of **Dysfunctional Uterine Bleeding (DUB)**. Constant estrogen stimulation without progesterone leads to endometrial hyperplasia; eventually, the endometrium outgrows its blood supply, leading to irregular, heavy "estrogen breakthrough bleeding." **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard for Ovulation:** Histological evidence of a **secretory endometrium** on endometrial biopsy (done on Day 21-23). * **Best Biochemical Marker:** Serum Progesterone >3 ng/mL (measured 7 days before expected menses). * **Commonest cause of Anovulatory DUB:** Polycystic Ovary Syndrome (PCOS) and extremes of reproductive life (puberty and perimenopause).

Question 65: Which of the following structures normally closes before birth?

A. Ductus arteriosus
B. Ductus venosus
C. Cardinal vein (Correct Answer)
D. Umbilical vein

Explanation: **Explanation:** The correct answer is **C. Cardinal vein**. In fetal development, the **cardinal veins** are the main venous drainage system of the embryo. Most components of the cardinal system (specifically the posterior cardinal veins) undergo spontaneous regression and remodeling into the permanent venous system (like the IVC and azygos system) **during the embryonic and early fetal period (around 8 weeks)**. Therefore, they "close" or transform long before birth. **Why the other options are incorrect:** * **A. Ductus arteriosus:** This shunts blood from the pulmonary artery to the aorta. It closes **functionally** within 10–15 hours after birth due to increased oxygen tension and decreased prostaglandins, and **anatomically** by 2–3 weeks (becoming the *ligamentum arteriosum*). * **B. Ductus venosus:** This shunts oxygenated blood from the umbilical vein to the IVC, bypassing the liver. It closes after birth, becoming the *ligamentum venosum*. * **D. Umbilical vein:** This carries oxygenated blood from the placenta to the fetus. It collapses after the umbilical cord is clamped at birth, eventually becoming the *ligamentum teres hepatis*. **High-Yield NEET-PG Pearls:** * **Remnants to Remember:** * Umbilical Vein $\rightarrow$ Ligamentum teres. * Umbilical Artery $\rightarrow$ Medial umbilical ligament. * Ductus Arteriosus $\rightarrow$ Ligamentum arteriosum. * Ductus Venosus $\rightarrow$ Ligamentum venosum. * Foramen Ovale $\rightarrow$ Fossa ovalis. * **Clinical Note:** Indomethacin (a prostaglandin inhibitor) is used to close a Patent Ductus Arteriosus (PDA), while PGE1 is used to keep it open in cyanotic heart diseases.

Question 66: Menstruation occurring every 15 days is:

A. Polymenorrhea (Correct Answer)
B. Epimenorrhea
C. Cryptomenorrhea
D. Hypomenorrhea

Explanation: **Explanation:** The correct answer is **Polymenorrhea**. **1. Why Polymenorrhea is correct:** Polymenorrhea is defined as a menstrual cycle that is abnormally frequent, occurring at intervals of **less than 21 days**. In this case, menstruation every 15 days falls well below the normal range (21–35 days). It is often associated with a shortened follicular phase or luteal phase deficiency. **2. Analysis of Incorrect Options:** * **Epimenorrhea:** This is an older, synonymous term for polymenorrhea. However, in modern medical terminology and standard textbooks (like Dutta or Williams), **Polymenorrhea** is the preferred and more frequently tested term in competitive exams. * **Cryptomenorrhea:** This refers to "hidden menstruation." Menstrual blood is produced but fails to escape the genital tract due to an anatomical obstruction, such as an **imperforate hymen** or transverse vaginal septum. * **Hypomenorrhea:** This refers to an abnormally low amount of menstrual bleeding (scanty flow) or a short duration of flow (less than 2 days), while the cycle interval remains normal. **3. NEET-PG High-Yield Clinical Pearls:** * **Normal Menstrual Cycle:** Interval: 21–35 days; Duration: 2–7 days; Blood loss: 20–80 ml. * **Oligomenorrhea:** Cycle interval >35 days (infrequent periods). * **Menorrhagia (Hypermenorrhea):** Cyclic bleeding that is excessive in amount (>80 ml) or duration (>7 days). * **Metrorrhagia:** Acyclic, irregular bleeding occurring between periods. * **Menometrorrhagia:** Bleeding that is both excessive in amount and irregular in frequency. * **PALM-COEIN:** Remember this FIGO classification for the causes of Abnormal Uterine Bleeding (AUB).

Question 67: Which of the following is NOT a treatment for menorrhagia?

A. NSAIDs
B. Tranexamic acid
C. Norethisterone
D. Clomiphene (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Clomiphene**. **Why Clomiphene is the correct answer:** Clomiphene citrate is a Selective Estrogen Receptor Modulator (SERM) used primarily as an **ovulation-inducing agent** in infertility treatment. It works by inhibiting the negative feedback of estrogen on the hypothalamus, leading to increased FSH and LH secretion. It is not used to treat menorrhagia; in fact, by inducing ovulation and follicular growth, it may indirectly increase endometrial thickness in some cycles. **Analysis of other options:** * **NSAIDs (A):** These are first-line non-hormonal treatments. They inhibit cyclooxygenase (COX) enzymes, reducing the levels of **prostaglandins (PGE2 and PGF2α)** in the endometrium, which are typically elevated in women with menorrhagia. * **Tranexamic Acid (B):** An antifibrinolytic agent that reversibly binds to plasminogen, preventing its conversion to plasmin. This stabilizes clots within the endometrial vasculature and reduces menstrual blood loss by 40–50%. * **Norethisterone (C):** A potent progestogen. When given in the luteal phase or as a long-cycle regimen (Day 5–25), it stabilizes the endometrium and prevents excessive proliferation, effectively reducing bleeding. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** For medical management of Menorrhagia (non-hormonal), Tranexamic acid is often preferred. * **Gold Standard Medical Management:** The **Levonorgestrel Intrauterine System (LNG-IUS/Mirena)** is the most effective medical treatment for heavy menstrual bleeding, often reducing loss by >90%. * **Surgical Management:** Hysterectomy is the definitive treatment, while Endometrial Ablation is a conservative surgical alternative for those who have completed their family.

Question 68: Which of the following statements is false regarding oligomenorrhoea?

A. It is frequent
B. Regularly timed episodes of bleeding
C. Menstruation occurring at an interval of more than 30 days
D. All of the above (Correct Answer)

Explanation: **Explanation:** Oligomenorrhoea is defined as infrequent menstruation occurring at intervals of **more than 35 days** (or fewer than 9 cycles per year). The question asks for the **false** statement; since all three individual options (A, B, and C) contain factual inaccuracies regarding the definition of oligomenorrhoea, "All of the above" is the correct choice. **Breakdown of Options:** * **Option A (False):** Oligomenorrhoea refers to **infrequent** periods, not frequent ones. Frequent menstruation (intervals <21 days) is termed *Polymenorrhoea*. * **Option B (False):** While the episodes can sometimes be regular, oligomenorrhoea is classically associated with **irregularly timed** episodes, often reflecting underlying anovulation or oligo-ovulation. * **Option C (False):** The clinical threshold for oligomenorrhoea is an interval of **>35 days**. An interval of 30 days is considered within the normal physiological range (21–35 days). **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Cause:** Polycystic Ovary Syndrome (PCOS) is the leading cause of oligomenorrhoea in reproductive-age women. * **Normal Cycle:** 28 days ± 7 days (Range: 21–35 days). * **Amenorrhoea vs. Oligomenorrhoea:** If the interval exceeds **6 months** (or 3 cycles in a previously regular woman), it is classified as secondary amenorrhoea. * **Adolescence:** Oligomenorrhoea is often physiological in the first 1–2 years post-menarche due to the immaturity of the Hypothalamic-Pituitary-Ovarian (HPO) axis. * **Other Causes:** Hyperprolactinemia, thyroid dysfunction (hypothyroidism), and perimenopause.

Question 69: Which of the following is the most appropriate treatment for abnormal uterine bleeding - endometrial (AUB-E)?

A. NSAIDs
B. Tranexamic acid
C. Oral progestins (Correct Answer)
D. Combined OCPs

Explanation: **Explanation:** **Abnormal Uterine Bleeding - Endometrial (AUB-E)** refers to heavy menstrual bleeding (HMB) occurring in the presence of regular ovulatory cycles, where no structural or systemic cause is identified. It is primarily a diagnosis of exclusion, attributed to primary dysfunction of the local endometrial mechanisms (e.g., imbalances in prostaglandins or increased fibrinolysis). **Why Oral Progestins are the Correct Answer:** In the context of AUB-E, **Oral Progestins** (specifically during the luteal phase or as long-term therapy) are considered the first-line medical management. They work by stabilizing the endometrium, counteracting the effects of estrogen, and inducing a secretory change that leads to a more controlled and complete shedding of the lining. For acute episodes or chronic management, progestins (like Medroxyprogesterone acetate or Norethisterone) effectively reduce menstrual blood loss. **Analysis of Incorrect Options:** * **NSAIDs (A):** These inhibit prostaglandin synthesis. While they reduce blood loss by 20-30%, they are generally considered secondary or adjunct treatments compared to hormonal stabilization. * **Tranexamic Acid (B):** This is an antifibrinolytic. While highly effective for symptomatic relief of HMB, it does not address the underlying endometrial hormonal environment. * **Combined OCPs (D):** These are effective for AUB-O (Ovulatory dysfunction) or general HMB, but in specific AUB-E cases, pure progestational agents are often prioritized to stabilize the local endometrial environment. **Clinical Pearls for NEET-PG:** * **FIGO Classification (PALM-COEIN):** AUB-E falls under the "Non-structural" (COEIN) category. * **Gold Standard:** The **Levonorgestrel-releasing Intrauterine System (LNG-IUS)** is actually the most effective medical treatment for AUB-E, but among the *oral* options provided, progestins are the standard. * **Diagnosis:** AUB-E is suspected when cycles are regular (predictable) but heavy, and imaging/biopsy are normal.

Question 70: What does polymenorrhea mean?

A. Menses occurring more frequently than every 21 days (Correct Answer)
B. Menses occurring less frequently than every 35 days
C. Painful menses
D. Dysfunctional uterine bleeding

Explanation: **Explanation:** **Polymenorrhea** is a term used to describe a menstrual cycle that is abnormally short. In a normal clinical scenario, the average menstrual cycle lasts between 21 to 35 days. Polymenorrhea occurs when the cycle length is **less than 21 days**, leading to menses occurring more frequently than normal. This is often associated with an abbreviated follicular phase or a luteal phase defect. **Analysis of Options:** * **Option A (Correct):** This aligns with the clinical definition. Frequent cycles (<21 days) mean the patient has more periods in a calendar year. * **Option B (Incorrect):** Menses occurring less frequently than every 35 days is termed **Oligomenorrhea**. * **Option C (Incorrect):** Painful menstruation is termed **Dysmenorrhea**. * **Option D (Incorrect):** **Dysfunctional Uterine Bleeding (DUB)**—now largely replaced by the PALM-COEIN classification—refers to abnormal uterine bleeding (AUB) not caused by pelvic pathology, medications, or systemic disease. **High-Yield Clinical Pearls for NEET-PG:** * **Terminology Update:** According to FIGO nomenclature, the term "Polymenorrhea" is being replaced by **"Frequent Menstrual Bleeding."** * **Menorrhagia:** Cyclic bleeding that is excessive in amount (>80 ml) or duration (>7 days). * **Metrorrhagia:** Irregular, acyclic bleeding occurring between periods. * **Hypomenorrhea:** Regularly timed but scanty bleeding (<2 days or <20 ml). * **Key Rule:** Always rule out pregnancy and thyroid dysfunction (Hypothyroidism) in any patient presenting with menstrual irregularities.

Question 71: What is the most common cause of menorrhagia in the childbearing period?

A. Fibroid
B. Dysfunctional uterine bleeding (Correct Answer)
C. Pelvic endometriosis
D. Adenomyosis

Explanation: **Explanation:** **1. Why Dysfunctional Uterine Bleeding (DUB) is correct:** Dysfunctional Uterine Bleeding (now often classified under the FIGO PALM-COEIN system as 'Non-structural' causes) remains the most common cause of menorrhagia in women of reproductive age. It is defined as abnormal bleeding from the uterine endometrium unrelated to structural or systemic disease. In the childbearing period, it is most frequently associated with **anovulatory cycles**, where the absence of progesterone leads to prolonged estrogen stimulation, resulting in an unstable, thickened endometrium that sheds irregularly and heavily. **2. Why the other options are incorrect:** * **Fibroid (Leiomyoma):** While fibroids are the most common **benign tumor** of the uterus and a very frequent cause of menorrhagia, they are statistically secondary to DUB in overall prevalence across the entire childbearing population. * **Adenomyosis:** This typically presents in multiparous women in their late 30s or 40s. While it causes menorrhagia and dysmenorrhea, its incidence is lower than DUB and fibroids. * **Pelvic Endometriosis:** The hallmark of endometriosis is **dysmenorrhea** (pain) and infertility, not menorrhagia. If heavy bleeding occurs with endometriosis, it is usually due to associated pathology like fibroids or adenomyosis. **Clinical Pearls for NEET-PG:** * **Gold Standard Investigation** for menorrhagia in women >35 years: Endometrial biopsy (to rule out hyperplasia/malignancy). * **Investigation of Choice** for structural causes: Transvaginal Ultrasound (TVS). * **Medical Management:** Levonorgestrel Intrauterine System (LNG-IUS/Mirena) is the first-line treatment for DUB. * **Terminology Note:** The term "DUB" is being replaced by the **PALM-COEIN** classification, where DUB corresponds primarily to Coagulopathy, Ovulatory dysfunction, or Endometrial causes.

Question 72: Dysfunctional uterine bleeding (DUB) is due to:

A. Endometriosis
B. Fibroid
C. Endometrial carcinoma
D. Irregular shedding of the endometrium (Correct Answer)

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)** is defined as abnormal uterine bleeding in the absence of any detectable organic, systemic, or iatrogenic cause (e.g., pelvic tumors, inflammation, or pregnancy). It is primarily a diagnosis of exclusion and is caused by an endocrine imbalance affecting the hypothalamic-pituitary-ovarian axis. **Why Option D is Correct:** **Irregular shedding of the endometrium** is a classic subtype of ovulatory DUB. It occurs due to the persistent action of the corpus luteum, leading to prolonged progesterone secretion. This prevents the synchronous shedding of the endometrium, resulting in heavy and prolonged menses (menorrhagia). On a biopsy, this is characterized by the presence of both secretory and proliferative patterns simultaneously. **Why Other Options are Incorrect:** * **A. Endometriosis:** This is an organic condition where endometrial tissue grows outside the uterus. While it causes dysmenorrhea and pelvic pain, it is not classified as DUB. * **B. Fibroid (Leiomyoma):** This is a benign monoclonal tumor of the myometrium. It is a structural/organic cause of bleeding (categorized under "L" in the PALM-COEIN classification). * **C. Endometrial Carcinoma:** This is a malignant neoplastic condition. DUB, by definition, excludes any pelvic malignancy. **High-Yield Clinical Pearls for NEET-PG:** * **PALM-COEIN Classification:** DUB now falls under the "COEIN" (Non-structural) category of Abnormal Uterine Bleeding (AUB). * **Anovulatory DUB:** The most common type (80%), often seen at extremes of reproductive life (puberty and perimenopause) due to "unopposed estrogen." * **Irregular Ripening:** Another ovulatory DUB caused by poor corpus luteum function (progesterone deficiency), leading to premenstrual spotting. * **Gold Standard Diagnosis:** Dilatation and Curettage (D&C) or endometrial biopsy is essential in women >35 years to rule out malignancy before labeling it as DUB.

Question 73: Hypothalamic amenorrhoea is seen in which of the following conditions?

A. Asherman syndrome
B. Stein-Leventhal syndrome
C. Kallman syndrome (Correct Answer)
D. Sheehan's syndrome

Explanation: **Explanation:** Amenorrhea is classified based on the anatomical level of the defect: Hypothalamus, Pituitary, Ovary, or Outflow tract. **Why Kallman Syndrome is the Correct Answer:** Kallman syndrome is a form of **hypogonadotropic hypogonadism** caused by the failure of GnRH-secreting neurons to migrate from the olfactory placode to the **hypothalamus**. This results in a deficiency of GnRH, leading to low levels of FSH and LH. Clinically, it is characterized by primary amenorrhea and **anosmia** (loss of smell) due to the associated agenesis of the olfactory bulbs. **Analysis of Incorrect Options:** * **Asherman Syndrome:** This is an **outflow tract disorder** where intrauterine adhesions (synechiae) form, usually post-curettage. The hormonal axis is normal, but the endometrium is non-functional. * **Stein-Leventhal Syndrome (PCOS):** This is a complex **endocrine/ovarian metabolic disorder** characterized by hyperandrogenism and insulin resistance. While it involves altered GnRH pulsatility, it is primarily categorized under ovarian dysfunction/anovulation rather than a primary hypothalamic defect. * **Sheehan’s Syndrome:** This is a **pituitary disorder** caused by ischemic necrosis of the anterior pituitary gland following severe postpartum hemorrhage. **High-Yield Clinical Pearls for NEET-PG:** * **Kallman Syndrome Inheritance:** Most commonly X-linked recessive (KAL1 gene). * **Diagnostic Trio:** Primary amenorrhea + Anosmia + Hypogonadotropic hypogonadism. * **Functional Hypothalamic Amenorrhea:** Often triggered by "The Female Athlete Triad" (Stress, Exercise, and Weight loss/Anorexia). * **Progesterone Challenge Test:** Patients with hypothalamic amenorrhea will be **negative** (no withdrawal bleed) due to low endogenous estrogen levels.

Question 74: A 45-year-old woman presents with a history of polymenorrhea for the last six months. What is the first-line management?

A. Hysterectomy
B. Progesterone for 3 cycles
C. Dilatation and curettage
D. Oral contraceptive pills for 3 cycles (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is Correct:** Polymenorrhea (menstrual cycles occurring at intervals of less than 21 days) in a 45-year-old woman is most commonly a manifestation of **Abnormal Uterine Bleeding (AUB)** due to ovulatory dysfunction (AUB-O), typical of the perimenopausal period. The primary goal of management is to regulate the cycle and stabilize the endometrium. **Combined Oral Contraceptive Pills (OCPs)** are considered first-line medical management because they provide exogenous estrogen and progesterone, which suppress the pituitary-ovarian axis, ensure regular withdrawal bleeds, and reduce menstrual blood loss. A 3-cycle trial is standard to assess clinical response. **2. Why Other Options are Incorrect:** * **A. Hysterectomy:** This is a major surgical intervention and is reserved for cases where medical management fails, or there is a confirmed malignancy/large fibroids. It is never the first-line treatment for uncomplicated polymenorrhea. * **B. Progesterone for 3 cycles:** While cyclical progestins are used in AUB, OCPs are generally preferred in this age group for better cycle control and contraception, unless contraindicated (e.g., smoking, hypertension). * **C. Dilatation and Curettage (D&C):** D&C is primarily a diagnostic tool to rule out endometrial hyperplasia or malignancy in women >40 years. While it may be performed alongside medical management, it is not a "treatment" for regulating cycles. **3. NEET-PG High-Yield Pearls:** * **PALM-COEIN Classification:** Always categorize AUB using this FIGO system (Structural vs. Non-structural). * **Age Factor:** In any woman >35–40 years with AUB, **Endometrial Biopsy** is the gold standard investigation to rule out endometrial carcinoma before starting long-term therapy. * **Drug of Choice:** For acute heavy bleeding, high-dose IV Estrogen or Tranexamic acid is used; for chronic regulation, OCPs or the Levonorgestrel Intrauterine System (LNG-IUS) are preferred.

Question 75: Cystoglandular hyperplasia is a feature of:

A. Metropathia hemorrhagica (Correct Answer)
B. Oligomenorrhea
C. Polymenorrhea
D. Menorrhagia

Explanation: **Explanation:** **Metropathia Hemorrhagica** (also known as Schroeder’s Disease) is a specific type of Abnormal Uterine Bleeding (AUB) typically seen in perimenopausal women. It is characterized by specialized histopathological changes due to **persistent unovulation**. 1. **Why Option A is Correct:** In this condition, a follicular cyst persists in the ovary, leading to a state of **continuous estrogen stimulation** without the balancing effect of progesterone (due to the absence of a corpus luteum). This prolonged estrogenic phase causes the endometrium to become hyperplastic. Microscopically, the glands become dilated and vary in size, resembling "Swiss-cheese" patterns. This is termed **Cystoglandular Hyperplasia**. Clinically, it presents as a period of amenorrhea (6–8 weeks) followed by heavy, painless, prolonged bleeding. 2. **Why Other Options are Incorrect:** * **Oligomenorrhea:** Refers to infrequent cycles (>35 days). While it involves hormonal imbalances, it does not specifically define the histopathological finding of cystoglandular hyperplasia. * **Polymenorrhea:** Refers to frequent cycles (<21 days), usually due to a shortened follicular phase or luteal phase defect, not persistent estrogenic hyperplasia. * **Menorrhagia:** This is a symptom (heavy cyclic bleeding). While Metropathia Hemorrhagica causes heavy bleeding, "Menorrhagia" is a general term and does not imply the specific "Swiss-cheese" endometrial morphology. **High-Yield Clinical Pearls for NEET-PG:** * **Classic Triad:** Amenorrhea followed by heavy bleeding + Cystoglandular hyperplasia + Follicular cyst in one ovary. * **Endometrial Pattern:** Often described as the **"Swiss-cheese" pattern**. * **Key Hormone Profile:** High Estrogen, Zero Progesterone (Anovulatory). * **Treatment of Choice:** In perimenopausal women, Dilation and Curettage (D&C) is both diagnostic and therapeutic.

Question 76: A 45-year-old lady presented with dysfunctional uterine bleeding. Transvaginal ultrasound revealed an endometrial thickness of 8 mm. What should be the next step in the management of this patient?

A. Histopathology (Correct Answer)
B. Hysterectomy
C. Progesterone
D. Oral contraceptive pills

Explanation: **Explanation:** The primary objective in a 45-year-old woman presenting with Abnormal Uterine Bleeding (AUB) is to **exclude endometrial hyperplasia or malignancy**. **1. Why Histopathology is the Correct Answer:** In perimenopausal women (age >40–45 years), any irregular bleeding must be investigated with endometrial sampling. According to standard protocols, an endometrial thickness (ET) of **>4 mm in postmenopausal women** or **persistent/heavy bleeding in women over 40** warrants histopathological examination. In this patient, an ET of 8 mm is significant. Histopathology (via Endometrial Biopsy or D&C) is the "Gold Standard" to rule out premalignant or malignant changes before initiating medical or surgical therapy. **2. Why Other Options are Incorrect:** * **B. Hysterectomy:** This is a definitive surgical treatment. It should never be performed for AUB without first obtaining a tissue diagnosis to ensure there is no occult malignancy, which would require a different surgical approach (e.g., staging laparotomy). * **C & D. Progesterone / OCPs:** These are medical management options for Dysfunctional Uterine Bleeding (DUB). While they may control the bleeding, they are contraindicated as a *first step* in this age group until malignancy is ruled out, as they may mask symptoms of underlying cancer. **Clinical Pearls for NEET-PG:** * **Cut-off for Postmenopausal ET:** >4 mm requires biopsy. * **Cut-off for Perimenopausal ET:** There is no absolute "normal" ET, but >8–10 mm in the follicular phase is often considered suspicious. * **First-line Investigation for AUB:** TVS (Transvaginal Ultrasound). * **Gold Standard Investigation for AUB:** Endometrial Biopsy/Histopathology. * **Age Factor:** Any woman >40 years with AUB must undergo endometrial sampling.

Question 77: A 45-year-old lady presents with dysfunctional uterine bleeding (DUB) and has an 8 mm thick endometrial echo on sonography. What is the recommended next step?

A. Hysterectomy
B. Start progesterone therapy
C. Histopathological examination of the curettage (Correct Answer)
D. Follow-up sonography

Explanation: **Explanation:** The primary objective in managing a perimenopausal woman (age >40 years) with abnormal uterine bleeding (AUB/DUB) is to **exclude endometrial hyperplasia or malignancy**. 1. **Why Option C is correct:** In a 45-year-old woman, any abnormal bleeding pattern necessitates an endometrial sampling to obtain a tissue diagnosis. An endometrial thickness (ET) of **>4 mm** in postmenopausal women or persistent bleeding in perimenopausal women (especially with an ET of 8 mm) is a significant finding. Histopathological examination (HPE) via endometrial biopsy or Dilatation & Curettage (D&C) is the "gold standard" to rule out premalignant or malignant changes before starting medical or surgical treatment. 2. **Why other options are incorrect:** * **Option A (Hysterectomy):** This is a major surgical intervention and is never the first step without a definitive tissue diagnosis. * **Option B (Progesterone therapy):** While progesterones are used to treat DUB, they should only be started *after* malignancy has been ruled out. Blindly starting hormones can mask the symptoms of underlying cancer. * **Option D (Follow-up sonography):** Delaying diagnosis with repeat imaging is inappropriate when the current ET (8 mm) already warrants investigation in a symptomatic 45-year-old. **High-Yield Clinical Pearls for NEET-PG:** * **Age Cut-off:** For any woman **>40 years** presenting with AUB, endometrial sampling is the mandatory first-line investigation. * **Postmenopausal Bleeding:** The most common cause is atrophic endometritis, but the most important to rule out is endometrial carcinoma. An ET **>4 mm** in a postmenopausal woman requires immediate biopsy. * **TVUS vs. HPE:** Transvaginal Ultrasound (TVUS) is a screening tool; HPE is the confirmatory diagnostic tool.

Question 78: Cystoglandular hyperplasia is seen in which of the following conditions?

A. Menorrhagia
B. Polymenorrhea
C. Oligomenorrhea
D. Metropathia hemorrhagica (Correct Answer)

Explanation: **Explanation:** **Metropathia Hemorrhagica** (also known as Schroeder’s Disease) is a specific type of Dysfunctional Uterine Bleeding (DUB) typically seen in perimenopausal women. The underlying pathophysiology is **anovulation**, which leads to a state of **unopposed estrogen**. Without ovulation, no corpus luteum is formed, resulting in a lack of progesterone. The continuous estrogenic stimulation causes the endometrium to proliferate excessively without shedding, leading to **Cystoglandular Hyperplasia**. Histologically, this is characterized by a "Swiss-cheese appearance," where endometrial glands are dilated into various sizes (some cystic) and the stroma is hyperplastic. Clinically, this manifests as a period of amenorrhea (due to high estrogen) followed by heavy, painless, prolonged bleeding. **Analysis of Incorrect Options:** * **A. Menorrhagia:** This is a symptom (cyclic heavy bleeding) rather than a specific pathological entity. While it can be caused by hyperplasia, it is also caused by fibroids, adenomyosis, or IUDs, which do not show cystoglandular changes. * **B. Polymenorrhea:** Refers to frequent cycles (<21 days). It is usually due to a shortened follicular phase or luteal phase deficiency, not the prolonged unopposed estrogen seen in cystoglandular hyperplasia. * **C. Oligomenorrhea:** Refers to infrequent cycles (>35 days). While often anovulatory (e.g., PCOS), it does not specifically define the pathological state of Metropathia Hemorrhagica. **High-Yield Clinical Pearls for NEET-PG:** * **Classic Triad:** Amenorrhea followed by heavy bleeding in a perimenopausal woman. * **Histology:** "Swiss-cheese" endometrium (dilated glands). * **Ovarian finding:** Presence of a follicular cyst (unruptured follicle); absence of corpus luteum. * **Treatment of choice:** Dilation and Curettage (D&C) serves both a diagnostic and therapeutic purpose.

Question 79: The presentation of Asherman syndrome typically involves?

A. Hypomenorrhea (Correct Answer)
B. Oligomenorrhea
C. Menorrhagia
D. Metrorrhagia

Explanation: **Explanation:** **Asherman Syndrome** (intrauterine synechiae) is characterized by the formation of fibrous adhesions within the uterine cavity, usually following trauma to the basal layer of the endometrium (e.g., over-zealous curettage post-abortion or postpartum). **1. Why Hypomenorrhea is Correct:** The primary pathology is the replacement of functional endometrium with non-secretory scar tissue. This reduces the total surface area of the endometrium available to bleed during menstruation. Consequently, patients present with **hypomenorrhea** (scanty menses) or **amenorrhea** (complete absence of menses). This is a classic example of "outflow tract" or "uterine" cause of secondary amenorrhea where the hormonal axis remains intact. **2. Analysis of Incorrect Options:** * **Oligomenorrhea (B):** Refers to infrequent cycles (>35 days). In Asherman syndrome, the cycle frequency is usually regular (ovulatory), but the *volume* is reduced. * **Menorrhagia (C) & Metrorrhagia (D):** These involve heavy or irregular bleeding, typically caused by structural lesions (polyps, fibroids) or hormonal imbalances. In Asherman syndrome, the lack of functional tissue makes heavy bleeding physiologically impossible. **3. High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** **Hysteroscopy** (both diagnostic and therapeutic). * **Initial Investigation of Choice:** Hysterosalpingography (HSG), which shows characteristic "filling defects." * **Treatment:** Hysteroscopic adhesiolysis followed by an IUCD or Foley catheter insertion and high-dose estrogen therapy to promote endometrial regrowth. * **Prognosis:** While menstruation often returns, fertility remains guarded due to increased risks of placenta accreta and miscarriage.

Question 80: Which of the following statements regarding spasmodic dysmenorrhea is FALSE?

A. Often cured by delivery of a child.
B. Pain usually appears on the first day of menstruation.
C. Pain persists for 2-3 days. (Correct Answer)
D. Rare above age of 35 years.

Explanation: **Explanation:** Spasmodic (Primary) Dysmenorrhea is menstrual pain associated with ovulatory cycles in the absence of any identifiable pelvic pathology. It is primarily mediated by the release of **Prostaglandin F2α (PGF2α)**, which causes intense uterine contractions and ischemia. **1. Why Option C is False (The Correct Answer):** In spasmodic dysmenorrhea, the pain typically begins a few hours before or just at the onset of menstruation when the prostaglandin levels are at their peak. Crucially, the pain is short-lived, usually lasting only **12 to 24 hours**, and rarely persists beyond 48 hours. Pain persisting for 2–3 days or longer is more characteristic of **Congestive (Secondary) Dysmenorrhea**, often associated with conditions like endometriosis or PID. **2. Analysis of Other Options:** * **Option A:** Delivery of a child often cures primary dysmenorrhea because vaginal birth causes stretching or destruction of the adrenergic nerve terminals in the isthmus and cervix (Frankenhauser’s plexus), leading to reduced uterine activity. * **Option B:** Pain typically coincides with the start of the flow (first day) because that is when the endometrial shedding releases the maximum amount of prostaglandins. * **Option B:** It is a condition of young age, typically appearing shortly after menarche (once ovulatory cycles are established) and usually improves by the late 20s or early 30s. It is indeed rare above age 35. **High-Yield Clinical Pearls for NEET-PG:** * **First-line treatment:** NSAIDs (Prostaglandin synthetase inhibitors) like Mefenamic acid. * **Treatment for those seeking contraception:** Combined Oral Contraceptive Pills (OCPs) which inhibit ovulation. * **Key distinction:** Primary dysmenorrhea is **spasmodic** (colicky); Secondary dysmenorrhea is **congestive** (dull ache starting 3-5 days before menses).

Question 81: Hypothalamic amenorrhea is seen in which of the following conditions?

A. Stein-leventhal syndrome
B. Asherman syndrome
C. Kallman syndrome (Correct Answer)
D. Sheehan's syndrome

Explanation: **Explanation:** **Kallmann Syndrome (Correct Answer):** Kallmann syndrome is a form of **hypogonadotropic hypogonadism** caused by the failure of GnRH-secreting neurons to migrate from the olfactory placode to the **hypothalamus**. This results in a deficiency of Gonadotropin-Releasing Hormone (GnRH), leading to low levels of FSH and LH, and subsequent amenorrhea. A hallmark clinical feature is **anosmia** (loss of smell) due to the agenesis of olfactory bulbs. **Analysis of Incorrect Options:** * **A. Stein-Leventhal Syndrome (PCOS):** This is an ovarian/endocrine disorder characterized by hyperandrogenism and insulin resistance. While it involves altered GnRH pulsatility, it is primarily classified as an **ovulatory dysfunction** rather than a primary hypothalamic failure. * **B. Asherman Syndrome:** This is a cause of **outflow tract obstruction** (uterine/anatomical amenorrhea). It involves the formation of intrauterine adhesions (synechiae), usually post-curettage, preventing the menstrual flow despite normal hormonal axes. * **C. Sheehan’s Syndrome:** This is a **pituitary** cause of amenorrhea. It results from ischemic necrosis of the anterior pituitary gland due to severe postpartum hemorrhage (PPH). **High-Yield Clinical Pearls for NEET-PG:** * **Hypothalamic Amenorrhea** can also be "functional," triggered by excessive exercise (Female Athlete Triad), severe weight loss (Anorexia Nervosa), or psychological stress. * **Kallmann Syndrome Inheritance:** Most commonly X-linked recessive (KAL1 gene). * **Diagnostic Tip:** In hypothalamic or pituitary amenorrhea, the **Progesterone Challenge Test** will be negative (no withdrawal bleed) because the endometrium has not been primed by estrogen.

Question 82: Which of the following conditions is associated with dysfunctional uterine bleeding?

A. Metropathia haemorrhagica (Correct Answer)
B. Polycystic ovary syndrome
C. Endometrial tuberculosis
D. Hypothyroidism

Explanation: **Explanation:** **Metropathia Haemorrhagica** (also known as Schroeder’s Disease) is the classic clinical manifestation of **Anovulatory Dysfunctional Uterine Bleeding (DUB)**. The underlying pathophysiology involves a persistent unruptured graafian follicle, leading to a state of **unopposed estrogen**. Without ovulation, no corpus luteum forms, resulting in a lack of progesterone. This causes the endometrium to undergo continuous hyperplasia until it outgrows its blood supply, leading to irregular, heavy, and prolonged bleeding (menorrhagia) after a period of amenorrhea. **Analysis of Incorrect Options:** * **B. Polycystic Ovary Syndrome (PCOS):** While PCOS involves anovulation, it is a complex endocrine syndrome characterized by hyperandrogenism and insulin resistance. DUB is a *symptom* that can occur in PCOS, but Metropathia Haemorrhagica is the specific *pathological entity* defined as DUB. * **C. Endometrial Tuberculosis:** This is an organic cause of menstrual irregularities (usually leading to oligomenorrhea or amenorrhea due to synechiae/Asherman syndrome). DUB, by definition, excludes organic pelvic pathology. * **D. Hypothyroidism:** This is a systemic/endocrinological cause of abnormal uterine bleeding (AUB). Under the FIGO **PALM-COEIN** classification, hypothyroidism falls under "Endocrinopathy" (AUB-E), whereas DUB is strictly categorized under "Ovulatory Dysfunction" (AUB-O). **High-Yield Clinical Pearls for NEET-PG:** * **Classic Triad of Metropathia:** Amenorrhea (usually 6–8 weeks) followed by heavy painless bleeding in a perimenopausal woman. * **Hysterectomy Finding:** The uterus is usually slightly enlarged (myometrial hypertrophy) with a "Swiss-cheese" appearance of the endometrium (cystic glandular hyperplasia). * **Ovarian Finding:** Presence of a single large follicular cyst; absence of corpus luteum.

Question 83: A 45-year-old woman presents with amenorrhea for 9 months. She expresses a desire to become pregnant again. After excluding pregnancy, what is the next best test indicated in the evaluation of this patient's amenorrhea?

A. LH and FSH levels (Correct Answer)
B. Endometrial biopsy
C. Karyotyping
D. HSG (Hysterosalpingography)

Explanation: ### Explanation The patient is 45 years old and presents with secondary amenorrhea (absence of menses for >6 months). In a woman of this age, the most likely diagnosis is **Premature Ovarian Insufficiency (POI)** or the onset of **Menopause**. **1. Why LH and FSH levels are the correct next step:** After excluding pregnancy (the most common cause of secondary amenorrhea), the goal is to determine the anatomical or hormonal level of the defect. In a 45-year-old, measuring **FSH and LH** is the gold standard to assess ovarian reserve and function. * **High FSH (>40 IU/L)** on two occasions indicates hypergonadotropic hypogonadism (Menopause/POI), confirming that the ovaries are no longer responding to gonadotropins. * Given her desire for pregnancy, these levels are crucial for counseling regarding the feasibility of conception (likely requiring oocyte donation). **2. Why other options are incorrect:** * **Endometrial Biopsy:** Used to evaluate abnormal uterine bleeding or rule out hyperplasia/malignancy. It does not help diagnose the cause of amenorrhea. * **Karyotyping:** Indicated for primary amenorrhea or POI in women **under age 30** (to rule out Turner syndrome or Mosaicism). It is not routine for a 45-year-old. * **HSG:** Used to evaluate tubal patency and uterine cavity in infertility workups, but only after the hormonal cause of amenorrhea is established. **Clinical Pearls for NEET-PG:** * **Definition of Menopause:** 12 months of amenorrhea in a woman over 40. * **Premature Ovarian Insufficiency (POI):** Menopause occurring before age 40. * **Hormonal Profile in Menopause:** ↑ FSH, ↑ LH, ↓ Estrogen (FSH rises more significantly than LH due to loss of Inhibin-B). * **Progesterone Challenge Test:** Historically used to check estrogen priming and outflow tract patency, but FSH measurement is now the preferred initial hormonal assay.

Question 84: Puberty menorrhagia is treated by:

A. Progesterone
B. Progesterone and estrogen
C. GnRH analogues
D. All (Correct Answer)

Explanation: **Explanation:** **Puberty menorrhagia** is defined as excessive bleeding between the onset of menarche and 19 years of age. The underlying pathophysiology is usually an **unripe Hypothalamic-Pituitary-Ovarian (HPO) axis**, leading to **anovulatory cycles**. Without ovulation, there is no corpus luteum formation and no progesterone production. This results in "unopposed estrogen" action, causing the endometrium to become hyperplastic, fragile, and vascular, leading to heavy, irregular shedding. **Why "All" is the Correct Answer:** The management strategy depends on the severity of the bleeding and the clinical status of the patient: * **Option A (Progesterone):** This is the **first-line hormonal treatment**. It stabilizes the estrogen-primed endometrium and induces a "medical curettage" (withdrawal bleed), effectively stopping the heavy flow. * **Option B (Progesterone and Estrogen):** Combined Oral Contraceptive Pills (COCPs) are highly effective for cycle regulation and are used when progesterone alone is insufficient or if the patient requires long-term cycle control. * **Option C (GnRH Analogues):** These are reserved for **refractory or severe cases** (e.g., patients with underlying bleeding disorders like von Willebrand disease) to induce a temporary state of medical menopause, allowing the patient to recover from severe anemia. **Clinical Pearls for NEET-PG:** 1. **Most common cause:** Anovulatory cycles due to HPO axis immaturity. 2. **Most common systemic cause:** von Willebrand Disease (vWD) should be suspected if menorrhagia occurs from the very first period. 3. **Initial Investigation:** Complete Blood Count (CBC) and Pelvic Ultrasound (to rule out structural causes, though rare in this age group). 4. **Drug of Choice (Acute heavy bleed):** High-dose Progestogens or COCPs. 5. **Non-hormonal options:** Tranexamic acid (antifibrinolytic) and NSAIDs (mefenamic acid) are used for mild cases.

Question 85: Metropathia hemorrhagica is best treated by:

A. Curettage of uterus
B. Progestogen (Correct Answer)
C. Oestrogen
D. Clomiphene

Explanation: **Metropathia Hemorrhagica** (also known as Schroeder’s Disease) is a specific form of Dysfunctional Uterine Bleeding (DUB) characterized by anovulation. The underlying pathophysiology involves a persistent unruptured follicle, leading to **continuous estrogen stimulation** without the counter-balancing effect of progesterone. This results in endometrial hyperplasia, which eventually breaks down, causing heavy, irregular, and painless bleeding. ### Why Progestogen is the Correct Answer: Since the primary defect is the **absence of progesterone** (due to lack of a corpus luteum), the most logical and effective treatment is the administration of exogenous progestogens. Progestogens convert the proliferative/hyperplastic endometrium into a secretory one, stabilize the endometrial lining, and induce a "chemical curettage" upon withdrawal, thereby controlling the bleeding. ### Explanation of Incorrect Options: * **A. Curettage of uterus:** While diagnostic curettage helps rule out malignancy and provides temporary symptomatic relief, it is not the definitive treatment for the underlying hormonal imbalance. * **C. Oestrogen:** Estrogen is already in excess in this condition. Adding more would worsen the endometrial hyperplasia and increase the risk of endometrial carcinoma. * **D. Clomiphene:** This is an ovulation-inducing agent. While it may be used if the patient desires pregnancy, it is not the primary treatment for the acute management of the bleeding episode in Metropathia Hemorrhagica. ### Clinical Pearls for NEET-PG: * **Classic Presentation:** A period of amenorrhea (6–8 weeks) followed by heavy, painless bleeding. * **Histology:** Shows **Cystic Glandular Hyperplasia** (Swiss-cheese pattern). * **Ovarian Finding:** Presence of a follicular cyst (persistent unruptured follicle) and absence of corpus luteum. * **Uterine Finding:** The uterus is often slightly enlarged, soft, and symmetrical (myometrial hypertrophy due to hyperestrogenism).

Question 86: Which is not a feature of dysfunctional uterine bleeding?

A. Tender uterus (Correct Answer)
B. Uterine size of 8-10 weeks
C. Menorrhagia
D. Proliferative endometrium

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)** is defined as abnormal uterine bleeding in the absence of any detectable organic pelvic pathology, systemic disease, or pregnancy. It is a diagnosis of exclusion. **1. Why "Tender Uterus" is the correct answer:** Tenderness is a hallmark of **inflammatory or infective conditions** (like Pelvic Inflammatory Disease/Endometritis) or **Adenomyosis**. Since DUB is by definition non-organic and non-inflammatory, the uterus should be **non-tender**. Finding a tender uterus points toward an alternative diagnosis, making it "not a feature" of DUB. **2. Analysis of Incorrect Options:** * **Uterine size of 8-10 weeks:** In DUB, the uterus is typically normal in size or slightly bulky (up to 8–10 weeks) due to prolonged estrogen stimulation causing myometrial hypertrophy. Sizes beyond 12 weeks usually suggest fibroids or pregnancy. * **Menorrhagia:** This is the most common clinical presentation of DUB, particularly in ovulatory cycles or due to irregular shedding in anovulatory cycles. * **Proliferative endometrium:** This is a classic finding in **anovulatory DUB**. Without ovulation, there is no corpus luteum and no progesterone; the endometrium remains in the proliferative phase under the influence of unopposed estrogen until it outgrows its blood supply and sheds irregularly. **Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis:** Dilation and Curettage (D&C) or Hysteroscopy-guided biopsy to rule out malignancy (especially in patients >35 years). * **Most common type:** Anovulatory DUB (80%), common at extremes of reproductive life (puberty and perimenopause). * **Management:** Combined Oral Contraceptives (COCs) are first-line for most; **Levonorgestrel Intrauterine System (LNG-IUS)** is the most effective medical management for heavy menstrual bleeding.

Question 87: Which of the following is not a cause of primary amenorrhea?

A. Sheehan's syndrome (Correct Answer)
B. Kallman's syndrome
C. Turner's syndrome
D. Rokitansky syndrome

Explanation: **Explanation:** The distinction between primary and secondary amenorrhea is a high-yield concept in NEET-PG. **Primary amenorrhea** refers to the failure of menses to occur by age 15 (with secondary sexual characteristics) or age 13 (without them). **Secondary amenorrhea** is the cessation of menses for >3–6 months in a woman who previously had regular cycles. **Why Sheehan’s Syndrome is the correct answer:** Sheehan’s syndrome is **postpartum pituitary necrosis** caused by severe obstetric hemorrhage. Since it occurs as a complication of childbirth, the patient must have been menstruating and fertile previously. Therefore, it is a classic cause of **secondary amenorrhea**, not primary. **Analysis of Incorrect Options:** * **Kallmann’s Syndrome:** A hypogonadotropic hypogonadism caused by failure of GnRH neurons to migrate. It presents with primary amenorrhea and anosmia. * **Turner’s Syndrome (45,XO):** The most common cause of primary amenorrhea. It involves gonadal dysgenesis (streak ovaries), leading to hypergonadotropic hypogonadism. * **Rokitansky Syndrome (MRKH):** Characterized by Müllerian agenesis (absent uterus and upper 2/3 of the vagina) despite a 46,XX karyotype and normal ovaries. It is a common cause of primary amenorrhea with normal secondary sexual characteristics. **Clinical Pearls for NEET-PG:** * **Most common cause of Primary Amenorrhea:** Turner’s Syndrome. * **Most common cause of Secondary Amenorrhea:** Pregnancy (always rule this out first!). * **Sheehan’s Syndrome presentation:** Failure of lactation (earliest sign), followed by loss of pubic/axillary hair and secondary amenorrhea. * **Kallmann’s Syndrome:** Look for the keyword "anosmia" or "hyposmia" in the clinical stem.

Question 88: What is the most common cause of menorrhagia?

A. Anovulation (Correct Answer)
B. Malignancy
C. Endometriosis
D. Bleeding disorder

Explanation: **Explanation:** **Correct Answer: A. Anovulation** Anovulation is the most common cause of menorrhagia, particularly in the adolescent and perimenopausal age groups. In an anovulatory cycle, there is no corpus luteum formation, leading to a lack of **progesterone**. This results in "unopposed estrogen" action on the endometrium, causing it to proliferate excessively. Eventually, the hyperplastic endometrium outgrows its blood supply and undergoes irregular, asynchronous shedding, manifesting as heavy and prolonged menstrual bleeding (menorrhagia). **Analysis of Incorrect Options:** * **B. Malignancy:** While endometrial or cervical cancer can cause abnormal uterine bleeding (AUB), they are statistically less common than functional causes like anovulation, especially in younger populations. * **C. Endometriosis:** This typically presents with dysmenorrhea (painful periods) and chronic pelvic pain. While it can coexist with menorrhagia, it is not the primary cause of heavy bleeding; Adenomyosis is a more common structural cause of menorrhagia than endometriosis. * **D. Bleeding disorder:** Conditions like Von Willebrand Disease (vWD) are significant causes of menorrhagia (especially in adolescents), but they account for a much smaller percentage of cases compared to hormonal anovulation. **NEET-PG High-Yield Pearls:** * **PALM-COEIN Classification:** The FIGO system classifies AUB into Structural (Polyp, Adenomyosis, Leiomyoma, Malignancy) and Non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified). * **AUB-O (Ovulatory dysfunction):** This is the category for anovulation and is the most frequent diagnosis in clinical practice. * **First-line Investigation:** Transvaginal Ultrasound (TVS) is the gold standard for initial assessment of the uterus and adnexa. * **Gold Standard for Endometrial Assessment:** Endometrial biopsy (D&C or Pipelle) is mandatory in women >45 years (or >35 with risk factors) to rule out hyperplasia or malignancy.

Question 89: An 18-year-old college student who has recently become sexually active presents with severe primary dysmenorrhea. She does not want to become pregnant and has not found relief with heating pads or mild analgesics. Which of the following medications is most appropriate for this patient?

A. Prostaglandin inhibitors
B. Narcotic analgesics
C. Oxytocin
D. Oral contraceptives (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Oral Contraceptives** Primary dysmenorrhea is caused by excessive production of **Prostaglandin F2α (PGF2α)** in the secretory endometrium, leading to painful uterine contractions and ischemia. In this patient, Combined Oral Contraceptive Pills (OCPs) are the most appropriate choice because: 1. **Mechanism:** They suppress ovulation and thin the endometrial lining. A thinner endometrium produces significantly less prostaglandins, thereby reducing uterine contractility and pain. 2. **Clinical Context:** The patient is sexually active and desires contraception. OCPs address both the primary dysmenorrhea and her need for birth control, making them the first-line therapy in this scenario. **Analysis of Incorrect Options:** * **A. Prostaglandin inhibitors (NSAIDs):** While these are typically the first-line treatment for primary dysmenorrhea, the question states she has already tried "mild analgesics" without relief. Furthermore, OCPs provide the added benefit of contraception which she specifically requires. * **B. Narcotic analgesics:** These are contraindicated for chronic menstrual pain due to the high risk of dependence and side effects. * **C. Oxytocin:** This would worsen the condition as it stimulates uterine contractions, increasing pain. **NEET-PG High-Yield Pearls:** * **Primary Dysmenorrhea:** Pain usually begins 6–12 months after menarche (once ovulatory cycles are established). It typically starts 1–2 days before or with the onset of menses. * **First-line for non-sexually active:** NSAIDs (e.g., Mefenamic acid, Ibuprofen). * **First-line for sexually active/desiring contraception:** OCPs. * **Secondary Dysmenorrhea:** If pain does not respond to NSAIDs or OCPs, investigate for secondary causes like **Endometriosis** (most common) or Adenomyosis.

Question 90: Spasmodic dysmenorrhea is most commonly associated with which of the following conditions?

A. Endometriosis
B. Dysfunctional uterine bleeding (DUB)
C. Submucous fibroid (Correct Answer)
D. Ovarian cyst

Explanation: **Explanation:** **Spasmodic dysmenorrhea** (also known as primary-like secondary dysmenorrhea) is characterized by sharp, colicky pains in the lower abdomen. The underlying mechanism is the **active contraction of the uterine muscle** attempting to expel a foreign body or mass through the cervical canal. 1. **Why Submucous Fibroid is Correct:** A submucous fibroid acts as an intrauterine "foreign body." When the uterus tries to expel this pedunculated mass (often referred to as a "fibroid in evolution"), it triggers intense, spasmodic myometrial contractions. This mimics the mechanism of labor pains, leading to the classic spasmodic nature of the pain. 2. **Analysis of Incorrect Options:** * **Endometriosis:** Typically associated with **congestive (secondary) dysmenorrhea**. The pain is dull, aching, and begins a few days before menstruation due to pelvic congestion and inflammatory cytokines, rather than spasmodic contractions. * **Dysfunctional Uterine Bleeding (DUB):** Usually characterized by painless, heavy, or irregular bleeding (especially in anovulatory cycles). It does not typically present with spasmodic pain unless large clots are being expelled. * **Ovarian Cyst:** Generally causes chronic pelvic pain or acute pain in cases of torsion/rupture. It does not involve the uterine contractile mechanism required for spasmodic dysmenorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Dysmenorrhea:** Always spasmodic; occurs in ovulatory cycles due to **PGF2α** excess. Pain starts with the onset of menses. * **Secondary Dysmenorrhea:** Usually congestive. However, **submucous fibroids, endometrial polyps, and cervical stenosis** are specific causes of *spasmodic* secondary dysmenorrhea. * **Treatment of choice for Spasmodic Dysmenorrhea:** NSAIDs (Prostalglandin synthetase inhibitors) like Mefenamic acid.

Question 91: A child presents with primary amenorrhea. She has a negative progesterone challenge test but a positive combined estrogen and progesterone test. What is the most likely diagnosis?

A. Mullerian agenesis
B. Polycystic ovarian disease (PCOD)
C. Asherman syndrome
D. Prolactinoma (Correct Answer)

Explanation: ### Explanation This question tests the clinical approach to primary amenorrhea using the hormone challenge algorithm. **1. Understanding the Hormone Challenges:** * **Negative Progesterone Challenge Test (PCT):** This indicates that the patient did not bleed after receiving progesterone. This occurs if there is either **low endogenous estrogen** (failed proliferation of the endometrium) or an **outflow tract obstruction/uterine defect**. * **Positive Estrogen + Progesterone (E+P) Challenge:** The patient bled after receiving sequential E+P. This confirms that the **outflow tract and uterus are functional**. Therefore, the cause of amenorrhea is a lack of endogenous estrogen (Hypogonadism). **2. Why Prolactinoma is the Correct Answer:** A prolactinoma causes hyperprolactinemia, which inhibits the pulsatile release of GnRH from the hypothalamus. This leads to low FSH/LH levels (**Hypogonadotropic Hypogonadism**) and subsequent low estrogen. Because estrogen is absent, the PCT is negative; however, because the anatomy is normal, the E+P challenge is positive. **3. Why Other Options are Incorrect:** * **Mullerian Agenesis:** This involves the absence of the uterus and upper vagina. These patients will have a **negative E+P challenge** because there is no endometrium to bleed. * **Asherman Syndrome:** This involves intrauterine synechiae (scarring). Like Mullerian agenesis, it results in a **negative E+P challenge** due to end-organ failure. * **PCOD:** In PCOD, there is "unopposed estrogen" but no ovulation (no progesterone). These patients typically have a **positive PCT** because their endometrium is already primed with estrogen. **Clinical Pearls for NEET-PG:** * **Step 1 in Amenorrhea:** Rule out pregnancy (hCG test). * **Step 2:** Progesterone Challenge (Medroxyprogesterone acetate 10mg for 5–10 days). * **Positive PCT:** Suggests Anovulation (e.g., PCOD). * **Negative PCT + Positive E+P Challenge:** Suggests Hypothalamic-Pituitary axis failure or Premature Ovarian Failure. * **Negative PCT + Negative E+P Challenge:** Suggests Outflow tract obstruction (Mullerian agenesis, Asherman, Imperforate hymen).

Question 92: A 30-year-old woman with hypertension and menorrhagia, para 2+0, requires the best treatment. What is it?

A. Combined oral contraceptive pills
B. Levonorgestrel-releasing intrauterine system (Mirena) (Correct Answer)
C. Hysterectomy
D. Transcervical endometrial resection

Explanation: **Explanation:** The patient presents with **menorrhagia** (Heavy Menstrual Bleeding) and comorbid **hypertension**. The **Levonorgestrel-releasing intrauterine system (LNG-IUS/Mirena)** is the first-line medical management for menorrhagia according to NICE and FIGO guidelines. It works by releasing progestogen locally, leading to profound endometrial atrophy and a reduction in menstrual blood loss by up to 90-95%. In this specific case, it is the "best" treatment because it avoids the systemic side effects of estrogen. **Why other options are incorrect:** * **Combined Oral Contraceptive Pills (COCPs):** These are **contraindicated** in patients with hypertension (especially if uncontrolled or associated with other risk factors) due to the increased risk of thromboembolism and stroke caused by the estrogen component. * **Hysterectomy:** While definitive, it is a major surgical procedure with significant morbidity. It is reserved for cases where medical management fails or the patient has completed her family and specifically requests it. * **Transcervical Endometrial Resection (TCER):** This is a second-line surgical alternative to hysterectomy. It is generally considered only after medical management (like LNG-IUS) has failed. **NEET-PG High-Yield Pearls:** * **First-line medical management for HMB:** LNG-IUS (Mirena). * **Mechanism of LNG-IUS:** Local release of 20 mcg/day of levonorgestrel → Endometrial decidualization and atrophy. * **Contraindication for COCP:** Hypertension (BP >160/100 mmHg), smoking (>35 years), history of VTE, and migraine with aura. * **Non-hormonal first-line for HMB:** Tranexamic acid (Antifibrinolytic).

Question 93: Which of the following can cause dysfunctional uterine bleeding?

A. Uterine polyp
B. Fibroid
C. Granulosa cell tumour
D. Irregular ripening of the endometrium (Correct Answer)

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)** is defined as abnormal uterine bleeding in the absence of any detectable organic, systemic, or iatrogenic cause (e.g., pelvic pathology, pregnancy, or blood dyscrasias). It is primarily a diagnosis of exclusion and is typically caused by a hormonal imbalance affecting the hypothalamic-pituitary-ovarian axis. **Why Option D is Correct:** **Irregular ripening of the endometrium** is a classic example of ovulatory DUB. It occurs due to **corpus luteum insufficiency**, where inadequate progesterone production leads to poor endometrial support. This results in spotting before the onset of menses. Conversely, "irregular shedding" occurs due to a persistent corpus luteum (Halban’s disease). Both are functional disturbances of the cycle rather than structural lesions. **Why Other Options are Incorrect:** * **A. Uterine Polyp:** This is a structural/organic cause of bleeding (classified under 'P' in the FIGO **PALM-COEIN** classification). * **B. Fibroid (Leiomyoma):** This is a benign neoplastic growth of the myometrium and is a structural cause ('L' in PALM-COEIN). * **C. Granulosa Cell Tumour:** This is an estrogen-secreting ovarian tumor. While it causes bleeding, it is considered an organic/systemic cause rather than DUB. **High-Yield Clinical Pearls for NEET-PG:** * **FIGO Classification:** The term DUB is being replaced by the **PALM-COEIN** system. **PALM** (Polyp, Adenomyosis, Leiomyoma, Malignancy) represents structural causes, while **COEIN** (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified) represents non-structural/functional causes. * **Most Common Cause:** 80% of DUB cases are **Anovulatory** (common at extremes of age: puberty and perimenopause), characterized by "painless, heavy, irregular bleeding" due to unopposed estrogen. * **Investigation of Choice:** Transvaginal Ultrasound (TVS) is the initial investigation; however, **Endometrial Biopsy** is the gold standard to rule out malignancy in women >35 years.

Question 94: A 45-year-old female presents with polymenorrhoea for 6 months. On local examination, nothing abnormal was seen. Which of the following is the best line of management?

A. Progesterone for 3 cycles
B. Oral contraceptive pills for 3 cycles
C. Dilation and curettage (Correct Answer)
D. Hysterectomy

Explanation: **Explanation:** The primary concern in a 45-year-old woman presenting with abnormal uterine bleeding (AUB), such as polymenorrhoea, is to **exclude endometrial hyperplasia or malignancy**. 1. **Why Dilation and Curettage (D&C) is correct:** In perimenopausal women (age >40–45 years), any change in menstrual frequency or flow necessitates an endometrial biopsy or D&C to obtain a histopathological diagnosis. D&C serves a dual purpose: it is **diagnostic** (ruling out malignancy) and **therapeutic** (arresting the current bleeding episode). According to FIGO guidelines, endometrial sampling is the mandatory first-line investigation in this age group before starting hormonal therapy. 2. **Why other options are incorrect:** * **Progesterone/OCPs (Options A & B):** While hormonal therapy is used to manage AUB, it should never be initiated in a woman over 40 without first ruling out endometrial carcinoma. Starting hormones empirically may mask the symptoms of underlying malignancy, leading to a delayed diagnosis. * **Hysterectomy (Option D):** This is a major surgical intervention and is considered a definitive treatment only after a diagnosis is established and conservative/medical management has failed. It is not the "best first line" of management. **Clinical Pearls for NEET-PG:** * **Gold Standard:** Fractional curettage is the traditional gold standard for diagnosing endometrial pathology, though Pipelle biopsy is now often the preferred initial office procedure. * **TVUS Cut-off:** In postmenopausal women, an endometrial thickness (ET) >4 mm requires biopsy. In perimenopausal women, ET is less reliable due to cyclical variations, making sampling more critical. * **PALM-COEIN:** Remember this FIGO classification for AUB; in a 45-year-old, "M" (Malignancy and hyperplasia) must be ruled out first.

Question 95: What is the primary treatment for pubertal menorrhagia in a 16-year-old girl with 3 gm% Hb?

A. Dilatation and curettage with blood transfusion
B. Danazol with blood transfusion
C. Progestogen with blood transfusion
D. A combination of estrogen and progesterone with blood transfusion (Correct Answer)

Explanation: **Explanation:** The primary cause of pubertal menorrhagia is an **immature Hypothalamic-Pituitary-Ovarian (HPO) axis**, leading to anovulatory cycles. In the absence of ovulation, there is "unopposed estrogen" action on the endometrium, causing it to become hyperplastic, fragile, and prone to heavy, irregular shedding. **Why Option D is Correct:** In this clinical scenario, the patient is severely anemic (**Hb 3 gm%**), indicating an acute emergency. 1. **Blood Transfusion:** Essential to stabilize the patient and correct life-threatening anemia. 2. **Combined Oral Contraceptives (COCs):** Estrogen promotes rapid "healing" and stabilization of the denuded endometrial surface (hemostasis), while the progestogen stabilizes the stroma. This combination is the most effective medical method to stop acute, heavy bleeding in adolescents. **Analysis of Incorrect Options:** * **Option A (D&C):** Dilatation and Curettage is generally **contraindicated** in virgins/adolescents unless medical management fails or there is a suspicion of malignancy. It carries risks of trauma and Asherman syndrome. * **Option B (Danazol):** While it reduces menstrual loss, it is not used for acute stabilization due to its slow onset and significant androgenic side effects (acne, hirsutism). * **Option C (Progestogen alone):** While progestogens are used for maintenance, they are less effective than COCs in the *acute* phase of heavy bleeding where the endometrial lining is already shedding extensively. **Clinical Pearls for NEET-PG:** * **First-line investigation:** Always rule out **bleeding disorders** (e.g., von Willebrand disease) in any adolescent presenting with menorrhagia from the menarche. * **Management Goal:** The goal is to stabilize the endometrium and regulate the cycle until the HPO axis matures (usually within 2 years of menarche). * **Emergency Hemostasis:** High-dose Estrogen (IV or oral) is the fastest way to stop heavy bleeding by inducing rapid epithelialization.

Question 96: Bleeding from the umbilicus in an adult female during menstruation is suggestive of?

A. Bleeding diathesis
B. Vicarious menstruation (Correct Answer)
C. Persistent urachus
D. Purpura

Explanation: **Explanation:** The correct answer is **Vicarious Menstruation**. **1. Why Vicarious Menstruation is correct:** Vicarious menstruation refers to cyclical bleeding from extragenital sites during the normal menstrual cycle. It occurs due to the increased capillary permeability and fragility caused by high estrogen levels just before menstruation. The most common site is the **nasal mucosa** (epistaxis), but it can also occur from the umbilicus, stomach (hematemesis), lungs (hemoptysis), or skin. In the case of the umbilicus, it is often associated with **endometriosis** (Villar’s nodule), where ectopic endometrial tissue responds to hormonal fluctuations. **2. Why other options are incorrect:** * **Bleeding diathesis & Purpura:** These are systemic coagulation or platelet disorders. While they cause abnormal bleeding (e.g., petechiae, bruising, or menorrhagia), the bleeding is typically not strictly cyclical or synchronized with the menstrual phase. * **Persistent urachus:** This is a congenital anomaly where the connection between the bladder and the umbilicus fails to close. It typically presents with the leakage of **urine** from the umbilicus, not cyclical blood. **3. High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Nasal mucosa (Epistaxis). * **Villar’s Nodule:** Primary umbilical endometriosis; presents as a painful, bluish-purple umbilical swelling that bleeds cyclically. * **Mechanism:** Increased vascular congestion and capillary rupture triggered by the withdrawal of estrogen and progesterone. * **Treatment:** Usually involves hormonal suppression (OCPs, GnRH agonists) or surgical excision of the ectopic tissue.

Question 97: A child presents with primary amenorrhea. She has a negative progesterone challenge test but a positive combined estrogen and progesterone test. What is the most likely diagnosis?

A. Mullerian agenesis
B. Polycystic ovary disease (PCOD)
C. Asherman syndrome
D. Prolactinoma (Correct Answer)

Explanation: This question tests the systematic approach to primary amenorrhea using withdrawal bleeding tests. ### **Explanation of the Correct Answer** The withdrawal bleeding tests help localize the level of the defect in the Hypothalamic-Pituitary-Ovarian-Uterine axis: 1. **Negative Progesterone Challenge Test:** Indicates that the patient has either low endogenous estrogen (failing to prime the endometrium) or an anatomical outflow tract obstruction. 2. **Positive Combined Estrogen + Progesterone Test:** The occurrence of bleeding confirms that the **outflow tract (uterus and vagina) is patent** and the endometrium is responsive. Since the outflow tract is intact but estrogen is low, the defect lies in the **Ovaries** (Hypergonadotropic hypogonadism) or the **Hypothalamus/Pituitary** (Hypogonadotropic hypogonadism). Among the options, a **Prolactinoma** causes hyperprolactinemia, which inhibits GnRH pulsatility, leading to low FSH/LH and subsequent estrogen deficiency. This results in a negative progesterone challenge but a positive combined test. ### **Why Other Options are Wrong** * **Mullerian Agenesis:** There is a congenital absence of the uterus. Therefore, the patient will have a **negative** combined estrogen-progesterone test (no endometrium to bleed). * **Asherman Syndrome:** Characterized by intrauterine synechiae (adhesions). Like Mullerian agenesis, the combined test will be **negative** because the uterine cavity is obliterated. * **PCOD:** Patients typically have high endogenous estrogen and "unopposed" endometrial proliferation. They usually show a **positive** progesterone challenge test. ### **NEET-PG High-Yield Pearls** * **Step 1:** Progesterone challenge (e.g., Medroxyprogesterone 10mg for 5–10 days). If positive $\rightarrow$ Anovulation (e.g., PCOD). * **Step 2:** If Step 1 is negative, give Estrogen + Progesterone. If negative $\rightarrow$ Outflow tract obstruction (Mullerian agenesis, Asherman, MRKH). * **Step 3:** If Step 2 is positive, check FSH/LH levels. High FSH $\rightarrow$ Premature Ovarian Failure; Low FSH $\rightarrow$ Pituitary/Hypothalamic cause (e.g., Prolactinoma, Kallmann syndrome).

Question 98: All of the following conditions are associated with primary amenorrhea EXCEPT:

A. Testicular feminization syndrome
B. Stein-Leventhal syndrome (Correct Answer)
C. Turner's syndrome
D. Mayer-Rokitansky-Küster-Hauser syndrome

Explanation: **Explanation:** The correct answer is **Stein-Leventhal syndrome** (Polycystic Ovary Syndrome - PCOS). **1. Why Stein-Leventhal Syndrome is the correct answer:** Stein-Leventhal syndrome is characterized by hyperandrogenism, insulin resistance, and chronic anovulation. While it is a leading cause of **secondary amenorrhea** (cessation of menses after menarche), it is rarely a cause of primary amenorrhea. Patients typically achieve menarche but subsequently develop irregular cycles (oligomenorrhea) or amenorrhea due to hormonal imbalances. **2. Analysis of incorrect options (Causes of Primary Amenorrhea):** * **Testicular Feminization Syndrome (Androgen Insensitivity Syndrome):** These individuals are genotypically male (46, XY) but phenotypically female. Due to androgen receptor resistance, they have a blind vaginal pouch and absent uterus, leading to **primary amenorrhea**. * **Turner’s Syndrome (45, XO):** This is the most common cause of primary amenorrhea. Gonadal dysgenesis leads to "streak ovaries" and accelerated oocyte atresia, resulting in a failure to initiate puberty. * **Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome:** This involves Müllerian agenesis (congenital absence of the uterus and upper 2/3 of the vagina) in a genotypically and phenotypically normal female (46, XX). It is the second most common cause of **primary amenorrhea**. **Clinical Pearls for NEET-PG:** * **Most common cause of primary amenorrhea:** Turner’s Syndrome (Hypergonadotropic hypogonadism). * **Most common cause of secondary amenorrhea:** Pregnancy (Physiological); PCOS (Pathological). * **Differentiating MRKH vs. AIS:** Both present with primary amenorrhea and absent uterus. However, MRKH has **normal pubic/axillary hair** (46, XX), whereas AIS has **sparse/absent hair** (46, XY).

Question 99: Dysfunctional uterine bleeding is seen in which of the following conditions?

A. Metropathia haemorrhagia (Correct Answer)
B. Polycystic ovary syndrome
C. Endometrial tuberculosis
D. Hypothyroidism

Explanation: **Explanation:** **Metropathia Haemorrhagica** (also known as Schroeder’s Disease) is a classic clinical manifestation of **Dysfunctional Uterine Bleeding (DUB)**. It is characterized by specialized cystic glandular hyperplasia of the endometrium resulting from persistent un-antagonized estrogen. In this condition, a single follicle fails to rupture (no ovulation), leading to the absence of a corpus luteum and progesterone. The endometrium continues to proliferate under estrogenic influence until it outgrows its blood supply, leading to irregular, heavy, and prolonged bleeding. **Analysis of Incorrect Options:** * **Polycystic Ovary Syndrome (PCOS):** While PCOS involves anovulation and can cause abnormal uterine bleeding, it is classified as a systemic endocrine/metabolic disorder rather than "pure" DUB. In exams, Metropathia is the more specific pathological diagnosis for DUB. * **Endometrial Tuberculosis:** This is an organic/infective cause of bleeding (often leading to infertility or menstrual irregularities like oligomenorrhea/amenorrhea). DUB, by definition, occurs in the absence of any detectable organic pelvic pathology. * **Hypothyroidism:** This is a systemic endocrine cause of abnormal bleeding. While it affects the menstrual cycle, it is categorized as a secondary cause rather than primary DUB. **Clinical Pearls for NEET-PG:** * **DUB Definition:** Abnormal bleeding from the uterus in the absence of organic medical or pelvic pathology (e.g., no fibroids, polyps, or infection). * **Metropathia Haemorrhagica Triad:** Amenorrhea (usually 6–8 weeks) followed by heavy painless bleeding and a "Swiss-cheese" appearance of the endometrium on histology. * **Follicle Atresia:** The underlying pathology is the persistence of a Graafian follicle (Amnesic follicle) which fails to ovulate.

Question 100: What is the average blood loss during normal menstruation?

A. 50 mL (Correct Answer)
B. 80 mL
C. 100 mL
D. 120 mL

Explanation: **Explanation:** The average blood loss during a normal menstrual cycle is approximately **35–50 mL**. In clinical practice and for competitive exams like NEET-PG, **50 mL** is considered the standard mean value for a healthy menstruating woman. * **Option A (Correct):** 50 mL is the physiological average. Normal menstruation typically lasts 3–7 days, with the majority of blood loss occurring in the first 48 hours. * **Option B (Incorrect):** 80 mL is the **upper limit of normal**. Menstrual blood loss exceeding 80 mL per cycle is clinically defined as **Menorrhagia** (Heavy Menstrual Bleeding). This threshold is significant because losses above 80 mL often lead to a negative iron balance and subsequent iron-deficiency anemia. * **Options C & D (Incorrect):** 100 mL and 120 mL are well above the physiological average and the diagnostic threshold for menorrhagia. **High-Yield Clinical Pearls for NEET-PG:** 1. **Definition of Normal Menses:** Frequency of 24–38 days, duration of 4–8 days, and volume of 5–80 mL. 2. **Composition:** Menstrual discharge consists of blood, endometrial debris, vaginal epithelium, and cervical mucus. It is characterized by its **non-clotting nature** due to the presence of **plasmin** (fibrinolysin). The appearance of large clots usually indicates a loss exceeding 80 mL. 3. **Objective Measurement:** The "Gold Standard" for measuring blood loss is the **Alkaline Hematin method**, though the **PBAC (Pictorial Blood Loss Assessment Chart)** is more commonly used in clinical settings.

Question 101: Which of the following is NOT true about Abnormal Uterine Bleeding?

A. Blood loss of less than 50 ml (Correct Answer)
B. Cycle duration is more than 35 days or less than 21 days
C. Bleeding period lasting 7 days or more
D. Irregular bleeding during a regular cycle

Explanation: **Explanation:** Abnormal Uterine Bleeding (AUB) is defined as any variation from the normal menstrual cycle involving changes in frequency, regularity, duration, or volume of flow. **1. Why Option A is the Correct Answer (The "NOT True" statement):** In a normal menstrual cycle, the average blood loss is **30–40 ml**. AUB is clinically defined when blood loss exceeds **80 ml** per cycle (Menorrhagia/Heavy Menstrual Bleeding). A blood loss of less than 50 ml falls within the physiological normal range and does not constitute AUB. **2. Analysis of Incorrect Options (Features of AUB):** * **Option B:** A normal cycle length is 21–35 days. Cycles **<21 days** (Polymenorrhea) or **>35 days** (Oligomenorrhea) are classic presentations of AUB. * **Option C:** The normal duration of flow is 2–7 days. Bleeding lasting **≥7 days** is considered prolonged and is a criterion for AUB. * **Option D:** Irregular bleeding occurring between regular cycles (Intermenstrual bleeding/Metrorrhagia) is a hallmark sign of AUB, often associated with structural causes like polyps or malignancy. **High-Yield Clinical Pearls for NEET-PG:** * **FIGO Classification (PALM-COEIN):** Structural causes are **P**olyp, **A**denomyosis, **L**eiomyoma, **M**alignancy; Non-structural causes are **C**oagulopathy, **O**vulatory dysfunction, **E**ndometrial, **I**atrogenic, and **N**ot yet classified. * **Gold Standard for Blood Loss:** The **Alkaline Hematin Method** is the objective gold standard, though rarely used clinically. * **First-line Investigation:** Transvaginal Ultrasound (TVS) is the initial investigation of choice for AUB. * **Endometrial Sampling:** Indicated in all women **>45 years** with AUB to rule out endometrial hyperplasia or carcinoma.

Question 102: Which of the following is a cause of secondary amenorrhea?

A. Pelvic irradiation (Correct Answer)
B. Diabetes
C. Kallmann syndrome
D. Imperforate hymen

Explanation: **Explanation:** **Secondary amenorrhea** is defined as the absence of menses for 3 months in a woman with previously regular cycles, or 6 months in a woman with irregular cycles. **Why Option A is Correct:** **Pelvic irradiation** is a recognized cause of secondary amenorrhea due to **Premature Ovarian Insufficiency (POI)**. The ovaries are highly sensitive to radiation; high doses cause irreversible depletion of the primordial follicle pool and stromal fibrosis. This leads to hypergonadotropic hypogonadism, where the ovaries fail to produce estrogen despite stimulation from the pituitary. **Analysis of Incorrect Options:** * **B. Diabetes:** While uncontrolled diabetes can lead to metabolic stress and hypothalamic dysfunction, it is not a classic or primary cause of amenorrhea in the same way that PCOS or thyroid disorders are. It is generally considered a systemic association rather than a direct cause. * **C. Kallmann Syndrome:** This is a cause of **primary amenorrhea**. It is characterized by hypogonadotropic hypogonadism due to the failure of GnRH-producing neurons to migrate to the hypothalamus, often associated with anosmia. * **D. Imperforate Hymen:** This is a classic cause of **primary amenorrhea** (specifically, pseudoamenorrhea). It presents with cyclic pelvic pain and hematocolpos because the menstrual outflow is obstructed, though the hormonal axis is intact. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of secondary amenorrhea:** Pregnancy (always rule this out first with a UPT). * **Most common pathological cause:** Polycystic Ovary Syndrome (PCOS). * **Asherman Syndrome:** The most common uterine cause of secondary amenorrhea, often following over-zealous curettage. * **Sheehan Syndrome:** Pituitary necrosis post-postpartum hemorrhage, leading to secondary amenorrhea.

Question 103: What is the most common cause of dysfunctional uterine bleeding (DUB)?

A. Anovulatory causes (Correct Answer)
B. Ovulatory causes
C. Coagulopathy
D. Pregnancy-related complications

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)** is defined as abnormal uterine bleeding in the absence of any identifiable systemic or structural pathology (e.g., fibroids, polyps, or malignancy). **Why Anovulatory causes are correct:** Anovulation is the most common cause of DUB, accounting for approximately **80-90% of cases**. In anovulatory cycles, the absence of a corpus luteum leads to a lack of progesterone. This results in "unopposed estrogen" stimulation of the endometrium, causing it to become excessively vascular and fragile. Eventually, the endometrium outgrows its blood supply, leading to asynchronous, heavy, and irregular **estrogen breakthrough bleeding**. This is most frequently seen at the extremes of reproductive life (menarche and perimenopause). **Analysis of Incorrect Options:** * **B. Ovulatory causes:** These account for only 10-20% of DUB cases. Bleeding is usually regular but heavy (menorrhagia) due to defects in local endometrial hemostasis (e.g., prostaglandins). * **C. Coagulopathy:** While Von Willebrand disease is a common cause of heavy menstrual bleeding in adolescents, it is a systemic disorder and thus categorized under "Coagulopathy" in the PALM-COEIN classification, not DUB. * **D. Pregnancy-related complications:** These (e.g., ectopic pregnancy, miscarriage) are common causes of abnormal bleeding but are excluded by definition from DUB, which requires a non-pregnant state. **High-Yield Clinical Pearls for NEET-PG:** * **PALM-COEIN:** The FIGO classification has replaced the term DUB with "AUB" (Abnormal Uterine Bleeding). Anovulatory DUB falls under **AUB-O** (Ovulatory dysfunction). * **Drug of Choice:** For acute heavy anovulatory bleeding, **high-dose Estrogen** or Combined Oral Contraceptive Pills (OCPs) are used to stabilize the endometrium. * **Gold Standard Investigation:** For women >35 years with DUB, an **Endometrial Biopsy** is mandatory to rule out endometrial hyperplasia or malignancy.

Question 104: Primary amenorrhoea is a feature of all EXCEPT:

A. Turner's syndrome
B. Stein-Leventhal syndrome (Correct Answer)
C. Rokitansky-Kustner-Hauser syndrome
D. Kallman syndrome

Explanation: **Explanation:** The core concept of this question lies in distinguishing between conditions that cause a failure to start menstruation (Primary Amenorrhoea) versus those that typically cause a cessation of established cycles (Secondary Amenorrhoea). **Why Stein-Leventhal Syndrome is the Correct Answer:** Stein-Leventhal syndrome, commonly known as **Polycystic Ovary Syndrome (PCOS)**, is the most common cause of **secondary amenorrhoea** or oligomenorrhoea. In PCOS, the patient typically undergoes normal puberty and thelarche, and starts their periods (menarche). The menstrual irregularities or amenorrhoea develop later due to chronic anovulation and hyperandrogenism. While rare cases of primary amenorrhoea can occur if the hormonal imbalance is severe from puberty, it is classically a feature of secondary amenorrhoea. **Analysis of Incorrect Options:** * **Turner’s Syndrome (45, XO):** The most common cause of primary amenorrhoea. It involves streak ovaries (gonadal dysgenesis), leading to hypergonadotropic hypogonadism. * **Rokitansky-Kuster-Hauser (MRKH) Syndrome:** The second most common cause of primary amenorrhoea. It is characterized by Müllerian agenesis (absence of uterus and upper 2/3rd of the vagina) despite a normal 46, XX karyotype and normal ovarian function. * **Kallman Syndrome:** A form of hypogonadotropic hypogonadism caused by failure of GnRH-secreting neurons to migrate. It presents with primary amenorrhoea and anosmia (loss of smell). **High-Yield Clinical Pearls for NEET-PG:** * **Primary Amenorrhoea Definition:** No menses by age 13 (without secondary sexual characters) or age 15 (with secondary sexual characters). * **Most common cause of Primary Amenorrhoea:** Turner’s Syndrome. * **Most common cause of Secondary Amenorrhoea:** Pregnancy (Always rule this out first!). * **MRKH vs. AIS:** In MRKH, pubic hair is normal (46,XX); in Androgen Insensitivity Syndrome (AIS), pubic hair is absent/scanty (46,XY).

Question 105: Menorrhagia is defined as blood loss per vagina exceeding which of the following amounts?

A. 80 ml (Correct Answer)
B. 110 ml
C. 150 ml
D. 50 ml

Explanation: **Explanation:** **Menorrhagia** (now clinically referred to under the umbrella of Abnormal Uterine Bleeding or AUB-Heavy Menstrual Bleeding) is objectively defined as cyclic bleeding that is excessive in amount (**>80 ml**) or duration (>7 days) occurring at regular intervals. 1. **Why 80 ml is correct:** The threshold of 80 ml is the gold standard used in medical literature (based on the Hallberg et al. studies). It was determined that women losing more than 80 ml of blood per cycle are at a significantly higher risk of developing iron-deficiency anemia, as this loss exceeds the body's regenerative capacity for iron. 2. **Why other options are incorrect:** * **50 ml:** This is within the normal range of menstrual blood loss (average is 30–40 ml). * **110 ml and 150 ml:** While these amounts certainly constitute menorrhagia, they are not the *defining threshold*. The diagnostic criteria begin at the 80 ml mark. **High-Yield Clinical Pearls for NEET-PG:** * **Measurement:** In clinical practice, the **PBAC (Pictorial Blood Loss Assessment Chart)** is often used to estimate loss, where a score >100 suggests >80 ml loss. * **Terminology Update:** FIGO now recommends the term **"Heavy Menstrual Bleeding" (HMB)** instead of menorrhagia. * **PALM-COEIN:** Remember this FIGO classification for causes of AUB (Polyp, Adenomyosis, Leiomyoma, Malignancy; Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified). * **First-line Investigation:** Transvaginal Ultrasound (TVS). * **Medical Management:** Levonorgestrel Intrauterine System (LNG-IUS/Mirena) is the gold standard medical treatment for HMB.

Question 106: A 25-year-old female developed secondary amenorrhea of 6 months' duration. Even after administration of estrogen and progesterone for two weeks, there was no vaginal bleeding. The underlying cause could be in the:

A. Pituitary gland
B. Hypothalamus
C. Uterus (Correct Answer)
D. Ovary

Explanation: This question tests your understanding of the **Step-wise Evaluation of Secondary Amenorrhea**. ### **Explanation** The diagnosis is based on the **Progesterone Challenge Test (PCT)** followed by the **Estrogen-Progesterone (E+P) Challenge Test**. 1. **Why Uterus is Correct:** When a patient with secondary amenorrhea fails to bleed after receiving combined Estrogen and Progesterone, it indicates an **end-organ failure**. For menstruation to occur, there must be a functional endometrium and a patent outflow tract. A negative E+P challenge (no withdrawal bleed) confirms that the endometrium is either absent, scarred, or unresponsive, or there is an anatomical obstruction. The most common cause in this scenario is **Asherman’s Syndrome** (intrauterine synechiae) or cervical stenosis. 2. **Why Other Options are Incorrect:** * **Hypothalamus (B) & Pituitary (A):** If the defect were at the level of the HPO axis (low GnRH or low FSH/LH), the endometrium would still be responsive. Providing exogenous E+P would prime the endometrium and cause a withdrawal bleed. * **Ovary (D):** In Premature Ovarian Failure, the endogenous estrogen is low, but the uterus remains functional. Administering exogenous E+P would result in a withdrawal bleed. ### **NEET-PG High-Yield Pearls** * **Step 1:** Rule out pregnancy (Urine Pregnancy Test). * **Step 2:** Check TSH and Prolactin levels. * **Step 3 (PCT):** Give Medroxyprogesterone acetate (10mg for 5–10 days). Bleeding = Anovulation (PCOS is the most common cause). * **Step 4 (E+P Challenge):** If PCT is negative, give Estrogen (21 days) + Progesterone (last 10 days). * **Bleeding:** Problem is in the HPO Axis (Hypothalamus/Pituitary) or Ovaries. * **No Bleeding:** Problem is in the **Outflow tract/Uterus** (e.g., Asherman’s Syndrome).

Question 107: What is the drug of choice in premenstrual syndrome?

A. Antipsychotics
B. SSRI (Selective Serotonin Reuptake Inhibitors) (Correct Answer)
C. OCP (Oral Contraceptive Pills)
D. Depo-progesterone

Explanation: ### Explanation **Premenstrual Syndrome (PMS)** and its more severe form, **Premenstrual Dysphoric Disorder (PMDD)**, are characterized by cyclic physical and emotional symptoms occurring during the luteal phase. The pathophysiology is linked to the interaction between fluctuating ovarian steroids and central neurotransmitters, particularly **Serotonin**. **1. Why SSRIs are the Drug of Choice (DOC):** Selective Serotonin Reuptake Inhibitors (SSRIs) like **Fluoxetine, Sertraline, and Paroxetine** are the first-line treatment because they directly address the underlying serotonergic deficiency. Unlike their use in major depression (which takes weeks to work), SSRIs in PMS/PMDD provide rapid symptom relief and can be administered either continuously or **luteal-phase only** (starting on day 14 and stopping at the onset of menses). **2. Analysis of Incorrect Options:** * **Antipsychotics:** These are not indicated for PMS. While PMS involves mood changes, it is not a psychotic disorder. * **OCPs:** These are second-line treatments. While they suppress ovulation (the trigger for PMS), they may sometimes worsen mood symptoms due to the progestogen component. However, OCPs containing **Drospirenone** are specifically effective for physical symptoms. * **Depo-progesterone:** Progestogens alone are generally not effective and can occasionally exacerbate the depressive symptoms of PMS. **3. High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis:** Prospective charting of symptoms for at least **two consecutive cycles** (e.g., using the Daily Record of Severity of Problems). * **First-line Non-pharmacological:** Lifestyle modifications (exercise, complex carbohydrates, and reducing caffeine/alcohol). * **Definitive Treatment:** Surgical oophorectomy (only in extreme, refractory cases). * **Spironolactone:** The drug of choice specifically for **premenstrual bloating** and edema. * **Vitamin B6 (Pyridoxine):** Often used as a supplement to aid serotonin synthesis.

Question 108: Dysfunctional uterine bleeding (DUB) is seen in which of the following conditions?

A. Polycystic ovarian disease
B. Endometrial tuberculosis
C. Metropathia haemorrhagica (Correct Answer)
D. Multiple fibroids

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)** is defined as abnormal uterine bleeding in the absence of any detectable organic, systemic, or iatrogenic cause (e.g., pregnancy, tumors, or infection). It is primarily a diagnosis of exclusion resulting from hormonal imbalances, most commonly **anovulation**. **Why Metropathia Haemorrhagica is correct:** Metropathia Haemorrhagica (Schroeder’s Disease) is a classic clinical manifestation of DUB. It occurs due to persistent un-antagonized estrogen levels (follicular cyst) without ovulation. The absence of progesterone leads to an overgrowth of the endometrium (hyperplasia), which eventually breaks down, causing a characteristic period of amenorrhea followed by prolonged, painless, heavy bleeding. **Analysis of Incorrect Options:** * **Polycystic Ovarian Disease (PCOD):** While PCOD involves anovulation, it is considered a **systemic endocrine disorder**. Modern classifications (FIGO) separate systemic/ovulatory dysfunctions from the traditional "DUB" umbrella when a specific syndrome like PCOD is identified. * **Endometrial Tuberculosis:** This is an **infectious/organic cause** of bleeding (or more commonly, amenorrhea due to synechiae). * **Multiple Fibroids:** These are **structural/organic lesions** (Leiomyomas). According to the FIGO **PALM-COEIN** classification, fibroids (Leiomyoma) fall under structural causes, whereas DUB falls under non-structural causes (specifically Ovulatory dysfunction or Endometrial). **High-Yield Clinical Pearls for NEET-PG:** * **PALM-COEIN Classification:** Structural causes (Polyp, Adenomyosis, Leiomyoma, Malignancy) vs. Non-structural (Coagulopathy, Ovulatory, Endometrial, Iatrogenic, Not classified). * **DUB Management:** The first-line medical management for DUB is often **Combined Oral Contraceptive Pills (COCPs)** or the **Levonorgestrel-releasing Intrauterine System (LNG-IUS/Mirena)**. * **Metropathia Haemorrhagica** is most common in perimenopausal women.

Question 109: The presentation of Asherman syndrome typically involves which of the following?

A. Hypomenorrhea (Correct Answer)
B. Oligomenorrhea
C. Menorrhagia
D. Metrorrhagia

Explanation: **Explanation:** **Asherman Syndrome** is characterized by the formation of intrauterine adhesions (synechiae) following trauma to the basal layer of the endometrium, most commonly due to over-zealous curettage (D&C) after a miscarriage or postpartum hemorrhage. **Why Hypomenorrhea is Correct:** The primary pathology is the partial or complete obliteration of the uterine cavity by fibrous bands. This reduces the functional surface area of the endometrium available for hormonal response and shedding. Consequently, patients present with **hypomenorrhea** (scanty menses) or **amenorrhea** (absence of menses). Since the ovaries remain functional, the hormonal profile is normal, but the "end-organ" (uterus) cannot respond. **Analysis of Incorrect Options:** * **B. Oligomenorrhea:** This refers to infrequent cycles (>35 days apart), usually caused by hypothalamic-pituitary-ovarian axis dysfunction (e.g., PCOS). In Asherman syndrome, the cycle frequency is often regular, but the flow volume is reduced. * **C. Menorrhagia & D. Metrorrhagia:** These involve heavy or irregular bleeding, typically associated with structural lesions like fibroids, polyps, or hormonal imbalances. Asherman syndrome involves a *loss* of tissue, making heavy bleeding clinically impossible. **NEET-PG High-Yield Pearls:** * **Gold Standard Investigation:** Hysteroscopy (it is both diagnostic and therapeutic). * **HSG Finding:** Shows characteristic "filling defects" or a "honeycomb appearance." * **Treatment:** Hysteroscopic adhesiolysis followed by an IUCD or Foley catheter insertion and high-dose estrogen therapy to promote endometrial regrowth. * **Netter’s Syndrome:** A specific form of Asherman syndrome caused by genital tuberculosis.

Question 110: Amenorrhea for three months in a female may indicate the following EXCEPT:

A. Pregnancy
B. Tuberculosis of the genital tract
C. Endometriosis (Correct Answer)
D. Sheehan's syndrome

Explanation: **Explanation:** The core concept tested here is the etiology of **secondary amenorrhea** (the absence of menses for 3 months in a woman with previously normal cycles). **Why Endometriosis is the Correct Answer:** Endometriosis is defined as the presence of functioning endometrial tissue outside the uterine cavity. Clinically, it is characterized by **cyclical pelvic pain (dysmenorrhea)**, dyspareunia, and infertility. Crucially, endometriosis **does not cause amenorrhea**; in fact, it is often associated with regular cycles or even menorrhagia (heavy bleeding). Therefore, it is the "except" in this list. **Analysis of Incorrect Options:** * **Pregnancy:** This is the **most common cause** of secondary amenorrhea in women of reproductive age. It must always be ruled out first via a urine pregnancy test (hCG). * **Genital Tuberculosis:** In developing countries, TB is a major cause of secondary amenorrhea. It causes chronic endometritis leading to intrauterine synechiae (**Asherman’s Syndrome**) or destruction of the ovaries, resulting in permanent cessation of menses. * **Sheehan’s Syndrome:** This is post-partum pituitary necrosis due to severe obstetric hemorrhage. The resulting panhypopituitarism leads to a failure of gonadotropin (FSH/LH) secretion, causing secondary amenorrhea and failure of lactation. **High-Yield NEET-PG Pearls:** * **First investigation for secondary amenorrhea:** Urine Pregnancy Test. * **Most common cause of primary amenorrhea:** Turner Syndrome (45,XO). * **Asherman’s Syndrome:** Diagnosis is best made via Hysteroscopy (Gold Standard) or HSG (shows "honeycomb" appearance). * **Sheehan’s Syndrome:** The earliest clinical sign is the failure of lactation (prolactin deficiency).

Question 111: Which of the following is the definition of primary amenorrhea?

A. Absence of menses by the age of 12 years, irrespective of the presence of normal growth and development of secondary sexual characteristics.
B. Absence of menses by the age of 13 years, irrespective of the presence of normal growth and development of secondary sexual characteristics.
C. Absence of menses by the age of 14 years, irrespective of the presence of normal growth and development of secondary sexual characteristics.
D. Absence of menses by the age of 15 years, irrespective of the presence of normal growth and development of secondary sexual characteristics. (Correct Answer)

Explanation: Primary amenorrhea is defined based on the failure of menarche to occur within a specific developmental timeline. According to the current guidelines (ACOG), the diagnosis is made if there is an **absence of menses by age 15 years** in the presence of normal growth and secondary sexual characteristics. ### Why Option D is Correct: The medical rationale is based on the statistical distribution of menarche. By age 15, approximately 98% of girls have started their periods. If menses have not occurred by this age, even with normal breast development (thelarche) and pubic hair (adrenarche), a clinical evaluation for outflow tract obstructions (e.g., imperforate hymen) or genetic/endocrine disorders is warranted. ### Why Other Options are Incorrect: * **Options A & B (12 and 13 years):** These are too early. While the average age of menarche is approximately 12.4 years, many healthy girls start later. * **Option C (14 years):** Previously, 14 years was the cutoff if secondary sexual characteristics were absent. However, for a girl with **normal** secondary sexual characteristics, the threshold is 15 years. ### NEET-PG High-Yield Pearls: * **The "Rule of 13 & 15":** Primary amenorrhea is also diagnosed if there is no menses **and** no secondary sexual characteristics by **age 13**. * **Most Common Cause:** The most common cause of primary amenorrhea is **Genetic/Gonadal dysgenesis (Turner Syndrome, 45,XO)**. * **Second Most Common Cause:** Müllerian agenesis (Mayer-Rokitansky-Küster-Hauser syndrome). * **Initial Step in Evaluation:** A thorough physical exam (to check for secondary sexual characteristics) followed by a pregnancy test (to rule out the most common cause of any amenorrhea) and an ultrasound to confirm the presence of a uterus.

Question 112: Which of the following is associated with cystic glandular hyperplasia in premenopausal women?

A. Menorrhagia
B. Polymenorrhea
C. Oligomenorrhea
D. Metropathia haemorrhagica (Correct Answer)

Explanation: **Explanation:** **Metropathia Haemorrhagica** (also known as Schroeder’s Disease) is a specific type of Dysfunctional Uterine Bleeding (DUB) typically seen in premenopausal women. The underlying pathophysiology is **persistent anovulation**, leading to a state of **unopposed estrogen**. In the absence of ovulation, no corpus luteum is formed, and progesterone is not produced. The endometrium remains in a continuous proliferative phase, leading to **Cystic Glandular Hyperplasia** (Swiss-cheese appearance). Eventually, the hyperplastic endometrium outgrows its blood supply, leading to irregular, heavy, and prolonged shedding. **Analysis of Options:** * **Metropathia Haemorrhagica (Correct):** It is classically characterized by a period of amenorrhea (6–8 weeks) followed by heavy, painless bleeding. The hallmark histopathological finding is cystic glandular hyperplasia. * **Menorrhagia:** While metropathia involves heavy bleeding, "menorrhagia" is a general symptom (cyclic heavy bleeding). Metropathia is the specific clinical entity associated with this specific pathology. * **Polymenorrhea:** This refers to cycles shorter than 21 days. While it can occur in anovulatory cycles, it is not the classic association for cystic glandular hyperplasia. * **Oligomenorrhea:** This refers to infrequent cycles. While metropathia begins with a short period of amenorrhea, the defining clinical feature is the subsequent hemorrhagic episode. **High-Yield Clinical Pearls for NEET-PG:** * **Histology:** The "Swiss-cheese appearance" is due to dilated glands of varying sizes with flattened epithelium. * **Clinical Presentation:** Typically a woman in her 40s presenting with a period of amenorrhea followed by "flooding" (painless, heavy bleeding). * **Management:** In premenopausal women, the first line is often hormonal (progestogens) or D&C (diagnostic and therapeutic). Hysterectomy is the definitive treatment if medical management fails.

Question 113: What is the most common cause of menorrhagia during puberty?

A. Anovulation (Correct Answer)
B. Malignancy
C. Endometriosis
D. Bleeding disorder

Explanation: **Explanation:** **1. Why Anovulation is Correct:** In the first few years following menarche, the Hypothalamic-Pituitary-Ovarian (HPO) axis is immature. This leads to **anovulatory cycles**, which are the most common cause of Abnormal Uterine Bleeding (AUB) in adolescents. In the absence of ovulation, no corpus luteum is formed, leading to a lack of progesterone. The endometrium remains under the continuous, unopposed influence of estrogen, causing it to become hyperplastic and vascular. Eventually, this thickened lining outgrows its blood supply, leading to irregular, heavy, and prolonged shedding (estrogen breakthrough bleeding). **2. Why Other Options are Incorrect:** * **Malignancy:** While a concern in postmenopausal women, genital tract malignancies (like endometrial cancer) are extremely rare in the pubertal age group. * **Endometriosis:** This typically presents with chronic pelvic pain and secondary dysmenorrhea rather than heavy menstrual bleeding (menorrhagia). * **Bleeding Disorders:** Conditions like Von Willebrand Disease (vWD) are the most common *organic* or *systemic* cause of adolescent menorrhagia (found in up to 20% of severe cases), but they are statistically less common than physiological anovulation. **Clinical Pearls for NEET-PG:** * **First-line investigation** for AUB in adolescents: Pelvic Ultrasound (usually shows a thick endometrium). * **First-line management** for mild/moderate anovulatory AUB: Combined Oral Contraceptive Pills (OCPs) or cyclic progestins to stabilize the endometrium. * **High-Yield Fact:** If an adolescent presents with menorrhagia requiring hospitalization or blood transfusion at the time of **menarche**, always screen for **Von Willebrand Disease**.

Question 114: Which of the following is NOT a cause of amenorrhea?

A. Pituitary adenoma
B. Chronic nephritis
C. Tubercular endometritis
D. Adenomyosis (Correct Answer)

Explanation: **Explanation:** The correct answer is **Adenomyosis**. To understand why, we must look at the pathophysiology of the menstrual cycle. Amenorrhea (absence of menses) occurs when there is a disruption in the Hypothalamic-Pituitary-Ovarian (HPO) axis or an anatomical defect in the outflow tract. **Why Adenomyosis is the correct answer:** Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. This leads to an enlarged, globular uterus and increased surface area of the endometrium. Clinically, it presents with **menorrhagia** (heavy menstrual bleeding) and **dysmenorrhea** (painful periods), rather than the absence of periods. It is a cause of Abnormal Uterine Bleeding (AUB-A), not amenorrhea. **Analysis of Incorrect Options:** * **Pituitary Adenoma:** Prolactin-secreting tumors (prolactinomas) inhibit the pulsatile release of GnRH, leading to hypogonadotropic hypogonadism and **secondary amenorrhea**. * **Chronic Nephritis:** Chronic systemic illnesses (like renal failure or severe anemia) act as metabolic stressors that suppress the HPO axis, leading to **functional hypothalamic amenorrhea**. * **Tubercular Endometritis:** In developing countries, TB is a leading cause of **Asherman-like syndrome**. Chronic infection leads to the destruction of the basal layer of the endometrium and subsequent intrauterine adhesions (synechiae), causing permanent amenorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of Primary Amenorrhea:** Turner Syndrome (45, XO). * **Most common cause of Secondary Amenorrhea:** Pregnancy (always rule this out first!). * **Asherman Syndrome:** Diagnosis is confirmed via Hysterosalpingography (HSG) or Hysteroscopy (Gold Standard). * **Adenomyosis Triad:** Menorrhagia, Dysmenorrhea, and a symmetrically enlarged "bulky" uterus.

Question 115: A 45-year-old lady presented with recurrent uterine bleeding. On transvaginal ultrasound, the thickness of the endometrium was found to be 8 mm. What should be the next step in the management of this patient?

A. Histopathology (Correct Answer)
B. Hysterectomy
C. Progesterone
D. Oral contraceptive pills

Explanation: **Explanation:** The management of Abnormal Uterine Bleeding (AUB) in the perimenopausal age group (age >40 years) focuses primarily on ruling out **Endometrial Hyperplasia or Malignancy**. **1. Why Histopathology is the Correct Answer:** In a 45-year-old woman with recurrent bleeding and an endometrial thickness (ET) of **8 mm**, the gold standard next step is endometrial sampling for **histopathology**. While the cutoff for ET in postmenopausal women is 4 mm, in perimenopausal women, any thickness >3–5 mm in the presence of symptoms, or a persistent thickness >8–10 mm, warrants a biopsy. Histopathology is mandatory to exclude premalignant conditions before initiating medical or surgical therapy. **2. Why Other Options are Incorrect:** * **Hysterectomy:** This is a definitive surgical treatment. It should never be performed without a prior tissue diagnosis, as the presence of malignancy would change the surgical approach (e.g., staging laparotomy vs. simple hysterectomy). * **Progesterone & OCPs:** These are medical management options for Dysfunctional Uterine Bleeding (DUB). However, they should only be started *after* organic causes and malignancy have been ruled out via histopathology. **Clinical Pearls for NEET-PG:** * **Age >40 years + AUB:** Always perform an endometrial biopsy (Pipelle or D&C) as the first-line investigation. * **Postmenopausal Bleeding:** The "Safe" ET cutoff is **<4 mm**. If ET is >4 mm, biopsy is mandatory. * **Gold Standard:** While TVS is the initial screening tool, **Fractional Curettage** or **Hysteroscopic-guided biopsy** provides the definitive diagnosis. * **TV-USG Timing:** In premenopausal women, TVS should ideally be done on Day 4–6 of the cycle (when the endometrium is thinnest).

Question 116: All of the following are true about pubertal menorrhagia EXCEPT:

A. Associated with anovulatory bleeding
B. Endometrial biopsy confirms diagnosis (Correct Answer)
C. Routine screening for bleeding disorder is done
D. Hematinics and hormone therapy is the treatment of choice

Explanation: **Explanation:** Pubertal menorrhagia refers to excessive menstrual bleeding occurring between menarche and 19 years of age. Understanding its pathophysiology is crucial for NEET-PG. **Why Option B is the Correct Answer (The "Except"):** Endometrial biopsy is **contraindicated** and unnecessary in adolescents. The primary cause of pubertal menorrhagia is an immature Hypothalamic-Pituitary-Ovarian (HPO) axis, not malignancy. In this age group, the risk of endometrial cancer is near zero; therefore, invasive procedures like biopsy or D&C are avoided unless there is a high suspicion of rare pathology or failure of medical management in older patients. **Analysis of Other Options:** * **Option A:** Most cases (up to 80%) are due to **anovulatory cycles**. The immature HPO axis fails to trigger a LH surge, leading to persistent estrogen stimulation without progesterone. This results in an unstable, thickened endometrium that sheds irregularly and heavily. * **Option C:** Up to 20% of adolescents presenting with severe menorrhagia have an underlying **bleeding disorder**, most commonly **von Willebrand Disease (vWD)**. Routine screening (CBC, PT, APTT, Bleeding time) is mandatory. * **Option D:** Management is primarily medical. **Hematinics** (Iron supplements) treat the resulting anemia, while **hormonal therapy** (OCPs or cyclic progestins) stabilizes the endometrium and regulates the cycle. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause:** Anovulatory DUB (due to HPO axis immaturity). * **Most common systemic cause:** von Willebrand Disease. * **First-line investigation:** Pelvic Ultrasound (USG) to rule out structural causes and blood work for coagulopathy. * **Drug of choice for acute heavy bleeding:** High-dose Estrogen or OCPs to "seal" the bleeding vessels.

Question 117: Which of the following is NOT a cause of abnormal uterine bleeding prior to menarche?

A. Vulvovaginitis
B. Foreign body and abuse
C. Anovulation (Correct Answer)
D. Precocious puberty

Explanation: **Explanation:** The key to answering this question lies in understanding the physiological state of the female reproductive system **prior to menarche**. **1. Why Anovulation is the Correct Answer:** Anovulation refers to the absence of ovulation during a menstrual cycle. For anovulation to be a cause of abnormal uterine bleeding (AUB), the **Hypothalamic-Pituitary-Ovarian (HPO) axis** must already be active and the endometrium must be primed by estrogen. Since menarche marks the first occurrence of menstruation (signaling the start of HPO activity), anovulation cannot occur *prior* to menarche. It is, however, the most common cause of AUB in the post-menarchal adolescent period. **2. Analysis of Incorrect Options:** * **Vulvovaginitis (A):** This is the most common cause of prepubertal vaginal bleeding/discharge. The thin, hypoestrogenic vaginal mucosa in children is highly susceptible to infection and irritation. * **Foreign Body and Abuse (B):** These are critical differential diagnoses in children. Foreign bodies (like toilet paper) cause foul-smelling bloody discharge, while sexual abuse must always be ruled out in cases of unexplained genital bleeding. * **Precocious Puberty (D):** This involves the premature activation of the HPO axis (before age 8). It leads to early endometrial stimulation and subsequent withdrawal bleeding, making it a recognized cause of pre-menarchal bleeding. **Clinical Pearls for NEET-PG:** * **Most common cause of prepubertal bleeding:** Vulvovaginitis. * **Most common cause of adolescent AUB:** Anovulation (due to immature HPO axis). * **Most common cause of postmenopausal bleeding:** Atrophic endometritis/vaginitis (though malignancy must be ruled out). * **Red Flag:** Any vaginal bleeding before the development of secondary sexual characteristics (Thelarche) requires immediate investigation for trauma, foreign bodies, or tumors (e.g., Sarcoma botryoides).

Question 118: Spasmodic pain during dysmenorrhea is attributed to:

A. PGE1
B. PGE2
C. PGI2
D. PGF2-$\alpha$ (Correct Answer)

Explanation: **Explanation:** The correct answer is **PGF2-$\alpha$**. **1. Why PGF2-$\alpha$ is correct:** Primary dysmenorrhea is characterized by spasmodic pain caused by increased production of prostaglandins in the secretory endometrium. Under the influence of progesterone, the enzyme **cyclooxygenase (COX)** is activated during menstruation. This leads to high levels of **PGF2-$\alpha$**, which is a potent **vasoconstrictor and myometrial stimulant**. It causes high-frequency, uncoordinated uterine contractions and reduces uterine blood flow (ischemia), leading to the classic "crampy" spasmodic pain. **2. Why the other options are incorrect:** * **PGE1:** This is a synthetic prostaglandin (e.g., Misoprostol) used for cervical ripening and induction of labor, but it is not the primary endogenous mediator of dysmenorrhea. * **PGE2:** While PGE2 is present in the menstrual fluid and contributes to pain by sensitizing nerve endings, it is primarily a **vasodilator**. PGF2-$\alpha$ is the dominant factor responsible for the intense spasmodic contractions. * **PGI2 (Prostacyclin):** This is a potent vasodilator and inhibitor of platelet aggregation. It actually counteracts the effects of PGF2-$\alpha$; a deficiency in PGI2 relative to PGF2-$\alpha$ is often noted in women with severe dysmenorrhea. **3. Clinical Pearls for NEET-PG:** * **First-line treatment:** NSAIDs (e.g., Mefenamic acid) are the drug of choice because they inhibit the COX enzyme, directly reducing PGF2-$\alpha$ synthesis. * **Timing:** Prostaglandin levels are highest during the first 48 hours of menstruation, which correlates with the peak intensity of symptoms. * **Secondary Dysmenorrhea:** If pain does not respond to NSAIDs or OCPs, clinicians should investigate for secondary causes like **Endometriosis** (most common) or Adenomyosis.

Question 119: Irregular shedding of the endometrium occurs due to:

A. Epithelium being immature
B. It does not show the decidual-like oedema of the secretory phase
C. Regression of the corpus luteum function
D. Overactivity of the corpus luteum function (Correct Answer)

Explanation: **Explanation:** **Irregular shedding of the endometrium** is a type of Dysfunctional Uterine Bleeding (DUB) characterized by prolonged and heavy menstrual bleeding. **1. Why Option D is Correct:** The underlying pathophysiology is the **persistent activity or overactivity of the corpus luteum**. Normally, the corpus luteum regresses, leading to a sharp drop in progesterone and uniform shedding. In irregular shedding, the corpus luteum continues to secrete low levels of progesterone beyond the usual 14 days. This "prolonged progesterone effect" prevents the entire endometrium from shedding simultaneously. Consequently, some parts of the endometrium begin to shed while others remain in the secretory phase, leading to a mixture of secretory and proliferative patterns on biopsy (Arias-Stella-like reaction) and clinically prolonged bleeding. **2. Why Other Options are Incorrect:** * **Option A & B:** These descriptions are more characteristic of **Irregular Ripening** of the endometrium, where the endometrium fails to respond adequately to progesterone, showing poor secretory changes or lack of decidualization. * **Option C:** Regression of the corpus luteum is the **normal physiological process** that triggers menstruation. Rapid regression leads to normal menses, not irregular shedding. **3. Clinical Pearls for NEET-PG:** * **Diagnostic Hallmark:** A Dilatation and Curettage (D&C) performed on the **5th or 6th day** of the cycle showing **persistent secretory endometrium** alongside new proliferative patches. * **Halban’s Disease:** Another term sometimes used for persistent corpus luteum function. * **Management:** Progesterone is generally not helpful; the condition is often self-limiting or managed with NSAIDs/OCPs to regulate the cycle. * **Contrast:** Irregular **Ripening** is due to *deficiency* of corpus luteum (Luteal Phase Defect), whereas Irregular **Shedding** is due to *prolongation* of corpus luteum.

Question 120: A 19-year-old female develops bleeding from the nose during menstruation. What is she most likely suffering from?

A. Vicarious menstruation (Correct Answer)
B. Henosch Schonlein Purpura
C. Persistent urachus
D. Bleeding diathesis

Explanation: ### Explanation **Correct Answer: A. Vicarious Menstruation** **1. Why it is correct:** Vicarious menstruation is defined as cyclical bleeding from an extragenital site during the time of normal menstruation. The most common site is the **nasal mucosa** (epistaxis), though it can also occur from the skin, lungs (hemoptysis), or eyes (bloody tears). This phenomenon is thought to be caused by the increased capillary permeability and fragility of extragenital tissues in response to the high levels of circulating estrogens during the premenstrual phase. **2. Why other options are incorrect:** * **B. Henoch-Schönlein Purpura (HSP):** This is an IgA-mediated small-vessel vasculitis. While it presents with a purpuric rash, joint pain, and abdominal pain, the bleeding is not cyclical or synchronized with the menstrual cycle. * **C. Persistent Urachus:** This is a congenital anomaly where the connection between the bladder and the umbilicus remains patent. It typically presents with urinary drainage from the umbilicus, not cyclical nasal bleeding. * **D. Bleeding Diathesis:** Conditions like Von Willebrand Disease or hemophilia cause generalized bleeding tendencies (bruising, prolonged bleeding from cuts). While they can cause heavy menstrual bleeding (menorrhagia), the bleeding is not restricted to a specific extragenital site only during menstruation. **3. NEET-PG High-Yield Pearls:** * **Most common site:** Nasal mucosa (Epistaxis). * **Pathophysiology:** Increased vascular permeability due to estrogen; occasionally associated with **endometriosis** at extragenital sites. * **Clinical Clue:** Always look for the keyword **"cyclical"** or **"during menstruation"** in the history of extragenital bleeding. * **Treatment:** Usually involves hormonal suppression (e.g., OCPs or GnRH analogs) to stabilize the hormonal fluctuations.

Question 121: A woman is said to have menorrhagia if the menstrual blood loss is more than:

A. 20 ml
B. 40 ml
C. 60 ml
D. 80 ml (Correct Answer)

Explanation: **Explanation:** **Menorrhagia** (now clinically referred to as Heavy Menstrual Bleeding or HMB) is defined as excessive menstrual blood loss occurring at regular intervals. The classic objective definition is a blood loss exceeding **80 ml per cycle** or a period lasting longer than **7 days**. 1. **Why 80 ml is correct:** Studies (notably by Hallberg et al.) demonstrate that iron deficiency anemia becomes significantly more prevalent when menstrual loss exceeds 80 ml. This threshold represents the point at which the average woman can no longer maintain a positive iron balance through dietary intake alone. 2. **Analysis of Incorrect Options:** * **20 ml:** This is significantly below the average loss. * **40 ml:** This is considered the **average (mean) menstrual blood loss** in a healthy woman. * **60 ml:** While higher than average, it is still within the physiological range (normal range is 20–80 ml). **High-Yield Clinical Pearls for NEET-PG:** * **FIGO Nomenclature:** The term "Menorrhagia" is being replaced by **Heavy Menstrual Bleeding (HMB)**. * **Polymenorrhea:** Cycle length <21 days. * **Oligomenorrhea:** Cycle length >35 days. * **Metrorrhagia:** Irregular, acyclic bleeding. * **Assessment:** In clinical practice, objective measurement is difficult. Subjective indicators of >80 ml loss include: passing large clots (>2.5 cm), "flooding" through clothes, or the need to change pads/tampons every 1–2 hours. * **Gold Standard Measurement:** The **Alkaline Hematin Method** is the most accurate way to quantify blood loss in research settings.

Question 122: Menorrhagia is defined as blood loss per vagina exceeding which amount?

A. 80 ml (Correct Answer)
B. 110 ml
C. 150 ml
D. 50 ml

Explanation: **Explanation:** **Menorrhagia** (now clinically referred to under the umbrella of **Abnormal Uterine Bleeding - Heavy Menstrual Bleeding or AUB-HMB**) is defined as cyclic bleeding at normal intervals, where the total blood loss exceeds **80 ml** or the duration of flow exceeds **7 days**. 1. **Why 80 ml is correct:** This threshold is based on the classic studies by Hallberg et al., which demonstrated that iron deficiency anemia becomes significantly more prevalent when menstrual blood loss exceeds 80 ml. In a normal cycle, the average blood loss is approximately 35–40 ml. 2. **Why other options are incorrect:** * **50 ml:** This is within the upper limit of a normal menstrual cycle (normal range is 20–80 ml). * **110 ml and 150 ml:** While these amounts certainly constitute menorrhagia, they are not the *defining* threshold. The diagnostic criteria begin at the 80 ml mark. **High-Yield Clinical Pearls for NEET-PG:** * **PALM-COEIN:** The FIGO classification for AUB causes. **PALM** (Structural: Polyp, Adenomyosis, Leiomyoma, Malignancy) and **COEIN** (Non-structural: Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified). * **Objective Measurement:** In research, the **Alkaline Hematin Method** is the gold standard for measuring blood loss. Clinically, the **Pictorial Blood Loss Assessment Chart (PBAC)** is used; a score **>100** suggests loss >80 ml. * **Most Common Cause:** In the reproductive age group, the most common cause of menorrhagia is **Uterine Fibroids (Leiomyoma)**. * **Medical Management:** **Levonorgestrel Intrauterine System (LNG-IUS/Mirena)** is the first-line medical treatment for HMB.

Question 123: What is the first line treatment for Abnormal Uterine Bleeding?

A. Versapoint
B. Novasure
C. Medical management (Correct Answer)
D. Surgical management

Explanation: **Explanation:** Abnormal Uterine Bleeding (AUB) is a broad diagnosis encompassing any variation from the normal menstrual cycle. According to FIGO and ACOG guidelines, **Medical Management** is the established **first-line treatment** for most cases of AUB, particularly those related to ovulatory dysfunction (AUB-O), endometrial causes (AUB-E), or coagulopathy (AUB-C). The goal is to stabilize the endometrium, reduce blood loss, and avoid the risks associated with surgery. Common first-line agents include Combined Oral Contraceptive Pills (COCPs), high-dose Progestogens, Tranexamic acid, and the Levonorgestrel Intrauterine System (LNG-IUS), which is often considered the most effective medical intervention. **Analysis of Options:** * **Medical Management (Correct):** It is non-invasive, preserves fertility, and effectively manages symptoms for the majority of patients. Surgery is reserved for cases where medical therapy fails, is contraindicated, or if there is a structural pathology (like a large polyp or fibroid) requiring excision. * **Versapoint (Incorrect):** This is a bipolar electrosurgical system used during hysteroscopy for targeted tissue resection (e.g., polyps or small submucosal fibroids). It is a surgical intervention, not first-line. * **Novasure (Incorrect):** This is a brand of global endometrial ablation. While effective for AUB-E, it is a second-line surgical procedure used only when medical therapy fails and the patient has completed childbearing. * **Surgical Management (Incorrect):** Includes procedures like D&C, ablation, or hysterectomy. These are secondary options due to higher morbidity and impact on future fertility. **NEET-PG High-Yield Pearls:** * **Investigation of Choice (IOC):** Transvaginal Ultrasound (TVS) is the initial investigation; Saline Infusion Sonohysterography (SIS) is superior for intracavitary lesions. * **Gold Standard Investigation:** Hysteroscopy with guided biopsy (especially to rule out malignancy in women >45 years). * **LNG-IUS (Mirena):** Currently considered the "medical gold standard" for AUB-E and AUB-O, often reducing blood loss by over 90%.

Question 124: A 35-year-old multigravida aborted 5 months back at 17 weeks of gestation. She has not had her periods yet, and her urine pregnancy test is negative. An estrogen-progesterone withdrawal test is also negative. What is the likely diagnosis?

A. Pituitary failure
B. Ovarian failure
C. Anovulation
D. Asherman syndrome (Correct Answer)

Explanation: **Explanation:** The patient presents with **secondary amenorrhea** following a mid-trimester abortion. The key to this diagnosis lies in the **negative Estrogen-Progesterone (E+P) withdrawal test**. 1. **Why Asherman Syndrome is correct:** A negative E+P withdrawal test indicates that even with adequate hormonal stimulation, the endometrium fails to bleed. This signifies an **outflow tract obstruction** or **endometrial destruction**. In the clinical context of a recent pregnancy-related evacuation (abortion at 17 weeks), the most likely cause is intrauterine adhesions (synechiae) that have obliterated the uterine cavity, known as Asherman Syndrome. 2. **Why other options are incorrect:** * **Anovulation:** In anovulation, the endometrium is primed with estrogen but lacks progesterone. A progesterone challenge would be negative, but an **E+P challenge would be positive** (bleeding would occur). * **Pituitary Failure (Secondary Hypogonadism) & Ovarian Failure (Primary Hypogonadism):** In both conditions, the uterus and outflow tract are intact, but endogenous hormones are deficient. Therefore, providing exogenous Estrogen and Progesterone would result in a **positive withdrawal bleed**. **High-Yield Clinical Pearls for NEET-PG:** * **Step-wise approach to Amenorrhea:** 1. Rule out pregnancy (UPT) → 2. Progesterone Challenge → 3. E+P Challenge → 4. FSH/LH levels. * **Gold Standard Investigation** for Asherman Syndrome: **Hysteroscopy** (Diagnostic and Therapeutic). * **HSG Finding:** Characterized by "honeycomb appearance" or irregular filling defects. * **Most common cause:** Vigorous curettage of a pregnant or postpartum uterus (due to the softness of the basal layer of the endometrium).

Question 125: Dysfunctional uterine bleeding (DUB) is most commonly associated with which of the following conditions?

A. Polycystic ovarian disease
B. Endometrial tuberculosis
C. Metropathia haemorrhagica (Correct Answer)
D. Multiple fibroids

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)** is defined as abnormal uterine bleeding in the absence of any detectable organic pelvic pathology, systemic disease, or pregnancy. It is primarily a diagnosis of exclusion and is most commonly associated with **anovulation**. **1. Why Metropathia Haemorrhagica is correct:** Metropathia Haemorrhagica (also known as Schroeder’s Disease) is a specialized form of DUB typically seen in perimenopausal women. It is characterized by **anovulation**, leading to a state of "unopposed estrogen." The absence of a corpus luteum means no progesterone is produced. This results in continuous endometrial proliferation without secretory changes. Eventually, the hyperplastic endometrium outgrows its blood supply and sheds irregularly. Classically, it presents as a period of amenorrhea (6–8 weeks) followed by heavy, painless bleeding (epimenorrhagia). **2. Why the other options are incorrect:** * **Polycystic Ovarian Disease (PCOD):** While PCOD involves anovulation and can cause DUB, it is a systemic endocrine disorder. Metropathia Haemorrhagica is the classic pathological description specifically linked to the DUB mechanism in textbooks. * **Endometrial Tuberculosis:** This is an **organic/infectious** cause of bleeding (often leading to infertility or synechiae/amenorrhea), which excludes it from the definition of DUB. * **Multiple Fibroids:** These are **structural (organic)** lesions. Bleeding caused by fibroids is classified under "Leiomyoma" in the FIGO PALM-COEIN classification, not DUB. **Clinical Pearls for NEET-PG:** * **FIGO Classification:** DUB is now categorized under the **COEIN** (Non-structural) component of the PALM-COEIN system (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified). * **Histology of Metropathia:** Characterized by **Swiss-cheese hyperplasia** of the endometrium. * **Treatment of choice:** In DUB, medical management (OCPs, Progestogens, or LNG-IUS) is the first line. For Metropathia, D&C is often done to rule out malignancy and stop acute bleeding.

Question 126: A positive progesterone challenge test in a patient with secondary amenorrhea indicates:

A. Asherman syndrome
B. Endometrial tuberculosis
C. Hypopituitarism
D. Polycystic ovarian disease (Correct Answer)

Explanation: ### Explanation The **Progesterone Challenge Test (PCT)** is a diagnostic tool used to assess the functional status of the hypothalamic-pituitary-ovarian (HPO) axis and the patency of the outflow tract. **1. Why Polycystic Ovarian Disease (PCOD) is Correct:** A **positive PCT** (defined as withdrawal bleeding within 2–7 days of stopping progesterone) requires two essential conditions: * **Patent Outflow Tract:** The uterus, cervix, and vagina must be anatomically intact. * **Estrogen Priming:** The endometrium must have been previously exposed to sufficient endogenous estrogen to cause proliferation. In **PCOD**, patients have anovulation but high levels of endogenous estrogen (due to peripheral conversion of androgens). This estrogen thickens the endometrium; when exogenous progesterone is given and then withdrawn, the endometrium sheds, resulting in a positive test. **2. Why Other Options are Incorrect:** * **Asherman Syndrome & Endometrial Tuberculosis:** These conditions involve the destruction of the endometrial lining or the presence of intrauterine synechiae (adhesions). Even with adequate estrogen, there is no functional tissue to shed, leading to a **negative PCT**. * **Hypopituitarism:** This results in low FSH/LH levels, leading to **hypoestrogenism**. Without estrogen to prime the endometrium, progesterone cannot induce a withdrawal bleed, resulting in a **negative PCT**. **3. High-Yield Clinical Pearls for NEET-PG:** * **Next Step after Negative PCT:** Perform an **Estrogen + Progesterone Challenge Test**. If bleeding occurs, the outflow tract is intact, and the cause is likely Hypogonadotropic Hypogonadism (Pituitary/Hypothalamic failure). If no bleeding occurs, it confirms an **Outflow Tract Obstruction** (e.g., Asherman’s). * **Dose:** Medroxyprogesterone acetate (10 mg) for 5–10 days is the standard regimen. * **Key Concept:** Positive PCT = Anovulation + Adequate Estrogen + Intact Outflow Tract.

Question 127: Heavy menstrual bleeding is assessed by all of the following EXCEPT:

A. Passing clots more than 1 inch in diameter
B. Hemoglobin concentration below 12 g/dL
C. Menses lasting longer than 7 days
D. Blood loss more than 120 ml (Correct Answer)

Explanation: **Explanation:** Heavy Menstrual Bleeding (HMB) is clinically defined as excessive menstrual blood loss which interferes with a woman's physical, social, emotional, and/or material quality of life. **1. Why Option D is the Correct Answer:** The classic objective definition of HMB (formerly menorrhagia) is a total blood loss of **more than 80 ml** per cycle. Option D states "more than 120 ml," which is an incorrect threshold for the standard definition. While 120 ml is indeed heavy, it is not the diagnostic cutoff used in medical literature or clinical guidelines. **2. Analysis of Incorrect Options (Criteria for HMB):** * **Option A:** Passing large clots (greater than 1 inch or 2.5 cm) is a reliable clinical indicator of heavy flow, as the natural anticoagulants in the uterus cannot keep up with the volume of bleeding. * **Option B:** A drop in hemoglobin (Anemia) is a common objective consequence of chronic HMB. If a patient presents with iron deficiency anemia and heavy periods, it confirms the clinical significance of the blood loss. * **Option C:** Prolonged menses lasting more than 7 days is one of the primary criteria used to define HMB/menorrhagia. **3. NEET-PG High-Yield Pearls:** * **Gold Standard Measurement:** The alkaline hematin method is the gold standard for objective measurement but is only used in research. * **PBAC Score:** The Pictorial Blood Loss Assessment Chart (PBAC) is used in clinics; a score **>100** indicates HMB. * **PALM-COEIN:** This is the FIGO classification for the etiology of Abnormal Uterine Bleeding (AUB). * **First-line Investigation:** Transvaginal Ultrasound (TVUS). * **Medical Management:** Levonorgestrel Intrauterine System (LNG-IUS) is the first-line treatment for HMB.

Question 128: Withdrawal bleeding with progesterone is seen in an otherwise amenorrheic woman due to which of the following?

A. Hypogonadotropic hypogonadism
B. Anovulation (Correct Answer)
C. Ovarian failure
D. Tuberculous endometritis

Explanation: **Explanation:** The **Progesterone Challenge Test (PCT)** is a fundamental diagnostic tool in amenorrhea. For withdrawal bleeding to occur after progesterone administration, two physiological prerequisites must be met: 1. **Endometrial Priming:** The endometrium must have been previously exposed to endogenous **estrogen**, causing it to proliferate. 2. **Patent Outflow Tract:** There must be a functional uterus, cervix, and vagina. In **Anovulation (Option B)**, the ovaries produce estrogen (leading to endometrial proliferation), but because ovulation does not occur, no corpus luteum is formed and no progesterone is produced. This results in a state of "unopposed estrogen." Administering exogenous progesterone and then stopping it mimics the natural decline of the corpus luteum, causing the primed endometrium to shed (withdrawal bleed). **Why other options are incorrect:** * **Hypogonadotropic Hypogonadism (Option A):** Low FSH/LH levels lead to minimal estrogen production. Without estrogen to prime the endometrium, progesterone cannot cause a withdrawal bleed. * **Ovarian Failure (Option C):** In Premature Ovarian Failure, the follicles are depleted. Estrogen levels are critically low, resulting in a negative PCT. * **Tuberculous Endometritis (Option D):** This causes destruction of the endometrial lining or synechiae (Asherman-like syndrome). Even with adequate hormones, there is no functional tissue to shed. **NEET-PG High-Yield Pearls:** * **Positive PCT:** Confirms anovulation (e.g., PCOS) and implies adequate endogenous estrogen. * **Negative PCT:** Indicates either **low estrogen** (Hypothalamic/Ovarian failure) or an **outflow tract obstruction** (Asherman’s/Mulleris agenesis). * The next step after a negative PCT is the **Estrogen-Progesterone Challenge Test** to differentiate between low estrogen and anatomical defects.

Question 129: What is a cause of secondary dysmenorrhea in a young female?

A. Tuberculosis
B. Subserous fibroid
C. Endometriosis
D. All of the above (Correct Answer)

Explanation: **Explanation:** Dysmenorrhea is classified into primary (spasmodic, no underlying pathology) and **secondary (congestive, due to pelvic pathology)**. Secondary dysmenorrhea typically presents in women in their 20s or 30s and is characterized by pain that begins several days before menses and persists throughout the cycle. **Why "All of the Above" is correct:** * **Endometriosis (Option C):** This is the **most common cause** of secondary dysmenorrhea. Ectopic endometrial tissue undergoes cyclic bleeding, leading to inflammation, adhesions, and deep-seated pelvic pain. * **Tuberculosis (Option A):** In developing countries like India, Genital TB is a significant cause of chronic pelvic inflammatory disease (PID). Chronic inflammation and pelvic adhesions result in congestive dysmenorrhea. * **Subserous Fibroid (Option B):** While intramural fibroids are more commonly associated with pain, subserous fibroids can cause dysmenorrhea if they undergo torsion, degeneration, or exert pressure on surrounding pelvic nerves. **Clinical Pearls for NEET-PG:** 1. **Primary vs. Secondary:** Primary dysmenorrhea is caused by **PGF2α** excess and usually starts within 6–12 months of menarche (ovulatory cycles). Secondary dysmenorrhea appears years later. 2. **Gold Standard Investigation:** For most causes of secondary dysmenorrhea (like endometriosis or PID), **Laparoscopy** is the gold standard for diagnosis. 3. **Adenomyosis:** Another high-yield cause; suspect this in multiparous women with a "bulky, globular uterus" and severe dysmenorrhea. 4. **Treatment:** While NSAIDs are first-line for primary dysmenorrhea, secondary dysmenorrhea requires treating the **underlying pathology**.

Question 130: Cryptomenorrhea occurs due to:

A. Imperforate hymen (Correct Answer)
B. Asherman's syndrome
C. Mullerian agenesis
D. All

Explanation: **Explanation:** **Cryptomenorrhea** (hidden menstruation) refers to a condition where menstrual blood is produced by the uterus but cannot escape the genital tract due to an anatomical obstruction in the outflow tract. **1. Why Option A is Correct:** The **imperforate hymen** is the most common cause of cryptomenorrhea. In this condition, the vaginal opening is completely occluded by a membrane. During puberty, the endometrium sheds normally, but the blood accumulates in the vagina (**hematocolpos**), and eventually the uterus (**hematometra**). This presents clinically as primary amenorrhea with cyclical pelvic pain and a bulging, bluish membrane on examination. **2. Why Other Options are Incorrect:** * **Asherman’s Syndrome (Option B):** This involves intrauterine adhesions that obliterate the uterine cavity. Here, the endometrium is damaged or absent; therefore, **no blood is produced**. This is a cause of true secondary amenorrhea, not hidden menstruation. * **Mullerian Agenesis (Option C):** Also known as MRKH syndrome, this is characterized by the congenital absence of the uterus and upper two-thirds of the vagina. Since there is **no functional uterus** to produce menstrual blood, cryptomenorrhea cannot occur. **Clinical Pearls for NEET-PG:** * **Classic Presentation:** A pubertal girl with primary amenorrhea, cyclical abdominal pain, and a palpable midline mass (distended bladder or hematometra). * **Other causes of Cryptomenorrhea:** Transverse vaginal septum and atresia of the cervix. * **Treatment:** For imperforate hymen, the definitive treatment is a **cruciate incision** to allow the drainage of the "chocolate-colored" old blood. * **Distinction:** Always differentiate cryptomenorrhea (outflow obstruction) from true amenorrhea (hormonal or end-organ failure).

Question 131: Which of the following modalities has shown the best result for premenstrual syndrome?

A. SSRI (Correct Answer)
B. Progesterone
C. Estrogen
D. Anxiolytics

Explanation: ### Explanation **Correct Option: A (SSRI)** Selective Serotonin Reuptake Inhibitors (SSRIs) are considered the **first-line pharmacological treatment** and the "gold standard" for Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD). The underlying pathophysiology involves a maladaptive response of the neurotransmitter serotonin to normal fluctuations in ovarian steroids. Unlike their use in depression, SSRIs for PMS work rapidly (often within hours to days) and can be administered either continuously or restricted to the **luteal phase** (starting on day 14 of the cycle). **Analysis of Incorrect Options:** * **B. Progesterone:** While historically used based on the theory of progesterone deficiency, multiple randomized controlled trials have shown that progesterone supplementation is **no more effective than placebo** in treating PMS symptoms. * **C. Estrogen:** Estrogen (often via patches) can be used to suppress ovulation as a second-line treatment, but it is not the primary modality. It also requires the addition of a progestogen to protect the endometrium, which may trigger PMS-like symptoms in sensitive women. * **D. Anxiolytics:** While Alprazolam may be used as a targeted treatment for specific anxiety symptoms in PMDD, it is considered a **second-line or adjunctive therapy** due to the risk of dependence and withdrawal. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Fluoxetine, Sertraline, and Paroxetine are the most commonly used SSRIs. * **Diagnosis:** PMS is a clinical diagnosis; the most important tool is a **prospective symptom diary** (e.g., Daily Record of Severity of Problems) for at least two consecutive cycles. * **Symptom-Free Period:** Symptoms must be absent during the follicular phase (days 4–12) to confirm the diagnosis. * **Definitive Treatment:** For severe, refractory cases, surgical oophorectomy (surgical menopause) is the final resort.

Question 132: A 36-year-old woman has absence of menses for the last 4 months. Pregnancy test is negative. Serum levels of LH and FSH are raised. Serum estradiol level is low. What do these findings suggest?

A. Bilateral tubal obstruction
B. Polycystic ovarian disease (PCOD)
C. Premature menopause (Correct Answer)
D. Exogenous estrogen administration

Explanation: ### Explanation **1. Why Premature Menopause is Correct:** The patient presents with secondary amenorrhea (absence of menses for >3 months) and a hormonal profile indicating **Hypergonadotropic Hypogonadism**. * **Low Estradiol:** Indicates ovarian failure; the ovaries are no longer producing estrogen. * **Raised LH and FSH:** Due to the lack of negative feedback from estrogen and inhibin, the anterior pituitary secretes high levels of gonadotropins (FSH >40 IU/L is typically diagnostic). When this occurs before the age of 40, it is termed **Premature Ovarian Insufficiency (POI)** or Premature Menopause. **2. Why Other Options are Incorrect:** * **Bilateral Tubal Obstruction:** This causes infertility but does not affect the hormonal axis or the menstrual cycle, as the ovaries and uterus remain functional. * **PCOD:** Characterized by hyperandrogenism and chronic anovulation. Hormonally, there is typically an **increased LH:FSH ratio (2:1 or 3:1)**, but FSH is usually normal or low, and estrogen is not deficient (often elevated due to peripheral conversion). * **Exogenous Estrogen Administration:** This would lead to **low LH and FSH** levels due to artificial negative feedback on the hypothalamus and pituitary. **3. High-Yield Clinical Pearls for NEET-PG:** * **Definition:** Menopause occurring before age 40. * **Most Common Karyotype Abnormality:** Turner Syndrome (45,XO) or Mosaicism (45,X/46,XX). * **Fragile X Premutation:** The most common genetic cause of "sporadic" POI. * **Diagnostic Criteria:** Amenorrhea for $\geq$ 4 months with FSH levels in the menopausal range (usually $>25-40$ IU/L) on two occasions at least 4 weeks apart. * **Management:** Hormone Replacement Therapy (HRT) is mandatory until the age of natural menopause (approx. 50 years) to prevent osteoporosis and cardiovascular disease.

Question 133: A 26-year-old female presents with menstrual bleeding occurring 10 days prior to her usual menses. She reports her last menstrual period was heavier than usual. After a negative pregnancy test, a physician diagnoses dysfunctional uterine bleeding likely due to anovulation. If an endometrial biopsy were performed, what would be the most likely histologic appearance of the endometrium?

A. Asynchronous secretory endometrium
B. Decidualized stroma with inactive glands
C. Early proliferative endometrium
D. Proliferative endometrium with stromal breakdown (Correct Answer)

Explanation: **Explanation:** The clinical presentation describes **Anovulatory Dysfunctional Uterine Bleeding (DUB)**. In anovulatory cycles, there is a failure of ovulation, meaning no corpus luteum is formed and no progesterone is produced. **1. Why Option D is Correct:** In the absence of progesterone, the endometrium remains in a continuous **proliferative phase** driven by unopposed estrogen. Without the stabilizing effect of progesterone, the endometrium thickens excessively and outgrows its blood supply. This leads to focal necrosis and irregular shedding, histologically seen as **proliferative endometrium with stromal breakdown** (evidenced by condensed stromal cells and "blue balls" of stroma). **2. Why Other Options are Incorrect:** * **Option A (Asynchronous secretory):** This is characteristic of a **Luteal Phase Defect**, where there is a lag between the glandular development and the menstrual date, but ovulation still occurs. * **Option B (Decidualized stroma):** This is seen in pregnancy or with exogenous progestin use (e.g., Mirena or OCPs). It represents a high-progesterone state. * **Option C (Early proliferative):** While the endometrium is proliferative, the presence of active bleeding (menorrhagia/metrorrhagia) specifically correlates with the "breakdown" morphology rather than a healthy, early-phase growth. **Clinical Pearls for NEET-PG:** * **Most common cause of DUB:** Anovulation (especially at extremes of age: menarche and perimenopause). * **Gold Standard for diagnosis in women >35:** Endometrial biopsy (to rule out hyperplasia/malignancy). * **Unopposed Estrogen:** Long-term anovulation increases the risk of endometrial hyperplasia and adenocarcinoma. * **Management:** First-line medical management for acute bleeding is often high-dose Estrogen or OCPs to stabilize the endometrial lining.

Question 134: A period of amenorrhea followed by massive bleeding is seen in premenopausal women with which of the following conditions?

A. Irregular ripening
B. Irregular shedding
C. Metropathia hemorrhagica (Correct Answer)
D. All of the above

Explanation: **Explanation:** **Metropathia Hemorrhagica (Schroeder’s Disease)** is a specific form of Dysfunctional Uterine Bleeding (DUB) typically seen in perimenopausal women. The underlying pathophysiology is **anovulation**. 1. **Why it is correct:** In anovulatory cycles, there is a failure of the follicle to rupture, leading to persistent estrogen production without the formation of a corpus luteum (and thus, no progesterone). This results in **prolonged endometrial hyperplasia**. Eventually, the estrogen levels fluctuate or the endometrium outgrows its blood supply, leading to breakthrough bleeding. Clinically, this manifests as a **period of amenorrhea (6–8 weeks)** due to the hyperestrogenic state, followed by **profuse, painless, prolonged bleeding** (epimenorrhagia). 2. **Why other options are incorrect:** * **Irregular Ripening:** This is due to **corpus luteum insufficiency** (poor progesterone production). It results in spotting before the actual period begins, not a period of amenorrhea followed by massive bleeding. * **Irregular Shedding:** This is due to the **persistent corpus luteum** (prolonged progesterone). It causes the functional layer of the endometrium to shed in a patchy, slow manner. The clinical hallmark is prolonged bleeding, but the period starts on time, and there is no preceding amenorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Classic Triad:** Amenorrhea, followed by heavy bleeding, in a perimenopausal woman. * **Endometrial Finding:** Swiss-cheese hyperplasia (cystic glandular hyperplasia). * **Ovarian Finding:** Follicular cyst (usually unilateral). * **Uterus:** May be slightly enlarged, soft, and "myopathic." * **Management:** Dilation and Curettage (D&C) is both diagnostic (to rule out malignancy) and therapeutic.

Question 135: A 34-year-old woman presents with abnormal uterine bleeding. Which of the following is the LEAST likely cause of abnormal bleeding in this age group?

A. Adenomyosis
B. Fibroids
C. Endometrial atrophy (Correct Answer)
D. Polyps

Explanation: **Explanation:** The correct answer is **Endometrial atrophy**. Abnormal Uterine Bleeding (AUB) in reproductive-age women (typically 15–45 years) is classified by the **FIGO PALM-COEIN** criteria. In a 34-year-old woman, the uterus is under the constant influence of estrogen, which promotes endometrial proliferation. **Endometrial atrophy** occurs due to a state of estrogen deficiency, making it the hallmark cause of postmenopausal bleeding. It is highly unlikely in a woman of reproductive age unless there is severe premature ovarian insufficiency or prolonged use of certain hormonal contraceptives (e.g., DMPA). **Analysis of Incorrect Options:** * **Adenomyosis (A):** Common in women in their 30s and 40s, typically presenting with heavy menstrual bleeding (HMB) and dysmenorrhea. * **Fibroids (B):** Leiomyomas are the most common benign tumors in women of reproductive age and a leading cause of HMB and pelvic pressure. * **Polyps (C):** Endometrial polyps are frequent causes of intermenstrual bleeding and AUB in the premenopausal age group. **NEET-PG High-Yield Pearls:** * **Most common cause of AUB in postmenopausal women:** Endometrial atrophy (60-80%), though malignancy must always be ruled out. * **Most common cause of AUB in adolescents:** Anovulation due to an immature Hypothalamic-Pituitary-Ovarian (HPO) axis. * **Gold Standard Investigation for AUB:** Hysteroscopy (allows direct visualization and directed biopsy). * **First-line investigation:** Transvaginal Ultrasound (TVS).

Question 136: What is the commonest cause of secondary amenorrhea?

A. Tuberculosis
B. Pregnancy (Correct Answer)
C. Post-pill amenorrhea
D. Anemia

Explanation: **Explanation:** **Why Pregnancy is the Correct Answer:** In any woman of reproductive age presenting with a cessation of menses, **pregnancy** is the most common cause of secondary amenorrhea. Physiologically, the persistence of the corpus luteum and subsequent production of hCG, progesterone, and estrogen prevents the shedding of the endometrial lining. For NEET-PG, the first step in the clinical evaluation of secondary amenorrhea is always a **urine pregnancy test (UPT)** to rule this out before proceeding to hormonal or anatomical investigations. **Analysis of Incorrect Options:** * **A. Tuberculosis:** While Genital TB is a significant cause of secondary amenorrhea in developing countries (leading to Asherman’s syndrome or endometrial destruction), it is far less frequent than pregnancy. * **C. Post-pill amenorrhea:** This refers to a delay in the resumption of menses after discontinuing oral contraceptives. While common, it usually resolves within 3–6 months and is statistically less frequent than pregnancy. * **D. Anemia:** Severe systemic illness or chronic anemia can cause hypothalamic dysfunction leading to amenorrhea, but it is a secondary systemic factor rather than the primary statistical cause. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** Secondary amenorrhea is the absence of menses for **3 months** (in women with previously regular cycles) or **6 months** (in those with irregular cycles). * **Most common pathological cause:** Polycystic Ovary Syndrome (PCOS). * **Most common cause of primary amenorrhea:** Turner Syndrome (45,XO). * **Asherman’s Syndrome:** The most common cause of secondary amenorrhea due to uterine synechiae (often post-curettage or TB). * **First Investigation:** Urine Pregnancy Test (UPT). * **First Hormonal Test:** Serum Prolactin and TSH (after ruling out pregnancy).

Question 137: A 30-year-old woman with 2+0 hypertension has menorrhagia. Which of the following is the best treatment for her?

A. Combined pills
B. MIRENA (Correct Answer)
C. Hysterectomy
D. Transcervical resection of the endometrium

Explanation: **Explanation:** The patient is a 30-year-old woman presenting with **menorrhagia** and a comorbid condition of **hypertension**. **Why MIRENA (LNG-IUS) is the correct answer:** The Levonorgestrel-releasing Intrauterine System (LNG-IUS), commonly known as Mirena, is considered the **first-line medical management** for Heavy Menstrual Bleeding (HMB) according to NICE and FIGO guidelines. It works by causing profound endometrial atrophy, reducing menstrual blood loss by up to 90-95%. In this specific case, the patient has hypertension; Mirena is a progestogen-only method and does not contain estrogen, making it safe for women with cardiovascular risk factors or hypertension. **Why other options are incorrect:** * **Combined Oral Contraceptive Pills (COCPs):** These are generally **contraindicated** in patients with hypertension (especially if poorly controlled) due to the estrogen component, which can further increase blood pressure and the risk of thromboembolic events. * **Hysterectomy:** This is a major surgical intervention. In a 30-year-old patient, conservative and medical management must be exhausted first unless there is a malignancy or significant pathology. It is considered a last resort. * **Transcervical Resection of the Endometrium (TCRE):** While effective, this is a surgical procedure usually reserved for women who have completed their family and for whom medical management has failed. Mirena offers similar efficacy with a much less invasive profile. **Clinical Pearls for NEET-PG:** * **First-line for HMB:** LNG-IUS (Mirena). * **Mechanism:** Local release of Levonorgestrel (20 µg/day) → Endometrial decidualization and atrophy. * **Hypertension & Contraception:** Avoid Estrogen (WHO Eligibility Criteria 3 or 4 depending on BP levels). Progestogen-only methods (LNG-IUS, POP, Implants) are preferred. * **Non-contraceptive benefits of Mirena:** Reduces dysmenorrhea and provides endometrial protection during HRT.

Question 138: Polymenorrhagia is defined as:

A. Increase in frequency of cycle along with excessive or prolonged bleeding. (Correct Answer)
B. Increase in frequency of cycle with average normal bleeding.
C. Increase in duration of cycle with less bleeding.
D. Regular cycle with less bleeding.

Explanation: **Explanation:** **Polymenorrhagia** is a descriptive term for a menstrual pattern that combines two distinct abnormalities: **Polymenorrhea** (increased frequency) and **Menorrhagia** (increased amount/duration). 1. **Why Option A is correct:** The term is a portmanteau. "Poly" refers to frequent cycles (intervals <21 days), and "menorrhagia" refers to heavy or prolonged bleeding (>80 ml or >7 days). Therefore, it is defined as cycles occurring too frequently associated with excessive or prolonged blood loss. 2. **Analysis of Incorrect Options:** * **Option B:** This describes **Polymenorrhea** (or Epimenorrhea). The frequency is increased, but the flow amount and duration remain within normal limits. * **Option C:** This describes **Oligomenorrhea** (infrequent cycles, interval >35 days) combined with **Hypomenorrhea** (scanty flow). * **Option D:** This describes **Hypomenorrhea**. The rhythm is regular, but the duration is <2 days or the total blood loss is <20 ml. **High-Yield Clinical Pearls for NEET-PG:** * **Metrorrhagia:** Irregular, acyclic bleeding occurring between periods (intermenstrual bleeding). * **Menometrorrhagia:** Bleeding that is irregular in frequency and excessive in amount/duration. * **Normal Menstrual Parameters:** Interval: 21–35 days; Duration: 2–7 days; Blood loss: 20–80 ml. * **PALM-COEIN Classification:** The FIGO system has largely replaced these older terms in clinical practice. "PALM" (Polyp, Adenomyosis, Leiomyoma, Malignancy) represents structural causes, while "COEIN" (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified) represents non-structural causes.

Question 139: A 35-year-old lady has not had menses for the last 4 months. She has high serum FSH and LH levels with low estradiol. What is the likely cause?

A. Panhypopituitarism
B. Polycystic ovarian disease
C. Exogenous estrogen administration
D. Premature menopause (Correct Answer)

Explanation: **Explanation:** The clinical presentation of secondary amenorrhea (4 months) associated with **high gonadotropins (FSH and LH)** and **low estradiol** indicates **Hypergonadotropic Hypogonadism**. This hormonal profile signifies a primary ovarian failure where the negative feedback loop is disrupted; because the ovaries are not producing estrogen, the pituitary gland compensates by secreting excessive FSH and LH. **Why Premature Menopause is correct:** Premature Ovarian Insufficiency (POI), or premature menopause, is defined as the cessation of menses before age 40. The hallmark is an FSH level consistently >40 IU/L (though >25 IU/L in two readings is often used clinically) and low estradiol. At 35 years old, this patient fits the criteria for POI. **Analysis of Incorrect Options:** * **Panhypopituitarism:** This would result in **Hypogonadotropic Hypogonadism**, characterized by low FSH, low LH, and low estradiol due to pituitary failure. * **Polycystic Ovarian Disease (PCOS):** Typically presents with an **increased LH:FSH ratio** (often 2:1 or 3:1) and normal or slightly elevated estrogen levels, not low estradiol. * **Exogenous Estrogen:** High levels of exogenous estrogen would exert negative feedback on the pituitary, resulting in **low FSH and LH levels**. **NEET-PG High-Yield Pearls:** * **Primary Ovarian Insufficiency (POI):** Defined by amenorrhea, hypoestrogenism, and elevated gonadotropins before age 40. * **Most common chromosomal cause:** Turner Syndrome (45,X) or its mosaics. * **Most common genetic cause of "Premature Menopause":** FMR1 gene premutation (Fragile X carrier). * **Diagnostic marker:** FSH is the most sensitive marker; a level >40 IU/L is diagnostic of ovarian failure in the context of amenorrhea.

Question 140: In a patient with secondary amenorrhea who does not experience withdrawal bleeding after estrogen and progesterone administration, the underlying issue is most likely at which level?

A. Pituitary
B. Hypothalamus
C. Ovary
D. Endometrium (Correct Answer)

Explanation: This question tests the understanding of the **stepwise evaluation of secondary amenorrhea**. ### **Explanation of the Correct Answer** The **Estrogen-Progesterone Challenge Test** is the final step in localizing the cause of amenorrhea. 1. **Estrogen** is given to prime the endometrium (proliferation). 2. **Progesterone** is then given to induce secretory changes. 3. Upon withdrawal, if the outflow tract is patent and the endometrium is functional, **withdrawal bleeding must occur.** If there is **no bleeding** after this combined therapy, it indicates that the target organ—the **endometrium**—is either absent, damaged, or the outflow tract is obstructed. This is characteristic of **Asherman’s Syndrome** (intrauterine synechiae) or **Müllerian agenesis** (though the latter usually presents as primary amenorrhea). ### **Why Other Options are Incorrect** * **A & B (Pituitary & Hypothalamus):** If the defect were at the level of the brain (low GnRH or FSH/LH), the endometrium would still be responsive. Providing exogenous estrogen and progesterone bypasses the brain, so these patients **would** experience withdrawal bleeding. * **C (Ovary):** In premature ovarian failure, the endogenous estrogen is low, but the endometrium remains responsive. These patients **would** bleed after receiving exogenous hormones. ### **High-Yield NEET-PG Clinical Pearls** * **Step 1:** Rule out pregnancy (most common cause of secondary amenorrhea). * **Step 2:** Progesterone Challenge Test (PCT). If bleeding occurs = **Anovulation** (e.g., PCOS). * **Step 3:** If PCT is negative, perform the Estrogen + Progesterone Challenge. * **Negative E+P Challenge:** Confirms **End-organ failure** (Asherman’s Syndrome). * **Gold Standard Investigation** for Asherman’s Syndrome: **Hysteroscopy.**

Question 141: Massive painless vaginal bleeding after a 6-8 week period of amenorrhea, in a premenopausal woman, is suggestive of?

A. Irregular ripening
B. Irregular shedding (Halban Disease)
C. Metropathia haemorrhagica (Correct Answer)
D. Endometrial carcinoma

Explanation: **Explanation:** **Metropathia Haemorrhagica (Schroeder’s Disease)** is a specialized form of Dysfunctional Uterine Bleeding (DUB) typically seen in perimenopausal women. It occurs due to **persistent unovulation**. 1. **Why it is correct:** The pathophysiology involves a single follicle that matures but fails to rupture (no ovulation). This leads to a state of **unopposed estrogen** with an absolute absence of progesterone. The estrogen causes the endometrium to proliferate excessively (hyperplasia). Eventually, the estrogen levels fluctuate or the endometrium outgrows its blood supply, leading to **painless, massive, and prolonged bleeding** following a period of amenorrhea (usually 6-8 weeks). This classic clinical triad is often referred to as the "Metropathic pattern." 2. **Why other options are incorrect:** * **Irregular Ripening:** Caused by poor corpus luteum function (progesterone deficiency). It presents as premenstrual spotting, not massive bleeding after amenorrhea. * **Irregular Shedding (Halban Disease):** Caused by a persistent corpus luteum. It presents as prolonged, heavy bleeding, but the bleeding starts *on time* with the expected menses, not after a period of amenorrhea. * **Endometrial Carcinoma:** While it causes abnormal bleeding in older women, it typically presents as postmenopausal bleeding or intermenstrual bleeding, rather than the specific cyclic pattern of amenorrhea followed by flooding. **High-Yield Clinical Pearls for NEET-PG:** * **Characteristic Finding:** On D&C, the endometrium shows **Swiss-Cheese Hyperplasia** (cystic glandular hyperplasia). * **Ovarian Finding:** Presence of a follicular cyst (Amnestic follicle) on one ovary; the other ovary is usually small/atrophic. * **Uterine Finding:** The uterus is often symmetrically enlarged (myohyperplasia) due to prolonged estrogen stimulation.

Question 142: Which of the following is NOT a cause for secondary amenorrhea?

A. Pregnancy
B. Polycystic Ovarian Disease (PCOD)
C. Hyperprolactinemia
D. Turner syndrome (Correct Answer)

Explanation: **Explanation:** The distinction between primary and secondary amenorrhea is a high-yield concept in NEET-PG. **Secondary amenorrhea** is defined as the absence of menses for 3 months (in women with regular cycles) or 6 months (in those with irregular cycles) after menarche has already occurred [1]. **Why Turner Syndrome is the Correct Answer:** **Turner Syndrome (45, XO)** is the most common cause of **Primary Amenorrhea**. It is characterized by hypergonadotropic hypogonadism due to "streak ovaries" (gonadal dysgenesis). Since the ovaries fail to function from birth, these patients typically never achieve menarche. While a very small percentage (approx. 5-10%) with mosaicism (45,X/46,XX) may experience menstruation or even pregnancy, it remains the classic textbook cause of primary, not secondary, amenorrhea. **Analysis of Incorrect Options:** * **Pregnancy:** This is the **most common cause** of secondary amenorrhea worldwide. It must always be ruled out first with a urine pregnancy test (uPT). * **PCOD:** This is the most common **pathological** cause of secondary amenorrhea/oligomenorrhea [1]. It involves chronic anovulation due to hormonal imbalances (high LH:FSH ratio and hyperandrogenism). * **Hyperprolactinemia:** Elevated prolactin (due to prolactinoma or drugs) inhibits GnRH pulsatility, leading to low FSH/LH levels and subsequent secondary amenorrhea [1]. **NEET-PG Clinical Pearls:** * **Most common cause of Primary Amenorrhea:** Turner Syndrome. * **Most common cause of Secondary Amenorrhea:** Pregnancy. * **Asherman Syndrome:** The most common **uterine** cause of secondary amenorrhea (post-curettage intrauterine adhesions) [1]. * **Sheehan Syndrome:** Postpartum pituitary necrosis leading to secondary amenorrhea [1].

Question 143: Delayed puberty is defined if menstruation does not occur by which age?

A. 13 years
B. 14 years
C. 15 years
D. 16 years (Correct Answer)

Explanation: **Explanation:** Delayed puberty in females is clinically defined by the absence of secondary sexual characteristics or the failure to achieve menarche within specific age limits. **Why 16 years is the correct answer:** According to standard gynecological guidelines (including Williams and Berek & Novak), **Primary Amenorrhea** (delayed puberty) is diagnosed if: 1. Menarche has not occurred by **age 16**, regardless of the presence of normal growth and secondary sexual characteristics. 2. Menarche has not occurred by **age 13** in the absence of secondary sexual characteristics (e.g., thelarche/breast development). Since the question asks for the age of menstruation (menarche) without specifying the status of secondary sexual characteristics, the standard threshold of 16 years is applied. **Analysis of Incorrect Options:** * **A (13 years):** This is the cutoff for delayed puberty *only if* there is a total absence of secondary sexual characteristics. * **B (14 years):** While some older texts used 14 as a cutoff for girls without breast development, current international guidelines prioritize 13 and 16. * **C (15 years):** The American College of Obstetricians and Gynecologists (ACOG) recently suggested evaluating girls at age 15, but for the purpose of NEET-PG and standard textbook definitions, 16 remains the definitive answer for primary amenorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Sequence of Puberty:** Thelarche (Breast) → Pubarche (Hair) → Growth Spurt → Menarche (Bleeding). Remember the mnemonic: **"T-P-G-M"**. * **First Sign of Puberty:** Thelarche (usually occurs around age 8–10). * **Most Common Cause of Primary Amenorrhea:** Turner Syndrome (45,XO) – characterized by streak ovaries and short stature. * **Müllerian Agenesis (MRKH Syndrome):** Second most common cause; presents with 46,XX karyotype, normal secondary sexual characteristics, but absent uterus/vagina.

Question 144: Congestive dysmenorrhea is seen in patients with:

A. Fibroid
B. IUD wearers
C. PID
D. All the above (Correct Answer)

Explanation: **Explanation:** **Congestive dysmenorrhea** (also known as secondary dysmenorrhea) is characterized by pelvic pain that typically begins 3–5 days before the onset of menstruation and is relieved once the menstrual flow starts. The underlying pathophysiology is **chronic pelvic venous congestion** or increased vascularity within the pelvic organs. **Why "All the above" is correct:** 1. **Fibroids (Leiomyoma):** Large intramural or submucous fibroids increase the surface area of the endometrium and lead to pelvic vascular engorgement and uterine congestion. 2. **IUD Wearers:** Intrauterine devices can act as a foreign body, causing a local inflammatory response in the endometrium. This leads to increased vascular permeability and pelvic congestion. 3. **PID (Pelvic Inflammatory Disease):** Chronic PID causes persistent inflammation and adhesions, leading to fixed retroversion of the uterus and chronic pelvic adnexal congestion. **Clinical Pearls for NEET-PG:** * **Primary vs. Secondary:** Primary dysmenorrhea is spasmodic (due to Prostaglandin F2α), starts with the onset of menses, and has no organic pathology. Secondary (Congestive) dysmenorrhea always has an underlying organic cause. * **Key Symptom:** The "crescendo" premenstrual pain that subsides after the flow begins is the hallmark of congestive dysmenorrhea. * **Other Causes:** Endometriosis, adenomyosis, and pelvic varicosities (Pelvic Congestion Syndrome) are also frequent causes of congestive dysmenorrhea. * **Management:** Unlike primary dysmenorrhea (treated with NSAIDs/OCPs), secondary dysmenorrhea requires treating the specific underlying pathology (e.g., antibiotics for PID or surgery for fibroids).

Question 145: Which of the following medications can be used in the treatment of primary dysmenorrhea?

A. Indomethacin
B. Oral contraceptive pills
C. Mefenamic acid
D. All of the above (Correct Answer)

Explanation: **Explanation:** **Primary dysmenorrhea** is defined as painful menstruation in the absence of pelvic pathology. The underlying pathophysiology involves the release of excess **Prostaglandins (specifically PGF2α)** from the secretory endometrium during menstruation. This leads to increased uterine tone, high-amplitude contractions, and uterine ischemia, which manifest as spasmodic pain. **Why "All of the above" is correct:** The management of primary dysmenorrhea focuses on inhibiting prostaglandin synthesis or suppressing ovulation. * **NSAIDs (Mefenamic acid and Indomethacin):** These are the **first-line medical treatment**. They act by inhibiting the enzyme cyclooxygenase (COX), thereby reducing the production of prostaglandins. Mefenamic acid is often preferred due to its dual action (inhibiting synthesis and blocking prostaglandin receptors). * **Oral Contraceptive Pills (OCPs):** These are highly effective for patients who also require contraception or do not respond to NSAIDs. OCPs work by **suppressing ovulation** and thinning the endometrial lining, which significantly reduces the total prostaglandin content in the menstrual fluid. **High-Yield Clinical Pearls for NEET-PG:** * **First-line drug of choice:** NSAIDs (specifically Mefenamic acid or Ibuprofen). * **Timing:** NSAIDs should ideally be started 1–2 days before the onset of menses or at the very first sign of pain for maximum efficacy. * **Secondary Dysmenorrhea:** If a patient does not respond to NSAIDs or OCPs within 3–6 months, clinicians must investigate for secondary causes, most commonly **Endometriosis**. * **Risk Factors:** Early menarche, long menstrual periods, and smoking are associated with increased severity.

Question 146: Dysfunctional uterine bleeding is associated with which of the following conditions?

A. Metropathia haemorrhagica (Correct Answer)
B. Fibroid uterus
C. Endometriosis
D. Ovarian tumour

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)** is defined as abnormal uterine bleeding in the absence of any detectable organic pelvic pathology, systemic disease, or pregnancy-related complications. It is primarily an endocrine disorder resulting from a disturbance in the hypothalamic-pituitary-ovarian axis. **Why Option A is Correct:** **Metropathia Haemorrhagica** (also known as Schroeder’s Disease) is a classic clinical variant of DUB. It is characterized by **anovulation**, which leads to a state of **unopposed estrogen**. Without ovulation, no corpus luteum is formed, and progesterone is absent. This causes the endometrium to undergo continuous hyperplasia without shedding, eventually leading to "breakthrough bleeding" when the estrogen levels fluctuate or the endometrium outgrows its blood supply. It typically presents as a period of amenorrhea followed by heavy, painless bleeding. **Why Other Options are Incorrect:** * **B. Fibroid Uterus:** This is a structural/organic pathology (leiomyoma). Bleeding caused by fibroids is classified under "Leiomyoma" in the PALM-COEIN classification, not DUB. * **C. Endometriosis:** This typically presents with dysmenorrhea and pelvic pain. While it can coexist with menstrual irregularities, it is an organic condition involving ectopic endometrial tissue. * **D. Ovarian Tumour:** These are organic growths. While some (like Granulosa cell tumors) can cause hormonal imbalances leading to bleeding, the bleeding is secondary to a primary organic lesion. **High-Yield Clinical Pearls for NEET-PG:** * **PALM-COEIN Classification:** DUB now falls under the "COEIN" (Non-structural) categories: **C**oagulopathy, **O**vulatory dysfunction, **E**ndometrial, **I**atrogenic, and **N**ot yet classified. * **Metropathia Haemorrhagica** is most common in perimenopausal women. * **Histology:** The classic finding in Metropathia Haemorrhagica is **Cystic Glandular Hyperplasia**, often described as a **"Swiss-Cheese" appearance** of the endometrium. * **Treatment of Choice:** In DUB, medical management (like combined oral contraceptives or Progestogens) is the first line, unlike organic causes which often require surgery.

Question 147: Which of the following is NOT a feature of Metropathia haemorrhagica?

A. Occurs in younger women (Correct Answer)
B. Uterus is bulky
C. Menorrhagia
D. Endometrial hyperplasia

Explanation: **Explanation:** **Metropathia Haemorrhagica** (also known as Schroeder’s Disease) is a specific form of Abnormal Uterine Bleeding (AUB) associated with anovulation. **1. Why Option A is the correct answer:** Metropathia haemorrhagica typically occurs in **perimenopausal women** (women in their 40s), not younger women. The underlying pathology is the persistence of an unruptured Graafian follicle, leading to a prolonged follicular phase without ovulation. This results in a period of amenorrhea (usually 6–8 weeks) followed by heavy, painless bleeding. **2. Analysis of incorrect options:** * **B. Uterus is bulky:** Due to the continuous, unopposed stimulation of estrogen without the counter-effect of progesterone (since no corpus luteum is formed), the myometrium undergoes hypertrophy, making the uterus feel symmetrically bulky (myometrial hyperplasia). * **C. Menorrhagia:** The hallmark clinical presentation is heavy, prolonged, and painless bleeding. Because the endometrium outgrows its blood supply in the absence of progesterone, it sheds irregularly and profusely. * **D. Endometrial hyperplasia:** Continuous estrogen causes the endometrium to become hyperplastic. Classically, this presents as **Swiss-cheese endometrium** (Cystoglandular hyperplasia), where glands of varying sizes are seen on histopathology. **NEET-PG High-Yield Pearls:** * **Classic Triad:** Amenorrhea (short period) → Followed by profuse, painless bleeding → In a perimenopausal woman. * **Ovarian finding:** Presence of a follicular cyst (unruptured follicle) and absence of corpus luteum. * **Histology:** "Swiss-cheese" appearance of the endometrium. * **Treatment of choice:** Dilatation and Curettage (D&C) serves both a diagnostic and therapeutic purpose (to stop the bleeding).

Question 148: Secondary amenorrhea after abortion due to intrauterine adhesions is seen in:

A. Uterine inertia
B. Imperforate hymen
C. Bicornuate uterus
D. Asherman's syndrome (Correct Answer)

Explanation: **Explanation:** **Asherman’s Syndrome** is the correct answer because it refers to the formation of intrauterine adhesions (synechiae) following trauma to the basal layer of the endometrium. This most commonly occurs after vigorous curettage (D&C) for an incomplete abortion or postpartum hemorrhage. The destruction of the endometrium leads to the fusion of the uterine walls, resulting in secondary amenorrhea or hypomenorrhea and infertility. **Analysis of Incorrect Options:** * **Uterine Inertia:** This refers to weak or absent uterine contractions during labor (primary or secondary). It is a functional complication of the first or second stage of labor and has no association with intrauterine adhesions or amenorrhea. * **Imperforate Hymen:** This is a congenital anatomical cause of **primary amenorrhea**. It leads to cryptomenorrhea (hidden menstruation) where blood collects in the vagina (hematocolpos), but it is not acquired after an abortion. * **Bicornuate Uterus:** This is a congenital Mullerian duct anomaly where the uterus is heart-shaped with two horns. While it can lead to recurrent pregnancy loss or malpresentation, it does not cause secondary amenorrhea or adhesions. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** Hysteroscopy is the gold standard for both diagnosis and treatment (adhesiolysis) of Asherman’s Syndrome. * **HSG Finding:** Classically shows "filling defects" within the uterine cavity. * **Treatment:** Hysteroscopic adhesiolysis followed by the placement of an IUCD or Foley catheter and high-dose estrogen therapy to promote endometrial regrowth. * **Amniotic Band Syndrome** is a different entity; do not confuse it with intrauterine synechiae.

Question 149: Primary amenorrhea is seen in all of the following except?

A. Kallman syndrome
B. Turner syndrome
C. MRKHS syndrome
D. Sheehan syndrome (Correct Answer)

Explanation: **Explanation:** The core concept in this question is distinguishing between **primary amenorrhea** (failure to initiate menstruation by age 15 with secondary sexual characteristics or age 13 without) and **secondary amenorrhea** (cessation of menses after they have already been established). **Why Sheehan Syndrome is the Correct Answer:** Sheehan syndrome is a form of postpartum pituitary necrosis caused by severe obstetric hemorrhage and hypovolemic shock. Since it occurs as a complication of childbirth, the patient must have been fertile and menstruating previously. Therefore, it is a classic cause of **secondary amenorrhea**, not primary. **Analysis of Incorrect Options:** * **Kallman Syndrome:** A hypogonadotropic hypogonadism caused by the failure of GnRH-secreting neurons to migrate. It presents with primary amenorrhea and anosmia. * **Turner Syndrome (45, XO):** The most common genetic cause of primary amenorrhea. It involves ovarian dysgenesis (streak ovaries), leading to hypergonadotropic hypogonadism. * **MRKHS (Mayer-Rokitansky-Küster-Hauser Syndrome):** Characterized by Müllerian agenesis (absent uterus and upper 2/3rd of the vagina) despite a normal 46,XX karyotype and functioning ovaries. It is a leading cause of primary amenorrhea with normal secondary sexual characteristics. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of primary amenorrhea:** Turner Syndrome. * **Most common cause of secondary amenorrhea:** Pregnancy (Physiological). * **Sheehan Syndrome Hallmark:** Failure of lactation (due to prolactin deficiency) is often the earliest clinical sign, followed by loss of pubic/axillary hair and secondary amenorrhea. * **MRKHS vs. AIS:** In MRKHS, pubic hair is normal (female testosterone levels); in Androgen Insensitivity Syndrome (AIS), pubic hair is absent/scanty.

Question 150: What is the most common cause of primary amenorrhea?

A. Gonadal dysgenesis (Correct Answer)
B. Mullerian agenesis
C. Androgen insensitivity syndrome
D. Stein-Levinthal syndrome

Explanation: **Explanation:** Primary amenorrhea is defined as the absence of menarche by age 13 in the absence of secondary sexual characteristics, or by age 15 if secondary sexual characteristics are present. **Why Gonadal Dysgenesis is Correct:** **Gonadal dysgenesis** (specifically **Turner Syndrome, 45,XO**) is the most common cause of primary amenorrhea, accounting for approximately **43% of cases**. The underlying pathology involves the accelerated attrition of germ cells, leading to "streak gonads." This results in hypergonadotropic hypogonadism (elevated FSH/LH due to lack of estrogen feedback). Clinically, these patients present with short stature and absent secondary sexual characteristics. **Analysis of Incorrect Options:** * **B. Mullerian Agenesis (MRKH Syndrome):** This is the **second most common cause** (~15%). It is characterized by the congenital absence of the uterus and upper two-thirds of the vagina, but with normal ovaries and 46,XX karyotype. * **C. Androgen Insensitivity Syndrome (AIS):** A less common cause where the genotype is 46,XY. Patients have functioning testes (undescended) but a female phenotype due to receptor resistance. They present with scant pubic hair and a blind-ending vagina. * **D. Stein-Levinthal Syndrome (PCOS):** While a very common cause of *secondary* amenorrhea or oligomenorrhea, it is an infrequent cause of primary amenorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause overall:** Gonadal Dysgenesis (Turner’s). * **Most common cause with normal breast development:** Mullerian Agenesis. * **Initial Investigation:** Serum FSH levels. High FSH indicates gonadal failure; low/normal FSH suggests hypothalamic/pituitary causes or anatomical obstructions. * **Karyotyping** is mandatory in all cases of primary amenorrhea with high FSH to rule out Turner Syndrome or Y-chromosome material (risk of gonadoblastoma).

Question 151: Which of the following statements regarding spasmodic dysmenorrhea is false?

A. Often cured by delivery of a child
B. Pain usually appears on the first day of menstruation
C. Pain persists for 2-3 days (Correct Answer)
D. Rare above the age of 35 years

Explanation: ### Explanation **Spasmodic (Primary) Dysmenorrhea** is characterized by painful uterine contractions caused by the release of **Prostaglandin F2α (PGF2α)** from the secretory endometrium. #### Why Option C is False (The Correct Answer) In spasmodic dysmenorrhea, the pain typically begins a few hours before or exactly at the onset of menstruation. Crucially, the pain is **short-lived**, usually lasting only **12 to 24 hours**. It rarely persists beyond the first 48 hours. If pain persists for 2–3 days or longer, clinicians should suspect **Congestive (Secondary) Dysmenorrhea**, often associated with conditions like endometriosis or PID. #### Analysis of Other Options * **A. Often cured by delivery:** This is **true**. Vaginal delivery causes stretching of the adrenergic nerves in the isthmus and cervix (Frankenhauser’s plexus) and widens the cervical canal, which significantly reduces or eliminates primary dysmenorrhea. * **B. Pain appears on the first day:** This is **true**. The pain is spasmodic/colicky in nature and coincides with the peak of prostaglandin release and the heaviest menstrual flow on day one. * **D. Rare above the age of 35:** This is **true**. Primary dysmenorrhea typically begins shortly after menarche (once ovulatory cycles are established) and tends to improve with increasing age and parity. #### High-Yield Clinical Pearls for NEET-PG * **Mechanism:** High levels of PGF2α → Uterine hypercontractility → Ischemia → Pain. * **Prerequisite:** It occurs only in **ovulatory cycles** (Progesterone is required for PGF2α production). * **First-line Treatment:** NSAIDs (Mefenamic acid), which act as prostaglandin synthetase inhibitors. * **Drug of Choice for Contraception Seekers:** Combined Oral Contraceptive Pills (OCPs), which induce anovulation.

Question 152: Which progestogen has the greatest haemostatic effect for treating dysfunctional uterine bleeding (DUB)?

A. Medroxyprogesterone
B. Hydroxyprogesterone
C. Norethisterone (Correct Answer)
D. Dydrogesterone

Explanation: **Explanation:** The primary goal in treating acute dysfunctional uterine bleeding (DUB) is to stabilize the sloughing endometrium and induce a "medical curettage." **Why Norethisterone is the Correct Answer:** Norethisterone (a 19-nortestosterone derivative) is the most potent oral progestogen for achieving rapid haemostasis. It possesses high **progestational activity** and significant **anti-estrogenic effects** on the endometrium. It works by inducing a rapid secretory change in a proliferative endometrium, effectively "bracing" the tissue and stopping the bleeding. Once the high-dose therapy is stopped, it results in a predictable, organized withdrawal bleed. **Analysis of Incorrect Options:** * **Medroxyprogesterone (MPA):** While commonly used for cycle regulation, it is less potent than 19-nor derivatives. It is often used for long-term maintenance rather than acute, heavy haemostasis. * **Hydroxyprogesterone:** This is a naturally occurring progestogen derivative (usually given as an injectable caproate). It has a slower onset of action and is primarily used for preventing preterm labor or recurrent miscarriages, not for acute DUB. * **Dydrogesterone:** This is a "retro-progesterone" with high selectivity for progesterone receptors. While it has fewer side effects (no androgenic activity), it is less effective at achieving rapid endometrial stability compared to Norethisterone in acute bleeding scenarios. **High-Yield NEET-PG Pearls:** * **Drug of Choice (DOC):** For acute heavy menstrual bleeding, Norethisterone (5mg TDS) is the clinical favorite. * **Mechanism:** Progestogens inhibit further estrogen-driven endometrial hyperplasia and stabilize the lysosomal membranes within endometrial cells. * **Contraindication:** Avoid Norethisterone in patients with a high risk of thromboembolism or active liver disease. * **LNG-IUS (Mirena):** Remember that for *chronic* management of DUB/AUB, the Levonorgestrel Intrauterine System is considered the "Gold Standard" medical treatment.

Question 153: What is the best pharmacological agent for the management of premenstrual syndrome?

A. Progesterone
B. Anxiolytic
C. SSRI (Correct Answer)
D. Vitamin E

Explanation: **Explanation:** **Selective Serotonin Reuptake Inhibitors (SSRIs)** are considered the first-line pharmacological treatment for moderate to severe Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD). The underlying pathophysiology involves a maladaptive response of the neurotransmitter serotonin to normal fluctuations in gonadal steroids (estrogen and progesterone). SSRIs like Fluoxetine, Sertraline, and Paroxetine effectively modulate these serotonergic pathways, providing rapid relief of both emotional and physical symptoms. **Why other options are incorrect:** * **Progesterone (A):** While PMS occurs during the luteal phase (when progesterone is high), clinical trials have shown that progesterone supplementation is no more effective than a placebo in treating PMS symptoms. * **Anxiolytics (B):** While Alprazolam may be used as a second-line therapy for specific anxiety symptoms, it is not the primary treatment due to the risk of dependence and side effects. * **Vitamin E (D):** Nutritional supplements like Vitamin E, Vitamin B6, and Calcium may offer mild relief for very minor symptoms but lack robust clinical evidence to be considered the "best" pharmacological agent. **High-Yield Clinical Pearls for NEET-PG:** * **Dosing:** Unlike in depression (where SSRIs take 4–6 weeks to work), in PMS, they work rapidly. They can be given **luteal-phase only** (Day 14 to the onset of menses) or continuously. * **Gold Standard Diagnosis:** Prospective charting of symptoms for at least **two consecutive menstrual cycles** (e.g., using the Daily Record of Severity of Problems). * **Definitive Treatment:** For refractory cases, **GnRH agonists** (to induce medical menopause) or bilateral oophorectomy are considered.

Question 154: What is the most common histological finding of the endometrium in dysfunctional uterine bleeding (DUB)?

A. Atrophic
B. Hyperplastic (Correct Answer)
C. Cystic glandular hyperplasia
D. Dysplastic

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)**, now more accurately referred to under the PALM-COEIN classification as AUB-O (Ovulatory dysfunction), is most commonly associated with **anovulation**. 1. **Why Hyperplastic is correct:** In anovulatory cycles, there is a failure of ovulation, meaning no corpus luteum is formed and no progesterone is produced. This results in a state of **"unopposed estrogen."** Estrogen causes the endometrium to continuously proliferate without the stabilizing effect of progesterone. This leads to a **hyperplastic** endometrium that eventually outgrows its blood supply, resulting in irregular, heavy, and prolonged shedding. 2. **Why other options are incorrect:** * **Atrophic:** This is the most common cause of postmenopausal bleeding, not DUB. It occurs due to a lack of estrogen. * **Cystic glandular hyperplasia:** While this is a *type* of hyperplasia (often called "Swiss-cheese" appearance), "Hyperplastic" is the broader and more accurate histological category for DUB across various age groups. * **Dysplastic:** Dysplasia (atypia) is a premalignant change. While long-term unopposed estrogen can lead to atypical hyperplasia, it is not the *most common* finding in routine DUB. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of DUB:** Anovulation (90% of cases), typically seen at the extremes of reproductive life (menarche and perimenopause). * **Gold Standard Investigation:** Endometrial biopsy (D&C) is mandatory in women >35 years to rule out endometrial carcinoma. * **Drug of Choice (Medical):** Combined Oral Contraceptive Pills (COCPs) or Progestogens (to "oppose" the estrogen). * **Drug of Choice (Long-term/Heavy bleeding):** Levonorgestrel-releasing intrauterine system (LNG-IUS/Mirena).

Question 155: Which of the following statements is false regarding ablative procedures for abnormal uterine bleeding?

A. They are safe and effective with less morbidity.
B. They offer a quicker recovery.
C. Fertility is preserved. (Correct Answer)
D. The method destroys 2-3mm of myometrium.

Explanation: **Explanation:** Endometrial ablation is a surgical procedure designed to destroy the uterine lining (endometrium) to treat heavy menstrual bleeding (AUB-E/AUB-P) in women who wish to avoid a hysterectomy. **Why Option C is the correct (False) statement:** The primary goal of endometrial ablation is the permanent destruction of the basal layer of the endometrium. While it is not a guaranteed form of sterilization, it **significantly impairs fertility** and makes the uterine environment hostile for implantation. Furthermore, if pregnancy does occur, it is associated with high risks of placenta accreta, miscarriage, and growth restriction. Therefore, patients must be counseled that the procedure is **not fertility-preserving**, and reliable contraception is mandatory post-procedure. **Analysis of other options:** * **Options A & B:** These are **true**. Compared to hysterectomy, ablative procedures (like thermal balloons or radiofrequency) are minimally invasive, have lower morbidity (no major abdominal incision, less blood loss), and offer a much faster recovery time (usually returning to work within 1–2 days). * **Option D:** This is **true**. To ensure the endometrium does not regenerate, the procedure must destroy the entire thickness of the endometrium plus **2–3 mm of the underlying myometrium**, where the deep basal glands reside. **NEET-PG High-Yield Pearls:** * **Prerequisites:** Before ablation, a **hysteroscopy and endometrial biopsy** are mandatory to rule out malignancy or atypical hyperplasia. * **Ideal Candidate:** Women with AUB who have completed childbearing, have a uterine size <10–12 weeks, and no structural abnormalities like large submucosal fibroids. * **Amenorrhea Rate:** Approximately 30–50% of women achieve total amenorrhea, while the rest experience significantly reduced flow.

Question 156: Secondary amenorrhea is defined as:

A. Absence of menstruation for one normal menstrual cycle.
B. Absence of menstruation for three normal menstrual cycles. (Correct Answer)
C. Absence of menstruation for six normal menstrual cycles.
D. Absence of menstruation for one year.

Explanation: **Explanation:** Secondary amenorrhea is defined as the cessation of menstruation in a woman who has previously established a regular menstrual pattern. The standard clinical criteria for diagnosis are: 1. Absence of menses for **3 months** (3 cycles) in a woman with previously regular cycles. 2. Absence of menses for **6 months** in a woman with previously irregular cycles. **Analysis of Options:** * **Option B (Correct):** This aligns with the standard diagnostic criteria for women with regular cycles. It represents a sufficient duration to warrant clinical investigation for underlying pathology (e.g., PCOS, pregnancy, or hyperprolactinemia). * **Option A:** Missing one cycle is common due to transient stress or illness and is not clinically classified as amenorrhea. * **Option C:** While 6 months is the criteria for women with *irregular* cycles, the standard textbook definition for secondary amenorrhea (unless specified otherwise) typically highlights the 3-month threshold for regular cycles. * **Option D:** One year is the duration required to diagnose **menopause**, not secondary amenorrhea. **NEET-PG High-Yield Pearls:** * **Most Common Cause:** The most common cause of secondary amenorrhea is **pregnancy**; this must always be ruled out first with a UPT. * **Most Common Pathological Cause:** Polycystic Ovary Syndrome (PCOS). * **Asherman Syndrome:** The most common cause of secondary amenorrhea following a D&C (uterine synechiae). * **Progesterone Challenge Test:** Used to assess endogenous estrogen levels and outflow tract patency. Withdrawal bleeding indicates an intact HPO axis and adequate estrogen.

Question 157: What is the most common cause of pubertal menorrhagia?

A. Anovulation (Correct Answer)
B. Malignancy
C. Endometriosis
D. Bleeding disorder

Explanation: **Explanation:** **1. Why Anovulation is Correct:** Pubertal menorrhagia refers to excessive menstrual bleeding occurring between menarche and 19 years of age. The most common cause is an **immature Hypothalamic-Pituitary-Ovarian (HPO) axis**. In the first few years following menarche, the feedback mechanism is not fully developed, leading to **anovulatory cycles**. Without ovulation, there is no corpus luteum formation and, consequently, no progesterone production. This results in "unopposed estrogen" action, causing the endometrium to proliferate excessively. Eventually, this thickened, unstable lining outgrows its blood supply and sheds asynchronously, leading to heavy, prolonged, and irregular bleeding. **2. Why Other Options are Incorrect:** * **Malignancy:** Genital tract malignancies (like endometrial or cervical cancer) are extremely rare in the pubertal age group; they are typically diseases of postmenopausal or older reproductive-age women. * **Endometriosis:** While endometriosis can cause dysmenorrhea (painful periods) and pelvic pain in adolescents, it is not a primary cause of heavy menstrual bleeding (menorrhagia). * **Bleeding Disorders:** While systemic coagulopathies (like **Von Willebrand Disease**) are the most common *organic* or *systemic* cause (found in up to 20% of severe cases), they are still statistically less frequent than physiological anovulation. **3. High-Yield Clinical Pearls for NEET-PG:** * **First-line Investigation:** Ultrasound (to rule out structural causes) and a Complete Blood Count (to assess anemia). * **Management:** Most cases are managed with reassurance or **Combined Oral Contraceptive Pills (OCPs)** to regulate the cycle. * **Rule of Thumb:** If a teenager presents with menorrhagia from the very first period (menarche) requiring hospitalization, always screen for **Von Willebrand Disease**.

Question 158: What is the most common endometrial pattern in dysfunctional uterine bleeding?

A. Normal (Correct Answer)
B. Hyperplastic with Swiss-Cheese pattern
C. Nonsecretory
D. Atrophic

Explanation: **Explanation:** Dysfunctional Uterine Bleeding (DUB) is defined as abnormal uterine bleeding in the absence of any detectable organic pelvic pathology, systemic disease, or pregnancy. **1. Why "Normal" is correct:** In the majority of cases, particularly in women of reproductive age, the endometrial histology in DUB is found to be **normal (proliferative or secretory)**. This occurs because the bleeding is often due to transient hormonal imbalances or local vascular dysregulation rather than a persistent structural change in the endometrium. While DUB is a diagnosis of exclusion, statistical data and clinical studies confirm that a "normal" endometrial pattern is the most frequent finding upon biopsy. **2. Analysis of Incorrect Options:** * **Hyperplastic (Swiss-Cheese pattern):** This is characteristic of cystic glandular hyperplasia, typically seen in **metropathia haemorrhagica** (a specific type of anovulatory DUB). While high-yield for exams, it is not the *most* common overall pattern. * **Nonsecretory (Proliferative):** This indicates anovulatory cycles. While common in extremes of reproductive life (puberty and perimenopause), it ranks second to a normal pattern across the general population. * **Atrophic:** This is the most common cause of postmenopausal bleeding, but it is a less common finding in DUB during the reproductive years. **Clinical Pearls for NEET-PG:** * **Most common cause of DUB:** Anovulation (approx. 80% of cases). * **Metropathia Haemorrhagica (Schroeder’s Disease):** Characterized by specialized "Swiss-cheese" hyperplasia, usually occurring in perimenopausal women due to persistent estrogen stimulation without progesterone. * **Gold Standard Investigation:** For women >35 years with DUB, **Fractional Curettage or Endometrial Biopsy** is mandatory to rule out endometrial carcinoma.

Question 159: What is the initial treatment of dysfunctional uterine bleeding in a young female?

A. Oral contraceptive pills (Correct Answer)
B. Danazol
C. Hysterectomy
D. Androgens

Explanation: **Explanation:** Dysfunctional Uterine Bleeding (DUB), now often referred to under the **PALM-COEIN** classification as AUB-O (Ovulatory dysfunction), is most common in young females due to an immature hypothalamic-pituitary-ovarian axis. This leads to anovulatory cycles where estrogen acts unopposed by progesterone, causing the endometrium to become hyperplastic and unstable, eventually sloughing off irregularly. **1. Why Oral Contraceptive Pills (OCPs) are the correct choice:** OCPs are the first-line medical management for DUB in young patients. They provide a combination of estrogen and progestin which stabilizes the endometrial lining, regulates the cycle, and reduces menstrual blood loss by approximately 50%. In acute episodes, high-dose OCPs can be used to "triage" the bleeding, followed by a maintenance cyclic regimen. **2. Why other options are incorrect:** * **Danazol:** While it suppresses the pituitary-ovarian axis and causes endometrial atrophy, it is rarely used as first-line therapy due to significant androgenic side effects (acne, hirsutism, weight gain), which are poorly tolerated by young females. * **Hysterectomy:** This is a definitive surgical treatment but is **contraindicated** as an initial step in a young female. It is reserved for older women who have completed their family or when medical management fails. * **Androgens:** These are not standard therapy for DUB due to virilizing side effects and the availability of safer, more effective hormonal alternatives. **Clinical Pearls for NEET-PG:** * **First-line for acute heavy bleeding:** IV Conjugated Estrogen (if available) or high-dose OCPs. * **Drug of choice for DUB in a woman >35 years:** Progestogens (e.g., Medroxyprogesterone acetate) or LNG-IUS. * **Gold Standard Investigation for AUB (General):** Hysteroscopy-guided biopsy (though Ultrasound is the initial investigation). * **Young patients:** Always rule out pregnancy and coagulation disorders (like von Willebrand disease) before diagnosing DUB.

Question 160: Which of the following is NOT a treatment for dysfunctional uterine bleeding?

A. Oral contraceptive pills
B. Estrogen
C. Progesterone
D. Ovariotomy (Correct Answer)

Explanation: **Explanation:** Dysfunctional Uterine Bleeding (DUB), now more commonly classified under the **PALM-COEIN** criteria as AUB-E (Endometrial) or AUB-O (Ovulatory dysfunction), is primarily a hormonal imbalance resulting in abnormal shedding of the endometrium. **Why Ovariotomy is the Correct Answer:** Ovariotomy refers to the surgical removal of an ovary. This is **not** a treatment for DUB because DUB is a functional disorder of the uterine lining, not a primary surgical disease of the ovaries. Removing the ovaries would induce premature menopause and does not address the underlying endometrial instability. Surgical management for DUB, when medical therapy fails, typically involves endometrial ablation or hysterectomy, not ovariotomy. **Analysis of Incorrect Options:** * **Oral Contraceptive Pills (OCPs):** These are first-line treatments. They regulate the cycle, provide progestational support to stabilize the endometrium, and induce withdrawal bleeds. * **Estrogen:** High-dose estrogen is used in acute, heavy bleeding episodes to promote rapid "re-epithelialization" of the denuded endometrial surface, effectively stopping the hemorrhage. * **Progesterone:** Often considered the "medical curette," progestins (like Medroxyprogesterone acetate or Norethisterone) are used to treat DUB by counteracting estrogen-induced hyperplasia and ensuring organized shedding. **High-Yield Clinical Pearls for NEET-PG:** * **DOC for DUB:** In most stable cases, **NSAIDs or Tranexamic acid** are used for symptom relief, but **OCPs/Levonorgestrel-IUD (Mirena)** are the gold standard for long-term medical management. * **Mirena (LNG-IUD):** Currently considered the most effective medical treatment for heavy menstrual bleeding, often superior to oral medications. * **Aged >35 years:** Always perform an endometrial biopsy to rule out endometrial hyperplasia or malignancy before starting hormonal therapy for DUB.

Question 161: Which of the following is NOT a cause of primary amenorrhea?

A. Rokitansky syndrome
B. Sheehan syndrome (Correct Answer)
C. Kollman syndrome
D. Turner syndrome

Explanation: **Explanation:** The distinction between primary and secondary amenorrhea is a high-yield topic for NEET-PG. **Primary amenorrhea** refers to the failure of menses to occur by age 15 (with secondary sexual characteristics) or age 13 (without them). **Secondary amenorrhea** is the cessation of menses for >3 months in a previously regular female. **Why Sheehan Syndrome is the Correct Answer:** Sheehan syndrome is a classic cause of **secondary amenorrhea**. It occurs due to postpartum pituitary necrosis following severe obstetric hemorrhage and hypotension. Since the patient must have been pregnant to develop this condition, she must have already achieved menarche. Therefore, it cannot be a cause of primary amenorrhea. **Analysis of Incorrect Options:** * **Rokitansky Syndrome (MRKH):** The second most common cause of primary amenorrhea. It involves Müllerian agenesis (absent uterus and upper 2/3rd of the vagina) but with normal ovaries and 46,XX karyotype. * **Kallmann Syndrome:** A form of hypogonadotropic hypogonadism (low FSH/LH) due to failure of GnRH neuron migration. It presents with primary amenorrhea and **anosmia**. * **Turner Syndrome (45,XO):** The most common cause of primary amenorrhea. It is characterized by streak ovaries (gonadal dysgenesis), short stature, and webbed neck. **High-Yield Clinical Pearls:** * **Most common cause of Primary Amenorrhea:** Turner Syndrome. * **Most common cause of Secondary Amenorrhea:** Pregnancy (always rule this out first!). * **Sheehan Syndrome Presentation:** Failure of lactation (earliest sign), followed by loss of pubic/axillary hair and secondary amenorrhea. * **Kallmann Syndrome Key:** Look for the keyword "anosmia" or "inability to smell" in the clinical stem.

Question 162: Which of the following is false regarding Mittelschmerz?

A. Treatment is with estrogen (Correct Answer)
B. Rarely lasts more than 12 hours
C. Spotting may be present
D. Usually occurs around the 14th day of the menstrual cycle

Explanation: **Explanation:** **Mittelschmerz** (German for "middle pain") refers to mid-cycle ovulatory pain. The correct answer is **A** because the treatment for Mittelschmerz is **not** estrogen; rather, it is managed with reassurance, analgesics (NSAIDs), or **Combined Oral Contraceptive Pills (COCPs)** if the pain is recurrent and severe. COCPs work by suppressing ovulation, which is the underlying cause of the pain. **Analysis of Options:** * **Option B (Duration):** This is a true statement. The pain typically lasts from a few minutes to a few hours and rarely exceeds 12–24 hours. * **Option C (Spotting):** This is true. The sudden drop in estrogen levels just before ovulation can cause slight endometrial shedding, leading to mid-cycle "spotting." * **Option D (Timing):** This is true. In a typical 28-day cycle, ovulation occurs around day 14. The pain coincides with the rupture of the Graafian follicle. **Pathophysiology & Clinical Pearls:** The pain is attributed to the rapid expansion of the dominant follicle or the irritation of the pelvic peritoneum by follicular fluid and blood released during ovulation. **High-Yield Facts for NEET-PG:** 1. **Diagnosis:** It is a diagnosis of exclusion. One must rule out appendicitis, ectopic pregnancy, and PID. 2. **Lateralization:** The pain is typically unilateral and switches sides from month to month depending on which ovary is ovulating. 3. **Key Feature:** It is a physiological condition, not a pathological one. 4. **Management:** Reassurance is the first line of management. For severe cases, **ovulation suppression** (via COCPs) is the definitive medical approach.

Question 163: In dysfunctional uterine bleeding (DUB), what is the typical hormonal imbalance?

A. Increased estrogen (Correct Answer)
B. Decreased progesterone receptors
C. Decreased estrogen receptors
D. Pituitary hormone imbalance

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)**, now classified under the PALM-COEIN system as AUB-O (Ovulatory dysfunction), most commonly results from **anovulation**. **Why "Increased Estrogen" is correct:** In an anovulatory cycle, the failure of ovulation means no corpus luteum is formed. Consequently, there is no production of **progesterone**. This leads to a state of **"unopposed estrogen"** action on the endometrium. The estrogen causes continuous proliferation of the endometrial lining without the stabilizing effect of progesterone. Eventually, the endometrium outgrows its blood supply, leading to asynchronous breakdown and heavy, irregular bleeding (estrogen breakthrough bleeding). **Analysis of Incorrect Options:** * **B & C (Receptor Imbalance):** DUB is primarily a hormonal signaling issue rather than a primary pathology of the estrogen or progesterone receptors themselves. While receptor sensitivity can vary, the hallmark of the condition is the systemic lack of progesterone. * **D (Pituitary hormone imbalance):** While the hypothalamus-pituitary-ovarian (HPO) axis is disrupted, the term "pituitary hormone imbalance" is too vague. The specific clinical manifestation of DUB is driven by the local effect of estrogen on the uterus. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of DUB:** Anovulation (especially at extremes of reproductive age—puberty and perimenopause). * **Endometrial Histology:** Typically shows **proliferative phase** or endometrial hyperplasia due to unopposed estrogen. * **Drug of Choice:** For acute bleeding, high-dose estrogen or OCPs; for long-term management of anovulatory DUB, **Progestogens** (to stabilize the lining) or **Levonorgestrel-IUS (Mirena)** are preferred. * **Gold Standard Investigation:** Transvaginal Ultrasound (TVS) to assess endometrial thickness; Endometrial biopsy is mandatory if age >35–45 years to rule out malignancy.

Question 164: A patient presents with a history of frequent cycles accompanied by heavy bleeding. What is this condition called?

A. Menorrhagia
B. Polymenorrhea
C. Polymenorrhagia (Correct Answer)
D. Metrorrhagia

Explanation: This question tests your understanding of the terminology used to describe abnormal uterine bleeding (AUB). To arrive at the correct answer, you must break down the clinical presentation into its two components: **frequency** and **volume**. ### 1. Why Polymenorrhagia is Correct The patient presents with two distinct issues: * **Frequent cycles:** A cycle length of less than 21 days is termed **Polymenorrhea**. * **Heavy bleeding:** Excessive blood loss (>80 ml) or prolonged duration (>7 days) during a regular cycle is termed **Menorrhagia**. When these two conditions coexist—meaning the patient bleeds too often and too much—the combined term is **Polymenorrhagia** (also known as Epimenorrhagia). ### 2. Analysis of Incorrect Options * **A. Menorrhagia:** This refers only to heavy or prolonged bleeding occurring at regular intervals (21–35 days). It does not account for the increased frequency mentioned in the stem. * **B. Polymenorrhea:** This refers only to the increased frequency of cycles (cycles <21 days). The flow itself may be normal in amount and duration. * **D. Metrorrhagia:** This refers to irregular, acyclic bleeding occurring between expected menstrual periods (intermenstrual bleeding). ### 3. NEET-PG High-Yield Pearls * **Normal Menstrual Parameters:** Cycle length: 21–35 days; Duration: 2–7 days; Blood loss: 20–80 ml. * **Oligomenorrhea:** Infrequent cycles occurring at intervals >35 days. * **Hypomenorrhea:** Scanty flow or decreased duration (<2 days) at regular intervals. * **FIGO Classification (PALM-COEIN):** Modern clinical practice is moving away from these traditional terms toward the PALM-COEIN system, which classifies AUB by etiology (e.g., Polyp, Adenomyosis, Leiomyoma, Malignancy, etc.). However, these descriptive terms remain high-yield for competitive exams.

Question 165: Bleeding associated with anovulation is due to which of the following?

A. Persistent proliferative endometrium. (Correct Answer)
B. Alterations in endometrial vascular structure.
C. Increased endometrial responsiveness to vasodilating prostaglandins.
D. Impaired prostaglandin concentration.

Explanation: **Explanation:** In a normal ovulatory cycle, the production of progesterone following ovulation induces a secretory change in the endometrium. When progesterone levels drop, the endometrium sheds in a synchronized, organized manner. In **anovulation**, there is no corpus luteum formation, leading to a **lack of progesterone**. Consequently, the endometrium is subjected to continuous, unopposed estrogen stimulation. This results in a **persistent proliferative endometrium** that continues to thicken without the stabilizing effect of progesterone. Eventually, the endometrium outgrows its blood supply or experiences estrogen fluctuations, leading to asynchronous, irregular shedding known as **Estrogen Breakthrough Bleeding**. **Analysis of Options:** * **Option A (Correct):** Anovulation leads to unopposed estrogen, causing the endometrium to remain in the proliferative phase indefinitely until it becomes unstable and bleeds. * **Option B:** While vascular changes occur during bleeding, they are a *consequence* of the hormonal imbalance, not the primary mechanism of anovulatory bleeding. * **Option C & D:** Alterations in prostaglandin levels (specifically an increase in PGE2/PGF2α ratio) are primarily associated with **Ovulatory Abnormal Uterine Bleeding (AUB)** and menorrhagia, where the endometrial cycle is otherwise regular but the local hemostatic mechanisms are impaired. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of AUB in adolescents and perimenopausal women:** Anovulation. * **Histology:** Anovulatory bleeding typically shows a proliferative or hyperplastic endometrium; it *never* shows secretory changes. * **Risk:** Long-term unopposed estrogen (persistent proliferation) is a major risk factor for **Endometrial Hyperplasia** and **Endometrial Carcinoma**. * **Management:** The mainstay of treatment for anovulatory AUB is cyclic progestins to "stabilize" the endometrium and induce withdrawal bleeds.

Question 166: A 30-year-old woman, para 2, with hypertension presents with menorrhagia. What is the best treatment for her?

A. Combined oral contraceptive pills
B. Mirena (Levonorgestrel-releasing intrauterine system) (Correct Answer)
C. Hysterectomy
D. Transcervical resection of the endometrium

Explanation: **Explanation:** The patient is a 30-year-old multiparous woman presenting with **menorrhagia** (Heavy Menstrual Bleeding) and a co-morbidity of **hypertension**. **Why Option B is Correct:** The **Mirena (LNG-IUS)** is the medical treatment of choice for menorrhagia. It works by releasing levonorgestrel directly into the uterine cavity, causing profound endometrial atrophy and reducing menstrual blood loss by up to 90-97%. In this specific case, Mirena is preferred over hormonal pills because the patient is **hypertensive**. Estrogen-containing contraceptives are generally avoided or used with caution in hypertension due to the risk of stroke and worsening blood pressure. Mirena provides effective local treatment without the systemic risks associated with estrogen. **Why Other Options are Incorrect:** * **Option A (COCPs):** Combined oral contraceptive pills contain estrogen, which is contraindicated in patients with uncontrolled hypertension or those with high cardiovascular risk. * **Option C (Hysterectomy):** This is a major surgical intervention. It is considered the definitive treatment but is reserved for cases where medical management fails or the patient has completed her family and specifically requests surgery. * **Option D (TCRE):** Endometrial ablation/resection is a second-line surgical alternative to hysterectomy. Medical management (Mirena) should always be attempted first in a 30-year-old. **NEET-PG High-Yield Pearls:** * **First-line medical management for HMB:** LNG-IUS (Mirena). * **Mechanism of Mirena:** Endometrial decidualization followed by atrophy. * **WHO Eligibility Criteria:** Estrogen is Category 3/4 for smokers >35 years and those with severe hypertension (BP >160/100). * **Non-hormonal first-line:** Tranexamic acid (Antifibrinolytic).

Question 167: What is typically observed in the uterine lining during the proliferative phase of the menstrual cycle?

A. Increased estrogen (Correct Answer)
B. Decreased progesterone receptors
C. Decreased estrogen receptors
D. Pituitary imbalance of hormones

Explanation: **Explanation:** The menstrual cycle is divided into the ovarian cycle and the uterine cycle. The **proliferative phase** of the uterine cycle corresponds to the follicular phase of the ovarian cycle. **Why Option A is Correct:** During the early follicular phase, the rising levels of **Follicle Stimulating Hormone (FSH)** lead to the development of ovarian follicles. These follicles secrete increasing amounts of **estrogen** (primarily estradiol). Estrogen acts on the endometrium to stimulate mitotic activity, leading to the regeneration of the functional layer, thickening of the stroma, and elongation of the spiral arteries. Therefore, increased estrogen is the hallmark of this phase. **Why Other Options are Incorrect:** * **Options B & C:** Estrogen actually **upregulates** (increases) the expression of both estrogen receptors (ER) and progesterone receptors (PR) in the endometrial tissue. This "priming" effect is essential because it allows the endometrium to respond to progesterone during the subsequent secretory phase. * **Option D:** While the pituitary hormones (FSH/LH) drive the cycle, the term "imbalance" implies a pathological state (like PCOS or hyperprolactinemia). In a normal physiological proliferative phase, the pituitary hormones are in a coordinated, functional flux, not an imbalance. **NEET-PG High-Yield Pearls:** * **Histology:** The proliferative phase is characterized by **tubular, straight glands** and numerous mitotic figures. * **Dominant Hormone:** Estrogen (Proliferative phase); Progesterone (Secretory phase). * **Dating the Endometrium:** The most reliable sign of ovulation on an endometrial biopsy is **subnuclear vacuolation** (the earliest sign of the secretory phase). * **Triple Line Sign:** On ultrasound, the proliferative endometrium appears as a "triple-line" pattern.

Question 168: Primary amenorrhoea is most commonly associated with which of the following?

A. Developmental defect of the genital tract
B. Tuberculosis
C. Endocrine disorders
D. Chromosomal abnormality (Correct Answer)

Explanation: **Explanation:** The most common cause of **Primary Amenorrhoea** is **Chromosomal Abnormality**, accounting for approximately **45-50%** of cases. Among these, **Turner Syndrome (45,XO)** is the single most frequent etiology. These abnormalities lead to gonadal dysgenesis, where ovaries are replaced by non-functional fibrous streaks, resulting in hypergonadotropic hypogonadism (low estrogen, high FSH/LH). **Analysis of Options:** * **A. Developmental defect of the genital tract:** This is the second most common cause (approx. 15-20%). The most frequent defect is **Müllerian Agenesis** (Mayer-Rokitansky-Küster-Hauser syndrome), characterized by the absence of the uterus and upper vagina despite normal ovaries and secondary sexual characteristics. * **B. Tuberculosis:** While Genital TB is a significant cause of *secondary* amenorrhoea in developing countries (due to Asherman’s syndrome), it rarely presents as primary amenorrhoea unless the infection occurs prepubertally and causes extensive endo-myometrial destruction. * **C. Endocrine disorders:** Conditions like PCOS, thyroid dysfunction, or Congenital Adrenal Hyperplasia (CAH) can cause primary amenorrhoea, but statistically, they occur less frequently than chromosomal or structural defects. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** Absence of menarche by age 13 (without secondary sexual characteristics) or age 15 (with secondary sexual characteristics). * **First Investigation:** The most important initial step is assessing for the presence or absence of **secondary sexual characteristics** (Breast development/Tanner Staging). * **Karyotyping:** Essential if FSH is elevated (to diagnose Turner’s) or if there is Müllerian agenesis (to rule out Androgen Insensitivity Syndrome - 46,XY). * **Most common cause of Secondary Amenorrhoea:** Pregnancy (Physiological); PCOS (Pathological).

Question 169: A 30-year-old woman, para 2+0, with hypertension presents with menorrhagia. What is the best treatment option for her?

A. Combined oral contraceptive pills
B. Levonorgestrel-releasing intrauterine system (Mirena) (Correct Answer)
C. Hysterectomy
D. Transcervical endometrial resection

Explanation: ### Explanation **Correct Answer: B. Levonorgestrel-releasing intrauterine system (Mirena)** **Why it is the correct choice:** The **Levonorgestrel-releasing intrauterine system (LNG-IUS)** is currently considered the **first-line medical management** for Heavy Menstrual Bleeding (HMB) according to NICE and FIGO guidelines. It works by releasing 20 mcg of levonorgestrel daily, causing profound endometrial atrophy and thickening of cervical mucus. In this specific case, the patient has **hypertension**. Estrogen-containing preparations are generally contraindicated or used with extreme caution in hypertensive patients due to the risk of stroke and thromboembolism. The LNG-IUS is a progestogen-only method, making it safe for women with cardiovascular risk factors while providing a 70–90% reduction in menstrual blood loss. **Why other options are incorrect:** * **A. Combined Oral Contraceptive Pills (COCPs):** These contain estrogen, which can further elevate blood pressure and increase the risk of cardiovascular events in a hypertensive patient. * **C. Hysterectomy:** This is a major surgical procedure and is considered the last resort when medical management and less invasive surgeries fail or when the patient has completed her family and specifically requests it. * **D. Transcervical Endometrial Resection (TCER):** This is a second-line surgical option for women who do not wish to conceive. Medical management (LNG-IUS) should always be attempted first unless contraindicated. **High-Yield Clinical Pearls for NEET-PG:** * **First-line for HMB:** LNG-IUS (Mirena). * **Mechanism:** Local endometrial atrophy (not inhibition of ovulation). * **Failure rate:** Comparable to tubal sterilization (Pearl Index ~0.2). * **Hypertension & Contraception:** Avoid Estrogen (COCPs); Progestogen-only methods (LNG-IUS, POPs, DMPA) are preferred. * **Non-hormonal first-line:** Tranexamic acid (Antifibrinolytic) is the preferred non-hormonal treatment for HMB.

Question 170: All are true about spasmodic dysmenorrhea EXCEPT:

A. Present just before menstruation
B. Present after the 3rd day of the menstrual period (Correct Answer)
C. The pain may persist for 12-24 hours
D. Dyspareunia

Explanation: ### Explanation **Spasmodic Dysmenorrhea**, also known as Primary Dysmenorrhea, is menstrual pain occurring in the absence of any identifiable pelvic pathology. It is primarily mediated by the release of **Prostaglandins (PGF2α)**, which cause intense uterine contractions and ischemia. #### Why Option B is the Correct Answer (The Exception) Spasmodic dysmenorrhea typically begins a few hours before or at the onset of menses and lasts for **12–72 hours**. The pain is most intense during the first and second days when prostaglandin levels are at their peak. It characteristically **subsides after the second day**. Therefore, pain persisting or starting after the 3rd day is atypical for primary dysmenorrhea and suggests secondary causes (like endometriosis). #### Analysis of Other Options * **Option A (Present just before menstruation):** This is a classic feature. The pain starts just before or with the onset of the flow as the endometrium begins to shed and release prostaglandins. * **Option C (Persist for 12-24 hours):** This is true. While it can last up to 3 days, the most acute spasmodic phase often lasts 12–24 hours. * **Option D (Dyspareunia):** While dyspareunia is a hallmark of *secondary* dysmenorrhea (especially endometriosis), it is generally **absent** in classic spasmodic/primary dysmenorrhea. However, in the context of this specific question and standard medical entrance patterns, Option B is the "most" incorrect statement regarding the temporal pattern of the pain. #### NEET-PG High-Yield Pearls * **Age Group:** Usually affects young girls (adolescents) shortly after the onset of ovulatory cycles (6–12 months after menarche). * **Pain Character:** Suprapubic, colicky, or "labor-like" pain that may radiate to the inner thighs. * **First-line Treatment:** NSAIDs (Prostaglandin synthetase inhibitors) like Mefenamic acid. * **Second-line/Contraceptive need:** Combined Oral Contraceptive Pills (OCPs) which inhibit ovulation. * **Key Association:** It is almost always associated with **ovulatory cycles**. If a patient is anovulatory, she rarely experiences spasmodic dysmenorrhea.

Question 171: Which of the following is NOT a feature of anovulatory menstruation?

A. The only symptom may be failure of conception.
B. It is usually associated with painless periods.
C. May be associated with dysfunctional uterine bleeding (DUB).
D. May be associated with premenstrual syndrome. (Correct Answer)

Explanation: **Explanation:** The core concept to understand here is the relationship between **progesterone** and the menstrual cycle. Anovulatory cycles are characterized by the absence of ovulation, meaning no corpus luteum is formed and, consequently, no progesterone is produced. **Why Option D is the Correct Answer:** Premenstrual Syndrome (PMS) is strictly associated with **ovulatory cycles**. The symptoms of PMS occur during the luteal phase and are triggered by the hormonal fluctuations following ovulation (specifically the rise and fall of progesterone). In anovulatory cycles, there is no luteal phase and no progesterone production; therefore, PMS cannot occur. **Analysis of Other Options:** * **Option A:** In many women, anovulatory cycles are regular and mimic normal menses. In such cases, the inability to release an oocyte (infertility) may be the only presenting symptom. * **Option B:** Primary dysmenorrhea (painful periods) is caused by prostaglandins ($PGF_{2\alpha}$) produced by a secretory endometrium under the influence of progesterone. Since anovulatory cycles lack progesterone, the endometrium remains proliferative, and periods are typically **painless**. * **Option C:** Dysfunctional Uterine Bleeding (DUB), now classified under PALM-COEIN as AUB-O (Ovulatory dysfunction), is frequently caused by anovulation. Estrogen acts unopposed, leading to endometrial hyperplasia and irregular "estrogen breakthrough bleeding." **NEET-PG High-Yield Pearls:** 1. **Painless periods** in a young girl usually indicate anovulatory cycles (common in the first 1-2 years post-menarche). 2. **Basal Body Temperature (BBT):** Anovulatory cycles show a monophasic curve (no mid-cycle rise). 3. **Endometrial Biopsy:** In anovulatory cycles, the biopsy (taken on Day 21-23) will show a **proliferative** rather than a secretory pattern. 4. **Fern Test:** Persistent ferning throughout the cycle indicates anovulation (due to unopposed estrogen).

Question 172: Halba disease is related to which of the following?

A. Irregular shedding due to persistent corpus luteum (Correct Answer)
B. Irregular menstruation
C. Irregular ripening
D. Adenomatous polyp

Explanation: **Explanation:** **Halban’s Disease** (also known as Halban’s syndrome) refers to **irregular shedding of the endometrium** caused by a **persistent corpus luteum**. ### 1. Why Option A is Correct: Under normal physiological conditions, the corpus luteum regresses if pregnancy does not occur, leading to a drop in progesterone and subsequent menstruation. In Halban’s disease, the corpus luteum persists abnormally, continuing to secrete low levels of progesterone. This prevents the synchronous shedding of the endometrium. Instead, the endometrium sheds in patches over a prolonged period. * **Clinical Presentation:** Patients typically present with a short period of amenorrhea followed by prolonged, heavy, and irregular bleeding. * **Diagnosis:** Confirmed by a D&C (Dilatation and Curettage) performed on the 5th or 6th day of the cycle, which reveals a mixture of secretory and proliferative endometrium. ### 2. Why Other Options are Incorrect: * **Option B (Irregular menstruation):** This is a broad clinical symptom (metrorrhagia) rather than a specific pathological entity like Halban’s disease. * **Option C (Irregular ripening):** This is the opposite of irregular shedding. It is caused by **poor formation/function of the corpus luteum** (Luteal Phase Defect), leading to premature spotting before the period. * **Option D (Adenomatous polyp):** This is a structural/anatomical cause of bleeding, whereas Halban’s is a functional/hormonal disorder. ### 3. NEET-PG High-Yield Pearls: * **Key Histology:** The hallmark of irregular shedding is the presence of **secretory endometrium on the 5th day of menstruation** (normally, it should be proliferative by then). * **Differential Diagnosis:** Halban’s disease is a common mimic of **Ectopic Pregnancy** because both present with a period of amenorrhea, irregular bleeding, and a persistent corpus luteum (or adnexal mass). * **Treatment:** Progesterone therapy or D&C (which is often curative).

Question 173: A 35-year-old lady has not had her menses for the last 4 months. She has high serum FSH and LH levels with low estradiol. What is the likely cause?

A. Panhypopituitarism
B. Polycystic ovarian disease
C. Exogenous estrogen administration
D. Premature menopause (Correct Answer)

Explanation: ### **Explanation** The clinical presentation of secondary amenorrhea (4 months) associated with **high gonadotropins (FSH and LH)** and **low estradiol** indicates **Hypergonadotropic Hypogonadism**. **1. Why Premature Menopause is Correct:** Premature menopause, or Premature Ovarian Insufficiency (POI), occurs when ovarian follicles are depleted or dysfunctional before age 40. In this state, the ovaries fail to produce estradiol. The lack of negative feedback from estradiol on the HPO axis leads to a compensatory rise in FSH and LH from the anterior pituitary. A serum **FSH level >40 IU/L** on two occasions is the diagnostic hallmark. **2. Analysis of Incorrect Options:** * **Panhypopituitarism:** This results in *Hypogonadotropic Hypogonadism*. Both FSH/LH and estradiol would be low because the pituitary fails to secrete gonadotropins. * **Polycystic Ovarian Disease (PCOS):** Characterized by an increased LH:FSH ratio (often 2:1 or 3:1) and normal or elevated estrogen levels. FSH is typically normal or low-normal, not high. * **Exogenous Estrogen Administration:** High levels of exogenous estrogen would exert negative feedback on the pituitary, resulting in **low** FSH and LH levels. **3. NEET-PG High-Yield Pearls:** * **Definition:** Menopause before age 40 is Premature Ovarian Insufficiency; before age 45 is Early Menopause. * **Most common chromosomal cause:** Turner Syndrome (45,X) or Mosaicism. * **Most common reversible cause:** Autoimmune oophoritis. * **Kariotype:** Mandatory in all women with POI under age 30 to rule out Y-chromosome material (risk of gonadoblastoma). * **Management:** Hormone Replacement Therapy (HRT) is essential until the natural age of menopause (approx. 50 years) to prevent osteoporosis and cardiovascular disease.

Question 174: In dysmenorrhea, how does indomethacin exert its therapeutic effect?

A. Inhibiting prostaglandin synthetase (Correct Answer)
B. Suppressing ovulation
C. Reducing inflammation
D. Relaxing smooth muscle

Explanation: **Explanation:** **Primary Dysmenorrhea** is primarily caused by the excessive production of **Prostaglandins (specifically PGF2α and PGE2)** in the secretory endometrium. During menstruation, the breakdown of endometrial cells releases arachidonic acid, which is converted into prostaglandins via the cyclooxygenase (COX) pathway. High levels of PGF2α lead to potent uterine contractions, myometrial ischemia, and sensitization of nerve endings, resulting in pain. **Why Option A is Correct:** Indomethacin is a Non-Steroidal Anti-Inflammatory Drug (NSAID) that acts as a potent **inhibitor of prostaglandin synthetase (COX enzyme)**. By blocking this enzyme, it reduces the synthesis of PGF2α, thereby decreasing intrauterine pressure and alleviating menstrual cramps. **Why Other Options are Incorrect:** * **B. Suppressing ovulation:** While Combined Oral Contraceptive Pills (OCPs) work by suppressing ovulation (which prevents the formation of a secretory endometrium and reduces prostaglandin levels), NSAIDs like indomethacin do not interfere with the hypothalamic-pituitary-ovarian axis. * **C. Reducing inflammation:** Although indomethacin has anti-inflammatory properties, the primary mechanism in *dysmenorrhea* is the specific reduction of prostaglandin-induced uterine hypercontractility, not the resolution of a systemic inflammatory process. * **D. Relaxing smooth muscle:** While the end result is reduced contraction, indomethacin is not a direct myometrial relaxant (like Tocolytics); it works upstream by removing the stimulus (prostaglandins) that causes the contraction. **High-Yield NEET-PG Pearls:** * **First-line treatment** for primary dysmenorrhea: NSAIDs (Mefenamic acid is often preferred due to dual action: inhibiting synthesis and blocking PG receptors). * **Timing:** NSAIDs are most effective if started 1–2 days before the onset of menses or at the very first sign of pain. * **Secondary Dysmenorrhea:** If NSAIDs fail to provide relief, clinicians should investigate for underlying pathology like **Endometriosis** (most common cause) or Adenomyosis.

Question 175: All of the following conditions present with secondary amenorrhoea EXCEPT:

A. Pregnancy
B. PCOD
C. Asherman's syndrome
D. Turner syndrome (Correct Answer)

Explanation: ### Explanation **Core Concept: Primary vs. Secondary Amenorrhoea** The distinction lies in the timing of onset. **Primary amenorrhoea** is the failure to start menses by age 15 (with secondary sexual characteristics) or age 13 (without them). **Secondary amenorrhoea** is the cessation of previously established menses for ≥3 months (regular cycles) or ≥6 months (irregular cycles). **Why Turner Syndrome (Option D) is the Correct Answer:** Turner Syndrome (45, XO) is the most common cause of **primary amenorrhoea**. It is characterized by gonadal dysgenesis (streak ovaries) due to accelerated oocyte atresia. Since these patients typically never achieve menarche, it is classified as primary amenorrhoea. *Note: Rarely, mosaic Turner (45,X/46,XX) can present with secondary amenorrhoea, but in the context of competitive exams, it is the classic prototype for primary amenorrhoea.* **Analysis of Incorrect Options:** * **A. Pregnancy:** The most common cause of secondary amenorrhoea worldwide. It must always be ruled out first with a UPT. * **B. PCOD (Polycystic Ovarian Disease):** A common endocrine cause of secondary amenorrhoea/oligomenorrhoea due to chronic anovulation and hyperandrogenism. * **C. Asherman’s Syndrome:** An outflow tract cause where intrauterine adhesions (usually post-curettage) prevent menstruation despite normal hormonal axes. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of Primary Amenorrhoea:** Turner Syndrome (Hypergonadotropic Hypogonadism). * **Most common cause of Secondary Amenorrhoea:** Pregnancy (Physiological). * **Most common pathological cause of Secondary Amenorrhoea:** PCOD. * **Kallmann Syndrome:** A key differential for primary amenorrhoea presenting with **anosmia** (Hypogonadotropic Hypogonadism). * **Mullerian Agenesis (MRKH):** Second most common cause of primary amenorrhoea; characterized by 46,XX karyotype and normal ovaries but absent uterus/vagina.

Question 176: A 28-year-old female presents with irregular slight bleeding after taking combined oral contraceptive pills for three months to manage heavy menstrual bleeding. What is your advice?

A. Endometrial sampling to rule out neoplasia.
B. Change over to progestin-only preparations.
C. Reassure the patient as this is breakthrough bleeding. (Correct Answer)
D. Discontinue oral contraceptive pills.

Explanation: **Explanation:** **1. Why Option C is Correct:** The patient is experiencing **breakthrough bleeding (BTB)**, which is the most common side effect of Combined Oral Contraceptive Pills (COCPs), especially during the first **3–6 months** of use. This occurs because the exogenous hormones cause the endometrium to become thin and fragile, leading to asynchronous breakdown and spotting. Since the patient has only been on the pills for three months, the initial management is **reassurance and observation**, as this side effect usually resolves spontaneously once the endometrium stabilizes. **2. Why Other Options are Incorrect:** * **Option A:** Endometrial sampling is generally reserved for women >35 years or those with persistent abnormal uterine bleeding (AUB) despite medical therapy. In a 28-year-old with a clear pharmacological cause (COCP initiation), neoplasia is highly unlikely. * **Option B:** Progestin-only preparations (POPs) are actually *more* likely to cause irregular spotting and breakthrough bleeding compared to COCPs due to the lack of estrogen-induced endometrial stabilization. * **Option D:** Discontinuing the pills is unnecessary and would lead to the return of her original complaint (heavy menstrual bleeding) and loss of contraceptive protection. **Clinical Pearls for NEET-PG:** * **Breakthrough Bleeding (BTB):** Most common in the first 3 cycles. * **Management of persistent BTB:** If bleeding persists beyond 3 months, the dose of estrogen can be increased or the type of progestin changed. * **Early vs. Late Cycle Bleeding:** * Bleeding in the **early/follicular phase** suggests estrogen deficiency (increase estrogen). * Bleeding in the **late/luteal phase** suggests progestin deficiency (increase progestin). * **Most common cause of BTB:** Missing a pill (non-compliance). Always rule this out first in clinical practice.

Question 177: What is the most common cause of pubertal menorrhagia?

A. Anovulation (Correct Answer)
B. Malignancy
C. Endometriosis
D. Bleeding disorder

Explanation: **Explanation:** **1. Why Anovulation is the Correct Answer:** Pubertal menorrhagia refers to excessive menstrual bleeding occurring between menarche and 19 years of age. The most common cause is an **immature Hypothalamic-Pituitary-Ovarian (HPO) axis**. In the first few years following menarche, the feedback mechanism is not fully developed, leading to **anovulatory cycles**. Without ovulation, there is no corpus luteum formation and no progesterone production. This results in "unopposed estrogen" action, causing the endometrium to proliferate excessively. Eventually, this thickened lining becomes unstable and sheds in an irregular, heavy, and prolonged manner (estrogen breakthrough bleeding). **2. Analysis of Incorrect Options:** * **Malignancy:** Extremely rare in the adolescent age group. Genital tract cancers (like cervical or endometrial cancer) typically present in postmenopausal or older reproductive-age women. * **Endometriosis:** Usually presents with chronic pelvic pain and secondary dysmenorrhea rather than heavy menstrual bleeding (menorrhagia). * **Bleeding Disorders:** While **Von Willebrand Disease (vWD)** is the most common *systemic* or *organic* cause of pubertal menorrhagia (found in up to 20% of severe cases), it is still statistically less common than physiological anovulation. **3. NEET-PG High-Yield Pearls:** * **First-line investigation:** Pelvic Ultrasound (to rule out structural causes) and CBC (to assess anemia). * **Management:** Most cases are managed with reassurance or Combined Oral Contraceptive Pills (COCPs) to stabilize the endometrium. * **Rule of Thumb:** If a teenager presents with menorrhagia requiring hospitalization or blood transfusion from the very first period (menarche), always suspect a **coagulation disorder** (vWD).

Question 178: What is the most common cause of secondary amenorrhea?

A. Pregnancy (Correct Answer)
B. Tuberculosis
C. Thyrotoxicosis
D. None of the above

Explanation: **Explanation:** **1. Why Pregnancy is the Correct Answer:** Secondary amenorrhea is defined as the absence of menses for 3 months in a woman with previously regular cycles, or 6 months in those with irregular cycles. In any woman of reproductive age presenting with a cessation of menses, **pregnancy** is the most common physiological cause and must be ruled out first using a urine pregnancy test (hCG). It is the single most frequent reason for secondary amenorrhea globally. **2. Analysis of Incorrect Options:** * **B. Tuberculosis:** Genital tuberculosis is a significant cause of secondary amenorrhea in developing countries (leading to Asherman’s syndrome or endometrial destruction), but it is far less common than pregnancy. * **C. Thyrotoxicosis:** While thyroid dysfunctions (both hyper- and hypothyroidism) can cause menstrual irregularities, they typically present more frequently with oligomenorrhea or polymenorrhea rather than complete amenorrhea. * **D. None of the above:** Incorrect, as pregnancy is the established primary cause. **3. NEET-PG High-Yield Clinical Pearls:** * **Step 1 Investigation:** The first investigation for secondary amenorrhea is always a **Urine Pregnancy Test**. * **Most Common Pathological Cause:** Polycystic Ovary Syndrome (PCOS) is the most common *pathological* cause of secondary amenorrhea. * **Asherman’s Syndrome:** This is the most common *uterine* cause of secondary amenorrhea, often following over-zealous curettage or TB endometritis. * **Premature Ovarian Failure (POF):** Defined as menopause occurring before the age of 40; it is a common hypergonadotropic cause. * **Progesterone Challenge Test:** Used to assess endogenous estrogen levels and outflow tract patency; a positive bleed indicates anovulation (commonly seen in PCOS).

Question 179: What is the cause of dysmenorrhea?

A. Ovulation
B. Decreased progesterone (Correct Answer)
C. Increased progesterone
D. Secretory epithelium

Explanation: **Explanation:** The primary cause of primary dysmenorrhea is the **withdrawal of progesterone** at the end of the luteal phase. When fertilization does not occur, the corpus luteum regresses, leading to a sharp decline in progesterone levels. This drop triggers the release of **Prostaglandin F2α (PGF2α)** from the lysosomal enzymes of the degenerating secretory endometrium. PGF2α is a potent vasoconstrictor and myometrial stimulant, leading to uterine hypercontractility, ischemia, and the characteristic cramping pain. **Analysis of Options:** * **B. Decreased progesterone (Correct):** The fall in progesterone is the physiological trigger that initiates the prostaglandin cascade responsible for uterine contractions. * **A. Ovulation:** While primary dysmenorrhea occurs only in ovulatory cycles (as progesterone is only produced post-ovulation), ovulation itself is not the direct cause of the pain; the subsequent hormonal withdrawal is. * **C. Increased progesterone:** High levels of progesterone actually have a relaxing effect on the myometrium (progestational effect). Pain occurs only when these levels fall. * **D. Secretory epithelium:** While the secretory endometrium (formed under the influence of progesterone) is the source of prostaglandins, the presence of the epithelium alone does not cause pain until the progesterone levels drop and breakdown begins. **NEET-PG High-Yield Pearls:** * **Gold Standard Treatment:** NSAIDs (e.g., Mefenamic acid) are the first-line treatment as they are COX inhibitors that decrease prostaglandin synthesis. * **Secondary Dysmenorrhea:** If pain begins 3–5 days before menses or persists after menses, suspect **Endometriosis** (most common cause of secondary dysmenorrhea). * **Risk Factors:** Early menarche, long menstrual periods, and smoking are associated with increased severity.

Question 180: All of the following are characteristic of anovulatory uterine (AUB-O) bleeding except:

A. Dysfunctional uterine bleeding.
B. Amenorrhea for weeks to months followed by heavy bleeding.
C. Availability of arachidonic acid is reduced at the cellular level.
D. Increased progesterone levels. (Correct Answer)

Explanation: **Explanation:** In **Anovulatory Uterine Bleeding (AUB-O)**, the fundamental pathology is the absence of ovulation, which leads to a lack of corpus luteum formation. Without a corpus luteum, there is no production of **progesterone**. This results in "unopposed estrogen" action on the endometrium, causing it to proliferate continuously without the stabilizing effect of progesterone. Eventually, the endometrium outgrows its blood supply, leading to asynchronous breakdown and heavy, irregular bleeding (estrogen breakthrough bleeding). Therefore, **increased progesterone levels** are never seen; rather, progesterone is characteristically absent or low. **Analysis of Options:** * **A. Dysfunctional uterine bleeding (DUB):** Historically, DUB was defined as abnormal bleeding in the absence of organic pelvic pathology, most commonly caused by anovulation. While the FIGO classification now prefers "AUB-O," the terms are often used interchangeably in exams. * **B. Amenorrhea followed by heavy bleeding:** This is the classic clinical presentation. Unopposed estrogen causes prolonged endometrial buildup (amenorrhea/delayed menses) followed by a heavy, painless collapse of the thickened tissue. * **C. Reduced arachidonic acid:** In anovulatory cycles, the lack of progesterone leads to lower levels of arachidonic acid and altered prostaglandin ratios (PGE2 vs. PGF2α) in the endometrium, contributing to abnormal vascular tone and bleeding. **NEET-PG High-Yield Pearls:** * **Most common cause of AUB-O:** Polycystic Ovary Syndrome (PCOS). * **Age groups:** Most common at the extremes of reproductive life (adolescence and perimenopause) due to immature or failing HPO axis. * **Histology:** Typically shows proliferative or hyperplastic endometrium; never secretory (as secretory changes require progesterone). * **Treatment of choice:** Cyclic progestins or Combined Oral Contraceptive Pills (COCPs) to stabilize the endometrium.

Question 181: What is the mechanism of action of combination oral contraceptive pills in the treatment of abnormal uterine bleeding (AUB)?

A. Diminished prostaglandin synthesis.
B. Decreased endometrial fibrinolysis.
C. Endometrial atrophy.
D. All of the above. (Correct Answer)

Explanation: **Explanation:** Combined Oral Contraceptive Pills (COCPs) are a first-line medical management for Abnormal Uterine Bleeding (AUB), particularly AUB-O (Ovulatory dysfunction) and AUB-E (Endometrial). Their efficacy is derived from a multi-modal impact on the endometrium: 1. **Endometrial Atrophy (Option C):** The primary mechanism is the delivery of a potent progestin which antagonizes the proliferative effect of estrogen. This leads to a state of endometrial decidualization followed by significant atrophy. A thinner, stable endometrium results in reduced menstrual blood loss (MBL). 2. **Diminished Prostaglandin Synthesis (Option A):** COCPs suppress ovulation and limit endometrial growth. This reduces the production of arachidonic acid and subsequent inflammatory prostaglandins (PGF2α and PGE2) within the uterine lining. Lower prostaglandin levels decrease uterine contractions and vasoconstriction-related pain. 3. **Decreased Endometrial Fibrinolysis (Option B):** COCPs help stabilize the endometrial vascular bed and modulate the local fibrinolytic environment, preventing the premature breakdown of clots during menstruation. Since all three mechanisms contribute to the reduction of menstrual flow and cycle regulation, **Option D** is the correct answer. **Clinical Pearls for NEET-PG:** * **MBL Reduction:** COCPs can reduce menstrual blood loss by approximately 40-50%. * **First-line choice:** For acute AUB, high-dose COCPs (tapering dose) are used to achieve "medical curettage." * **Contraindications:** Always screen for the "WHO Medical Eligibility Criteria" (e.g., history of DVT, migraine with aura, or smoking in women >35 years) before prescribing COCPs for AUB. * **Alternative:** The Levonorgestrel Intrauterine System (LNG-IUS) is considered even more effective than COCPs for long-term management of AUB-L (Leiomyoma) and AUB-A (Adenomyosis).

Question 182: A 45-year-old lady presented with dysfunctional uterine bleeding. On transvaginal ultrasound, the endometrial thickness was found to be 8 mm. What should be the next step in the management of this patient?

A. Histopathology (Correct Answer)
B. Hysterectomy
C. Progesterone
D. Oral contraceptive pills

Explanation: **Explanation:** The primary objective in a perimenopausal woman (age >40 years) presenting with Abnormal Uterine Bleeding (AUB) is to **exclude endometrial hyperplasia or malignancy**. **Why Histopathology is correct:** In women over 40 years of age, any change in menstrual pattern or dysfunctional bleeding is considered a high-risk factor for endometrial carcinoma. According to standard protocols, an **endometrial thickness (ET) >4 mm** in postmenopausal women or persistent AUB in perimenopausal women (regardless of ET, though 8 mm is significantly thickened) necessitates an endometrial biopsy. Histopathology via **Pipelle biopsy or D&C** is the gold standard to obtain a definitive tissue diagnosis before initiating medical or surgical therapy. **Why other options are incorrect:** * **Hysterectomy:** This is a definitive surgical treatment and should never be performed without a prior histological diagnosis to rule out malignancy, which would require a different surgical staging approach. * **Progesterone/OCPs:** While hormonal therapy is used to manage dysfunctional bleeding, it should only be started **after** malignancy has been ruled out. Starting hormones blindly can mask the symptoms of underlying cancer and delay diagnosis. **Clinical Pearls for NEET-PG:** * **Cut-off for Postmenopausal bleeding:** ET >4 mm requires biopsy. * **Age Criterion:** Any woman **>40 years** with AUB must undergo endometrial sampling as the first-line investigation. * **Gold Standard for AUB diagnosis:** Hysteroscopy-guided biopsy (more accurate than blind D&C). * **Most common cause of AUB in perimenopause:** Anovulatory cycles (due to waning follicular function).

Question 183: Which of the following is NOT considered a differential diagnosis for premenstrual tension?

A. Psychiatric depressive disorder
B. Panic disorder
C. General anxiety disorder
D. Chronic fatigue syndrome (Correct Answer)

Explanation: ### Explanation **Premenstrual Syndrome (PMS)** and **Premenstrual Dysphoric Disorder (PMDD)** are characterized by the cyclic recurrence of physical and psychological symptoms during the **luteal phase** of the menstrual cycle, which resolve completely with the onset of menses. **1. Why Chronic Fatigue Syndrome (CFS) is the correct answer:** The hallmark of PMS/PMDD is its **cyclicity**. Differential diagnoses must include conditions that mimic these cyclic mood or physical changes. **Chronic Fatigue Syndrome** is a persistent, non-cyclic condition characterized by debilitating exhaustion lasting for at least 6 months, regardless of the menstrual cycle phase. While PMS may involve lethargy, CFS does not follow the predictable luteal-phase pattern required for a PMS diagnosis. **2. Why the other options are incorrect:** * **Psychiatric Depressive Disorder (A), Panic Disorder (B), and General Anxiety Disorder (C):** These are the most common differential diagnoses. Many women with underlying psychiatric disorders experience **"Premenstrual Exacerbation" (PME)**, where their baseline symptoms worsen before menses. Distinguishing between a primary psychiatric disorder and PMDD requires a symptom-free interval during the follicular phase, documented via prospective daily charting for at least two cycles. **3. NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Prospective daily charting of symptoms for **two consecutive cycles** (e.g., using the Daily Record of Severity of Problems - DRSP). * **Timing:** Symptoms must occur in the 5 days before menses and remit within 4 days of onset. * **First-line Treatment:** Lifestyle modifications and **SSRIs** (Fluoxetine, Sertraline). SSRIs can be given continuously or strictly during the luteal phase. * **Definitive Treatment:** Bilateral Salpingo-oophorectomy (BSO) to eliminate the hormonal cycle (reserved for severe, refractory cases).

Question 184: Which of the following is not indicated in the management of menorrhagia?

A. NSAIDs
B. Clomiphene (Correct Answer)
C. Norethisterone
D. Tranexamic acid

Explanation: **Explanation:** The management of menorrhagia (heavy menstrual bleeding) focuses on reducing blood loss through hormonal regulation or inhibition of fibrinolysis and prostaglandins. **Why Clomiphene is the Correct Answer:** Clomiphene citrate is a **Selective Estrogen Receptor Modulator (SERM)** used primarily as an **ovulation-inducing agent** in infertility management. It works by blocking estrogen receptors in the hypothalamus, leading to an increase in FSH and LH. It is not used to treat menorrhagia; in fact, by inducing ovulation in anovulatory cycles, it may lead to the formation of a corpus luteum, but its primary clinical indication remains the treatment of infertility, not the reduction of menstrual flow. **Analysis of Incorrect Options:** * **NSAIDs (e.g., Mefenamic acid):** These inhibit cyclooxygenase (COX) enzymes, reducing the levels of prostaglandins in the endometrium. This leads to vasoconstriction and a reduction in menstrual blood loss by approximately 20-30%. * **Norethisterone:** This is a potent synthetic progestogen. When administered in the luteal phase or as part of a long-cycle regimen, it stabilizes the endometrium and prevents irregular shedding, effectively managing functional uterine bleeding. * **Tranexamic acid:** An antifibrinolytic agent that inhibits the activation of plasminogen to plasmin. It is one of the most effective non-hormonal treatments, reducing blood loss by up to 50%. **High-Yield Clinical Pearls for NEET-PG:** * **First-line medical management** for menorrhagia (WHO/NICE guidelines): Levonorgestrel Intrauterine System (LNG-IUS/Mirena). * **First-line non-hormonal treatment:** Tranexamic acid. * **Drug of choice for menorrhagia with dysmenorrhea:** NSAIDs (Mefenamic acid). * **Surgical Gold Standard:** Hysterectomy (definitive) or Endometrial Ablation (if fertility is not desired).

Question 185: The most common source of vicarious menstruation is:

A. Heart
B. Lungs
C. Nose (Correct Answer)
D. Kidney

Explanation: **Explanation:** **Vicarious Menstruation** is a rare clinical condition characterized by cyclical bleeding from extragenital sites during the normal menstrual cycle. This phenomenon occurs due to the response of extra-uterine tissues to the fluctuating levels of estrogen and progesterone, leading to increased vascular permeability and capillary fragility. **Why the Nose is the Correct Answer:** The **nasal mucosa** is the most common site for vicarious menstruation (epistaxis). This is because the nasal mucous membrane contains erectile tissue that is highly sensitive to ovarian hormones. During the premenstrual phase, high estrogen levels cause congestion and hyperemia of the nasal mucosa, making it prone to bleeding synchronized with the menstrual period. **Analysis of Incorrect Options:** * **Lungs (B):** While cyclical hemoptysis can occur (often associated with thoracic endometriosis), it is less common than nasal involvement. * **Heart (A) and Kidney (D):** These are extremely rare sites for vicarious menstruation. While hematuria (Kidney) can occur if there is endometriosis of the urinary tract, it does not represent the "most common" source in clinical practice. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** Bleeding from an extragenital site at the time of menstruation. * **Most Common Site:** Nasal mucosa (Epistaxis). * **Other Sites:** Skin (bloody sweat), lungs (hemoptysis), eyes (bloody tears/lacrimation), and stomach (hematemesis). * **Pathophysiology:** Often associated with **endometriosis** at the respective site, though it can occur in the absence of demonstrable endometriosis due to hormonal effects on local vasculature. * **Treatment:** Usually involves hormonal suppression (OCPs or GnRH agonists) to stabilize the endometrium and systemic vasculature.

Question 186: All of the following are true about spasmodic dysmenorrhea EXCEPT:

A. Pain present just before menstruation (Correct Answer)
B. Pain present after the day of the menstrual period
C. Pain may persist for 12 to 24 hours
D. Dyspareunia

Explanation: **Explanation:** Spasmodic dysmenorrhea (Primary Dysmenorrhea) is characterized by painful uterine contractions caused by the release of **Prostaglandin F2α (PGF2α)** from the secretory endometrium. **Why Option A is the correct answer (The Exception):** In spasmodic dysmenorrhea, the pain typically **begins with the onset of menstrual flow** or just a few hours before it. Pain that is present significantly before menstruation (premenstrual) is more characteristic of **Congestive Dysmenorrhea** (Secondary), which is associated with pelvic inflammatory disease or endometriosis. Therefore, "pain present just before menstruation" is the false statement in this context. **Analysis of other options:** * **Option B:** Pain usually subsides within 24–48 hours, but it can occasionally linger slightly after the first day as prostaglandin levels peak and then decline. * **Option C:** The typical duration of spasmodic pain is **12 to 24 hours**, coinciding with the maximum shedding of the endometrium. * **Option D:** While dyspareunia is a classic symptom of *secondary* dysmenorrhea (like endometriosis), it is generally **absent** in pure spasmodic (primary) dysmenorrhea. However, in the context of this specific MCQ structure, Option A is the most definitive "Except" because the timing of pain is the primary clinical differentiator. **High-Yield Clinical Pearls for NEET-PG:** * **Patient Profile:** Usually seen in young, nulliparous girls; starts shortly after menarche once ovulation is established. * **Mechanism:** High PGF2α causes uterine hypercontractility and ischemia. * **Treatment:** **NSAIDs** (Mefenamic acid) are the first-line treatment as they are prostaglandin synthetase inhibitors. Combined Oral Contraceptive Pills (COCPs) are used if NSAIDs fail or if contraception is desired. * **Key Differentiator:** Primary dysmenorrhea **improves after childbirth** (vaginal delivery) due to the destruction of adrenergic nerve endings in the isthmus.

Question 187: Which of the following is NOT an evidence-based treatment for menorrhagia?

A. Oral contraceptive pills (OCPs)
B. Progesterone cyclically for three months
C. Tranexamic acid
D. Methotrexate (Correct Answer)

Explanation: **Explanation:** The correct answer is **Methotrexate**. Menorrhagia (Heavy Menstrual Bleeding) is defined as excessive menstrual blood loss which interferes with a woman's physical, social, emotional, and/or material quality of life. **Why Methotrexate is the correct answer:** Methotrexate is a folate antagonist and a cytotoxic drug. It is primarily used in the management of ectopic pregnancy, gestational trophoblastic neoplasia, and certain autoimmune conditions (like rheumatoid arthritis). It has **no role** in the management of menorrhagia and can actually cause bone marrow suppression, leading to thrombocytopenia and potentially *worsening* bleeding. **Analysis of other options:** * **Oral Contraceptive Pills (OCPs):** These are a first-line medical management for menorrhagia. They work by inducing endometrial atrophy and inhibiting ovulation, reducing menstrual blood loss by approximately 40-50%. * **Cyclic Progesterone:** While less effective than the Levonorgestrel-IUS, oral progestogens administered in the luteal phase (or for 21 days) help regulate the cycle and stabilize the endometrium, particularly in cases of anovulatory bleeding. * **Tranexamic Acid:** This is a non-hormonal antifibrinolytic agent. It works by preventing the breakdown of fibrin clots in the endometrial vasculature. It is highly effective and taken only during menstruation. **High-Yield Clinical Pearls for NEET-PG:** * **First-line treatment (Medical):** Levonorgestrel-releasing Intrauterine System (LNG-IUS/Mirena) is considered the "Gold Standard" medical treatment, reducing blood loss by up to 90%. * **First-line (Non-hormonal):** Tranexamic acid is the preferred choice for women desiring pregnancy. * **Surgical Management:** Endometrial ablation or Hysterectomy are considered when medical management fails or is contraindicated. * **FIGO Classification:** Use the **PALM-COEIN** acronym to categorize causes (Polyp, Adenomyosis, Leiomyoma, Malignancy; Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified).

Question 188: Congenital erosion may reappear at:

A. One year of age
B. Two years of age
C. Five years of age
D. Puberty (Correct Answer)

Explanation: **Explanation:** **Congenital erosion** (also known as congenital ectopy) is a physiological condition where the columnar epithelium of the endocervix extends onto the vaginal portion of the cervix (ectocervix). 1. **Why Puberty is Correct:** The development and maintenance of the cervical columnar epithelium are highly dependent on **estrogen**. In utero, maternal estrogen crosses the placenta, stimulating the fetal cervix and often resulting in "congenital erosion" at birth. After birth, as maternal estrogen levels plummet, the erosion typically heals or regresses. It **reappears at puberty** because the endogenous production of estrogen by the maturing ovaries stimulates the proliferation and outward extension of the endocervical mucosa once again. 2. **Why Other Options are Incorrect:** * **One, Two, and Five years of age:** During these periods (the "juvenile" or "quiescent" phase), estrogen levels in a child are extremely low. Without estrogenic stimulation, the squamocolumnar junction remains retracted within the endocervical canal, making the reappearance of erosion clinically impossible during early childhood. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** Cervical erosion is not a true "ulcer"; it is the replacement of squamous epithelium by columnar epithelium. * **Etiology:** The three main physiological states associated with erosion are **Newborn period** (maternal estrogen), **Puberty**, and **Pregnancy/OCP use** (high estrogen states). * **Treatment:** Congenital erosion is physiological and usually asymptomatic; it requires no treatment unless it persists or becomes infected (cervicitis). * **Transformation Zone:** This is the area where columnar epithelium undergoes squamous metaplasia; it is the most common site for cervical intraepithelial neoplasia (CIN).

Question 189: What is the most common cause of secondary amenorrhea?

A. Polycystic Ovary Disease (PCOD)
B. Pregnancy (Correct Answer)
C. Hypothyroidism
D. Hyperprolactinemia

Explanation: **Explanation:** **1. Why Pregnancy is the Correct Answer:** In any woman of reproductive age presenting with a cessation of menses, **pregnancy** is statistically the most common cause of secondary amenorrhea. Physiologically, pregnancy leads to persistent high levels of progesterone and estrogen produced by the corpus luteum (and later the placenta), which maintains the endometrial lining and suppresses the hypothalamic-pituitary-ovarian (HPO) axis, preventing further menstruation. In clinical practice and for NEET-PG, the rule is: **"Always rule out pregnancy first"** using a Urine Pregnancy Test (UPT). **2. Analysis of Incorrect Options:** * **Polycystic Ovary Disease (PCOD):** While PCOD is the most common **pathological** cause of secondary amenorrhea and chronic anovulation, it is second to pregnancy in overall frequency. * **Hypothyroidism:** Thyroid dysfunction can cause menstrual irregularities (more commonly menorrhagia or oligomenorrhea), but it is a less frequent cause of total cessation of menses compared to pregnancy or PCOD. * **Hyperprolactinemia:** Elevated prolactin suppresses GnRH secretion, leading to amenorrhea. While a significant cause, it is less prevalent than pregnancy or PCOD in the general population. **3. Clinical Pearls for NEET-PG:** * **Definition:** Secondary amenorrhea is the absence of menses for **3 months** in a woman with previously regular cycles, or **6 months** in those with irregular cycles. * **Most common pathological cause:** PCOD. * **Most common pituitary cause:** Hyperprolactinemia (Prolactinoma). * **Most common uterine cause:** Asherman Syndrome (post-curettage intrauterine synechiae). * **Initial Investigation:** The first step in the workup of secondary amenorrhea is always a **Urine Pregnancy Test (UPT)** or serum beta-hCG.

Question 190: Progressive secondary amenorrhea is associated with:

A. Endometriosis
B. Psychosomatic cause (Correct Answer)
C. Uterine anomaly
D. None of the above

Explanation: **Explanation:** **Understanding the Correct Answer (B):** Secondary amenorrhea is defined as the absence of menses for more than 6 months in a woman who previously had regular cycles. **Psychosomatic causes** (such as severe emotional stress, anxiety, depression, or eating disorders like anorexia nervosa) are classic triggers for **Hypothalamic Amenorrhea**. The underlying mechanism involves a disruption of the pulsatile release of **Gonadotropin-Releasing Hormone (GnRH)** from the hypothalamus. This leads to decreased secretion of FSH and LH, resulting in anovulation and low estrogen levels. The term "progressive" refers to the clinical course where cycles initially become irregular (oligomenorrhea) before ceasing entirely as the psychological stressor persists or worsens. **Analysis of Incorrect Options:** * **A. Endometriosis:** This condition typically presents with **progressive secondary dysmenorrhea** (painful periods) and infertility, rather than amenorrhea. In fact, patients with endometriosis usually have regular, often heavy, menstrual cycles. * **C. Uterine Anomaly:** Structural anomalies (e.g., Mullerian agenesis) are usually causes of **primary amenorrhea**. While acquired uterine conditions like Asherman Syndrome can cause secondary amenorrhea, they are typically sudden (post-procedure) rather than "progressive" in the psychosomatic sense. **NEET-PG High-Yield Pearls:** * **Most common cause of secondary amenorrhea:** Pregnancy (Always rule this out first with a Beta-hCG test). * **Female Athlete Triad:** Disordered eating, amenorrhea, and osteoporosis (a specific type of psychosomatic/functional hypothalamic amenorrhea). * **Progestin Challenge Test:** In psychosomatic amenorrhea, the patient will typically have a **negative** withdrawal bleed if estrogen levels have dropped significantly due to prolonged GnRH suppression.

Question 191: Which of the following can be causes of dysfunctional uterine bleeding?

A. Uterine polyp
B. Fibroid
C. Granulosa cell tumor
D. Irregular shedding of endometrium (Correct Answer)

Explanation: **Explanation:** **Dysfunctional Uterine Bleeding (DUB)** is defined as abnormal uterine bleeding in the absence of any detectable organic, systemic, or iatrogenic cause. It is essentially a diagnosis of exclusion and is primarily caused by **hormonal imbalances** affecting the hypothalamic-pituitary-ovarian axis. 1. **Why the Correct Answer (D) is Right:** **Irregular shedding of the endometrium** (Halban’s disease) is a classic example of ovulatory DUB. It occurs due to the persistence of the corpus luteum, leading to prolonged progesterone secretion. This prevents the synchronous shedding of the endometrium, resulting in heavy and prolonged menses (menorrhagia). Because this is a functional/hormonal derangement rather than a structural lesion, it falls under the category of DUB. 2. **Why the Other Options are Incorrect:** * **Uterine Polyp (A) and Fibroid (B):** These are **organic/structural causes** of abnormal uterine bleeding. According to the FIGO **PALM-COEIN** classification, polyps (P) and leiomyomas (L) are structural causes, whereas DUB corresponds to the "COEIN" (Non-structural) side, specifically Ovulatory dysfunction (O) or Endometrial (E). * **Granulosa Cell Tumor (C):** This is a functional ovarian tumor that secretes estrogen. While it causes bleeding, it is considered a **neoplastic/organic cause**, not DUB. **NEET-PG High-Yield Pearls:** * **PALM-COEIN Classification:** Structural (PALM: Polyp, Adenomyosis, Leiomyoma, Malignancy) vs. Non-structural (COEIN: Coagulopathy, Ovulatory, Endometrial, Iatrogenic, Not yet classified). * **DUB** is most common at the extremes of reproductive life (adolescence and perimenopause) and is usually **anovulatory** (80%). * **Irregular Ripening:** Due to poor corpus luteum function (progesterone deficiency), leading to spotting before menses. * **Irregular Shedding:** Due to persistent corpus luteum, leading to prolonged bleeding. Diagnosis is made by D&C on the **5th or 6th day** of the cycle showing secretory endometrium.

Question 192: What is the treatment of choice in a young patient with primary dysmenorrhea?

A. Presacral neurectomy
B. Dilatation
C. Hysterectomy
D. Symptomatic (Correct Answer)

Explanation: **Explanation:** **Primary dysmenorrhea** is defined as painful menstruation in the absence of any identifiable pelvic pathology. It is primarily caused by the excessive production of **Prostaglandin F2α (PGF2α)** in the secretory endometrium, leading to potent uterine contractions and ischemia. **Why "Symptomatic" is the Correct Answer:** Since the condition is functional and not structural, the management is conservative and aimed at symptom relief. * **NSAIDs (First-line):** Drugs like Mefenamic acid or Ibuprofen act as prostaglandin synthetase inhibitors, directly targeting the underlying cause. * **Combined Oral Contraceptive Pills (OCPs):** These are the second-line treatment; they work by inhibiting ovulation and thinning the endometrium, thereby reducing prostaglandin levels. * **General measures:** Reassurance, heat application, and exercise are also effective. **Why Other Options are Incorrect:** * **Presacral Neurectomy (A):** This is a major surgical procedure involving the transection of sympathetic nerves. It is reserved only for severe, intractable cases of secondary dysmenorrhea (like deep infiltrating endometriosis) that fail all medical therapies. * **Dilatation (B):** Cervical dilatation was historically done based on the "obstruction theory," but it is no longer recommended as it provides only temporary relief and carries risks of cervical trauma. * **Hysterectomy (C):** This is a definitive surgical treatment for uterine pathology. It is never indicated in a "young patient" with primary dysmenorrhea, as it results in permanent loss of fertility. **Clinical Pearls for NEET-PG:** * **Timing:** Pain typically starts a few hours before or just at the onset of menses and lasts for 24–48 hours. * **Risk Factor:** It is most common in adolescent girls shortly after the establishment of ovulatory cycles. * **Gold Standard Medical Rx:** NSAIDs started 1–2 days before the expected period.

Question 193: Cryptomenorrhea occurs due to:

A. Imperforate hymen (Correct Answer)
B. Asherman's syndrome
C. Mullerian agenesis
D. All of the above

Explanation: **Explanation:** **Cryptomenorrhea** (literally "hidden menstruation") refers to a condition where menstrual blood is produced by the uterine endometrium but cannot escape the genital tract due to an anatomical obstruction in the outflow tract. **1. Why Option A is Correct:** The most common cause of cryptomenorrhea is an **imperforate hymen**. In this condition, the ovaries and uterus function normally, leading to regular endometrial shedding. However, the blood accumulates in the vagina (**hematocolpos**), and eventually the uterus (**hematometra**) and fallopian tubes (**hematosalpinx**). Patients typically present at puberty with primary amenorrhea and cyclical lower abdominal pain. **2. Why Other Options are Incorrect:** * **Asherman’s Syndrome (Option B):** This involves intrauterine adhesions that obliterate the uterine cavity. Here, the endometrium is damaged or absent; therefore, menstruation does not occur at all (true amenorrhea), rather than being "hidden." * **Mullerian Agenesis (Option C):** Also known as MRKH syndrome, this is the congenital absence of the uterus and upper vagina. Since there is no functional uterus to produce menstrual blood, cryptomenorrhea cannot occur. **3. Clinical Pearls for NEET-PG:** * **Classic Presentation:** A young girl with primary amenorrhea, cyclical pelvic pain, and a palpable "bulge" at the introitus or a pelvic mass. * **Physical Exam:** On per-rectal or local examination, a tense, bluish membrane (the hymen) is often visible. * **Management:** The treatment of choice is a **cruciate incision** on the hymen to drain the accumulated blood. * **Differential Diagnosis:** Transverse vaginal septum is the second most common cause of cryptomenorrhea.

Question 194: All are used in treating spasmodic dysmenorrhea except?

A. Bromocriptine (Correct Answer)
B. Ibuprofen
C. Mefenamic acid
D. Norethisterone and ethinyl estradiol

Explanation: **Explanation:** Spasmodic (Primary) Dysmenorrhea is characterized by painful uterine contractions caused by the excessive release of **Prostaglandins (PGF2α)** from the secretory endometrium. The management focuses on inhibiting prostaglandin synthesis or suppressing ovulation. **Why Bromocriptine is the correct answer:** **Bromocriptine** is a dopamine agonist used primarily to treat hyperprolactinemia, galactorrhea, and prolactinomas. It has **no role** in the pathophysiology or treatment of dysmenorrhea. In fact, by lowering prolactin, it may theoretically enhance gonadotropin release, which does not alleviate menstrual pain. **Analysis of other options:** * **Ibuprofen & Mefenamic Acid (NSAIDs):** These are the **first-line medical treatments** for spasmodic dysmenorrhea. They act by inhibiting the enzyme cyclooxygenase (COX), thereby reducing the production of prostaglandins that cause uterine hypercontractility. * **Norethisterone and Ethinyl Estradiol (OCPs):** Combined Oral Contraceptive Pills are the treatment of choice for patients who also desire contraception. They work by **inhibiting ovulation** and thinning the endometrial lining, which significantly reduces prostaglandin levels. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Dysmenorrhea:** Usually starts 1–2 years after menarche (once cycles become ovulatory). The pain typically begins just before or at the onset of menses. * **Drug of Choice (DOC):** NSAIDs (specifically Mefenamic acid) are the initial DOC. * **Secondary Dysmenorrhea:** Pain due to pelvic pathology (e.g., Endometriosis, Adenomyosis). Unlike primary dysmenorrhea, the pain often starts several days before menses and persists after the flow stops. * **Other treatments:** Heat application, regular exercise, and in refractory cases, TENS (Transcutaneous Electrical Nerve Stimulation).

Question 195: Which of the following is NOT a cause of primary amenorrhea?

A. Turner's syndrome
B. Kallmann syndrome
C. Asherman's syndrome (Correct Answer)
D. Rokitansky syndrome

Explanation: ### Explanation The key to answering this question lies in distinguishing between **primary amenorrhea** (failure to initiate menstruation) and **secondary amenorrhea** (cessation of established menses). **Why Asherman’s Syndrome is the Correct Answer:** Asherman’s syndrome refers to the formation of intrauterine adhesions (synechiae), typically following trauma to the basal layer of the endometrium (e.g., over-zealous D&C or genital tuberculosis). Because this condition requires a prior uterine insult or an established endometrial lining to "scar down," it is a classic cause of **secondary amenorrhea**. It does not typically present as primary amenorrhea because the anatomical and hormonal pathways for menstruation were initially functional. **Analysis of Incorrect Options:** * **Turner’s Syndrome (45,XO):** The most common cause of primary amenorrhea. It involves gonadal dysgenesis (streak ovaries), leading to hypergonadotropic hypogonadism. * **Kallmann Syndrome:** A form of hypogonadotropic hypogonadism caused by failure of GnRH-producing neurons to migrate. It presents with primary amenorrhea and anosmia. * **Rokitansky Syndrome (MRKH):** Characterized by Müllerian agenesis (absent uterus and upper 2/3 of the vagina) despite a normal 46,XX karyotype and functioning ovaries. It is the second most common cause of primary amenorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of Primary Amenorrhea:** Turner’s Syndrome. * **Most common cause of Secondary Amenorrhea:** Pregnancy (always rule this out first!). * **Asherman’s Diagnosis:** Hysterosalpingography (HSG) shows "filling defects"; Gold standard is **Hysteroscopy**. * **Progesterone Challenge Test:** Patients with Asherman’s syndrome will have a **negative** withdrawal bleed because the outflow tract/endometrium is obliterated, regardless of estrogen levels.

Question 196: All of the following are causes of primary amenorrhea EXCEPT?

A. MRKH syndrome
B. Sheehan's syndrome (Correct Answer)
C. Kallmann's syndrome
D. Turner's syndrome

Explanation: **Explanation:** The core concept in this question is the distinction between **Primary Amenorrhea** (failure to start menses by age 15 with secondary sexual characteristics or age 13 without) and **Secondary Amenorrhea** (cessation of menses after they have already been established). **Why Sheehan’s Syndrome is the correct answer:** Sheehan’s syndrome is **postpartum pituitary necrosis** caused by severe obstetric hemorrhage and hypotension. Since it occurs as a complication of childbirth, the patient must have been fertile and menstruating previously. Therefore, it is a classic cause of **secondary amenorrhea**, not primary. **Analysis of Incorrect Options (Causes of Primary Amenorrhea):** * **MRKH Syndrome (Müllerian Agenesis):** The most common cause of primary amenorrhea with normal secondary sexual characteristics. It involves congenital absence of the uterus and upper 2/3rd of the vagina. * **Kallmann’s Syndrome:** A form of hypogonadotropic hypogonadism (GnRH deficiency) associated with anosmia. It leads to primary amenorrhea due to failure of the hypothalamic-pituitary-ovarian axis to initiate puberty. * **Turner’s Syndrome (45,XO):** The most common genetic cause of primary amenorrhea. It presents with streak ovaries (gonadal dysgenesis), short stature, and lack of secondary sexual characteristics. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of Primary Amenorrhea:** Turner’s Syndrome (Overall); MRKH (if secondary sexual characteristics are present). * **Most common cause of Secondary Amenorrhea:** Pregnancy (must always be ruled out first). * **Sheehan’s Syndrome Hallmark:** Failure of lactation (due to prolactin deficiency) is often the earliest clinical sign, followed by loss of pubic/axillary hair and secondary amenorrhea.

Question 197: A 25-year-old female presents with infertility. Hysterosalpingogram reveals Asherman's syndrome. What are the likely symptoms?

A. Menorrhagia
B. Oligomenorrhea
C. Polymenorrhea
D. Hypomenorrhea (Correct Answer)

Explanation: **Explanation:** **Asherman’s Syndrome** is characterized by the presence of intrauterine adhesions (synechiae) that typically develop following trauma to the basal layer of the endometrium, most commonly due to over-zealous curettage (D&C) post-abortion or postpartum. **Why Hypomenorrhea is Correct:** The underlying pathology involves the partial or complete obliteration of the uterine cavity by fibrous bands. This leads to a significant reduction in the functional surface area of the endometrium available for shedding during menstruation. Consequently, patients present with **hypomenorrhea** (scanty menses) or **amenorrhea** (absence of menses). In this clinical scenario, the destruction of the endometrial lining explains both the infertility (due to lack of receptive tissue for implantation) and the reduced menstrual flow. **Why Incorrect Options are Wrong:** * **Menorrhagia (Heavy flow):** This is typically seen in conditions that increase the endometrial surface area or vascularity, such as uterine fibroids or adenomyosis—the opposite of Asherman’s. * **Oligomenorrhea (Infrequent cycles):** This usually suggests a hormonal or ovulatory dysfunction (e.g., PCOS). In Asherman’s, the cycle regularity is often maintained, but the *volume* is reduced. * **Polymenorrhea (Frequent cycles):** This refers to cycles occurring at intervals of less than 21 days, which is not a feature of structural intrauterine scarring. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis:** **Hysteroscopy** (allows both diagnosis and therapeutic adhesiolysis). * **HSG Finding:** Characterized by "filling defects" or a "honeycomb appearance." * **Treatment:** Hysteroscopic adhesiolysis followed by an IUCD or Foley catheter insertion and high-dose estrogen therapy to promote endometrial regrowth. * **Most common cause:** Post-traumatic (D&C), but in India, **Genital Tuberculosis** is a significant non-traumatic cause.

Question 198: Primary amenorrhoea is a feature of all EXCEPT:

A. Turner's syndrome
B. Stein-Leventhal syndrome (Correct Answer)
C. Rokitansky-Kustner-Hauser syndrome
D. Kallman syndrome

Explanation: **Explanation:** The core of this question lies in distinguishing between conditions that typically present with a failure to start menstruation (Primary Amenorrhoea) versus those that cause a cessation of established cycles (Secondary Amenorrhoea). **Why Stein-Leventhal Syndrome (Option B) is the correct answer:** Stein-Leventhal syndrome, commonly known as **Polycystic Ovary Syndrome (PCOS)**, is the most common cause of **secondary amenorrhoea** or oligomenorrhoea. In PCOS, the patient has usually achieved menarche but experiences subsequent cycle irregularities due to chronic anovulation and hyperandrogenism. While rare cases of primary amenorrhoea can occur if the hormonal imbalance is severe from puberty, it is classically defined as a cause of secondary amenorrhoea. **Analysis of Incorrect Options:** * **Turner’s Syndrome (45, XO):** The most common cause of primary amenorrhoea. It involves gonadal dysgenesis (streak ovaries), leading to hypergonadotropic hypogonadism. * **Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome:** The second most common cause of primary amenorrhoea. It is characterized by Müllerian agenesis (absent uterus and upper 2/3rd of the vagina) despite a normal 46, XX karyotype and normal ovarian function. * **Kallmann Syndrome:** A form of hypogonadotropic hypogonadism caused by failure of GnRH-secreting neurons to migrate. It presents with primary amenorrhoea and anosmia (loss of smell). **High-Yield Clinical Pearls for NEET-PG:** 1. **Most common cause of Primary Amenorrhoea:** Turner’s Syndrome. 2. **Most common cause of Secondary Amenorrhoea:** Pregnancy (always rule this out first). 3. **MRKH vs. AIS:** In MRKH, the karyotype is 46,XX with normal ovaries; in Androgen Insensitivity Syndrome (AIS), the karyotype is 46,XY with undescended testes. Both present with primary amenorrhoea and a blind vaginal pouch. 4. **PCOS Triad:** Hyperandrogenism, Ovulatory dysfunction, and Polycystic ovaries on ultrasound (Rotterdam Criteria).

Question 199: A 28-year-old woman experiences emotional lability and depression approximately 10 days before her menses. She reports feeling normal once her menstrual bleeding begins. She also describes premenstrual fatigue, bloating, and breast tenderness. What is the most appropriate treatment for this patient?

A. Evening primrose oil
B. Vitamin B6
C. Fluoxetine (Correct Answer)
D. Progesterone

Explanation: ### Explanation **Correct Answer: C. Fluoxetine** **Medical Concept:** The patient presents with classic symptoms of **Premenstrual Dysphoric Disorder (PMDD)**, a severe form of Premenstrual Syndrome (PMS) characterized by significant emotional symptoms (lability, depression) and physical symptoms (bloating, breast tenderness) during the luteal phase, which resolve with the onset of menses. The first-line pharmacological treatment for PMDD is **Selective Serotonin Reuptake Inhibitors (SSRIs)** like Fluoxetine. Unlike their use in major depression, SSRIs for PMDD have a rapid onset of action and can be administered either continuously or restricted to the **luteal phase** (starting on day 14 and stopping at the onset of menses). **Analysis of Incorrect Options:** * **A. Evening primrose oil:** Often used for cyclical mastalgia (breast pain), but clinical trials have shown it is no more effective than a placebo for the systemic emotional symptoms of PMDD. * **B. Vitamin B6 (Pyridoxine):** While sometimes used as a complementary therapy for mild PMS, it lacks robust evidence for treating the severe psychological symptoms of PMDD and can cause peripheral neuropathy in high doses. * **C. Progesterone:** Historically used based on the "progesterone deficiency" theory; however, large-scale studies have shown that progesterone supplementation is **not effective** in treating PMDD. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnosis:** Requires at least 5 symptoms, including at least one "core" emotional symptom (irritability, mood swings, anxiety, or depression), occurring during the luteal phase. * **First-line:** SSRIs (Fluoxetine, Sertraline, Paroxetine). * **Second-line:** Oral Contraceptive Pills (OCPs), specifically those containing **Drospirenone** (a progestin with anti-mineralocorticoid activity) with a shortened pill-free interval. * **Definitive Treatment:** GnRH agonists (with add-back therapy) or bilateral oophorectomy (last resort).

Question 200: A child presents with primary amenorrhea. She has a negative progesterone challenge test but a positive combined estrogen and progesterone test. What is the most likely diagnosis?

A. Mullerian agenesis
B. Polycystic ovary syndrome
C. Asherman syndrome
D. Prolactinoma (Correct Answer)

Explanation: ### Explanation This question tests the systematic approach to primary amenorrhea using withdrawal bleeding tests. **1. Understanding the Tests:** * **Negative Progesterone Challenge Test (PCT):** No bleeding occurs after giving progesterone. This indicates either **low estrogen levels** (the endometrium was never primed) or an **outflow tract obstruction**. * **Positive Combined Estrogen-Progesterone Test:** Bleeding occurs after giving both hormones. This confirms that the **outflow tract is patent** and the **endometrium is functional**. **Why Prolactinoma is Correct:** A positive combined test localized the defect to the **Hypothalamic-Pituitary-Ovarian (HPO) axis**. A prolactinoma causes hyperprolactinemia, which inhibits GnRH secretion. This leads to low FSH/LH and subsequent **hypoestrogenism**. Because estrogen levels are too low to build the endometrium, the PCT is negative; however, since the uterus is normal, exogenous estrogen/progesterone triggers withdrawal bleeding. **2. Analysis of Incorrect Options:** * **Mullerian Agenesis:** The uterus is absent. Therefore, the combined estrogen-progesterone test would be **negative** (no endometrium to bleed). * **Asherman Syndrome:** Intrauterine synechiae (scarring) obstruct the cavity. Like Mullerian agenesis, the combined test would be **negative**. * **Polycystic Ovary Syndrome (PCOS):** PCOS is characterized by anovulation with **normal or high estrogen** levels. These patients typically have a **positive PCT**. **3. High-Yield Clinical Pearls for NEET-PG:** * **Step 1 in Amenorrhea:** Rule out pregnancy (hCG test). * **Step 2:** Progesterone Challenge (Medroxyprogesterone acetate 10mg for 5-10 days). * **Negative PCT + Positive Combined Test** = HPO Axis failure (Hypogonadotropic Hypogonadism) or Premature Ovarian Failure (Hypergonadotropic Hypogonadism). * **Negative PCT + Negative Combined Test** = Outflow tract obstruction (e.g., Asherman, Mullerian agenesis).

Question 201: Mittelschmerz pain is:

A. Pain during onset of menstrual cycle
B. Pain during the usual time of ovulation in menstrual cycle (Correct Answer)
C. Pain during or at the end of menstrual cycle
D. Pain during menstrual bleeding

Explanation: ### Explanation **Correct Option: B. Pain during the usual time of ovulation in menstrual cycle** **Mittelschmerz** (German for "middle pain") refers to mid-cycle ovulatory pain. It typically occurs around day 14 of a 28-day cycle. The underlying pathophysiology is attributed to: 1. **Follicular Distension:** Rapid growth of the dominant follicle just before ovulation, stretching the ovarian capsule. 2. **Peritoneal Irritation:** Rupture of the follicle releases follicular fluid or a small amount of blood, which irritates the pelvic peritoneum. The pain is usually unilateral (on the side of ovulation), dull or crampy, and lasts from a few minutes to 48 hours. **Why other options are incorrect:** * **Option A & D:** Pain during the onset or during menstrual bleeding is termed **Dysmenorrhea**. Primary dysmenorrhea is caused by prostaglandin-induced uterine contractions, whereas Mittelschmerz is strictly intermenstrual. * **Option C:** Pain at the end of the menstrual cycle is not a characteristic feature of Mittelschmerz. Pain in the late luteal phase is more commonly associated with Premenstrual Syndrome (PMS) or endometriosis. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnosis:** It is a diagnosis of exclusion. It must be differentiated from acute appendicitis, ectopic pregnancy, and ovarian torsion. * **Key Feature:** It occurs mid-cycle and is often accompanied by an increase in **cervical mucus** (Spinnbarkeit phenomenon) and a slight rise in basal body temperature. * **Management:** Reassurance and NSAIDs are usually sufficient. Combined Oral Contraceptive Pills (OCPs) can be used to prevent it by suppressing ovulation. * **Sonographic Finding:** May show a small amount of free fluid in the Pouch of Douglas (POD) following follicular rupture.

Question 202: All of the following are true about abnormal uterine bleeding except:

A. Blood loss of less than 50 ml (Correct Answer)
B. Cycle duration is more than 35 days or less than 21 days
C. Bleeding period lasting 7 days or more
D. Irregular bleeding during a regular cycle

Explanation: **Explanation:** Abnormal Uterine Bleeding (AUB) is defined as any variation from the normal menstrual cycle, involving changes in frequency, regularity, duration, or volume of flow. **Why Option A is the Correct Answer:** Normal menstrual blood loss is typically between **5-80 ml** per cycle, with an average of 35 ml. Therefore, a blood loss of **less than 50 ml** falls within the physiological range and is considered normal. For a diagnosis of Menorrhagia (heavy menstrual bleeding), the blood loss must exceed **80 ml**. **Analysis of Other Options:** * **Option B (Cycle duration >35 or <21 days):** Normal cycle length is 21–35 days. Cycles >35 days (Oligomenorrhea) or <21 days (Polymenorrhea) are classic presentations of AUB. * **Option C (Bleeding period ≥7 days):** A normal period lasts 3–7 days. Bleeding that persists for 7 days or more is termed prolonged bleeding and is a criterion for AUB. * **Option D (Irregular bleeding during a regular cycle):** This refers to **Intermenstrual bleeding** (metrorrhagia), which is a hallmark of AUB and often indicates structural pathology like polyps or fibroids. **High-Yield Clinical Pearls for NEET-PG:** * **PALM-COEIN Classification:** Used to categorize AUB causes (Structural: Polyp, Adenomyosis, Leiomyoma, Malignancy; Non-structural: Coagulopathy, Ovulatory, Endometrial, Iatrogenic, Not classified). * **FIGO Definitions:** The terms "Menorrhagia" and "Metrorrhagia" are being replaced by "Heavy Menstrual Bleeding" (HMB) and "Intermenstrual Bleeding" (IMB). * **Gold Standard:** Alkaline hematin method is the objective way to measure blood loss, though rarely used clinically. * **First-line Investigation:** Transvaginal Ultrasound (TVS).

Question 203: Which of the following is not a cause of primary amenorrhea?

A. Sheehan's syndrome (Correct Answer)
B. Kallmann's syndrome
C. Mayer-Rokitansky-Kuster-Hauser syndrome
D. Turner syndrome

Explanation: **Explanation:** The distinction between primary and secondary amenorrhea is a high-yield concept for NEET-PG. **Primary amenorrhea** refers to the failure of menses to occur by age 15 (with secondary sexual characteristics) or age 13 (without them). **Secondary amenorrhea** is the cessation of menses for >3 months in a previously regular cycle or >6 months in an irregular cycle. **Why Sheehan’s Syndrome is the correct answer:** Sheehan’s syndrome is **postpartum pituitary necrosis** caused by severe obstetric hemorrhage. Since it occurs as a complication of childbirth, the patient must have been menstruating and fertile previously. Therefore, it is a classic cause of **secondary amenorrhea**, not primary. **Analysis of Incorrect Options:** * **Kallmann’s Syndrome:** A hypogonadotropic hypogonadism caused by failure of GnRH neurons to migrate. It presents with primary amenorrhea and anosmia. * **Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome:** Characterized by Müllerian agenesis (absent uterus and upper 2/3rd of vagina) despite normal ovaries and 46,XX karyotype. It is the second most common cause of primary amenorrhea. * **Turner Syndrome (45,XO):** The most common cause of primary amenorrhea. It involves gonadal dysgenesis (streak ovaries), leading to hypergonadotropic hypogonadism. **Clinical Pearls for NEET-PG:** * **Most common cause of primary amenorrhea:** Turner Syndrome. * **Most common cause of secondary amenorrhea:** Pregnancy (always rule this out first!). * **Sheehan’s Syndrome presentation:** Failure of lactation (earliest sign), followed by loss of pubic/axillary hair and secondary amenorrhea. * **Kallmann’s Syndrome:** Look for the keyword "anosmia" or "hyposmia" in the clinical stem.

Question 204: Halban's disease is due to which of the following?

A. Persistent corpus luteum (Correct Answer)
B. Deficient corpus luteum
C. Persistent trophoblast
D. Deficient trophoblast

Explanation: **Explanation:** **Halban’s Disease**, also known as **Corpus Luteum Persistens**, is a clinical condition characterized by the abnormal prolongation of the life of the corpus luteum. 1. **Why Option A is Correct:** In a normal menstrual cycle, the corpus luteum regresses after 12–14 days if fertilization does not occur. In Halban’s disease, the corpus luteum continues to function and secrete progesterone beyond its usual lifespan. This persistent progesterone prevents the shedding of the endometrium, leading to a delayed period followed by irregular, heavy, or prolonged bleeding (pseudohypermenorrhea). This mimics the clinical presentation of an early ectopic pregnancy. 2. **Why Other Options are Incorrect:** * **Option B (Deficient corpus luteum):** This refers to Luteal Phase Defect (LPD), where inadequate progesterone production leads to a shortened cycle and is a common cause of infertility or early miscarriage, rather than delayed bleeding. * **Options C & D (Trophoblast):** Trophoblastic tissue is related to pregnancy (normal or molar). Halban’s disease occurs in the **absence of pregnancy**; it is a functional hormonal disorder of the ovary. **Clinical Pearls for NEET-PG:** * **The "Halban’s Triad":** It often presents with (1) Delay in menses, (2) Irregular vaginal bleeding, and (3) A tender adnexal mass (the persistent cyst). * **Differential Diagnosis:** Its primary mimic is **Ectopic Pregnancy**. The key differentiator is a **negative pregnancy test (β-hCG)** in Halban’s disease. * **Histology:** Endometrial biopsy typically shows a **hypersecretory or decidualized endometrium** due to prolonged progesterone exposure.

Question 205: Halban's disease is due to which of the following?

A. Persistent corpus luteum (Correct Answer)
B. Deficient corpus luteum
C. Persistent trophoblast
D. Deficient trophoblast

Explanation: **Explanation:** **Halban’s Disease**, also known as **Corpus Luteum Persistens**, is a clinical condition characterized by the abnormal persistence of the corpus luteum beyond its typical 14-day lifespan in a non-pregnant cycle. **1. Why the Correct Answer is Right:** In a normal menstrual cycle, the corpus luteum undergoes luteolysis if fertilization does not occur, leading to a drop in progesterone and subsequent menstruation. In Halban’s disease, the corpus luteum continues to secrete progesterone. This results in a delayed menstrual period followed by irregular, often heavy bleeding (pseudomenstruation). Clinically, it mimics an ectopic pregnancy because it presents with the classic triad: **amenorrhea, irregular vaginal bleeding, and a tender adnexal mass** (the persistent cyst). **2. Why the Incorrect Options are Wrong:** * **B. Deficient corpus luteum:** This leads to Luteal Phase Defect (LPD), characterized by a short secretory phase and infertility/early miscarriage, rather than a delayed period or adnexal mass. * **C & D. Persistent/Deficient trophoblast:** These relate to gestational conditions (like molar pregnancy or retained products of conception). Halban’s disease is a functional ovarian disorder, not a primary trophoblastic pathology. **3. High-Yield Clinical Pearls for NEET-PG:** * **Differential Diagnosis:** The most important differential is **Ectopic Pregnancy**. To differentiate, a pregnancy test (Urine hCG or Serum β-hCG) is mandatory; it will be negative in Halban’s disease. * **Arias-Stella Reaction:** On endometrial biopsy, Halban’s disease may show the Arias-Stella reaction (hypersecretory changes), which is also seen in ectopic pregnancy. * **Management:** It is usually self-limiting. If the diagnosis is certain (negative hCG), observation or cyclic progesterone may be used.

Question 206: What is metrorrhagia?

A. Heavy menstrual bleeding
B. Intermenstrual bleeding (Correct Answer)
C. Breakthrough bleeding
D. Postcoital bleeding

Explanation: **Explanation:** **Metrorrhagia** is defined as irregular, acyclic bleeding occurring between expected menstrual periods. In the context of the FIGO nomenclature (AUB system), it is specifically referred to as **Intermenstrual Bleeding (IMB)**. The underlying medical concept involves bleeding that occurs at any time during the cycle other than during the actual menses, often caused by cervical polyps, endometrial hyperplasia, or hormonal fluctuations. **Analysis of Options:** * **Option A (Heavy Menstrual Bleeding):** Formerly known as **Menorrhagia**, this refers to excessive blood loss (>80 ml) or prolonged duration (>7 days) occurring at regular intervals. * **Option C (Breakthrough Bleeding):** This is a specific subtype of intermenstrual bleeding typically associated with the use of hormonal contraceptives (OCPs) or Hormone Replacement Therapy (HRT). * **Option D (Postcoital Bleeding):** This refers to bleeding triggered specifically by vaginal intercourse, most commonly associated with cervical pathology (e.g., cervical cancer or ectropion). **NEET-PG High-Yield Pearls:** * **Polymenorrhea:** Frequent cycles occurring at intervals of less than 21 days. * **Oligomenorrhea:** Infrequent cycles occurring at intervals greater than 35 days. * **Menometrorrhagia:** Heavy, prolonged bleeding occurring at irregular, frequent intervals. * **FIGO PALM-COEIN Classification:** Modern terminology replaces "Metrorrhagia" with **AUB-IMB** (Intermenstrual Bleeding) to standardize clinical diagnosis. Always rule out cervical malignancy in cases of irregular or postcoital bleeding.

Question 207: A patient presents with a history of dilation & curettage (D&C). Subsequent diagnostic tests reveal all hormone levels, including progesterone and estrogen, to be within the normal range. Based on this clinical presentation, which of the following is the most likely diagnosis?

A. Endometriosis
B. Asherman Syndrome (Correct Answer)
C. Premature Ovarian Insufficiency (POI)
D. Polycystic Ovary Syndrome (PCOS)

Explanation: ***Asherman Syndrome***- This diagnosis is characterized by the presence of **intrauterine adhesions** (synechiae), typically caused by injury to the **basal layer of the endometrium** following procedures like **D&C**.- The normal **estrogen** and **progesterone** levels indicate normal ovarian function, suggesting the pathology is uterine (end-organ failure to respond to hormones/obstruction) rather than central or ovarian.*Polycystic Ovary Syndrome (PCOS)*- PCOS is associated with chronic **anovulation** and features of **hyperandrogenism** (hirsutism, acne) but usually presents with oligomenorrhea rather than complete amenorrhea following D&C.- Hormonal analysis typically shows an elevated **LH/FSH ratio** and potentially high androgens, resulting in *abnormal* cyclical hormone patterns, unlike the normal levels noted here.*Premature Ovarian Insufficiency (POI)*- POI is characterized by the cessation of ovarian function before age 40, leading to a state of **hypoestrogenism** and low progesterone.- Lab tests would reveal *markedly elevated* **FSH** and *low* **estrogen** due to loss of negative feedback, directly contradicting the finding of normal hormone levels in this patient.*Endometriosis*- Endometriosis involves ectopic endometrial tissue and typically presents with symptoms like **severe dysmenorrhea**, **dyspareunia**, and chronic pelvic pain.- While severe cases can impact fertility, it does not typically cause complete secondary amenorrhea with *normal* cyclical estrogen and progesterone levels; this clinical picture points overwhelmingly to a mechanical uterine issue.

Question 208: A 36-year-old woman presents with secondary amenorrhea for the past 8 months. Laboratory investigations reveal FSH of 36 IU/L and AMH of 0.05 ng/mL. What is the most likely diagnosis?

A. Hypothalamic amenorrhea
B. Polycystic ovary syndrome (PCOS)
C. Hyperprolactinemia
D. Premature ovarian insufficiency (POI) (Correct Answer)

Explanation: ***Premature ovarian insufficiency (POI)*** - This diagnosis is defined by secondary amenorrhea before the age of 40 associated with **hypergonadotropic hypogonadism**. - The combination of severely elevated **FSH (36 IU/L)** and extremely low **AMH (0.05 ng/mL)** strongly indicates primary ovarian failure and depletion of the ovarian reserve. *Polycystic ovary syndrome (PCOS)* - PCOS is associated with normal or slightly low FSH levels and an elevated **LH:FSH ratio**. - Affected women usually have **normal or high AMH** levels due to an increased pool of small antral follicles, opposite of the findings here. *Hyperprolactinemia* - Amenorrhea is mediated by the inhibitory effect of prolactin on GnRH, leading to **hypogonadotropic hypogonadism** (low or normal FSH and LH). - The primary biochemical finding would be high **serum prolactin**, which doesn't match the high FSH observed. *Hypothalamic amenorrhea* - This is a form of **hypogonadotropic hypogonadism**, characterized by low **FSH** and **LH** levels due to impaired GnRH release. - It is inconsistent with the patient's markedly elevated FSH level, which signifies a problem originating in the ovary, not the hypothalamus.

Question 209: A 46-year-old woman presents with complaints of irregular menstrual cycles and heavy vaginal bleeding for several months. Transvaginal ultrasound reveals an endometrial thickness of 16 mm. What is the most appropriate next step in management?

A. Perform an endometrial biopsy (Correct Answer)
B. Hysterectomy
C. Start combined oral contraceptive pills
D. Observe and reassess after a few months

Explanation: ***Perform an endometrial biopsy*** - A thickened **endometrium (16 mm)** in a perimenopausal woman (46 years old) with **Abnormal Uterine Bleeding (AUB)** significantly increases the risk of endometrial pathology, including **endometrial hyperplasia** or **carcinoma**. - **Endometrial biopsy** is the most appropriate next step, as it provides a definitive tissue diagnosis required to guide subsequent, targeted treatment. *Hysterectomy* - Hysterectomy is a definitive treatment and is typically reserved only after a histological diagnosis of a high-grade abnormality, such as **endometrial cancer**, has been confirmed. - It is premature to proceed with such an invasive surgery before obtaining a tissue diagnosis. *Start combined oral contraceptive pills* - Hormonal therapy like COCPs is used to manage functional causes of AUB (e.g., anovulation), but it should be initiated only after **malignancy is ruled out** by biopsy, as it can mask symptoms of cancer. - A 16 mm endometrial thickness mandates tissue sampling due to the high index of suspicion for premalignant or malignant change. *Observe and reassess after a few months* - Delayed evaluation in this setting significantly increases the risk of diagnosing **endometrial carcinoma** at an advanced stage. - Any woman over 45 years presenting with AUB must undergo investigation, and observation is not acceptable given the pathological **endometrial thickness**.

Question 210: Identify the instrument shown in the image:

A. Karman syringe (Correct Answer)
B. Gastric lavage aspirator
C. Disposable syringe
D. Hegar dilator

Explanation: ***Karman syringe*** - This image displays a **Karman syringe**, characterized by its large capacity and specialized tip designed for manual vacuum aspiration (MVA) procedures. - It is specifically used in **gynecology** for procedures such as uterine evacuation, often in cases of miscarriage or abortion. *Gastric lavage aspirator* - A gastric lavage aspirator would be connected to a **nasogastric tube** for stomach irrigation, which is not depicted here. - Its purpose is to remove stomach contents, typically in cases of poisoning or overdose, and it generally does not resemble a simple syringe. *Disposable syringe* - While it shares some features with a disposable syringe, the **volume capacity** and the **specific design of the plunger handle** are distinct. - A standard disposable syringe, usually smaller (e.g., 1-60 mL), is used for injections, aspirations, or drawing blood, and typically has a simpler plunger. *Hegar dilator* - A Hegar dilator is a **solid, rod-shaped instrument** used to gradually widen the **cervix**. - It does not have a plunger or barrel for aspiration, making it visually distinct from the instrument shown.

Question 211: Causes of AUB are subdivided by the acronym PALM-COEIN. What are the characteristics of PALM causes? I. Structural lesions II. Diagnosed by ultrasound III. Confirmed by histopathology Select the correct answer using the code given below :

A. I and III only
B. I, II and III (Correct Answer)
C. I and II only
D. II and III only

Explanation: ***I, II and III*** - The PALM group of AUB causes refers to **structural abnormalities** of the uterus, including polyps (P), adenomyosis (A), leiomyomas (L), and malignancy/hyperplasia (M). - These conditions are typically identified through **imaging techniques** like ultrasound, saline infusion sonography, or hysteroscopy, and often confirmed with **histopathological examination** (e.g., biopsy) to provide a definitive diagnosis or characterize the lesion. *I and III only* - This option is incomplete as **ultrasound (II)** is a primary diagnostic tool for identifying PALM causes. - While structural lesions (I) are involved and histopathology (III) is often confirmatory, imaging remains crucial for initial detection and characterization. *I and II only* - This option is incomplete because **histopathology (III)** is frequently necessary for a definitive diagnosis or to rule out malignancy, especially for conditions like endometrial hyperplasia or malignancy. - While structural lesions (I) are detectable by ultrasound (II), microscopic examination provides crucial details. *II and III only* - This option is incomplete because the PALM causes are fundamentally **structural lesions (I)**. - Imaging and histopathology are methods of diagnosing and confirming these underlying structural changes, not the primary characteristic themselves.

Question 212: A 16-year-old girl with primary amenorrhoea presents to the gynaecology OPD for evaluation. She has normal secondary sexual characters. Her karyotype is 46,XX and ultrasound reveals normal ovaries and tubes but absent uterus. What is her clinical diagnosis?

A. Primary ovarian failure
B. Androgen insensitivity syndrome
C. Turner syndrome
D. Mayer-Rokitansky-Küster-Hauser syndrome (Correct Answer)

Explanation: ***Mayer-Rokitansky-Küster-Hauser syndrome (MRKH)*** - This syndrome is characterized by **agenesis of the uterus and upper vagina** in a genotypically and phenotypically normal female (46,XX karyotype, normal ovaries, and normal secondary sexual characteristics). - The presence of **normal secondary sexual characteristics** indicates normal ovarian function and estrogen production, ruling out ovarian failure as the primary cause of amenorrhea. *Primary ovarian failure* - This condition would typically lead to **absent or delayed development of secondary sexual characteristics** due to insufficient estrogen production by the ovaries. - The patient's **normal secondary sexual characteristics** contradict primary ovarian failure. *Androgen insensitivity syndrome* - Individuals with CAIS are **genetically male (46,XY)** but phenotypically female, with **absent or rudimentary uterus** and internal female reproductive organs. - While they have absent menses and normal secondary sexual characteristics (due to peripheral conversion of androgens to estrogens), their **karyotype is 46,XY**, not 46,XX as in this patient. *Turner syndrome* - This syndrome is characterized by a **45,X karyotype**, leading to **gonadal dysgenesis** (streak gonads) and thus absent or delayed secondary sexual characteristics. - The patient's **normal secondary sexual characteristics** and **46,XX karyotype** rule out Turner syndrome.

Question 213: A 25-year-old female comes to the gynaecology OPD for evaluation of secondary amenorrhoea. She gives history of previous dilatation and curettage, and her FSH levels are 8 IU/L. The probable cause of amenorrhoea is

A. incomplete abortion
B. Asherman syndrome (Correct Answer)
C. premature ovarian failure
D. Sheehan syndrome

Explanation: ***Asherman syndrome*** - This syndrome is characterized by the formation of **intrauterine adhesions** or scarring, often following uterine procedures such as **dilatation and curettage (D&C)**. - The **normal FSH level** (8 IU/L) indicates intact ovarian function, ruling out primary ovarian issues and pointing towards a structural uterine problem as the cause of secondary amenorrhea. *incomplete abortion* - An incomplete abortion would typically present with **vaginal bleeding and abdominal pain**, not secondary amenorrhea, unless it occurred significantly in the past and led to complications. - While D&C can be performed for incomplete abortion, the primary cause of amenorrhea in this context would be the subsequent formation of uterine adhesions, not the incomplete abortion itself. *premature ovarian failure* - This condition involves the cessation of ovarian function before age 40, which would result in **elevated FSH levels** due to lack of negative feedback from estrogen. - The patient's **normal FSH level** (8 IU/L) makes premature ovarian failure an unlikely diagnosis in this case. *Sheehan syndrome* - Sheehan syndrome is caused by **ischemic necrosis of the pituitary gland** typically following severe postpartum hemorrhage, leading to panhypopituitarism. - It would present with symptoms of **multiple hormone deficiencies**, including low FSH and LH (due to pituitary failure), along with other anterior pituitary hormone deficiencies, which contradicts the normal FSH and lack of mention of postpartum hemorrhage.

Question 214: Premenstrual Syndrome (PMS) should fulfil which of the following criteria? 1. It is not related to any organic lesion. 2. It regularly occurs during the luteal phase and each ovulatory menstruation cycle. 3. Symptoms must be severe enough to disturb the lifestyle of women and seeks medical help. 4. Symptoms persist after the period also.

A. 4. Symptoms persist after the period also.
B. 2. It regularly occurs during the luteal phase and each ovulatory menstruation cycle.
C. 1. It is not related to any organic lesion. (Correct Answer)
D. 3. Symptoms must be severe enough to disturb the lifestyle of women and seeks medical help.

Explanation: ***1. It is not related to any organic lesion.*** - PMS is a **functional disorder** and a diagnosis of exclusion, meaning its symptoms should not be attributable to an underlying physical or organic pathology. - While PMS involves hormonal fluctuations during the **luteal phase**, there is no detectable **structural or organic lesion** causing the symptoms. - This is a fundamental criterion to differentiate PMS from other medical conditions. ***2. It regularly occurs during the luteal phase and each ovulatory menstruation cycle.*** - PMS symptoms characteristically occur during the **luteal phase** (after ovulation and before menstruation) and are a key diagnostic feature. - Symptoms must occur in **most cycles** (typically documented in at least 2 out of 3 consecutive cycles) to establish the diagnosis. - This temporal relationship with the menstrual cycle is essential for diagnosis. ***3. Symptoms must be severe enough to disturb the lifestyle of women and seeks medical help.*** - **Functional impairment** is a fundamental diagnostic criterion for PMS. - Symptoms must cause **clinically significant distress** or interfere with work, school, usual activities, or relationships. - This distinguishes PMS from normal premenstrual symptoms that many women experience without functional impairment. *4. Symptoms persist after the period also.* - A key diagnostic criterion for PMS is that symptoms **resolve or significantly improve** with or shortly after the onset of menstruation. - If symptoms persist throughout the menstrual cycle, it suggests a different diagnosis, such as an underlying mood disorder (e.g., depression or anxiety with premenstrual exacerbation) rather than true PMS. - The cyclic nature with symptom-free interval is essential for PMS diagnosis.

Question 215: In the PALM-COEIN classification by FIGO for abnormal uterine bleeding, ovulatory dysfunction is the cause in which one of the following conditions?

A. Pelvic inflammatory disease
B. Adenomyosis
C. Polycystic ovarian syndrome (Correct Answer)
D. Ovarian cancer

Explanation: ***Polycystic ovarian syndrome*** - **Polycystic ovarian syndrome (PCOS)** is a chronic anovulatory disorder, making it a primary cause of **ovulatory dysfunction (O in PALM-COEIN)**. - The hormonal imbalances in PCOS interfere with normal follicular development and ovulation, leading to irregular or absent periods and abnormal uterine bleeding. *Pelvic inflammatory disease* - **Pelvic inflammatory disease (PID)** is an infection of the upper female reproductive tract causing inflammation, but it does not directly lead to primary ovulatory dysfunction. - PID falls under the **"E" for Endometrial causes** in the PALM-COEIN classification if it causes bleeding through endometrial inflammation or infection. *Adenomyosis* - **Adenomyosis** is a condition where endometrial tissue grows into the muscular wall of the uterus, causing heavy and painful periods. - This condition is classified under **"A" for Adenomyosis** in the PALM-COEIN classification, representing a structural cause of abnormal uterine bleeding, not ovulatory dysfunction. *Ovarian cancer* - **Ovarian cancer** is a malignancy of the ovaries and, while it can cause abnormal bleeding in advanced stages, it is not primarily due to ovulatory dysfunction. - Ovarian cancer is classified under **"M" for Malignancy and hyperplasia** in PALM-COEIN, indicating a structural and pathological cause, rather than an ovulatory problem.

Question 216: Which of the following is MOST effective as a first-line management for premenstrual syndrome?

A. Hysterectomy with oophorectomy
B. Diuretics
C. Niacin (vitamin B3)
D. Combined oral contraceptive pills (Correct Answer)

Explanation: ***Combined oral contraceptive pills*** - **Combined oral contraceptive pills** are the **most comprehensive first-line pharmacological treatment** for **premenstrual syndrome (PMS)** by suppressing ovulation and stabilizing hormonal fluctuations throughout the menstrual cycle. - They address both physical and mood-related symptoms of PMS effectively. - Continuous or extended-cycle regimens can be particularly beneficial by reducing the number of menstrual periods and related symptom flares. *Niacin (vitamin B3)* - There is **no robust scientific evidence** to support the efficacy of **niacin (vitamin B3)** in the management of PMS symptoms. - While **vitamin B6** has some evidence for mild PMS symptoms, **niacin (B3)** is not recommended. - High doses of niacin can cause side effects such as flushing, itching, and gastrointestinal upset. *Diuretics* - **Spironolactone**, a potassium-sparing diuretic, can be effective for managing **specific fluid retention symptoms** associated with PMS, such as bloating and breast tenderness. - However, diuretics are typically used as **adjunctive therapy** for specific symptoms rather than comprehensive first-line management. - They do not address the broader spectrum of emotional and psychological symptoms of PMS. *Hysterectomy with oophorectomy* - **Hysterectomy with oophorectomy** (removal of the uterus and ovaries) is a **last-resort treatment** for severe, refractory Premenstrual Dysphoric Disorder (PMDD) after all medical therapies have failed. - This is an **irreversible surgical procedure** that induces immediate surgical menopause with significant risks and long-term implications. - It is **never a first-line treatment** for PMS management.

Question 217: What is the IUCD of choice in women with menorrhagia ?

A. Lippe's loop
B. Copper-T 380A
C. Copper-T 200
D. Progesterone containing IUCD (Correct Answer)

Explanation: ***Progesterone containing IUCD*** - **Progesterone-releasing IUCDs** (like Mirena) are effective in treating menorrhagia because the localized release of progesterone causes **endometrial atrophy**, reducing menstrual blood loss. - This type of IUCD can **reduce menstrual bleeding by up to 90%** and is often used as a first-line treatment for heavy menstrual bleeding. *Lippe's loop* - **Lippe's loop** is an older, first-generation non-hormonal plastic IUCD that is no longer commonly used. - It works by causing a **sterile inflammatory reaction** in the uterus, which can actually increase menstrual bleeding and cramping. *Copper-T 380A* - **Copper-T 380A** is a highly effective non-hormonal IUCD primarily used for contraception. - The copper ions it releases induce an **inflammatory response** in the uterus, which can lead to heavier and more painful periods, thus worsening menorrhagia. *Copper-T 200* - **Copper-T 200** is an older generation of copper IUCD with a smaller copper surface area than newer models. - Similar to other copper IUCDs, it works primarily as a contraceptive but can **increase menstrual blood flow** and dysmenorrhea in some women.

Question 218: Match List-I with List-II and select the correct answer using the code given below the Lists:

A. A→1 B→2 C→3 D→4
B. A→2 B→1 C→4 D→3
C. A→3 B→4 C→1 D→2 (Correct Answer)
D. A→4 B→3 C→2 D→1

Explanation: ***A→3 B→4 C→1 D→2*** **Correct Matching:** - **A. Simple hyperplasia → 3. Estrogen stimulation**: Simple (cystic) hyperplasia results from **continuous estrogen stimulation without sufficient progesterone opposition**. Unopposed estrogen leads to endometrial proliferation and glandular changes. - **B. Ovulatory menorrhagia → 4. Regular, heavy bleeding**: Ovulatory menorrhagia represents **regular, cyclical heavy menstrual bleeding** where ovulation occurs normally, implying intact hypothalamic-pituitary-ovarian axis with normal hormonal cyclicity but excessive blood loss (>80 mL per cycle). - **C. Puberty menorrhagia → 1. Anovulation**: Puberty menorrhagia is frequently linked to **anovulation** in adolescent girls due to immature hypothalamic-pituitary-ovarian axis. This leads to unopposed estrogen, irregular endometrial buildup, and erratic shedding. - **D. Irregular shedding → 2. Progesterone deficiency**: Irregular shedding results from **inadequate progesterone** in the luteal phase, causing incomplete and prolonged breakdown of the secretory endometrium over 7-14 days instead of organized menstruation. *Incorrect Option A→1 B→2 C→3 D→4* - Incorrectly links simple hyperplasia to anovulation (simple hyperplasia is primarily due to estrogen stimulation) - Incorrectly links ovulatory menorrhagia to progesterone deficiency (ovulatory cycles have adequate progesterone by definition) - Incorrectly links puberty menorrhagia to estrogen stimulation (the mechanism is anovulation leading to unopposed estrogen) - Incorrectly links irregular shedding to regular heavy bleeding (irregular shedding involves prolonged, irregular bleeding) *Incorrect Option A→2 B→1 C→4 D→3* - Incorrectly links simple hyperplasia to progesterone deficiency (while related, the primary cause is estrogen stimulation) - Incorrectly links ovulatory menorrhagia to anovulation (these are contradictory - ovulatory means ovulation is occurring) - Incorrectly links puberty menorrhagia to regular heavy bleeding (puberty menorrhagia is typically irregular due to anovulation) - Incorrectly links irregular shedding to estrogen stimulation (irregular shedding is specifically due to progesterone deficiency) *Incorrect Option A→4 B→3 C→2 D→1* - Incorrectly links simple hyperplasia to regular heavy bleeding (simple hyperplasia may cause irregular bleeding, not regular) - Incorrectly links ovulatory menorrhagia to estrogen stimulation (ovulatory menorrhagia has normal hormonal balance with both estrogen and progesterone) - Incorrectly links puberty menorrhagia to progesterone deficiency (the root cause is anovulation, which then leads to hormone imbalance) - Incorrectly links irregular shedding to anovulation (irregular shedding occurs despite ovulation, due to inadequate progesterone)

Question 219: The following drugs are effective in the management of menorrhagia except :

A. Progestational agents
B. Prostaglandins (Correct Answer)
C. Non-steroidal anti-inflammatory drugs
D. Anti-fibrinolytic drugs

Explanation: ***Prostaglandins*** - Prostaglandins, particularly **PGE2** and **PGF2α**, are generally associated with **increased uterine contractions** and **vasodilation**, which can worsen menstrual bleeding rather than reduce it. - While cyclooxygenase inhibitors (NSAIDs) work by inhibiting prostaglandin synthesis, exogenous prostaglandins themselves are not used to treat menorrhagia and can exacerbate it. *Progestational agents* - Progestins help to **stabilize the endometrium**, reducing excessive bleeding by inducing decidualization and limiting endometrial growth. - They can be administered orally, via injection, or through an **intrauterine device (IUD)** like the levonorgestrel-releasing IUD (Mirena), which is highly effective. *Non-steroidal anti-inflammatory drugs* - NSAIDs reduce menorrhagia by **inhibiting prostaglandin synthesis** in the endometrium, which leads to reduced vasodilation and uterine contractions. - They also help alleviate associated **dysmenorrhea** (menstrual pain). *Anti-fibrinolytic drugs* - These drugs, such as **tranexamic acid**, work by **inhibiting plasminogen activation**, thereby preventing the breakdown of fibrin clots within the uterus. - This promotes clot stability and reduces menstrual blood loss significantly.

Question 220: A 15-year old unmarried girl comes with history of dysmenorrhea. Age of menarche is 12 years. Per abdominal and per rectum examination reveal nothing abnormal. You will treat the patient with :

A. Reassurance and giving antispasmodics throughout the month
B. Hormones
C. Antibiotics
D. Reassurance and giving antispasmodics during menses (Correct Answer)

Explanation: ***Reassurance and giving antispasmodics during menses*** - The patient presents with **primary dysmenorrhea**, indicated by the onset of symptoms with menarche and normal pelvic examination findings in an unmarried girl. - **Antispasmodics** (e.g., NSAIDs like ibuprofen or mefenamic acid) taken during menses effectively reduce pain by inhibiting prostaglandin synthesis, which causes uterine contractions. *Reassurance and giving antispasmodics throughout the month* - While **reassurance** is appropriate, taking antispasmodics throughout the entire month is **unnecessary** and can lead to adverse effects, as the pain is cyclical and directly related to menstruation. - **Antispasmodics** are most effective when taken a day or two before the onset of menstruation and continued during the painful days. *Hormones* - **Hormonal therapy** (e.g., combined oral contraceptives) is a valid treatment option for dysmenorrhea, especially if non-steroidal anti-inflammatory drugs (NSAIDs) are ineffective or if contraception is also desired. - However, for a 15-year-old unmarried girl with typical primary dysmenorrhea and no other complications, **NSAIDs/antispasmodics** are generally the first-line and usually sufficient treatment. *Antibiotics* - **Antibiotics** are used to treat bacterial infections, and there is no indication of infection (e.g., fever, unusual discharge, pelvic inflammatory disease) in this patient's presentation. - Using antibiotics without an identified infection is inappropriate and contributes to **antibiotic resistance**.

Question 221: Histological type of endometrium that is suggestive of ovulation is :

A. cystic glandular hyperplasia
B. secretory phase (Correct Answer)
C. adenomatous hyperplasia
D. proliferative phase

Explanation: ***secretory phase*** - The **secretory phase** of the endometrium occurs *after* ovulation and is characterized by the effects of **progesterone** produced by the corpus luteum. - Histologically, this phase shows **tortuous glands** with **secretory activity** (containing glycogen and mucus), and a **stroma that becomes edematous**, preparing the uterus for potential implantation. *cystic glandular hyperplasia* - This is a form of **endometrial hyperplasia** characterized by abundant, dilated glands of varying sizes and stroma, typically occurring due to **unopposed estrogen stimulation**. - It does not indicate ovulation; rather, it often results from **anovulation** or other conditions causing persistent estrogen exposure without a subsequent progesterone phase. *adenomatous hyperplasia* - **Adenomatous hyperplasia** (or complex hyperplasia) involves glandular crowding and architectural abnormalities, representing a more advanced form of hyperplasia compared to simple cystic hyperplasia. - It arises from **unopposed estrogen** and is not indicative of normal ovulation; it can be a precursor to endometrial carcinoma, especially if **atypia** is present. *proliferative phase* - The **proliferative phase** occurs *before* ovulation under the influence of **estrogen**, during which the endometrium regrows and thickens. - Histologically, it features relatively **straight, tubular glands** and a compact stroma, and while it precedes ovulation, it does not confirm that ovulation has occurred.

Question 222: What is the likely cause of primary amenorrhoea together with retention of urine in an adolescent girl ?

A. Testicular Feminizing syndrome
B. Adrenal hyperplasia
C. Haematocolpos (Correct Answer)
D. Turner's syndrome

Explanation: ***Haematocolpos*** - **Haematocolpos** is the accumulation of menstrual blood in the vagina due to an **imperforate hymen** or other outflow obstruction, causing primary amenorrhoea. - The retained blood can exert pressure on the urethra and bladder, leading to **urinary retention**. *Testicular Feminizing syndrome* - Also known as **Androgen Insensitivity Syndrome**, individuals have a 46, XY karyotype but appear female externally due to androgen receptor defects. - It causes primary amenorrhoea but typically does not present with urinary retention as the Mullerian ducts regress, meaning there is no uterus and therefore no menstrual blood to accumulate. *Adrenal hyperplasia* - **Congenital adrenal hyperplasia (CAH)** can cause virilization in females, leading to ambiguous genitalia and primary amenorrhoea due to hormonal imbalances. - While it can affect reproductive development, urinary retention due to menstrual blood accumulation is not a typical presentation. *Turner's syndrome* - **Turner's syndrome (45, XO)** is characterized by ovarian dysgenesis and primary amenorrhoea due to the absence of ovarian function. - Individuals often have distinctive features like a short stature and a webbed neck, but urinary retention is not a direct consequence of the syndrome itself.

Question 223: The common manifestations of genital tuberculosis include the following except

A. Pelvic pain
B. Foul-smelling vaginal discharge (Correct Answer)
C. Amenorrhoea
D. Infertility

Explanation: ***Foul-smelling vaginal discharge*** - While infections can cause vaginal discharge, a **foul-smelling discharge** is typically associated with bacterial vaginosis or trichomoniasis, not primarily with genital tuberculosis due to its granulomatous nature. - Genital tuberculosis often presents with **non-specific symptoms** or no symptoms at all, rather than purulent or foul-smelling discharge. *Pelvic pain* - **Chronic pelvic pain** is a very common symptom of genital tuberculosis, often due to inflammation and involvement of pelvic organs. - The pain can be constant or intermittent and may be difficult to localize. *Amenorrhoea* - **Amenorrhea**, particularly secondary amenorrhoea, can occur due to endometrial damage or destruction caused by the tuberculous infection. - This can lead to **intrauterine adhesions (Asherman's syndrome)** or functional impairment of the endometrium, hindering menstruation. *Infertility* - **Infertility** is one of the most frequent and significant manifestations of genital tuberculosis, especially in women. - It often results from **tubal occlusion** or distortion, endometrial damage, or ovarian dysfunction caused by the disease, leading to an inability to conceive or carry a pregnancy to term.

Question 224: In a patient with dysfunctional uterine bleeding with cyclical menorrhagia, the first line drug is

A. Progesterone
B. Oestrogen and progesterone
C. Tranexamic acid (Correct Answer)
D. Oestrogen

Explanation: ***Tranexamic acid*** - **Tranexamic acid** is an **antifibrinolytic** agent that reduces menstrual blood loss by inhibiting the breakdown of blood clots. - It is often considered a **first-line medical treatment** for heavy menstrual bleeding, including cyclical menorrhagia due to its effectiveness and non-hormonal nature. *Progesterone* - While progesterone can be used to manage dysfunctional uterine bleeding, it is typically used for **anovulatory bleeding** or to regulate the cycle, not primarily as a first-line agent for acute, cyclical menorrhagia where heavy bleeding is the main concern. - Its mechanism involves stabilizing the **endometrial lining** and can lead to withdrawal bleeding when stopped. *Oestrogen and progesterone* - Combination oral contraceptives (containing both oestrogen and progesterone) are effective in regulating menstrual cycles and reducing blood loss. - However, for acute, cyclical menorrhagia, especially if the patient does not need contraception, **tranexamic acid** is often preferred as a first-line non-hormonal option due to its rapid effect on bleeding. *Oestrogen* - Oestrogen can be used in cases of acute, very heavy bleeding to rapidly **stabilize the endometrium** and stop hemorrhage, often at high doses. - It helps in the **proliferation of the endometrium** but is not the first-line choice for ongoing cyclical menorrhagia as it can cause its own set of side effects and doesn't address the primary issue of excessive fibrinolysis.

Question 225: Which of the following statements regarding functional epimenorrhoea is not correct ?

A. It is seen more frequently at the ends of reproductive life
B. The cycle is reduced to an arbitrary limit of 21 days or less
C. It is a cyclic bleeding
D. If epimenorrhoea is associated with heavy menstrual loss it is called menometrorrhagia (Correct Answer)

Explanation: ***If epimenorrhoea is associated with heavy menstrual loss it is called menometrorrhagia*** - This statement is **INCORRECT** - when epimenorrhoea (frequent regular cycles) is associated with heavy bleeding, it should be called **epimenorrhagia** or **polymenorrhagia**. - **Menometrorrhagia** specifically refers to **irregular AND heavy bleeding**, not just frequent and heavy bleeding. - The key difference: epimenorrhoea maintains **regular cyclicity** (just more frequent), whereas metrorrhagia implies **irregular, acyclic bleeding**. *It is seen more frequently at the ends of reproductive life* - This is **CORRECT** - functional epimenorrhoea commonly occurs during **adolescence** (as cycles are maturing) and **perimenopause** (due to hormonal fluctuations, particularly anovulatory cycles). - Both periods are characterized by unstable hypothalamic-pituitary-ovarian axis function. *The cycle is reduced to an arbitrary limit of 21 days or less* - This is **CORRECT** - epimenorrhoea (polymenorrhea) is defined as menstrual cycles occurring at intervals of **21 days or less**. - Normal menstrual cycle length is 21-35 days; anything less than 21 days is considered epimenorrhoea. *It is a cyclic bleeding* - This is **CORRECT** - functional epimenorrhoea indicates that bleeding is **still cyclical and regular**, occurring at predictable (though shortened) intervals. - This distinguishes it from **metrorrhagia** (irregular, acyclic bleeding) and confirms ovulatory or regular hormonal cycling.

Question 226: A 20-year-old married woman anxious to get pregnant has cyclical cramps and sharp lower abdominal pain which lasts for 3 days starting from the day of her menstrual flow. Her menstrual periods are regular but heavy. On clinical examination, her pelvis is normal. The most probable diagnosis is

A. Primary dysmenorrhoea (Correct Answer)
B. Adenomyosis
C. Uterine leiomyomata
D. Endometriosis

Explanation: ***Primary dysmenorrhoea*** - This is the **most probable diagnosis** given the classic presentation of **cyclical cramping pain starting on day 1 of menstruation** lasting 3 days. - Primary dysmenorrhea is caused by **excessive prostaglandin production** from the endometrium, leading to uterine cramping and can be associated with **heavy menstrual bleeding**. - The **normal pelvic examination** is a key feature distinguishing primary from secondary causes of dysmenorrhea. - Typically affects young women in their **late teens to early 20s**, shortly after menarche when ovulatory cycles are established. *Endometriosis* - While endometriosis causes cyclical pain, the pain typically begins **1-2 days before menstruation** rather than starting precisely on day 1. - Associated symptoms often include **dyspareunia, dyschezia, and infertility**, which are not mentioned in this case. - Though pelvic examination can be normal in early endometriosis, the **pain timing pattern** does not fit the classic presentation. *Adenomyosis* - Characterized by **endometrial tissue within the myometrium**, typically presents with a **diffusely enlarged, tender, boggy uterus** on examination. - More common in women over 30 years, particularly those with **previous pregnancies**. - The patient's **normal pelvic examination** and young age make adenomyosis unlikely. *Uterine leiomyomata* - These **benign fibroids** typically cause heavy menstrual bleeding with **pressure symptoms** rather than severe cyclical cramping pain. - Usually result in an **irregularly enlarged uterus** on pelvic examination. - The patient's **normal pelvic examination** excludes this diagnosis.

Question 227: An 18-year-old girl presents with primary amenorrhoea and gives a history of cyclical colicky abdominal pain. The most probable diagnosis is

A. Encysted tuberculosis
B. Haematocolpos (Correct Answer)
C. Full bladder
D. Ovarian cyst

Explanation: ***Haematocolpos*** - **Primary amenorrhoea** combined with **cyclical colicky abdominal pain** strongly suggests an outflow tract obstruction, leading to the accumulation of menstrual blood. - **Haematocolpos** is the accumulation of menstrual blood in the vagina caused by an imperforate hymen or other anomalies, leading to distension and pain. *Encysted tuberculosis* - While tuberculosis can affect the reproductive system, it typically presents with **chronic abdominal pain**, weight loss, and infertility, not primary amenorrhoea with cyclical pain. - **Encysted tuberculosis** would not directly cause the cyclical colicky pain related to menstrual flow blockage. *Full bladder* - A **full bladder** can cause suprapubic discomfort but generally doesn't present as primary amenorrhoea or cyclical colicky abdominal pain. - This condition is easily resolved by urination and is not a chronic, cyclical issue. *Ovarian cyst* - **Ovarian cysts** can cause abdominal pain, which may be cyclical, but they do not cause primary amenorrhoea as the problem is with ovarian function or morphology, not menstrual outflow. - The pain is usually dull, aching, or sharp upon rupture, distinct from the **colicky pain** associated with retained menstrual blood.

Question 228: A woman who has secondary amenorrhea experiences withdrawal bleeding following progesterone administration. What is the likely diagnosis?

A. Anovulation (Correct Answer)
B. Asherman's syndrome
C. Premature ovarian failure
D. Hypothalamic amenorrhea

Explanation: ***Anovulation*** - Withdrawal bleeding after progesterone indicates that the **endometrium was adequately primed with estrogen** but there was no ovulation to produce progesterone. - This scenario points to **anovulation** as the underlying cause of secondary amenorrhea, where estrogen is present, but a corpus luteum does not form to secrete progesterone. *Asherman's syndrome* - This condition involves **intrauterine adhesions** that prevent endometrial shedding, even in the presence of hormones. - A woman with Asherman's syndrome would typically **not experience withdrawal bleeding** after progesterone, as the endometrium is damaged or absent. *Premature ovarian failure* - In **premature ovarian failure**, the ovaries stop functioning, leading to **low estrogen levels**. - Without sufficient estrogen to prime the endometrium, administering progesterone would **not result in withdrawal bleeding**. *Hypothalamic amenorrhea* - This type of amenorrhea is characterized by **low estrogen levels** due to dysfunction in the hypothalamus. - Similar to premature ovarian failure, a lack of estrogen would mean the endometrium is not prepared, and **progesterone withdrawal bleeding would not occur**.

Question 229: A 13-year-old, obese, unmarried girl presents with the history of amenorrhea and cyclical abdominal pain. On examination, the secondary sex characters are found to be well developed. What should be the next step?

A. Carry out the progesterone challenge test
B. Carry out a per-rectal examination (Correct Answer)
C. Keep her under observation for the next three months
D. Assess the TSH and Prolactin levels

Explanation: ***Carry out a per-rectal examination*** - This presentation of **amenorrhea with cyclical abdominal pain** in a girl with developed secondary sexual characteristics strongly suggests a **cryptomenorrhea** caused by an outflow tract obstruction, like an **imperforate hymen**. - A **per-rectal examination** can help identify a bulging hymen or a pelvic mass due to retained menstrual blood (hematocolpos or hematometra), which would guide further management. *Carry out the progesterone challenge test* - A progesterone challenge test assesses the presence of **estrogenization of the endometrium** and a patent outflow tract, but it is typically used for secondary amenorrhea or primary amenorrhea without cyclical pain. - In this case, **cyclical pain** points towards an obstructed outflow tract, making the challenge test less immediate than ruling out the obstruction. *Keep her under observation for the next three months* - Observing for three months would delay the diagnosis and definitive treatment of a potentially painful and concerning condition like **hematocolpos**. - Delaying intervention could lead to worsening pain, complications like **endometriosis**, or impact fertility. *Assess the TSH and Prolactin levels* - While hormonal imbalances can cause amenorrhea, the presence of **cyclical abdominal pain** and **developed secondary sexual characteristics** makes a primary outflow tract obstruction a more likely immediate concern. - **Hypothyroidism** (high TSH) or **hyperprolactinemia** would typically cause amenorrhea without cyclical pain but could be considered later if obstruction is ruled out.

Question 230: A 30-year-old woman with three children has dysfunctional uterine bleeding. What will be the most appropriate management?

A. Medical management with danazol
B. Levonorgestrel-releasing intrauterine device (Correct Answer)
C. Transcervical endometrial resection
D. Abdominal hysterectomy

Explanation: ***Levonorgestrel-releasing intrauterine device*** - The **levonorgestrel-releasing intrauterine device (Mirena IUD)** is highly effective for reducing **menstrual blood loss** in women with **dysfunctional uterine bleeding (DUB)** due to its local endometrial suppression. - It is an excellent choice for a 30-year-old woman with three children as it offers both **contraception** and **menstrual bleeding control** without permanent sterilization. *Medical management with danazol* - **Danazol** is an **androgen derivative** that can cause significant **androgenic side effects** such as hirsutism and voice changes, making it less desirable for long-term use. - While effective in reducing menstrual blood loss, it is typically reserved for severe cases or when other treatments fail due to its side effect profile. *Transcervical endometrial resection* - **Transcervical endometrial resection**, or **endometrial ablation**, is an effective procedure for reducing heavy menstrual bleeding but is generally considered for women who have completed childbearing and do not desire future pregnancies. - While this patient has three children, the IUD offers a less invasive, reversible, and effective alternative before resorting to surgical intervention. *Abdominal hysterectomy* - **Abdominal hysterectomy** is a major surgical procedure and is considered a definitive treatment for dysfunctional uterine bleeding, but it is the most invasive option. - Given the patient's age and the availability of less invasive and effective treatments, hysterectomy would typically be reserved for cases where conservative treatments have failed or other gynecological pathologies are present.

Question 231: A 15-year-old unmarried girl presents with complaints of dysmenorrhoea for about one year. She achieved menarche at 12 years of age. On abdominal and rectal examination, she has no abnormality. What will be the most appropriate management?

A. Prescribe clotrimazole vaginal ovules
B. Perform dilatation and curettage
C. Reassure her and prescribe analgesics (Correct Answer)
D. Prescribe antibiotics

Explanation: ***Reassure her and prescribe analgesics*** - This presentation is typical for **primary dysmenorrhea**, which is common in adolescent girls and not associated with underlying pathology. - Initial management involves **reassurance** about the benign nature of the condition and symptomatic relief with **analgesics**, particularly **NSAIDs**. *Prescribe clotrimazole vaginal ovules* - **Clotrimazole** is an antifungal medication indicated for candidal vaginitis, which is not suggested by the presented symptoms or examination findings. - Dysmenorrhea is pain associated with menstruation, not typically a symptom of **vaginal infection**. *Perform dilatation and curettage* - **Dilatation and curettage (D&C)** is an invasive surgical procedure used for various uterine conditions, such as abnormal uterine bleeding or miscarriage. - It is completely inappropriate for the initial management of **primary dysmenorrhea** in an adolescent with a normal examination. *Prescribe antibiotics* - **Antibiotics** are indicated for bacterial infections, which are not suggested by the patient's complaints of dysmenorrhea and normal abdominal/rectal examination. - There is no clinical evidence of **pelvic inflammatory disease** or other infectious causes.

Question 232: A 40-year-old woman presents with excessive menstrual bleeding. The most appropriate first surgical treatment will be

A. Hysteroscopy (Correct Answer)
B. Hysterectomy
C. Myomectomy
D. Dilatation and curettage

Explanation: ***Hysteroscopy*** - This procedure allows for **direct visualization of the uterine cavity**, enabling the identification and potential treatment of intracavitary causes of excessive menstrual bleeding, such as polyps or fibroids. - It is considered the **first-line surgical diagnostic and therapeutic approach** for abnormal uterine bleeding when medical management fails or a structural cause is suspected. *Hysterectomy* - While it definitively treats excessive menstrual bleeding by **removing the uterus**, it is generally considered a **definitive and more invasive treatment** reserved for cases where conservative methods have failed or when the patient desires no future pregnancies. - As a first surgical option, it is **overly aggressive** without first attempting less invasive diagnostic and therapeutic procedures. *Myomectomy* - This procedure involves the **surgical removal of uterine fibroids**, which can cause excessive menstrual bleeding. - However, performing a myomectomy without first **diagnosing the presence and location of fibroids** (which hysteroscopy can help identify) is not the appropriate first surgical step. *Dilatation and curettage* - This procedure involves the **scraping of the uterine lining** and can provide a sample for pathology, offering temporary relief from bleeding. - It is primarily a **diagnostic procedure** to obtain endometrial tissue and may offer temporary symptomatic relief, but it is less effective for treating structural causes and is not the most appropriate first-line surgical treatment in terms of diagnostic precision and targeted therapy for all causes of excessive bleeding compared to hysteroscopy.

Question 233: A 16-year-old girl presents with primary amenorrhoea and repeated periodic pain. On examination, a suprapubic mass is felt up to the umbilicus. The most likely diagnosis is

A. uterine leiomyoma
B. bladder-neck hypertrophy
C. cryptomenorrhoea (Correct Answer)
D. large ovarian cyst

Explanation: ***cryptomenorrhoea*** - Primary amenorrhoea with a palpable suprapubic mass and repeated periodic pain is highly suggestive of **cryptomenorrhoea**, where menstrual blood accumulates due to an outflow tract obstruction. - The accumulated blood (often due to an imperforate hymen or transverse vaginal septum) forms a **hematocolpos**, leading to the palpable suprapubic mass and cyclical pain. *uterine leiomyoma* - **Uterine leiomyomas** are benign tumors that are rare in adolescents, especially as a cause of primary amenorrhea. - While they can cause a palpable mass, they typically present with **menorrhagia** or pelvic pressure, not primary amenorrhea with cyclical pain due to retained menstrual flow. *bladder-neck hypertrophy* - **Bladder-neck hypertrophy** is an uncommon condition in adolescent females and primarily causes obstructive urinary symptoms, not primary amenorrhea or a palpable suprapubic mass from retained menstrual blood. - It would manifest as difficulty voiding or recurrent urinary tract infections, unrelated to menstrual function. *large ovarian cyst* - A **large ovarian cyst** can present as a pelvic/suprapubic mass and cause pain, but it would not typically cause **primary amenorrhoea** with cyclical pain representing trapped menstrual blood. - Ovarian cysts usually interfere with menstrual regularity or cause acute pain, but not complete absence of menstruation due to an anatomical obstruction of the outflow tract.

Question 234: A 28 year old woman develops amenorrhoea after having dilatation and curettage. The most likely diagnosis is :

A. Kallman syndrome
B. Turner syndrome
C. Asherman syndrome (Correct Answer)
D. Anorexia nervosa

Explanation: ***Asherman syndrome*** - It is characterized by the formation of **intrauterine adhesions** or **synechiae** that occur due to trauma to the endometrial lining, most commonly following a **D&C procedure**. - These adhesions can lead to **amenorrhea**, hypomenorrhea, infertility, and recurrent pregnancy loss due to the obstruction of the uterine cavity. *Kallman syndrome* - This is a **congenital hypogonadotropic hypogonadism** characterized by a deficiency in GnRH production and an associated **anosmia** (loss of smell), neither of which are suggested by the clinical presentation. - Patients typically present with **primary amenorrhea** and delayed puberty, not secondary amenorrhea following a D&C. *Turner syndrome* - A **chromosomal disorder (45, XO)** leading to **gonadal dysgenesis** and ovarian failure. - It typically presents with **primary amenorrhea**, short stature, webbed neck, and other distinct physical features, which are not mentioned here. *Anorexia nervosa* - This is an **eating disorder** associated with severe caloric restriction and low body weight. - It can cause **hypothalamic amenorrhea** due to impaired GnRH pulsatility but is usually accompanied by significant weight loss and psychological symptoms, not typically heralded by a D&C.

Question 235: A 44 year old woman presents with polymenorrhoea for one year. Clinical examination reveals bulky uterus with no other abnormality. D & C report is simple hyperplasia. What is the treatment of choice?

A. Progestogen therapy (Correct Answer)
B. GnRH analogues
C. Combined oral pills
D. Total hysterectomy with bilateral salpingo-oophorectomy

Explanation: ***Progestogen therapy*** - **Simple hyperplasia** is a benign condition of the endometrium and typically responds well to progestogen therapy, which helps to **antagonize estrogen's proliferative effects** on the endometrium. - This treatment helps to induce secretory changes and shedding of the hyperplastic tissue, effectively managing the associated **polymenorrhoea**. *GnRH analogues* - While GnRH analogues can induce a **hypoestrogenic state**, they are generally reserved for more severe forms of endometrial hyperplasia (e.g., atypical hyperplasia) or conditions like **endometriosis** and **fibroids** that do not respond to progestogens. - Their significant side effects, resembling menopause, make them less suitable as an initial choice for simple hyperplasia. *Combined oral pills* - Combined oral contraceptive pills primarily work by **suppressing ovulation** and thinning the endometrial lining, which can help with heavy bleeding but are not the primary treatment for established endometrial hyperplasia. - While they contain progestins, the progestin dose and regimen in combined oral pills are typically not sufficient or specifically tailored to reverse significant endometrial hyperplasia. *Total hysterectomy with bilateral salpingo-oophorectomy* - This is a **surgical intervention** and is an overly aggressive treatment for simple endometrial hyperplasia, which carries a very low risk of progression to cancer. - It would be considered only for persistent atypical hyperplasia, cancer, or if a woman has completed childbearing and has other compelling reasons for surgery.

Question 236: The treatment of primary spasmodic dysmenorrhoea in a young girl as a first measure would be:

A. Oral contraceptives
B. Presacral neurectomy
C. Analgesics and antispasmodics (Correct Answer)
D. Dilatation and curettage

Explanation: ***Analgesics and antispasmodics*** - **NSAIDs (analgesics)** like ibuprofen, naproxen, or mefenamic acid are the **first-line treatment** for primary spasmodic dysmenorrhea - They work by **inhibiting prostaglandin synthesis**, reducing uterine contractions and pain - **Antispasmodics** help relax the uterine muscle and alleviate cramping - Should be started at the onset of menses or just before for maximum effectiveness *Oral contraceptives* - Effective **second-line treatment** by suppressing ovulation and reducing endometrial prostaglandin production - Used when NSAIDs fail or are contraindicated - May be less suitable as a first measure for a young girl, especially if contraception is not desired *Presacral neurectomy* - **Surgical procedure** involving division of the superior hypogastric plexus - Reserved for **severe, refractory cases** that fail conservative management - Major surgery with potential complications—never a first-line option *Dilatation and curettage* - Diagnostic/therapeutic procedure for abnormal uterine bleeding or retained products - **No role in primary dysmenorrhea**, which is functional pain without organic pathology - D&C does not address the prostaglandin-mediated mechanism of primary dysmenorrhea

Question 237: A 45 year old woman presents with continuous vaginal bleeding for 15 days. Her bleeding should be controlled by:

A. Synthetic progestogens (Correct Answer)
B. Testosterone propionate
C. Curettage followed by progestogens
D. Conjugated equine oestrogens

Explanation: ***Synthetic progestogens*** - **Synthetic progestogens** are the **classic first-line medical treatment** for dysfunctional uterine bleeding (DUB) in the perimenopausal age group. - They work by **stabilizing the endometrium**, counteracting unopposed estrogen effects, and inducing organized withdrawal bleeding. - For **continuous moderate bleeding**, cyclic or continuous progestogens (e.g., norethisterone 5 mg BD for 21 days) are effective and non-invasive. - This represents the **traditional textbook approach** for anovulatory DUB management. *Testosterone propionate* - **Testosterone propionate** is an androgen with no role in managing dysfunctional uterine bleeding in women. - Its use is limited to male hypogonadism and specific anabolic requirements. *Curettage followed by progestogens* - While **curettage (D&C)** is both diagnostic and therapeutic, it is an **invasive procedure**. - In clinical practice, especially for a **45-year-old woman**, endometrial sampling is often warranted to rule out hyperplasia or malignancy, making this a reasonable clinical approach. - However, **medical management with progestogens alone** is traditionally considered first-line when the patient is hemodynamically stable and malignancy risk is low. - This option represents sound clinical practice but is not the classic "first choice" in exam contexts. *Conjugated equine oestrogens* - **High-dose estrogens** (25 mg IV every 4-6 hours) are actually used for **acute severe bleeding** and can stop bleeding within 24 hours by rapidly proliferating the endometrium. - However, for **continuous moderate bleeding** over 15 days in a perimenopausal woman, estrogen alone would not address the underlying issue of **unopposed estrogen** causing anovulatory cycles. - Estrogen is reserved for acute emergency management, not for the scenario described in this question.

Question 238: A 30 year old healthy woman presents with decreased bleeding during menstruation. The cause could be all of the following except:

A. Intrauterine adhesions
B. Breastfeeding
C. Endometriosis (Correct Answer)
D. Tuberculosis

Explanation: ***Endometriosis*** - **Endometriosis** is a condition where endometrial-like tissue grows outside the uterus, typically causing **heavy menstrual bleeding (menorrhagia)**, pelvic pain, and dyspareunia. - It does not typically lead to **decreased menstrual bleeding**; in fact, its cardinal symptom related to menstruation is often an increase in volume and pain. *Intrauterine adhesions* - **Intrauterine adhesions**, also known as **Asherman's syndrome**, involve scarring within the uterine cavity, often resulting from uterine trauma like D&C. - These adhesions can reduce the functional endometrial surface, leading to **hypomenorrhea** or amenorrhea (decreased or absent menstrual bleeding). *Breastfeeding* - **Breastfeeding** (lactational amenorrhea) causes the release of **prolactin**, which inhibits the pulsatile release of GnRH from the hypothalamus. - This suppression of ovarian function leads to **anovulation** and significantly reduced or absent menstrual bleeding. *Tuberculosis* - **Genital tuberculosis** can affect the endometrium, leading to widespread destruction and subsequent fibrosis and **adhesion formation** within the uterine cavity. - This damage to the endometrial lining can result in **asherman's syndrome**, causing hypomenorrhea or amenorrhea.

Question 239: Which one of the following is true regarding normal menstrual physiology?

A. Ovulation occurs after 12 hours of LH peak (Correct Answer)
B. Ovulation occurs after 48 hours of LH surge
C. Oestradiol levels peak at 48 hours prior to ovulation
D. LH surge duration is typically 12-24 hours

Explanation: ***Ovulation occurs after 12 hours of LH peak*** - Ovulation typically occurs approximately **10-12 hours after the luteinizing hormone (LH) peak** and about 34-36 hours after the initial rise in LH. This delay allows for the final maturation of the oocyte. - The **LH surge** is the crucial hormonal signal that triggers the ovulation process in the mature follicle. *Ovulation occurs after 48 hours of LH surge* - This statement is incorrect as **ovulation occurs much sooner** after the LH surge, typically within 34-36 hours from the onset of the surge, and 10-12 hours after its peak. - A 48-hour delay would mean the oocyte would likely be past its optimal viability for fertilization. *Oestradiol levels peak at 48 hours prior to ovulation* - **Estradiol levels peak approximately 24-36 hours before ovulation**, not 48 hours. This peak in estradiol is what triggers the surge in LH. - The timing of the estradiol peak is crucial in initiating the positive feedback loop that leads to the LH surge. *LH surge duration is typically 12-24 hours* - The **LH surge typically lasts for about 48 hours**, not 12-24 hours. A surge of this duration ensures sufficient time for the final maturation of the oocyte and the process of follicular rupture. - The prolonged nature of the LH surge is essential for the completion of meiosis I in the oocyte and the weakening of the follicular wall.

Question 240: Which one of the following is the most important haematological condition to be ruled out while investigating a case of puberty menorrhagia ?

A. Leukemia
B. G-6PD deficiency
C. Coagulation disorder (Correct Answer)
D. Anaemia

Explanation: ***Coagulation disorder*** - Puberty menorrhagia (excessive menstrual bleeding at puberty) is frequently linked to underlying **hemostatic dysfunction**, with **Von Willebrand Disease** being the most common cause. - A coagulation disorder can lead to **uncontrolled bleeding** during menstruation, necessitating thorough investigation to prevent severe blood loss and complications. *Leukemia* - While leukemia can cause **easy bruising** and **bleeding tendencies** due to thrombocytopenia or impaired platelet function, it is less common as the primary cause of isolated menorrhagia in puberty. - Leukemia would typically present with a broader range of symptoms, including systemic signs like **fatigue**, **fever**, and **lymphadenopathy**. *G-6PD deficiency* - G-6PD deficiency is primarily a cause of **hemolytic anemia**, triggered by certain drugs or foods, leading to red blood cell breakdown. - It does not directly cause prolonged or heavy menstrual bleeding (menorrhagia) as a primary symptom. *Anaemia* - Anaemia is often a **consequence** of heavy menstrual bleeding (menorrhagia) rather than its direct cause. - While iron deficiency anemia is common in young women with menorrhagia, addressing the underlying cause of the bleeding is crucial, which might be a coagulation disorder.

Question 241: Primary Dysmenorrhoea can be treated by which of the following? 1. Antiprostaglandin 2. Cyclic combined estrogen and progesterone preparations 3. Pre-sacral neurectomy 4. Uterine curettage

A. 1, 2, 3 and 4
B. 1, 2 and 4
C. 2, 3 and 4
D. 1, 2 and 3 (Correct Answer)

Explanation: ***1, 2 and 3*** - **Antiprostaglandins (NSAIDs)** are the first-line treatment for primary dysmenorrhea as they inhibit prostaglandin synthesis, reducing uterine contractions and pain. - **Cyclic combined estrogen and progesterone preparations (oral contraceptives)** are second-line therapy that suppress ovulation, leading to a thinner endometrium and reduced prostaglandin production, thereby alleviating dysmenorrhea. - **Pre-sacral neurectomy** is a surgical procedure that may be considered for severe, refractory primary dysmenorrhea that has failed medical management, though it is more commonly used for secondary dysmenorrhea and chronic pelvic pain. *1, 2, 3 and 4* - This option incorrectly includes **uterine curettage**, which is not a treatment for primary dysmenorrhea. - Uterine curettage is a diagnostic or therapeutic procedure for conditions like abnormal uterine bleeding or retained products of conception, not for menstrual pain management. *1, 2 and 4* - This option incorrectly includes **uterine curettage** while excluding pre-sacral neurectomy. - Curettage has no role in primary dysmenorrhea treatment, whereas the other interventions target the underlying pathophysiology. *2, 3 and 4* - This option incorrectly excludes **antiprostaglandins (NSAIDs)**, which are the cornerstone first-line therapy for primary dysmenorrhea. - It also incorrectly includes uterine curettage, which has no role in dysmenorrhea management.

Question 242: Which one of the following conditions simulates the menstrual pattern of pain?

A. Adenomyosis (Correct Answer)
B. Intramural fibroid
C. Granulosa cell tumour of ovary
D. Haematometra

Explanation: ***Adenomyosis*** - Adenomyosis is characterized by the presence of **endometrial tissue within the myometrium**, which responds cyclically to hormonal changes, similar to normal endometrium. - This leads to **dysmenorrhea** (painful periods) and **menorrhagia** (heavy bleeding) due to the cyclic growth and shedding of endometrial tissue within the uterine muscular wall. *Intramural fibroid* - Intramural fibroids are **benign uterine tumors** within the muscular wall that can cause heavy bleeding and pressure symptoms. - While they can cause pain and heavy bleeding, the pain is typically not directly related to a **menstrual pattern of cyclic pain** in the same manner as adenomyosis, as the fibroid tissue itself does not undergo cyclic shedding. *Granulosa cell tumour of ovary* - This is a **sex cord-stromal tumor** of the ovary that often produces **estrogen**, which can lead to irregular uterine bleeding or postmenopausal bleeding. - It does not directly cause pain that simulates a **regular menstrual pattern**, as its hormonal effects are typically sustained or irregular, not cyclic in the way normal menstruation or adenomyosis pain is. *Haematometra* - Haematometra is the accumulation of **menstrual blood within the uterus** due to an obstruction of the outflow tract, such as cervical stenosis. - This condition causes increasing pain and distension as blood accumulates, but the pain is usually **constant or progressively worsening**, not cyclic in a pattern that simulates normal menstruation, and typically leads to **amenorrhea** rather than patterned bleeding.

Question 243: Which one of the following about primary dysmenorrhea is NOT true?

A. Most commonly seen in adolescents and young women
B. Pain is related to uterine hypoxia
C. Pain increases following pregnancy and delivery (Correct Answer)
D. Always confined to ovulatory cycles

Explanation: ***Pain increases following pregnancy and delivery*** - It is a common clinical observation that primary dysmenorrhea often **improves or resolves** after pregnancy and childbirth, likely due to cervical dilatation, changes in uterine structure, or altered innervation. - Therefore, the statement that pain *increases* following pregnancy and delivery is **NOT true** and is the correct answer. *Most commonly seen in adolescents and young women* - This statement is **TRUE**. Primary dysmenorrhea typically begins within **6-12 months** after menarche once ovulatory cycles are established. - It is **most prevalent in adolescents and women in their 20s**, though it can persist into later reproductive years. - Incidence decreases with age and often improves after childbirth. *Pain is related to uterine hypoxia* - This statement is **TRUE**. The pain in primary dysmenorrhea is primarily caused by **excessive prostaglandin F2α production** during endometrial breakdown. - Prostaglandins cause **intense uterine contractions** leading to **ischemia** and reduced blood flow (hypoxia) to the myometrium. - This **uterine hypoxia** and ischemia are significant contributors to the painful cramps experienced. *Always confined to ovulatory cycles* - This statement is **TRUE**. Primary dysmenorrhea is intrinsically linked to **ovulatory menstrual cycles**. - It involves prostaglandin production in response to progesterone withdrawal and endometrial breakdown, which **only occurs in ovulatory cycles**. - Anovulatory cycles (common immediately after menarche) are typically **painless**.

Question 244: An 18-year-old unmarried girl comes with complaints of heavy, prolonged bleeding during menses. Which among the following investigations is NOT usually advised?

A. Urine pregnancy test
B. Coagulation profile
C. Dilatation and curettage (Correct Answer)
D. Ultrasound uterus and adnexa

Explanation: ***Dilatation and curettage*** - This is an **invasive surgical procedure** used diagnostically and therapeutically for heavy uterine bleeding, but it is generally *not* the initial or routinely advised investigation for an 18-year-old unmarried girl with heavy menstrual bleeding. - In a young, unmarried patient, less invasive methods are preferred unless other investigations point to a structural abnormality requiring tissue diagnosis or therapeutic intervention. *Urine pregnancy test* - A urine pregnancy test is **essential** to rule out pregnancy-related complications (e.g., ectopic pregnancy, miscarriage) as a cause of heavy vaginal bleeding, even in unmarried individuals. - **Abnormal uterine bleeding** can be the presenting symptom of an early pregnancy loss. *Coagulation profile* - Heavy and prolonged bleeding, especially from a young age (as suggested by "18-year-old girl"), raises suspicion for an **underlying coagulopathy** (e.g., Von Willebrand disease). - A coagulation profile (including PT, aPTT, platelet count, and sometimes specific factor assays) is crucial to **assess bleeding risk** and guide management. *Ultrasound uterus and adnexa* - An ultrasound is a **non-invasive imaging technique** that can identify structural causes of abnormal uterine bleeding, such as **fibroids, polyps, adenomyosis**, or ovarian pathologies. - It helps in assessing the **uterine lining and ovarian morphology**, which is important in evaluating the cause of heavy menstrual bleeding.

Question 245: Withdrawal bleeding following administration of progesterone in a case of secondary amenorrhea indicates all EXCEPT:

A. Defect in pituitary gland (Correct Answer)
B. Absence of pregnancy
C. Endometrium is responsive to estrogen
D. Production of endogenous estrogen

Explanation: ***Defect in pituitary gland*** - While withdrawal bleeding after progesterone suggests the problem lies at the **hypothalamic-pituitary level** (anovulation with adequate estrogen), it does **not definitively rule out all pituitary defects**. - The pituitary may still produce sufficient **FSH to stimulate ovarian estrogen production** but have defective **LH surge mechanism** (WHO Group II anovulation). - Examples include **hyperprolactinemia** or **functional hypothalamic amenorrhea** where estrogen production is preserved despite pituitary-hypothalamic dysfunction. - This is the **EXCEPT answer** because the other options are more definitively confirmed by withdrawal bleeding. *Absence of pregnancy* - Withdrawal bleeding after progesterone administration **definitively confirms absence of pregnancy**. - Pregnancy would prevent withdrawal bleeding due to sustained progesterone production by the corpus luteum and placenta. - This is a key diagnostic exclusion in the evaluation of **secondary amenorrhea**. *Endometrium is responsive to estrogen* - The occurrence of withdrawal bleeding **definitively demonstrates** that the endometrium has been exposed to adequate estrogen and has proliferated. - This proliferative endometrium then sheds when progesterone is withdrawn, confirming **normal endometrial responsiveness to hormonal stimulation**. - This rules out **Asherman syndrome** and other uterine factors. *Production of endogenous estrogen* - Withdrawal bleeding **definitively confirms** that there has been sufficient **endogenous estrogen production** to prime the endometrium. - The estrogen causes endometrial thickening, which then sheds when progesterone is withdrawn. - This indicates **adequate ovarian function** in terms of estrogen synthesis and rules out **hypergonadotropic hypogonadism** (ovarian failure).

Question 246: What is the most common cause of menorrhagia in puberty?

A. Endometriosis
B. Malignancy
C. Anovulation (Correct Answer)
D. Coagulation disorders

Explanation: ***Anovulation*** - **Anovulatory cycles** are very common in the initial years after menarche due to the immaturity of the hypothalamic-pituitary-ovarian (HPO) axis, leading to **unopposed estrogen** and a thickened, unstable endometrium that sheds irregularly and heavily. - This hormonal imbalance prevents the proper formation of a **corpus luteum** and subsequent progesterone production, which is essential for stabilizing the endometrial lining. *Endometriosis* - Endometriosis is a condition where **endometrial-like tissue** grows outside the uterus, causing pain and heavy bleeding, but it is rare before menarche and typically presents in older adolescents or adults. - While it can cause menorrhagia, it is not the most common cause in early puberty and usually presents with additional symptoms like chronic **pelvic pain** or **dysmenorrhea**. *Malignancy* - **Uterine malignancies** are exceedingly rare in puberty and are not a cause of menorrhagia in this age group. - When present, malignancies often involve other alarming symptoms besides heavy menstrual bleeding, such as persistent spotting, abdominal masses, or constitutional symptoms, which are not characteristic of typical pubertal menorrhagia. *Coagulation disorders* - While **coagulation disorders** (e.g., von Willebrand disease, platelet dysfunction) can certainly cause menorrhagia in puberty, they are not the *most common* cause. - Girls with coagulation disorders often have other signs of bleeding diathesis, such as **epistaxis**, easy bruising, or prolonged bleeding after minor trauma or surgery.

Question 247: A teenage girl presented with irregular cycles and increased facial hair. Her ovaries showed increased volume. Which of the following are used in the first line treatment? 1. Laparoscopic ovarian drilling 2. Anti-androgens 3. Lifestyle modifications 4. Combined oral contraceptive pills

A. 2,3,4 (Correct Answer)
B. 1,2,3
C. 1,2,4
D. 1,3,4

Explanation: ***2,3,4 (Correct Answer)*** - **Lifestyle modifications (3)** are the foundational first-line intervention for all PCOS patients, particularly those who are overweight or obese, as they improve insulin sensitivity, reduce androgen levels, and improve both metabolic and reproductive outcomes. - **Combined oral contraceptive pills/COCs (4)** are the first-line pharmacological treatment for menstrual irregularity and hyperandrogenism in PCOS when fertility is not desired. They regulate cycles, suppress ovarian androgen production, and reduce hirsutism and acne. - **Anti-androgens (2)** such as spironolactone are used in first-line management of moderate-to-severe hirsutism and acne in PCOS, typically in combination with COCs. They block androgen receptors or inhibit androgen synthesis, providing additional benefit for hyperandrogenic symptoms like the increased facial hair in this patient. *1,2,3* - **Laparoscopic ovarian drilling (1)** is a second-line surgical treatment reserved for anovulatory infertility in PCOS patients who fail to respond to ovulation induction with clomiphene citrate. It is NOT a first-line treatment for menstrual irregularity and hirsutism. - While lifestyle modifications (3) and anti-androgens (2) are appropriate first-line components, the inclusion of ovarian drilling makes this combination incorrect as a first-line approach. *1,2,4* - **Laparoscopic ovarian drilling (1)** is an invasive procedure indicated only as second-line therapy for specific cases of anovulatory infertility, not for initial management of irregular cycles and hirsutism. - Although anti-androgens (2) and COCs (4) are appropriate first-line pharmacological treatments, the inclusion of ovarian drilling excludes this from being a correct first-line treatment combination. *1,3,4* - This combination includes two appropriate first-line treatments: **lifestyle modifications (3)** and **combined oral contraceptive pills (4)**. - However, **laparoscopic ovarian drilling (1)** is a second-line or third-line surgical intervention for very specific indications (anovulatory infertility resistant to medical management), making this combination incorrect as a first-line approach for this clinical presentation.

Question 248: Which of the following is not a cause of secondary amenorrhea?

A. Kallman syndrome (Correct Answer)
B. Asherman's syndrome
C. Sheehan's syndrome
D. Turner's mosaic

Explanation: ***Kallman syndrome*** - This is a cause of **primary amenorrhea** because it involves congenital **GnRH deficiency**, preventing the onset of puberty and menstruation from the beginning. - Patients typically present with failure of pubertal development and **anosmia** (inability to smell). *Asherman's syndrome* - Characterized by **intrauterine adhesions** or scarring, often following uterine surgeries like D&C. - These adhesions can prevent the proper shedding of the endometrium, leading to **secondary amenorrhea** after previously established menses. *Sheehan's syndrome* - Occurs due to **ischemic necrosis of the pituitary gland** following severe postpartum hemorrhage, typically presenting with failure of lactation, fatigue, and **secondary amenorrhea**. - The pituitary damage leads to **deficiency of multiple pituitary hormones**, including FSH and LH. *Turner's mosaic* - While classic **Turner syndrome (45,XO)** is a common cause of primary amenorrhea and gonadal dysgenesis, **Turner's mosaic** (e.g., 45,XO/46,XX) can sometimes result in variable ovarian function. - In some mosaic cases, individuals may experience **menarche** and then develop premature ovarian failure, leading to **secondary amenorrhea**.

Question 249: Ovulation occurs:

A. 14 days prior to next menstruation (Correct Answer)
B. 14 days after menstruation
C. On 14th day of the cycle
D. None of the options

Explanation: ***14 days prior to next menstruation*** - Ovulation consistently occurs approximately **14 days before** the onset of the next menstrual period, regardless of the total cycle length. - This is because the **luteal phase** (from ovulation to menstruation) is relatively constant in duration, typically lasting 14 days. *14 days after menstruation* - This statement assumes a 28-day cycle, which is not universally true, as cycle lengths vary between individuals. - In shorter cycles, ovulation would occur earlier than 14 days after menstruation, and in longer cycles, it would be later. *On 14th day of the cycle* - This is only true for women with a **perfect 28-day menstrual cycle**, which is an average and not universally applicable. - For women with longer cycles (e.g., 35 days), ovulation would occur around day 21, and for shorter cycles (e.g., 21 days), it would occur around day 7. *None of the options* - One of the provided options accurately describes the timing of ovulation in relation to the next menstruation. - Therefore, this choice is incorrect.

Question 250: Swiss cheese pattern endometrium is seen in

A. Halban's disease
B. Carcinoma endometrium
C. Hydatidiform mole
D. Metropathia hemorrhagica (Correct Answer)

Explanation: ***Correct Answer: Metropathia hemorrhagica*** - Also known as **anovulatory dysfunctional uterine bleeding** or **cystic glandular hyperplasia** - The "Swiss cheese pattern" describes the **characteristic histological appearance** where endometrial glands are dilated and irregular, resembling holes in Swiss cheese - Results from **prolonged unopposed estrogen stimulation** causing overgrowth of benign endometrial tissue - Classic finding in anovulatory cycles with persistent estrogen exposure *Incorrect Option: Halban's disease* - Refers to **cystic changes within the fallopian tube** or paratubal cysts - Not related to endometrial morphology or the Swiss cheese pattern *Incorrect Option: Carcinoma endometrium* - Involves **malignant proliferation** with complex atypical hyperplasia - May show glandular atypia and crowding, but not the characteristic simple cystic glandular hyperplasia pattern - Swiss cheese appearance is typically seen in benign hyperplasia, not malignancy *Incorrect Option: Hydatidiform mole* - A **gestational trophoblastic disease** with abnormal placental development - Characterized by grape-like vesicles with **trophoblastic proliferation** and hydropic villi - Does not involve the Swiss cheese endometrial pattern

Question 251: Borax causes which of the following effects?

A. Induces uterine contractions (labor-inducing)
B. Irritates genitourinary tract (side effect)
C. Traditionally used to stimulate menstrual flow
D. Causes gastrointestinal irritation (side effect) (Correct Answer)

Explanation: ***Causes gastrointestinal irritation (side effect)*** - Borax, specifically its component **boric acid**, is rapidly absorbed through the **gastrointestinal tract** and can cause symptoms like nausea, vomiting, and diarrhea even in small amounts. - This **gastrointestinal irritation** is a common sign of acute borax toxicity. *Induces uterine contractions (labor-inducing)* - While certain substances can induce uterine contractions, **borax is not known** or traditionally used for this purpose. - It is **not an oxytocic agent** and does not act on uterine smooth muscle in a way that would induce labor. *Irritates genitourinary tract (side effect)* - Although borax can be toxic, its primary route of significant irritation and toxicity is not typically the **genitourinary tract** in the way implied for adverse effects. - While it can be absorbed through mucous membranes, the genitourinary tract is not its primary target for **direct irritant effects** in systemic exposure. *Traditionally used to stimulate menstrual flow* - There is **no reliable scientific or traditional medical evidence** to support the use of borax to stimulate menstrual flow. - Substances used for this purpose, known as **emmenagogues**, are typically herbal or pharmaceutical preparations, and borax is **not among them**.

Question 252: 35 yr old lady attends gynaec OPD with excessive bleeding since 6 months, not controlled with non hormonal drugs. USG and clinical examination reveals no abnormality. Next step is?

A. Hysterectomy
B. Endometrial sampling (Correct Answer)
C. Endometrial ablation
D. Hormonal therapy

Explanation: ***Endometrial sampling*** - In a 35-year-old with **excessive uterine bleeding** not controlled by non-hormonal drugs and with normal imaging/clinical exam, endometrial sampling is crucial to **rule out endometrial hyperplasia or malignancy**. - This diagnostic step is essential before considering definitive treatments, as it provides a **histological diagnosis** of the endometrial lining. *Hysterectomy* - Hysterectomy is a **definitive surgical treatment** for excessive bleeding, but it is typically reserved for cases where conservative or less invasive treatments have failed, or if there's a serious underlying pathology like malignancy. - It involves removing the uterus and is a **major surgery** with potential complications, thus not usually the first step given an otherwise normal examination and imaging. *Endometrial ablation* - Endometrial ablation is a procedure to destroy the lining of the uterus, aiming to **reduce or stop menstrual bleeding**. - It is a treatment option for **abnormal uterine bleeding (AUB)**, but it's typically performed after other diagnostic steps (like endometrial sampling) have ruled out malignancy or high-risk hyperplasia, and when conservative medical management has failed. *Hormonal therapy* - Hormonal therapy (e.g., combined oral contraceptives, progestin-only pills, levonorgestrel-releasing intrauterine device) is often a **first-line medical treatment** for excessive uterine bleeding. - However, the question states that non-hormonal drugs have already failed, and without a clear diagnosis, initiating new hormonal therapy without **evaluating the endometrium** is not the next best step for persistent bleeding.

Question 253: What is the predominant hormone secreted by the corpus luteum that influences the secretory changes in the endometrium?

A. Estrogen
B. Progesterone (Correct Answer)
C. Luteinizing hormone
D. Follicle-stimulating hormone

Explanation: **Progesterone** - The **corpus luteum** is the primary source of **progesterone** after ovulation, which is crucial for maintaining the uterine lining to support a potential pregnancy. - **Progesterone** induces **secretory changes** in the endometrium, such as increased vascularity and glandular secretion, preparing it for **implantation** of a fertilized egg. *Estrogen* - While the corpus luteum does produce some **estrogen**, its primary role in the secretory phase is to work in conjunction with progesterone to prepare the endometrium, not as the predominant hormone responsible for secretory changes. - **Estrogen** is predominantly secreted by the **developing follicle** in the proliferative phase, primarily responsible for endometrial growth. *Luteinizing hormone* - **Luteinizing hormone (LH)** is responsible for triggering **ovulation** and stimulating the development and function of the corpus luteum, but it is a pituitary hormone, not secreted by the corpus luteum itself. - LH levels peak just before ovulation and then decline, whereas progesterone secretion by the corpus luteum rises significantly after ovulation. *Follicle-stimulating hormone* - **Follicle-stimulating hormone (FSH)** is primarily involved in **follicle development** during the follicular phase of the menstrual cycle and is secreted by the anterior pituitary gland. - FSH levels are highest early in the cycle and decrease after ovulation, playing no direct role in the secretory function of the endometrium and not being secreted by the corpus luteum.

Question 254: A 35-year-old woman presents with abnormal uterine bleeding and a negative pregnancy test. Which initial laboratory test is the most appropriate to evaluate her condition?

A. Coagulation profile
B. Complete blood count (Correct Answer)
C. Thyroid function tests
D. Prolactin levels

Explanation: ***Complete blood count*** - **CBC is the most appropriate initial laboratory test** for abnormal uterine bleeding to assess for **anemia** secondary to acute or chronic blood loss. - Hemoglobin and hematocrit levels help determine the **severity and urgency** of the bleeding and guide immediate management decisions. - **Universal recommendation** in all major guidelines (ACOG, FIGO) as part of the initial evaluation of abnormal uterine bleeding. - Helps assess the **hemodynamic impact** of bleeding and need for urgent intervention. *Thyroid function tests* - Thyroid dysfunction (both hypo- and hyperthyroidism) can cause abnormal uterine bleeding through effects on the hypothalamic-pituitary-ovarian axis. - **Important part of the comprehensive workup** but not the single most appropriate initial test. - Prevalence of thyroid dysfunction as cause of AUB is approximately 5-10%. - Should be ordered as part of the initial panel but does not take priority over assessing anemia. *Coagulation profile* - Indicated when there is suspicion of **bleeding disorders** (von Willebrand disease, platelet dysfunction). - Consider in patients with heavy menstrual bleeding since menarche, personal or family history of bleeding disorders, or failure to respond to standard therapy. - Not routinely part of initial workup unless clinical history suggests coagulopathy. *Prolactin levels* - Hyperprolactinemia typically causes **oligomenorrhea or amenorrhea** rather than abnormal uterine bleeding. - Would be indicated if patient has associated symptoms like galactorrhea or if anovulation is suspected. - Not the initial priority when evaluating abnormal bleeding patterns.

Question 255: A 32-year-old woman presents with menorrhagia and dysmenorrhea. An ultrasound reveals adenomyosis. What is the best initial treatment option for this condition?

A. NSAIDs (Correct Answer)
B. Hysterectomy
C. Endometrial ablation
D. Gonadotropin-releasing hormone agonists

Explanation: **NSAIDs** - **Nonsteroidal anti-inflammatory drugs (NSAIDs)** are often the first-line treatment for pain and heavy bleeding associated with adenomyosis, as they help reduce prostaglandin production and uterine contractions. - They are a conservative, **symptomatic treatment** suitable for women who desire future fertility or milder symptoms. *Hysterectomy* - **Hysterectomy** is a definitive cure for adenomyosis but is typically reserved for women with severe symptoms who have completed childbearing or when other treatments have failed, as it is a major surgical procedure. - It permanently removes the uterus, thus eliminating all symptoms, but it's not the **initial, least invasive** option. *Endometrial ablation* - **Endometrial ablation** involves destroying the uterine lining and is effective for heavy menstrual bleeding, but it does not treat the deep myometrial invasion characteristic of adenomyosis and may provide only temporary relief for pain in such cases. - It is generally less effective for adenomyosis compared to its efficacy in treating typical dysfunctional uterine bleeding because the **adenomyotic tissue** is often located deep within the myometrium, beyond the reach of standard ablation techniques. *Gonadotropin-releasing hormone agonists* - **Gonadotropin-releasing hormone (GnRH) agonists** induce a temporary, reversible menopause-like state by suppressing ovarian hormone production, which can reduce symptoms of adenomyosis. - However, they are typically used for **short-term treatment** due to potential side effects like bone loss and menopausal symptoms, and are often considered after NSAIDs or as a bridge to surgery, not as the primary initial treatment.

Question 256: A 39-year-old woman presents for a routine exam and mentions intermittent heavy menstrual bleeding. What is the most appropriate minimally invasive treatment that can be offered initially?

A. Levonorgestrel-releasing intrauterine system (Correct Answer)
B. Endometrial ablation
C. Uterine artery embolization
D. Hormonal therapy

Explanation: ***Levonorgestrel-releasing intrauterine system*** - This is a highly effective, **minimally invasive**, and long-acting reversible option that is also approved for the management of **heavy menstrual bleeding** (menorrhagia). - It works by continuously releasing **progestin** locally into the uterus, causing endometrial suppression and significantly reducing menstrual blood loss by **up to 90%**. - It is recommended as **first-line treatment** for heavy menstrual bleeding in women who also desire contraception or long-term management. *Endometrial ablation* - This is a **surgical procedure** that destroys the uterine lining to reduce or stop menstrual bleeding and is more invasive than LNG-IUS. - It is typically reserved for women who have **completed childbearing** and for whom medical or hormonal management has been unsuccessful. - It is not reversible and significantly impairs future fertility. *Uterine artery embolization* - This is an **invasive radiological procedure** involving catheterization and blocking the blood supply to the uterus. - Primarily used to treat **uterine fibroids** causing heavy bleeding, not as first-line treatment for undiagnosed menorrhagia. - Carries risks including infection, pain, and potential impact on ovarian function. *Hormonal therapy* - While **oral contraceptives** or progestin-only pills are effective and truly non-invasive, they require daily compliance and may have systemic side effects. - The question asks for a **treatment** (device-based intervention), and LNG-IUS is superior due to its **local action**, minimal systemic effects, and **long-term efficacy** without daily adherence requirements.

Question 257: A 33-year-old female presents with heavy menstrual bleeding for 6 months. On examination, no abnormalities were found, and an ultrasound also appeared normal. After failing non-hormonal treatment, what is the next appropriate management step?

A. Perform endometrial sampling.
B. Initiate hormonal therapy. (Correct Answer)
C. Consider hysterectomy.
D. Perform dilation and curettage (D&C).

Explanation: ***Initiate hormonal therapy.*** - For unexplained **heavy menstrual bleeding (HMB)** in a young woman with a normal workup, hormonal therapy (e.g., combined oral contraceptives, progestin-only pills, or a progestin-releasing IUD) is the first-line medical treatment after non-hormonal options fail. - These treatments stabilize the **endometrial lining** and reduce blood flow, effectively managing symptoms. *Perform endometrial sampling.* - **Endometrial sampling** is typically reserved for women at higher risk of endometrial hyperplasia or cancer, such as those over 45 with HMB, or younger women with persistent irregular bleeding, risk factors for endometrial cancer (e.g., obesity, PCOS), or unresponsive to initial medical therapy. - In this 33-year-old with normal ultrasound and no other identified risk factors, the likelihood of endometrial pathology is low, making sampling less urgent as a *next* step. *Consider hysterectomy.* - **Hysterectomy** is a definitive surgical procedure usually reserved for severe, persistent HMB that has failed all less invasive medical and surgical treatments, or for cases where there is significant uterine pathology (e.g., large fibroids, adenomyosis) not present here. - It is an irreversible procedure and generally not considered early in the management of heavy menstrual bleeding in a 33-year-old without uterine abnormalities. *Perform dilation and curettage (D&C).* - A **D&C** is a procedure to remove tissue from the uterus, often used for diagnostic purposes (like endometrial sampling) or to remove retained products of conception. - While it can temporarily reduce bleeding by removing some endometrial lining, it is not a long-term solution for treating abnormal uterine bleeding and is typically not indicated as a primary therapeutic step for chronic HMB in the absence of acute severe bleeding or suspected pathology requiring tissue removal.

Question 258: A mother brought her 16-year-old daughter to Gynaecology OPD with a complaint of not attaining menarche. She gives a history of cyclic abdominal pain. On further examination, a midline abdominal swelling is seen. Per rectal examination reveals a bulging mass in the vagina. Which of the following conditions is most likely responsible for these findings?

A. Vaginal agenesis
B. Transverse vaginal septum
C. Imperforate hymen (Correct Answer)
D. Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome

Explanation: ***Imperforate hymen*** - An **imperforate hymen** obstructs the outflow of menstrual blood, leading to its accumulation in the vagina (**hematocolpos**) and uterus (**hematometra**), causing **cyclic abdominal pain** and a bulging mass (due to accumulated blood) in the vagina. - The patient presents with **primary amenorrhea** (not having attained menarche) and cyclical abdominal pain caused by the inability of menstrual blood to exit the body. *Transverse vaginal septum* - A **transverse vaginal septum** can also cause primary amenorrhea and cyclic abdominal pain due to obstruction of menstrual flow. However, it is a less common cause than an imperforate hymen. - While it can lead to hematocolpos, the characteristic bulging mass on per rectal examination is more strongly associated with an imperforate hymen presenting at the vaginal introitus. *Vaginal agenesis* - **Vaginal agenesis** (complete absence of the vagina) would present with primary amenorrhea, but there would be no cyclic abdominal pain if the uterus is also absent or rudimentary. If a uterus is present, there would be no accumulation of blood in the vagina or a bulging mass per rectum as there is no vaginal canal. - This condition is typically associated with a rudimentary or absent uterus, leading to an inability to menstruate rather than obstructed flow. *Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome* - **MRKH syndrome** is characterized by congenital aplasia of the uterus and the upper two-thirds of the vagina, with normal ovaries and external genitalia. - Patients present with **primary amenorrhea** but typically do not experience **cyclic abdominal pain** or a bulging vaginal mass because there is no functional uterus to produce menstrual blood or a vaginal canal for blood accumulation.

Question 259: Which of the following is not correlated with the ovarian cycle?

A. Vaginal cytology
B. Blood hormonal levels
C. Endometrial sampling
D. Estrous cycle (Correct Answer)

Explanation: ***Estrous cycle*** - The **estrous cycle** is characteristic of most mammals (e.g., cows, dogs, cats) and differs fundamentally from the human **menstrual cycle**. - Unlike the menstrual cycle which involves endometrial shedding, the estrous cycle typically involves the reabsorption of the **endometrium** with no bleeding. *Endometrial sampling* - **Endometrial sampling** (e.g., biopsy) is directly impacted by the ovarian cycle, as the **endometrium** undergoes proliferative and secretory phases under hormonal influence. - The appearance and cellular characteristics of the **endometrium** vary significantly depending on the cycle phase (e.g., changes in glandular architecture, stromal edema). *Vaginal cytology* - **Vaginal cytology** reflects the hormonal changes of the ovarian cycle, particularly the influence of **estrogen** and **progesterone**. - The types and proportions of **squamous cells** in a vaginal smear (e.g., basal, parabasal, intermediate, superficial cells) vary with the follicular and luteal phases. *Blood hormonal levels* - **Blood hormonal levels** (e.g., **estradiol**, **progesterone**, **LH**, **FSH**) are direct indicators and regulators of the ovarian cycle. - Fluctuations in these hormones drive the development of the **follicle**, **ovulation**, and the formation and regression of the **corpus luteum**.

Question 260: A 46-year-old P3L3 complains of menorrhagia since 3 months. Initial diagnostic steps, including history, physical examination, and imaging, have been performed. The next line of management is?

A. OC pills x 6 months
B. Hysterectomy
C. Dilation and Curettage (D & C)
D. Progesterone x 6 months (Correct Answer)

Explanation: ***Progesterone x 6 months*** - After initial diagnostic evaluation has ruled out structural pathology, **medical management** is the appropriate next step for menorrhagia in this 46-year-old patient. - **Cyclical progesterone therapy** (typically given for 10-14 days per cycle) is a commonly used first-line hormonal treatment for menorrhagia, particularly in perimenopausal women. - Progesterone helps **stabilize the endometrium** and regulate menstrual cycles by counteracting unopposed estrogen effects that can lead to excessive endometrial proliferation and bleeding. - In this age group approaching menopause, progesterone therapy is often preferred as it addresses the likely hormonal imbalance without introducing exogenous estrogen. *OC pills x 6 months* - **Combined oral contraceptive pills (OCPs)** are also an evidence-based first-line medical treatment for menorrhagia, reducing menstrual blood loss by 40-50%. - However, for a **46-year-old patient**, there may be relative contraindications to estrogen-containing preparations (smoking, hypertension, thrombosis risk) that need consideration. - While OCPs are effective, in perimenopausal women without need for contraception, **progesterone-only therapy** is often chosen as the initial approach with a more favorable risk-benefit profile. *Dilation and Curettage (D & C)* - **D & C** is primarily a **diagnostic procedure** for obtaining endometrial tissue when there's suspicion of endometrial pathology or hyperplasia. - It may provide temporary relief but is **not a definitive medical treatment** for menorrhagia and has been largely replaced by endometrial biopsy and hysteroscopy for diagnosis. - Since initial diagnostic steps including imaging have already been performed, D & C would only be indicated if there was suspicion of intrauterine pathology requiring tissue diagnosis. *Hysterectomy* - **Hysterectomy** is the definitive surgical treatment for menorrhagia but is reserved for cases where **medical management has failed** or there are significant structural pathologies (large fibroids, adenomyosis, severe endometrial pathology). - Given that this patient has just completed initial workup, surgical intervention is premature before attempting medical management. - Hysterectomy should only be considered after failure of conservative medical treatments.

Question 261: Which of the following is least likely to cause dysmenorrhea?

A. Endometriosis
B. Adenomyosis
C. Uterine polyp
D. Cervical polyp (Correct Answer)

Explanation: ***Cervical polyp*** - Cervical polyps are typically **benign growths** on the cervix and are usually **asymptomatic**, or may cause **light intermenstrual bleeding** or bleeding after intercourse. - They generally do **not cause pain** or dysmenorrhea because they are not involved in the hormonal and inflammatory processes that lead to uterine contractions and pain during menstruation. *Endometriosis* - Endometriosis is characterized by the presence of **stromal and glandular tissue** outside the uterus, which responds to hormonal fluctuations, leading to **inflammation and cyclical pain**. - This often results in severe **secondary dysmenorrhea**, chronic pelvic pain, and dyspareunia. *Adenomyosis* - Adenomyosis involves the invasion of **endometrial tissue into the myometrium**, leading to a thickened, enlarged uterus. - This condition causes significant **dysmenorrhea** due to increased prostaglandin production and uterine cramping, as well as heavy menstrual bleeding. *Uterine polyp* - Uterine polyps (endometrial polyps) are **overgrowths of endometrial tissue** within the uterine cavity. - While they primarily cause **abnormal uterine bleeding**, they can occasionally cause **dysmenorrhea** through interference with normal uterine contractions, though this is **less common** than bleeding symptoms.

Question 262: What is the definition of menometrorrhagia?

A. Excessive menstrual bleeding
B. Bleeding between menstrual periods
C. Heavy and irregular menstrual bleeding (Correct Answer)
D. Regular uterine bleeding

Explanation: ***Heavy and irregular menstrual bleeding*** - **Menometrorrhagia** is defined by menstrual bleeding that is both **excessively heavy** (menorrhagia) and **irregularly timed** (metrorrhagia), occurring frequently and lasting longer than usual. - This condition can lead to significant blood loss and impact a woman's quality of life. *Excessive menstrual bleeding* - This is the definition of **menorrhagia**, which refers only to the quantity of blood loss during a normal duration and frequency of menstruation. - It does not account for the **irregularity** in timing or duration of bleeding. *Bleeding between menstrual periods* - This symptom is primarily known as **metrorrhagia**, indicating irregular bleeding that occurs outside of the normal menstrual cycle. - It does not specifically describe the **heaviness** of the bleeding episodes. *Regular uterine bleeding* - **Regular uterine bleeding** is the characteristic of a normal menstrual cycle, which is predictable in its timing and duration. - This option does not describe any abnormal bleeding pattern, such as being **heavy** or **irregular**.

Question 263: What is the most common cause of primary amenorrhea?

A. None of the options
B. Mayer-Rokitansky-Küster-Hauser syndrome
C. Ovarian dysgenesis (Turner syndrome) (Correct Answer)
D. Constitutional delay

Explanation: ***Ovarian dysgenesis (Turner syndrome)*** - **Turner syndrome (45,XO karyotype)** is one of the most common causes of **primary amenorrhea**, accounting for approximately **12-15% of cases**. - It results from the complete or partial absence of one of the **X chromosomes**, leading to **gonadal dysgenesis** (streak gonads). - Characterized by **absent secondary sexual characteristics**, short stature, and elevated FSH/LH levels. - Turner syndrome is the most common form of **gonadal dysgenesis**, which collectively represents a leading category of primary amenorrhea. *Mayer-Rokitansky-Küster-Hauser syndrome* - This syndrome is characterized by **congenital agenesis of the uterus and upper two-thirds of the vagina**, but **normal ovaries** and secondary sexual characteristics. - Accounts for approximately **15% of primary amenorrhea** cases. - Less common than gonadal dysgenesis as a category, but MRKH is the second most common cause after gonadal dysgenesis. *None of the options* - This option is incorrect because **Turner syndrome** is a well-established and leading cause of primary amenorrhea among the choices provided. *Constitutional delay* - This refers to a **physiological delay in the onset of puberty**, where the individual will eventually develop secondary sexual characteristics and menarche. - While common, it represents a **delay rather than true amenorrhea**, and is typically diagnosed when other pathological causes are excluded. - Not considered the most common cause of **pathological primary amenorrhea**.

Question 264: A woman experiences menstrual blood loss of 100 ml every 30 days. How would this condition be classified?

A. Menorrhagia (Correct Answer)
B. Polymenorrhea
C. Hypomenorrhea
D. Normal menses

Explanation: ***Menorrhagia*** - **Menorrhagia** is characterized by abnormally **heavy or prolonged menstrual bleeding**, typically defined as blood loss exceeding **80 mL** per cycle or bleeding lasting more than 7 days. - In this case, a 100 mL blood loss is above the normal threshold, classifying it as menorrhagia. *Polymenorrhea* - **Polymenorrhea** refers to **frequently recurring menstrual cycles**, defined as a cycle length of fewer than **21 days**. - The woman's cycle length of 30 days falls within the normal range, so this term does not apply. *Hypomenorrhea* - **Hypomenorrhea** describes **unusually light or scanty menstrual bleeding**, with blood loss typically less than **30 mL** per cycle. - The 100 mL blood loss is significantly higher than what is seen in hypomenorrhea. *Normal menses* - **Normal menses** involve a typical blood loss ranging from **30 to 80 mL** per cycle and a cycle length between **21 and 35 days**. - A 100 mL blood loss exceeds the upper limit for normal menses, indicating an abnormal condition.

Question 265: Asherman's syndrome is associated with which of the following symptoms?

A. All of the options
B. Amenorrhea (Correct Answer)
C. Menorrhagia
D. Polymenorrhea

Explanation: ***Amenorrhea*** - **Asherman's syndrome** involves the formation of intrauterine adhesions (scar tissue) which can block the outflow of menstrual blood, leading to **amenorrhea** or significantly reduced menstrual flow (hypomenorrhea). - The scarring often damages the **endometrial basalis layer**, preventing the normal cyclical growth and shedding of the uterine lining necessary for menstruation. *Menorrhagia* - **Menorrhagia** is characterized by abnormally heavy or prolonged menstrual bleeding, which is the opposite of what occurs in Asherman's syndrome. - This symptom is typically associated with conditions like **uterine fibroids**, **adenomyosis**, or **coagulopathies**, not intrauterine adhesions. *Polymenorrhea* - **Polymenorrhea** refers to abnormally frequent menstrual cycles (occurring more often than every 21 days), which is not a hallmark symptom of Asherman's syndrome. - This condition is usually related to **hormonal imbalances** leading to a shortened follicular phase, rather than structural uterine abnormalities. *All of the options* - While other menstrual irregularities can occur, **amenorrhea** or **hypomenorrhea** is the primary and characteristic symptom linked to Asherman's syndrome due to the physical obstruction and endometrial damage caused by intrauterine adhesions. - The other options (menorrhagia, polymenorrhea) represent distinct menstrual abnormalities with different underlying etiologies, not typically seen in Asherman's syndrome.

Question 266: Cryptomenorrhea occurs due to which of the following conditions?

A. Fibroids
B. PCOS
C. Imperforate hymen (Correct Answer)
D. Asherman syndrome

Explanation: ***Imperforate hymen*** - **Cryptomenorrhea** is a condition where monthly cyclical symptoms of menstruation occur, but there is no visible external bleeding due to an **obstruction in the outflow tract**. - An **imperforate hymen** is a congenital anomaly where the hymen completely blocks the vaginal opening, leading to retention of menstrual blood and causing cryptomenorrhea. - Patients typically present with **primary amenorrhea, cyclical pelvic pain, and a bulging hymen** on examination. *Fibroids* - **Uterine fibroids** are benign tumors of the uterus that can cause heavy menstrual bleeding (menorrhagia) or abnormal uterine bleeding, but not cryptomenorrhea. - They do not typically cause an obstruction of the **menstrual outflow tract**. *PCOS* - **Polycystic Ovary Syndrome (PCOS)** is an endocrine disorder characterized by irregular or absent menstruation (oligomenorrhea or amenorrhea) due to anovulation. - While periods may be absent, there is no obstruction preventing menstrual flow, so it does not cause **cryptomenorrhea**. *Asherman syndrome* - **Asherman syndrome** involves intrauterine adhesions that can cause amenorrhea or hypomenorrhea. - While it causes **absent or reduced menstrual flow**, the underlying mechanism is endometrial destruction, not outflow tract obstruction, so true cryptomenorrhea does not occur.

Question 267: What is the upper age limit to diagnose a patient as having primary amenorrhea, if secondary sexual characteristics are present?

A. 14 years
B. 16 years (Correct Answer)
C. 18 years
D. 12 years

Explanation: **16 years** - Primary amenorrhea is defined as the absence of menarche by the age of **16 years** despite the presence of **secondary sexual characteristics**, or by age 14 if secondary sexual characteristics are absent. - This definition helps in identifying individuals who may have underlying anatomical or endocrine disorders affecting the reproductive system that require investigation. *12 years* - While it's early in the normal range for menarche, the absence of menses at 12 years with secondary sexual characteristics is not typically considered primary amenorrhea unless other signs of delayed puberty are present. - The average age for menarche is around 12.5 years, so waiting until an older age when secondary sexual characteristics are established is more appropriate for a definitive diagnosis of primary amenorrhea. *14 years* - This age is the cutoff for diagnosing primary amenorrhea if **secondary sexual characteristics are absent**. - However, if secondary sexual characteristics are present, indicating onset of puberty, a longer waiting period (up to 16 years) is allowed before diagnosis, as menarche may still occur spontaneously. *18 years* - By 18 years, the absence of menarche would certainly warrant investigation, but the diagnostic criteria for primary amenorrhea dictate an earlier intervention. - Waiting until 18 years could delay the identification and management of potential underlying causes, which ideally should be addressed earlier.

Question 268: Most common cause of menorrhagia in adolescents?

A. Thyroid disorder
B. Coagulation disorders (Correct Answer)
C. Leiomyomas
D. Polyps

Explanation: ***Coagulation disorders*** - **Coagulation disorders**, particularly **von Willebrand disease**, are the **most common identifiable pathological cause** of menorrhagia in adolescents, found in **13-20%** of cases with heavy menstrual bleeding. - These disorders lead to **impaired platelet function** or **coagulation factor deficiencies**, resulting in prolonged and heavy menstrual bleeding. - **ACOG recommends** screening for bleeding disorders in all adolescents presenting with menorrhagia, especially if present since menarche or refractory to treatment. - While anovulation due to immature HPO axis is common, coagulation disorders represent the key **underlying pathology** requiring investigation. *Thyroid disorder* - **Thyroid disorders** can affect menstrual cycles but are a less common primary cause of menorrhagia in adolescents compared to coagulation disorders. - Both **hypothyroidism** and **hyperthyroidism** can lead to menstrual irregularities, including heavy bleeding. *Leiomyomas* - **Leiomyomas (fibroids)** are benign uterine tumors that cause menorrhagia primarily in **older reproductive-aged women**, not typically in adolescents. - Their presence in adolescents is **rare**, making them an unlikely cause of menorrhagia in this age group. *Polyps* - **Endometrial polyps** can cause intermenstrual bleeding or menorrhagia, but they are **infrequent in adolescents**. - Polyps are more common in **perimenopausal** and **postmenopausal women**, so they are not the most common cause in younger patients.

Question 269: A 33-year-old female presents with heavy menstrual bleeding for 6 months. Examination and ultrasound show no abnormalities. After failing non-hormonal treatment, what is the next management step?

A. Hormonal therapy (Correct Answer)
B. Endometrial sampling
C. Hysterectomy
D. Surgical intervention (e.g., endometrial ablation)

Explanation: ***Hormonal therapy*** - When **non-hormonal treatments** for heavy menstrual bleeding fail and there are no structural abnormalities, **hormonal therapy** is the next appropriate step to regulate the menstrual cycle and reduce bleeding. - This typically includes options like **oral contraceptive pills**, progestin-only pills, or a **levonorgestrel-releasing intrauterine system (LNG-IUS)**. *Endometrial sampling* - **Endometrial sampling** is primarily indicated to rule out endometrial hyperplasia or carcinoma, particularly in women over 45, with risk factors like obesity, or persistent abnormal bleeding unresponsive to treatment. - In a 33-year-old with no ultrasound abnormalities and heavy menstrual bleeding, **hormonal treatment** for symptomatic relief is usually attempted before invasive diagnostics, unless there are specific risk factors for malignancy. *Hysterectomy* - **Hysterectomy** is a definitive surgical procedure for heavy menstrual bleeding and is typically considered a last resort after other medical and less invasive surgical options have failed, especially in women who desire future fertility or wish to avoid major surgery. - Given the patient's age and the lack of structural abnormalities, less invasive and conservative treatments are preferred initially. *Surgical intervention (e.g., endometrial ablation)* - **Endometrial ablation** is an option for heavy menstrual bleeding when medical management fails, but it is considered a more invasive step than hormonal therapy and is generally reserved for women who have completed childbearing. - It would typically be considered after the failure of hormonal therapy, not immediately after non-hormonal therapy, especially in a younger patient.

Question 270: Day 20 of menstrual cycle falls under which phase?

A. Menstrual phase
B. Follicular phase
C. Ovulation phase
D. Luteal phase (Correct Answer)

Explanation: ***Luteal phase*** - The **luteal phase** typically starts after ovulation, around day 14, and lasts until menstruation begins, usually day 28 of a 28-day cycle. Therefore, **day 20 falls squarely within this phase**. - During this phase, the **corpus luteum** forms and produces **progesterone**, preparing the uterus for potential pregnancy. *Menstrual phase* - The **menstrual phase** is the period of shedding of the uterine lining, typically occurring from **day 1 to day 5** of the menstrual cycle. - Day 20 is well past this phase, during which bleeding and low hormone levels are characteristic. *Follicular phase* - The **follicular phase** starts on day 1 of menstruation and lasts until ovulation, usually around **day 13-14** in a 28-day cycle. - During this phase, follicles mature under the influence of **FSH** and **estrogen** levels rise. Day 20 is beyond this period. *Ovulation phase* - The **ovulation phase** is a short period, typically around **day 14** of a 28-day cycle, when the mature egg is released from the ovary. - This phase is brief and marks the transition from the follicular to the luteal phase, so day 20 is considerably after ovulation.

Question 271: What is a common cause of unilateral dysmenorrhea?

A. One horn of malformed uterus (Correct Answer)
B. Small fibroid at the utero tubal junction
C. Endometriosis causing unilateral pain
D. All of the options

Explanation: ***One horn of malformed uterus*** - **Obstructed rudimentary horn** with functional endometrium or **obstructed hemivagina** in uterine anomalies is a **classic cause of unilateral dysmenorrhea**. - The obstruction leads to accumulation of menstrual blood in the non-communicating horn or hemivagina, causing **severe cyclical unilateral pelvic pain** that worsens progressively with each menstrual cycle. - This typically presents in **adolescents or young women** after menarche and is a well-recognized gynecological emergency requiring surgical intervention. - Examples include: **unicornuate uterus with non-communicating rudimentary horn**, **uterus didelphys with obstructed hemivagina** (OHVIRA syndrome). *Endometriosis causing unilateral pain* - While endometriosis causes **dysmenorrhea**, it typically presents with **bilateral pelvic pain** and diffuse tenderness. - Endometriosis pain is usually **generalized** rather than strictly unilateral, though asymmetric involvement can occur. - The pain is associated with **deep dyspareunia**, **dyschezia**, and chronic pelvic pain rather than strictly unilateral cyclical pain. *Small fibroid at the utero tubal junction* - Fibroids (leiomyomas) can cause **dysmenorrhea and menorrhagia**, but unilateral presentation is uncommon. - Cornual fibroids may cause localized pain, but this is not a typical or common presentation of **unilateral dysmenorrhea**. - Pain from fibroids is usually related to **degeneration** or pressure effects rather than cyclical unilateral menstrual pain. *All of the options* - While multiple conditions can cause pelvic pain, **obstructed müllerian anomalies** (one horn of malformed uterus) are the **most classic and important cause** of true unilateral dysmenorrhea. - This is the diagnosis that must be ruled out when a patient presents with unilateral cyclical pelvic pain.

Question 272: Oligomenorrhoea means ?

A. Cycle < 20 days
B. Cycle more than 45 days
C. Cycle more than 28 days
D. Cycle longer than 35 days (Correct Answer)

Explanation: ***Cycle longer than 35 days*** - **Oligomenorrhea** is defined by menstrual cycles that are **infrequently occurring**, specifically lasting longer than 35 days. - This condition is distinct from **amenorrhea**, which is the complete absence of menstruation. *Cycle < 20 days* - A menstrual cycle lasting less than 20 days is considered **polymenorrhea**, indicating abnormally frequent menstruation. - This is the opposite of oligomenorrhea, which refers to infrequent menstruation. *Cycle more than 45 days* - While a cycle longer than 45 days would technically fall under **oligomenorrhea**, the general definition begins at an interval longer than **35 days**. - Cycles significantly longer than 45 days might also point to **amenorrhea**, depending on the exact duration and pattern. *Cycle more than 28 days* - A cycle lasting more than 28 days is within the **normal range** for many individuals, as the average cycle length is 21-35 days. - Therefore, this duration alone does **not define oligomenorrhea**.

Question 273: What is the most common age range for women experiencing dysfunctional uterine bleeding?

A. 40-45 years (Correct Answer)
B. 50-55 years
C. 60-65 years
D. 20-25 years

Explanation: ***40-45 years*** - This age range typically represents the **perimenopausal period**, where fluctuating hormones (estrogen and progesterone) often lead to anovulatory cycles and thus, **dysfunctional uterine bleeding (DUB)**. - As women approach menopause, ovarian function becomes irregular, leading to inconsistent ovulation and endometrial instability. - This is the **most common age range** for DUB due to hormonal instability. *50-55 years* - While some women may still experience DUB into their early 50s, this range is more commonly associated with **menopause itself**, where bleeding generally ceases. - Persistent bleeding in this age group may signal other pathologies rather than typical anovulatory DUB. *60-65 years* - Bleeding at this age is considered **postmenopausal bleeding** and is always a red flag for serious underlying conditions such as **endometrial hyperplasia** or **endometrial cancer**, and is not attributed to DUB. - The ovaries have typically ceased functioning, and there should be no normal menstrual bleeding. *20-25 years* - DUB can occur in this age range due to factors like **polycystic ovary syndrome (PCOS)** or **immature hypothalamic-pituitary-ovarian axis** (especially in adolescents). - However, it is **less common** than during the perimenopausal period and often stems from different underlying causes.

Question 274: Which of the following is NOT a cause of metrorrhagia?

A. Polyp
B. CA endometrium
C. IUD
D. Intramural fibroid (Correct Answer)

Explanation: ***Intramural fibroid*** - **Intramural fibroids** are located within the uterine wall and are **primarily associated with menorrhagia** (heavy or prolonged menstrual bleeding during regular periods) rather than metrorrhagia. - Their main effect is to increase the endometrial surface area and impair uterine contractility, leading to **heavy regular menstrual flow**. - While they can occasionally cause irregular bleeding if complicated by degeneration or severe distortion, this is **not their typical presentation**, making them the **least characteristic cause** of metrorrhagia among the given options. *Polyp* - **Endometrial polyps** are **classic causes of metrorrhagia** because their friable surface bleeds irregularly, especially with hormonal fluctuations or minor trauma. - They commonly present with **intermenstrual spotting** and post-coital bleeding, making them a typical cause of irregular bleeding. *CA endometrium* - **Endometrial carcinoma** is a **frequent cause of metrorrhagia**, particularly in postmenopausal women, due to irregular shedding of friable malignant tissue. - The abnormal vascular supply and tissue breakdown in cancer results in **unpredictable, irregular bleeding episodes** characteristic of metrorrhagia. *IUD* - **Intrauterine devices** are **well-known causes of metrorrhagia**, particularly copper IUDs, which cause endometrial irritation and increased prostaglandin release. - Both copper and hormonal IUDs frequently cause **spotting and irregular intermenstrual bleeding**, especially in the first 3-6 months after insertion.

Question 275: Which of the following drugs is not commonly used for menorrhagia?

A. GnRH
B. NSAIDS
C. Methergin
D. Clomiphene (Correct Answer)

Explanation: ***Clomiphene*** - **Clomiphene citrate** is a selective estrogen receptor modulator used primarily to **induce ovulation** in women with infertility, not to treat menorrhagia. - Its mechanism involves blocking estrogen receptors in the hypothalamus, leading to increased release of **gonadotropins (FSH and LH)**. - It has no role in the management of heavy menstrual bleeding. *Methergin* - **Methergine (methylergonovine)** is an ergot alkaloid that causes sustained uterine contractions. - It is primarily used for **postpartum hemorrhage** and control of bleeding after abortions (acute obstetric bleeding). - While it can control acute uterine bleeding, it is **not used for chronic menorrhagia management** due to its side effects and availability of better alternatives. - It is an acute intervention, not a treatment for cyclic heavy menstrual bleeding. *GnRH* - **GnRH agonists** (e.g., leuprolide) are used to treat menorrhagia by inducing a **hypoestrogenic state**, which leads to endometrial atrophy and reduced menstrual bleeding. - They are often used as a temporary measure before surgery or for short-term management due to potential side effects like **hot flashes and bone loss**. *NSAIDS* - **Nonsteroidal anti-inflammatory drugs (NSAIDs)**, such as ibuprofen or naproxen, reduce prostaglandin production, which can decrease **menstrual blood loss** by affecting uterine contractility and vasoconstriction. - They are a common first-line treatment for menorrhagia, especially when associated with **painful periods (dysmenorrhea)**.

Question 276: Preferred treatment for menorrhagia in reproductive age group?

A. Cu IUD
B. Hysterectomy
C. NOVA T
D. OCPs (Correct Answer)

Explanation: ***OCPs*** - **Combined oral contraceptives (OCPs)** are a common and effective first-line treatment for menorrhagia in reproductive-aged women, particularly when contraception is also desired. - They work by stabilizing the **endometrial lining**, reducing menstrual blood loss and regulating cycles. *NOVA T* - NOVA T is a type of **copper IUD (intrauterine device)**, which is known to potentially *increase* menstrual bleeding and dysmenorrhea, making it unsuitable for menorrhagia. - Its primary function is contraception, not the management of heavy menstrual bleeding. *Cu IUD* - The **copper intrauterine device (Cu IUD)** is generally contraindicated in women with menorrhagia because it can exacerbate heavy menstrual bleeding. - While an effective contraceptive, it does not offer therapeutic benefits for managing heavy periods. *Hysterectomy* - **Hysterectomy** is a surgical procedure for removing the uterus and is considered a definitive treatment for menorrhagia. - However, it is an **invasive procedure** with irreversible loss of fertility, typically reserved for severe cases where conservative treatments have failed or when other uterine pathology is present.

Question 277: Primary amenorrhea is defined as:

A. Imperforate hymen exists
B. None of the above
C. Menstruation does not occur even after 15 years of age (Correct Answer)
D. Menstruation does not occur even after 18 years

Explanation: ***Menstruation does not occur even after 15 years of age*** - Primary amenorrhea is defined as the **absence of menstruation by age 15** in individuals with normal secondary sexual characteristics. - This definition is crucial for determining when to initiate investigation for underlying causes. *Imperforate hymen exists* - While an imperforate hymen can cause **cryptomenorrhea** (menstruation occurring but not flowing out), it is a specific cause of primary amenorrhea, not the definition itself. - An imperforate hymen is identified by a **bulging, bluish membrane** at the vaginal introitus. *None of the above* - This option is incorrect because the first option accurately defines primary amenorrhea. - The definition of primary amenorrhea is clinically well-established and widely accepted. *Menstruation does not occur even after 18 years* - This age cut-off is **too late** for the definition of primary amenorrhea, as investigations should ideally begin earlier. - Delaying evaluation until age 18 could potentially delay the diagnosis and treatment of underlying conditions affecting fertility and overall health.

Question 278: Which of the following statements is true regarding menorrhagia?

A. Bleeding volume greater than 80 ml per cycle
B. Heavy and irregularly timed episodes of bleeding
C. Heavy and regularly timed episodes of bleeding (Correct Answer)
D. Menstrual bleeding lasting more than 7 days

Explanation: ***Heavy and regularly timed episodes of bleeding*** - **Menorrhagia** is defined as **excessive menstrual blood loss** occurring at **regular intervals** (cyclical pattern). - This is the classic definition distinguishing it from other abnormal uterine bleeding patterns. - The key features are: **heavy flow** + **regular timing** (maintains normal cycle length). *Heavy and irregularly timed episodes of bleeding* - This describes **irregular heavy bleeding**, which would fall under abnormal uterine bleeding with irregular timing. - The **irregular timing** is the key differentiator that excludes this from being simple menorrhagia. *Bleeding volume greater than 80 ml per cycle* - While **>80 ml blood loss** is the objective measurement for menorrhagia, this alone doesn't capture the complete definition. - Menorrhagia specifically requires this heavy bleeding to occur at **regular intervals**. - In clinical practice, subjective assessment (soaking through pads/tampons, clots, impact on quality of life) is often more practical than measuring volume. *Menstrual bleeding lasting more than 7 days* - Duration **>7 days** describes **prolonged menstrual bleeding**. - This can occur with menorrhagia but is not the defining feature. - A patient can have menorrhagia with normal duration (3-7 days) if the volume is excessive during that period. - The definition of menorrhagia focuses on **amount** (heavy), not duration (prolonged).

Question 279: Dysfunctional uterine bleeding (DUB) is best treated by:

A. Curettage of uterus
B. Progestogen (Correct Answer)
C. Estrogen
D. Clomiphene

Explanation: ***Progestogen*** - **Progestogen** therapy helps stabilize the **endometrium**, reducing excessive or irregular bleeding in DUB by counteracting unopposed estrogen. - It induces a more organized shedding of the uterine lining, which can regularize the menstrual cycle. *Curettage of uterus* - While **curettage** can provide temporary relief by removing the endometrial lining, it is primarily a diagnostic procedure to rule out pathology rather than a primary long-term treatment for DUB. - It does not address the underlying hormonal imbalance that causes DUB, leading to a high recurrence rate of symptoms. *Estrogen* - **Estrogen** therapy alone is generally not used to treat DUB because unopposed estrogen is often the cause of DUB, leading to **endometrial overgrowth** and irregular shedding. - Administering estrogen without a progestin could exacerbate the condition and increase endometrial proliferation. *Clomiphene* - **Clomiphene** is an anti-estrogen medication primarily used to induce **ovulation** in women with infertility. - It is not indicated for the management of dysfunctional uterine bleeding or for regulating menstrual cycles directly.

Question 280: Menorrhagia is defined as:

A. Menses occurring in less than 28 days
B. Intermenstrual bleeding
C. Increased loss of blood than normal during menstruation (Correct Answer)
D. Menses occurring more than 45 days apart

Explanation: ***Increased loss of blood than normal during menstruation*** - **Menorrhagia** is specifically defined as **heavy or prolonged menstrual bleeding** that interferes with a woman's physical, emotional, social, and material quality of life. - This typically means a blood loss of more than 80 mL per cycle or menses lasting longer than 7 days, though a subjective assessment of excessive bleeding by the patient is also key. *Intermenstrual bleeding* - **Intermenstrual bleeding**, also known as metrorrhagia, refers to **bleeding that occurs between menstrual periods**. - It is distinct from menorrhagia, which concerns the characteristics of the menstrual period itself. *Menses occurring in less than 28 days* - This describes **polymenorrhea**, which is characterized by **frequent menstrual periods** (e.g., cycles shorter than 21 days). - While it can be associated with increased bleeding frequency, it does not directly define the volume or duration of blood loss like menorrhagia does. *Menses occurring more than 45 days apart* - This describes **oligomenorrhea**, which refers to **infrequent menstrual periods** (e.g., cycles longer than 35 days but less than 6 months). - It is the opposite of polymenorrhea and is not related to the excessive blood loss that defines menorrhagia.

Question 281: 22-year-old female comes to your outpatient department complaining of frequent periods, which occur every 18 days. What is this condition called?

A. Polymenorrhea (Correct Answer)
B. Metrorrhagia
C. Hypermenorrhea
D. Menorrhagia

Explanation: ***Polymenorrhea*** - This term describes **menstrual bleeding** that occurs **more frequently than normal**—specifically, an interval of **less than 21 days** between periods. - The patient's 18-day cycle falls within this definition, indicating abnormally frequent menstruation. *Menorrhagia* - **Menorrhagia** refers to **heavy or prolonged menstrual bleeding**, where the duration is typically more than 7 days or blood loss exceeds 80 mL. - It does not specifically describe the frequency of the periods. *Metrorrhagia* - **Metrorrhagia** is characterized by **irregular, acyclic bleeding** between menstrual periods, or bleeding that is not associated with the expected menstrual cycle. - This patient's periods are regular in their frequency, although too frequent, rather than irregular or intermenstrual. *Hypermenorrhea* - This term is often used interchangeably with **menorrhagia**, referring to **excessively heavy menstrual bleeding**. - It does not address the issue of the short interval between menstrual cycles.

Question 282: What is the IUCD of choice in women with menorrhagia?

A. Progesterone containing IUCD (Correct Answer)
B. Copper-T 200
C. Copper-T 380A
D. Lippe's loop

Explanation: ***Progesterone containing IUCD*** - **Progesterone-releasing IUCDs** (e.g., **Mirena**) are known to significantly reduce menstrual blood loss by causing **endometrial atrophy**. - This type of IUCD can effectively treat **menorrhagia** (heavy menstrual bleeding) and can even be used in some cases of **adenomyosis**. *Copper-T 200* - **Copper-containing IUCDs** generally **increase menstrual blood loss** and cramping, making them unsuitable for women with menorrhagia. - The **copper** evokes a local inflammatory reaction in the uterus, which can exacerbate heavy bleeding. *Copper-T 380A* - Similar to other **copper IUCDs**, the **Copper-T 380A** works by causing a local inflammatory reaction and releasing copper ions, which can lead to **increased menstrual bleeding**. - It would therefore worsen rather than improve menorrhagia. *Lippe's loop* - **Lippe's loop** is an older, non-medicated plastic IUCD that is no longer widely used and is associated with **increased menstrual bleeding** and cramping. - Its mechanism of action does not involve hormone release, and it does not offer any benefit for reducing menorrhagia.

Question 283: What is the average menstrual flow during normal menses?

A. 80ml
B. 15ml
C. 30ml (Correct Answer)
D. 50ml

Explanation: ***30ml*** - The average menstrual blood loss during a normal period is approximately **30 mL**. - While there is a range, 30 mL is often cited as the mean for defining **normal menses**. *50ml* - Although it falls within the broader definition of normal, 50ml is slightly higher than the statistically observed **average menstrual flow**. - Blood loss exceeding **80 mL** is generally considered **menorrhagia**. *15ml* - A menstrual flow of **15 mL** is on the lower end of the normal range and could sometimes be indicative of **hypomenorrhea**. - While not necessarily abnormal, it is less common as an average compared to 30 mL. *80ml* - A menstrual flow of **80 mL** is consistently considered **menorrhagia** or heavy menstrual bleeding. - This level of blood loss can lead to **anemia** and often requires investigation and treatment.

Question 284: At what age is menstruation considered precocious in females?

A. After 12 years of age
B. At 12 years of age
C. Before 10 years of age (Correct Answer)
D. At 11 years of age

Explanation: ***Before 10 years of age*** - Menstruation occurring **before the age of 10** is generally considered **precocious puberty**, warranting investigation. - While definitions can vary slightly, a threshold of **before 10 years** is a common diagnostic criterion for precocious menarche. *After 12 years of age* - Menarche **after 12 years** is within the normal range of pubertal development, with the average age being around 12.4 years in Western populations. - This age is considered **normal** or even slightly later than average, not precocious. *At 12 years of age* - **12 years of age** is well within the normal range for the onset of menstruation. - This age represents the **average or expected time** for menarche to occur. *At 11 years of age* - Menarche at **11 years of age** is considered to be within the normal, albeit earlier, end of the physiological spectrum. - This age does **not meet the criteria** for being precocious.

Question 285: Which of the following conditions can contribute to congestive dysmenorrhea?

A. Uterine fibroids causing pelvic congestion
B. Pelvic inflammatory disease leading to inflammation
C. Intrauterine device (IUD) usage causing pelvic inflammation
D. All of the options contribute to pelvic congestion (Correct Answer)

Explanation: ***All of the options contribute to dysmenorrhea*** - **Congestive dysmenorrhea** is an older term referring to secondary dysmenorrhea associated with pelvic pathology and vascular congestion. All mentioned conditions can contribute to painful menstruation through various mechanisms. - These conditions represent causes of **secondary dysmenorrhea** (dysmenorrhea with underlying pelvic pathology). *Uterine fibroids causing dysmenorrhea* - **Uterine fibroids** (leiomyomas) cause dysmenorrhea through multiple mechanisms: increased prostaglandin production, uterine distension, and compromised blood flow. - Submucosal fibroids are particularly associated with **menorrhagia and dysmenorrhea** due to increased endometrial surface area and altered uterine contractility. - Large fibroids can cause pelvic heaviness and pressure symptoms. *Pelvic inflammatory disease causing dysmenorrhea* - **Pelvic inflammatory disease (PID)** causes chronic pelvic pain and dysmenorrhea through inflammation, adhesion formation, and tubo-ovarian pathology. - The resulting **chronic inflammation** and scarring can lead to persistent pelvic pain that worsens during menstruation. - PID is a common cause of secondary dysmenorrhea in reproductive-age women. *Intrauterine device (IUD) causing dysmenorrhea* - **Copper IUDs** are particularly associated with increased dysmenorrhea and menorrhagia due to local inflammatory response and increased prostaglandin production. - The foreign body reaction causes increased uterine contractility and cramping, especially in the first few months after insertion. - Levonorgestrel IUDs typically reduce dysmenorrhea rather than cause it.

Question 286: A 32-year-old woman presents with irregular, heavy menstrual bleeding. After thorough evaluation including pelvic ultrasound, hormonal assays, coagulation profile, and endometrial sampling, no structural abnormalities, systemic disorders, or medication-related causes are identified. This clinical scenario is best described as:

A. Presence of systemic causes
B. Presence of iatrogenic causes
C. No identifiable causes present (Correct Answer)
D. Presence of identifiable organic causes

Explanation: ***No identifiable causes present*** - As per its definition, **dysfunctional uterine bleeding (DUB)** is diagnosed when no structural, systemic, or iatrogenic etiology for abnormal uterine bleeding can be found. - The diagnosis of DUB is essentially a **diagnosis of exclusion**, meaning it is made after ruling out other potential causes of bleeding. *Presence of systemic causes* - If systemic causes, such as **coagulation disorders** or **thyroid dysfunction**, are identified, the bleeding is attributed to these conditions, and it is not considered DUB. - DUB specifically implies that systemic factors have been investigated and found to be absent or not the primary cause of the bleeding. *Presence of iatrogenic causes* - **Iatrogenic causes** refer to abnormal bleeding induced by medical interventions, such as specific medications (e.g., anticoagulants, hormonal contraceptives) or medical devices (e.g., IUDs). - If such causes are identified, the bleeding is categorized accordingly, and the diagnosis of DUB is excluded. *Presence of identifiable organic causes* - **Organic causes** include structural abnormalities of the uterus or reproductive tract, such as **fibroids**, **polyps**, **adenomyosis**, or **malignancy**. - The presence of any of these identifiable pathology rules out DUB, as DUB is by definition non-organic.

Question 287: In a patient with secondary amenorrhea, failure to experience withdrawal bleeding after administration of estrogen and progesterone indicates dysfunction of which structure?

A. Pituitary
B. Hypothalamus
C. Ovary
D. Endometrium (Correct Answer)

Explanation: ***Endometrium*** - If the **endometrium** fails to respond to **estrogen and progesterone therapy**, it suggests a problem with the uterine lining itself, such as **Asherman's syndrome** or severe endometrial atrophy. - In such cases, despite adequate hormonal stimulation, there is **no withdrawal bleeding** because the target tissue (endometrium) cannot proliferate or shed. *Pituitary* - A **dysfunctional pituitary gland** would typically cause secondary amenorrhea by failing to produce adequate **gonadotropins (LH and FSH)**, which in turn leads to ovarian dysfunction. - However, in this scenario, if the pituitary were the primary issue, providing exogenous **estrogen and progesterone** would likely still induce withdrawal bleeding if the uterus is responsive. *Hypothalamus* - The **hypothalamus** controls pituitary function by releasing **GnRH**. Hypothalamic dysfunction (e.g., due to stress, extreme exercise, or weight loss) causes **hypogonadotropic hypogonadism**. - While it's a common cause of secondary amenorrhea, exogenous **estrogen and progesterone** should still induce withdrawal bleeding if the uterus is healthy and responsive. *Ovary* - **Ovarian failure** (e.g., premature ovarian insufficiency) leads to low **estrogen** and **high FSH/LH** levels. - If the ovaries are the cause, administering **estrogen and progesterone** would typically induce withdrawal bleeding because the uterus is usually functional and responsive to these hormones.

Question 288: In a young female of reproductive age with a regular menstrual cycle of 28 days, ovulation occurs around the 14th day of the period. When is the first polar body extruded?

A. 24 hours prior to ovulation
B. 48 hours after the ovulation
C. Accompanied by ovulation (Correct Answer)
D. At the time of fertilization

Explanation: ***Accompanied by ovulation*** - The **first meiotic division** is completed just prior to or with ovulation, extruding the **first polar body**. - This process transitions the oocyte from a primary to a **secondary oocyte**, making it ready for fertilization. *24 hours prior to ovulation* - The first polar body extrusion typically occurs very close to the moment of ovulation, not a full 24 hours before. - The **LH surge** triggers the completion of meiosis I, leading to polar body extrusion and ovulation. *48 hours after the ovulation* - By 48 hours post-ovulation, if fertilization has not occurred, the **oocyte begins to degenerate**. - Extrusion of the first polar body occurs much earlier, at the time of ovulation itself. *At the time of fertilization* - At the time of fertilization, the **second meiotic division** is completed, leading to the extrusion of the **second polar body**. - The first polar body is extruded much earlier, when the oocyte is released from the ovary.

Practice by Chapter

Normal Menstrual Physiology

Practice Questions

Primary Dysmenorrhea

Practice Questions

Secondary Dysmenorrhea

Practice Questions

Premenstrual Syndrome and PMDD

Practice Questions

Primary Amenorrhea

Practice Questions

Secondary Amenorrhea

Practice Questions

Polycystic Ovary Syndrome

Practice Questions

Abnormal Uterine Bleeding: Classification

Practice Questions

Evaluation of Menstrual Disorders

Practice Questions

Management Approaches to Menstrual Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Menstrual Disorders — MCQs

Menstrual Disorders — MCQs

On this page